Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)

Martin N, Manoharan K, Davies C, Lumbers RT

Analysis 4.2. Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 2: Cardiovascular mortality (HR) ................................................................. 197
Analysis 4.3. Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 3: Heart failure hospitalisation (RR) ........................................................... 197
Analysis 4.4. Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 4: Heart failure hospitalisation (HR) ................................................................. 198
Analysis 4.5. Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 5: Hyperkalaemia .......... 198
Analysis 4.6. Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 6: All-cause mortality (RR) .......................................................................................... 198
Analysis 4.7. Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 7: All-cause mortality (HR) ...................................................................................... 199
Analysis 4.8. Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 8: Quality of life (Minnesota) ............................................................. 199
Analysis 4.9. Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 9: Withdrawal due to adverse event ........................................................................... 199
Analysis 5.1. Comparison 5: ARNI versus usual care, Outcome 1: Cardiovascular mortality (RR) ...................................................... 200
Analysis 5.2. Comparison 5: ARNI versus usual care, Outcome 2: Heart failure hospitalisation, first (RR) ................................. 200
Analysis 5.3. Comparison 5: ARNI versus usual care, Outcome 3: Heart failure hospitalisation (HR) .................................................. 200
Analysis 5.4. Comparison 5: ARNI versus usual care, Outcome 4: Hyperkalaemia ............................................................... 201
Analysis 5.5. Comparison 5: ARNI versus usual care, Outcome 5: All-cause mortality (RR) ....................................................... 201
Analysis 5.6. Comparison 5: ARNI versus usual care, Outcome 6: Withdrawal due to adverse event ........................................ 201

APPENDICES .................................................................................................................................................................................. 202
WHAT'S NEW .................................................................................................................................................................................................................................. 210
HISTORY .................................................................................................................................................................................................................................... 210
CONTRIBUTIONS OF AUTHORS ................................................................................................................................................................. 210
DECLARATIONS OF INTEREST ................................................................................................................................................................. 210
SOURCES OF SUPPORT ............................................................................................................................................................................... 211
DIFFERENCES BETWEEN PROTOCOL AND REVIEW ....................................................................................................................... 211
INDEX TERMS ........................................................................................................................................................................................................ 211
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction

Nicole Martin, Karthick Manoharan, Ceri Davies, R Thomas Lumbers

1Institute of Health Informatics Research, University College London, London, UK. 2Emergency Department, John Radcliffe Hospital, London, UK. 3Department of Cardiology, Barts Heart Centre, St Bartholomew's Hospital, London, UK. 4Institute of Health Informatics, University College London, London, UK

Contact address: R Thomas Lumbers, t.lumbers@ucl.ac.uk.

Editorial group: Cochrane Heart Group.

Publication status and date: New search for studies and content updated (conclusions changed), published in Issue 5, 2021.

Citation: Martin N, Manoharan K, Davies C, Lumbers RT. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No.: CD012721. DOI: 10.1002/14651858.CD012721.pub3.

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background
Beta-blockers and inhibitors of the renin-angiotensin-aldosterone system improve survival and reduce morbidity in people with heart failure with reduced left ventricular ejection fraction (LVEF); a review of the evidence is required to determine whether these treatments are beneficial for people with heart failure with preserved ejection fraction (HFP EF).

Objectives
To assess the effects of beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor nepriysin inhibitors, and mineralocorticoid receptor antagonists in people with HFP EF.

Search methods
We updated searches of CENTRAL, MEDLINE, Embase, and one clinical trial register on 14 May 2020 to identify eligible studies, with no language or date restrictions. We checked references from trial reports and review articles for additional studies.

Selection criteria
We included randomised controlled trials with a parallel group design, enrolling adults with HFP EF, defined by LVEF greater than 40%.

Data collection and analysis
We used standard methodological procedures expected by Cochrane.

Main results
We included 41 randomised controlled trials (231 reports), totalling 23,492 participants across all comparisons. The risk of bias was frequently unclear and only five studies had a low risk of bias in all domains.

Beta-blockers (BBs)
We included 10 studies (3087 participants) investigating BBs. Five studies used a placebo comparator and in five the comparator was usual care. The mean age of participants ranged from 30 years to 81 years.
A possible reduction in cardiovascular mortality was observed (risk ratio (RR) 0.78, 95% confidence interval (CI) 0.62 to 0.99; number needed to treat for an additional benefit (NNTB) 25; 1046 participants; three studies), however, the certainty of evidence was low. There may be little to no effect on all-cause mortality (RR 0.82, 95% CI 0.67 to 1.00; 1105 participants; four studies; low-certainty evidence). The effects on heart failure hospitalisation, hyperkalaemia, and quality of life remain uncertain.

Mineralocorticoid receptor antagonists (MRAs)

We included 13 studies (4459 participants) investigating MRA. Eight studies used a placebo comparator and in five the comparator was usual care. The mean age of participants ranged from 54.5 to 80 years.

Pooled analysis indicated that MRA treatment probably reduces heart failure hospitalisation (RR 0.82, 95% CI 0.69 to 0.98; NNTB = 41; 3714 participants; three studies; moderate-certainty evidence). However, MRA treatment probably has little or no effect on all-cause mortality (RR 0.91, 95% CI 0.78 to 1.06; 4207 participants; five studies; moderate-certainty evidence) and cardiovascular mortality (RR 0.90, 95% CI 0.74 to 1.11; 4070 participants; three studies; moderate-certainty evidence). MRA treatment may have little or no effect on quality of life measures (mean difference (MD) 0.84, 95% CI -2.30 to 3.98; 511 participants; three studies; low-certainty evidence). MRA treatment was associated with a higher risk of hyperkalaemia (RR 2.11, 95% CI 1.77 to 2.51; number needed to treat for an additional harmful outcome (NNTH) = 11; 4291 participants; six studies; high-certainty evidence).

Angiotensin-converting enzyme inhibitors (ACEIs)

We included eight studies (2061 participants) investigating ACEIs. Three studies used a placebo comparator and in five the comparator was usual care. The mean age of participants ranged from 70 to 80 years.

Pooled analyses with moderate-certainty evidence suggest that ACEI treatment likely has little or no effect on cardiovascular mortality (RR 0.93, 95% CI 0.61 to 1.42; 945 participants; two studies), all-cause mortality (RR 1.04, 95% CI 0.75 to 1.45; 1187 participants; five studies) and heart failure hospitalisation (RR 0.86, 95% CI 0.64 to 1.15; 1019 participants; three studies), and may result in little or no effect on the quality of life (MD -0.09, 95% CI -3.66 to 3.48; 154 participants; two studies; low-certainty evidence). The effects on hyperkalaemia remain uncertain.

Angiotensin receptor blockers (ARBs)

Eight studies (8755 participants) investigating ARBs were included. Five studies used a placebo comparator and in three the comparator was usual care. The mean age of participants ranged from 61 to 75 years.

Pooled analyses with high certainty of evidence suggest that ARB treatment has little or no effect on cardiovascular mortality (RR 1.02, 95% 0.90 to 1.14; 7254 participants; three studies), all-cause mortality (RR 1.01, 95% CI 0.92 to 1.11; 7964 participants; four studies), heart failure hospitalisation (RR 0.92, 95% CI 0.83 to 1.02; 7254 participants; three studies), and quality of life (MD 0.41, 95% CI -3.66 to 3.48; 154 participants; two studies; high-certainty evidence). ARB treatment was associated with a higher risk of hyperkalaemia (RR 1.88, 95% CI 1.07 to 3.33; 7148 participants; two studies; high-certainty evidence).

Angiotensin receptor neprilysin inhibitors (ARNIs)

Three studies (7702 participants) investigating ARNIs were included. Two studies used ARBs as the comparator and one used standardised medical therapy, based on participants’ established treatments at enrolment. The mean age of participants ranged from 71 to 73 years.

Results suggest that ARNIs may have little or no effect on cardiovascular mortality (RR 0.96, 95% CI 0.79 to 1.15; 4796 participants; one study; moderate-certainty evidence), all-cause mortality (RR 0.97, 95% CI 0.84 to 1.11; 7663 participants; three studies; high-certainty evidence), or quality of life (high-certainty evidence). However, ARNI treatment may result in a slight reduction in heart failure hospitalisation, compared to usual care (RR 0.89, 95% CI 0.80 to 1.00; 7362 participants; two studies; moderate-certainty evidence). ARNI treatment was associated with a reduced risk of hyperkalaemia compared with valsartan (RR 0.88, 95% CI 0.77 to 1.01; 5054 participants; two studies; moderate-certainty evidence).

Authors’ conclusions

There is evidence that MRA and ARNI treatment in HFP EF probably reduces heart failure hospitalisation but probably has little or no effect on cardiovascular mortality and quality of life. BB treatment may reduce the risk of cardiovascular mortality, however, further trials are needed. The current evidence for BBs, ACEIs, and ARBs is limited and does not support their use in HFP EF in the absence of an alternative indication. Although MRAs and ARNIs are probably effective at reducing the risk of heart failure hospitalisation, the treatment effect sizes are modest. There is a need for improved approaches to patient stratification to identify the subgroup of patients who are most likely to benefit from MRAs and ARNIs, as well as for an improved understanding of disease biology, and for new therapeutic approaches.

Plain Language Summary

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction
Review question

We investigated the effects of beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs) and angiotensin receptor neprilysin inhibitors (ARNIs) on survival, hospital admissions for heart failure, quality of life and potassium levels in people with heart failure with preserved ejection fraction (HFpEF).

Background

Heart failure is a common condition that occurs when the function of the heart muscle is impaired, being associated with symptoms of breathlessness and fatigue, and a reduction in survival. In around half of cases of heart failure, where the left ventricular ejection fraction is reduced to less than 40% (reflecting significant impairment of contractile function), several drug treatments are known to be effective at improving survival and reducing hospitalisation. In the remaining cases, where the ejection fraction is normal or only mildly reduced (HFpEF), it is not clear whether the same drug treatments are effective at improving outcomes.

Selection criteria

We sought to investigate whether treatments for heart failure with reduced ejection fraction are also effective in HFpEF. We conducted a comprehensive search for all trials investigating BBs, MRAs, ACEIs, ARBs or ARNIs (evidence current to 14 May 2020).

Results and conclusions

We included 10 studies with 3087 randomised participants for BBs, 13 studies with 4459 randomised participants for MRAs, eight studies with 2061 randomised participants for ACEIs, eight studies with 8755 randomised participants for ARBs and three studies with 7702 randomised participants for ARNIs. We combined the evidence in a pooled analysis for each drug class and for each of the outcomes assessed. Not all included studies are part of each analysis.

We found that BBs may improve cardiovascular mortality. However, the certainty of evidence was low due to small trials and uncertainty about the methods used. For MRAs, the results suggest a reduction in heart failure hospitalisation but little or no effect on cardiovascular and all-cause mortality; however, the certainty of evidence was only moderate. For ACEIs, treatment probably has little or no effect on the outcomes of cardiovascular mortality, all-cause mortality and heart failure hospitalisation; however, the certainty of evidence was only moderate. We found high certainty of evidence for ARB treatment, with the results suggesting little or no effect. We found that ARNI treatment has little or no effect on cardiovascular mortality (moderate-certainty evidence), all-cause mortality (high-certainty evidence), or quality of life (high-certainty evidence). ARB treatment may reduce slightly heart failure hospitalisations (moderate-certainty evidence). Treatment with MRAs and ARBs was found to increase the risk of high potassium in the blood.

In conclusion, treatment with MRAs, and possibly ARNIs, was found to result in a slight reduction in the risk of hospitalisation due to heart failure. There was some evidence of a possible beneficial effect of BB on mortality due to cardiovascular disease. Treatment with ACEI probably has no beneficial effect in people with HFpEF, however, this remains uncertain due to a lack of evidence from clinical trials. For ARBs, the evidence suggested that treatment is of little or no benefit in people with HFpEF.

Certainty of the evidence

The certainty of evidence ranged from high to low across the outcomes and drug classes studied. With the exception of ARBs and ARNIs, there was a lack of large-scale trials in HFpEF for the interventions and outcomes tested.
**SUMMARY OF FINDINGS**

Summary of findings 1. Beta-blockers compared to placebo or no treatment for chronic heart failure with preserved ejection fraction

**Beta-blockers compared to placebo or no treatment for chronic heart failure with preserved ejection fraction**

- **Patient or population:** patients with chronic heart failure with preserved ejection fraction
- **Setting:** secondary care
- **Intervention:** beta-blockers
- **Comparison:** placebo or no treatment

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>N of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Risk with placebo or no treatment</td>
<td>Risk with beta-blockers</td>
<td>RR 0.78 (0.62 to 0.99)</td>
<td>1046 (3 RCTs)</td>
<td>☒ ☒ ☒ ☒ LOW 1 2</td>
</tr>
<tr>
<td>Cardiovascular mortality (RR)</td>
<td>study population</td>
<td>173 per 1000</td>
<td>135 per 1000 (107 to 171)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>follow-up: range 21 months to 3.2 years</td>
<td>Heart failure hospitalisation (RR)</td>
<td>117 per 1000</td>
<td>86 per 1000 (55 to 133)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>follow-up: range 6 months to 3.2 years</td>
<td>RR 0.73 (0.47 to 1.13)</td>
<td>449 (4 RCTs)</td>
<td>☒ ☒ ☒ ☒ VERY LOW 1 3</td>
<td>Follow-up unclear for SWEDIC. ELANDD reported that no hospitalisation due to heart failure occurred</td>
<td></td>
</tr>
<tr>
<td>Hyperkalaemia</td>
<td></td>
<td></td>
<td>245 (1 RCT)</td>
<td>☒ ☒ ☒ ☒ VERY LOW 1 6</td>
<td>J-DHF reported one participant in the intervention group (N = 120) experienced hyperkalaemia but did not report on this outcome for the control group. No further data were available from any of the other studies.</td>
</tr>
<tr>
<td>follow-up: mean 3.2 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All-cause mortality (RR)</td>
<td>study population</td>
<td>243 per 1000</td>
<td>199 per 1000 (163 to 243)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>follow-up: range 21 months to 3.2 years</td>
<td>RR 0.82 (0.67 to 1.00)</td>
<td>1105 (4 RCTs)</td>
<td>☒ ☒ ☒ ☒ LOW 1 2</td>
<td>Follow-up unclear for Adamy 2010. ELANDD, SWEDIC and Takeda 2004 reported that no deaths occurred.</td>
<td></td>
</tr>
<tr>
<td>Quality of life (MLHFQ): from 0 to 105 follow-up: mean 6 months</td>
<td>Mean quality of life (MLHFQ) was 24</td>
<td>MD 1 lower (9.05 lower to 7.05 higher)</td>
<td>-</td>
<td>93 (1 RCT)</td>
<td>☒ ☒ ☒ ☒ VERY LOW 4 5</td>
</tr>
</tbody>
</table>

Cochrane Library
The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; MD: Mean difference; MLHFQ: Minnesota Living with Heart Failure Questionnaire; RCT: Randomised controlled trial; RR: Risk ratio

**GRADE Working Group grades of evidence**

**High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect

**Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

---

1. Downgraded by one level due to study limitations (unclear selection bias in most studies).
2. Downgraded by one level due to imprecision (concerns about the smaller study being more precise than the larger study).
3. Downgraded by two levels due to imprecision (few events and wide CI).
4. Downgraded by two levels due to imprecision (very small sample size).
5. Downgraded by one level due to suspected publication bias (this is a patient-relevant outcome that is not reported in most studies).
6. Downgraded by two levels due to suspected publication bias (incomplete reporting).

**Summary of findings 2. Mineralocorticoid receptor antagonists (MRAs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction**

**MRAs compared to placebo or no treatment for chronic heart failure with preserved ejection fraction**

**Patient or population:** patients with chronic heart failure with preserved ejection fraction

**Setting:** secondary care

**Intervention:** MRAs

**Comparison:** placebo or no treatment

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>Nº of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Risk with placebo or no treatment</td>
<td>Risk with MRAs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular mortality (RR)</td>
<td>Study population</td>
<td>RR 0.90 (0.74 to 1.11)</td>
<td>4070 (3 RCTs)</td>
<td>⊕⊕⊕⊝</td>
<td>MODERATE ¹ Two additional trials (RAAM-PEF; Kurrelmeyer 2014) reported that no deaths occurred</td>
</tr>
<tr>
<td>follow-up: range 12 months to 3.3 years</td>
<td>88 per 1000</td>
<td>79 per 1000 (65 to 97)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart failure hospitalisation (RR)</td>
<td>Study population</td>
<td>RR 0.82 (0.69 to 0.98)</td>
<td>3714 (3 RCTs)</td>
<td>⊕⊕⊕⊝</td>
<td>MODERATE ¹</td>
</tr>
</tbody>
</table>
### Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction

**Follow-up: range 24 weeks to 3.3 years**

<table>
<thead>
<tr>
<th>Study population</th>
<th>RR (95% CI)</th>
<th>Number of RCTs</th>
<th>GRADE</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperkalaemia follow-up: range 24 weeks to 3.3 years</td>
<td>Hyperkalaemia ≥ 5.5 mEq/L</td>
<td>RR 2.11 (1.77 to 2.52)</td>
<td>6 RCTs</td>
<td>⊗⊗⊗⊗ HIGH</td>
</tr>
<tr>
<td>All-cause mortality follow-up: range 9 months to 3.3 years</td>
<td></td>
<td>RR 0.91 (0.78 to 1.06)</td>
<td>5 RCTs</td>
<td>⊗⊗⊗ MODERATE 1</td>
</tr>
<tr>
<td>Quality of life (MLHFQ): from 0 to 105 follow-up: range 9 months to 12 months</td>
<td></td>
<td>MD 0.84 higher (2.30 lower to 3.98 higher)</td>
<td>3 RCTs</td>
<td>⊗⊗⊗ LOW 2 3</td>
</tr>
</tbody>
</table>

We did not pre-specify which QoL scale was to be reported in the 'Summary of findings’ table. To aid comparisons among ‘Summary of findings’ tables we chose to include the Minnesota Living with Heart Failure questionnaire and not the SMD across two scales

---

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).*

CI: Confidence interval; MD: Mean difference; MLHFQ: Minnesota Living with Heart Failure Questionnaire; MRAs: Mineralocorticoid receptor antagonists; RCT: Randomised controlled trial; RR: Risk ratio

**GRADE Working Group grades of evidence**

- **High certainty**: We are very confident that the true effect lies close to that of the estimate of the effect
- **Moderate certainty**: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
- **Low certainty**: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
- **Very low certainty**: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

---

1. Downgraded by one level due to imprecision.
2. Downgraded by one level due to study limitations (one trial was open label).
3. Downgraded by one level due to imprecision (small sample size).
### Summary of findings 3. Angiotensin-converting enzyme inhibitors (ACEIs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction

ACEIs compared to placebo or no treatment for chronic heart failure with preserved ejection fraction

**Patient or population:** patients with chronic heart failure with preserved ejection fraction  
**Setting:** secondary care  
**Intervention:** ACEIs  
**Comparison:** placebo or no treatment

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects$^*$</th>
<th>Relative effect (95% CI)</th>
<th>Nº of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Risk with placebo/no treatment</td>
<td>Risk with ACEI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular mortality (RR) follow-up: range mean 12 months to mean 26.2 months</td>
<td>Study population</td>
<td>RR 0.93 (0.61 to 1.42)</td>
<td>945 (2 RCTs)</td>
<td>⊕⊕⊕MODERATE 1</td>
<td>One additional trial (Kitzman 2010) reported that no deaths occurred</td>
</tr>
<tr>
<td>Heart failure hospitalisation (RR) follow-up: range 6 months to 26.2 months</td>
<td>Study population</td>
<td>RR 0.86 (0.64 to 1.15)</td>
<td>1019 (3 RCTs)</td>
<td>⊕⊕MODERATE 1</td>
<td>One trial (Zi 2003) reported 2 events in the intervention group (N = 36), 0 events in the control group (N = 38) (RR 5.27, 95% CI 0.26 to 106.16)</td>
</tr>
<tr>
<td>Hyperkalaemia follow-up: 6 months</td>
<td></td>
<td></td>
<td>74 (1 RCTs)</td>
<td>⊕⊕⊕VERY LOW 1 3 4</td>
<td>One trial (Zi 2003) reported 2 events in the intervention group (N = 36), 0 events in the control group (N = 38) (RR 5.27, 95% CI 0.26 to 106.16)</td>
</tr>
<tr>
<td>All-cause mortality (RR) follow-up: range mean 6 months to mean 26.2 months</td>
<td>Study population</td>
<td>RR 1.04 (0.75 to 1.45)</td>
<td>1187 (5 RCTs)</td>
<td>⊕⊕MODERATE 1</td>
<td>One additional trial (Kitzman 2010) reported that no deaths occurred</td>
</tr>
<tr>
<td>Quality of life (MLHFQ): from 0 to 105 follow-up: mean 12 months</td>
<td>Mean quality of life (MLHFQ) ranged from 10.9 to 29</td>
<td>MD 0.09 lower (3.66 lower to 3.48 higher)</td>
<td>-</td>
<td>⊕⊕⊕LOW 2 3</td>
<td>Scale: 0 to 105, lower = better, 5 point difference considered clinically relevant One trial (SNEGIOVIX) reported mean change from baseline of -19.8 for intervention and -10.7 for control</td>
</tr>
</tbody>
</table>
The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

ACEI: Angiotensin-converting enzyme inhibitors; CI: Confidence interval; MD: Mean difference; MLHFQ: Minnesota Living with Heart Failure Questionnaire; RCT: Randomised controlled trial; RR: Risk ratio

**GRADE Working Group grades of evidence**

**High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect

**Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

---

1 Downgraded by one level due to imprecision (wide CI).
2 Downgraded by one level due to study limitations (risk of bias [open label]).
3 Downgraded by one level due to imprecision (low sample size).
4 Downgraded by one level due to study limitations (unclear selection bias).

**Summary of findings 4. Angiotensin receptor blockers (ARBs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction**

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>Number of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Risk with placebo or no treatment</td>
<td>Risk with ARBs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular mortality (RR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>follow-up: range mean 12 months to mean 49.5 months</td>
<td>RR 1.02 (0.90 to 1.14)</td>
<td>7254 (3 RCTs)</td>
<td>⊕⊕⊕⊕ HIGH</td>
<td>One additional trial (Parthasarathy 2009) reported that no deaths occurred</td>
<td></td>
</tr>
<tr>
<td>Study population</td>
<td>131 per 1000</td>
<td>133 per 1000 (118 to 149)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart failure hospitalisation (RR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>follow-up: range mean 12 months to mean 49.5 months</td>
<td>RR 0.92 (0.83 to 1.02)</td>
<td>7254 (3 RCTs)</td>
<td>⊕⊕⊕⊕ HIGH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study population</td>
<td>171 per 1,000</td>
<td>157 per 1,000 (142 to 174)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Hyperkalaemia
follow-up: range 36.6 months to 49.5 months

<table>
<thead>
<tr>
<th>Study population</th>
<th>RR 1.88 (1.07 to 3.33)</th>
<th>7148 (2 RCTs)</th>
<th>⬤⬤⬤⬤ HIGH</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 per 1,000</td>
<td>5 per 1,000 (3 to 8)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

All-cause mortality (RR)
follow-up: range 1 years to 4.4 years

<table>
<thead>
<tr>
<th>Study population</th>
<th>RR 1.01 (0.92 to 1.11)</th>
<th>7964 (4 RCTs)</th>
<th>⬤⬤⬤⬤ HIGH</th>
</tr>
</thead>
<tbody>
<tr>
<td>72 per 1000</td>
<td>73 per 1,000 (66 to 80)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Quality of life (MLHFQ): from 0 to 105
follow-up: range mean 13.8 weeks to mean 49.5 months

<table>
<thead>
<tr>
<th>Mean quality of life (MLHFQ) ranged from 10.9 to 31.6</th>
<th>MD 0.41 higher (0.86 lower to 1.67 higher)</th>
<th>-</th>
<th>3117 (3 RCTs)</th>
<th>⬤⬤⬤⬤ HIGH</th>
</tr>
</thead>
</table>

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

**ABRs**: Angiotensin receptor blockers; **CI**: Confidence interval; **MD**: Mean difference; **MLHFQ**: Minnesota Living with Heart Failure Questionnaire; **RCT**: Randomised controlled trial; **RR**: Risk ratio

**GRADE Working Group grades of evidence**

**High certainty**: We are very confident that the true effect lies close to that of the estimate of the effect

**Moderate certainty**: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low certainty**: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low certainty**: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

**Summary of findings 5. Angiotensin receptor neprilysin inhibitors (ARNIs) compared to usual care for chronic heart failure with preserved ejection fraction**

**ARNIs compared to usual care for chronic heart failure with preserved ejection fraction**

**Patient or population**: patients with chronic heart failure with preserved ejection fraction

**Setting**: secondary care

**Intervention**: ARNI (sacubitril-valsartan)

**Comparison**: ARB (valsartan)

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>Nº of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk with usual care</td>
<td>Risk with ARNI</td>
<td>Relative effect (95% CI)</td>
<td>Nº of participants (studies)</td>
<td>Certainty of the evidence (GRADE)</td>
<td>Comments</td>
</tr>
</tbody>
</table>

**Cochrane Library**


Cochrane Database of Systematic Reviews
### Cardiovascular mortality (RR)

<table>
<thead>
<tr>
<th>Study population</th>
<th>RR 0.96 (0.79 to 1.15)</th>
<th>4796 (1 study)</th>
<th>⊕⊕⊕⊝ MODERATE&lt;sup&gt;1&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median follow-up: 35 months</td>
<td>89 per 1,000 (70 to 102)</td>
<td>85 per 1,000 (70 to 102)</td>
<td>4796 (1 study)</td>
</tr>
</tbody>
</table>

Range of follow-up: 24 weeks to 35 months

<table>
<thead>
<tr>
<th>RR 0.89 (0.79 to 1.15)</th>
<th>7362 (2 studies)</th>
<th>⊕⊕⊕⊝ MODERATE&lt;sup&gt;1&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>142 per 1,000 (113 to 142)</td>
<td>126 per 1,000 (113 to 142)</td>
<td>7362 (2 studies)</td>
</tr>
</tbody>
</table>

### Heart failure hospitalisation, first (RR)

<table>
<thead>
<tr>
<th>Study population</th>
<th>RR 0.89 (0.80 to 1.00)</th>
<th>7362 (2 studies)</th>
<th>⊕⊕⊕⊝ MODERATE&lt;sup&gt;1&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Range of follow-up: 24 weeks to 35 months</td>
<td>142 per 1,000 (113 to 142)</td>
<td>126 per 1,000 (113 to 142)</td>
<td>7362 (2 studies)</td>
</tr>
</tbody>
</table>

### Hyperkalaemia

<table>
<thead>
<tr>
<th>Study population</th>
<th>RR 0.88 (0.77 to 1.01)</th>
<th>5054 (2 studies)</th>
<th>⊕⊕⊕⊝ MODERATE&lt;sup&gt;1&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Range of follow-up: 36 weeks to 35 months</td>
<td>147 per 1,000 (113 to 148)</td>
<td>129 per 1,000 (113 to 148)</td>
<td>5054 (2 studies)</td>
</tr>
</tbody>
</table>

### All-cause mortality (RR)

<table>
<thead>
<tr>
<th>Study population</th>
<th>RR 0.97 (CI 0.84 to 1.11)</th>
<th>7663 (3 studies)</th>
<th>⊕⊕⊕⊕ HIGH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Range of follow-up: 36 weeks to 35 months</td>
<td>138 per 1,000 (117 to 153)</td>
<td>134 per 1,000 (117 to 153)</td>
<td>7663 (3 studies)</td>
</tr>
</tbody>
</table>

### Quality of life

| PARAMOUNT reported change from baseline for the KCCQ overall summary score for the intervention arm (n = 118) as 11.25 (2.185) and the control arm (n = 116) as 11.31 (2.183) and summarised the findings as “no difference in KCCQ score between treatment groups”. | ⊕⊕⊕⊕ HIGH |
| PARAGON-HF reported a difference of the clinical summary score KCCQ between treatment arms as 1.0 (0.0 to 2.1). | ⊕⊕⊕⊕ HIGH |
| PARALLAX reported “KCCQ improved in both treatment groups, with an early benefit of S/V that was no longer significant after 24 week” | ⊕⊕⊕⊕ HIGH |

---

<sup>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).*

**ARB:** Angiotensin receptor blocker; **ARNIs:** Angiotensin receptor neprilysin inhibitors; **CI:** Confidence interval; **KCCQ:** Kansas City Cardiomyopathy Questionnaire; **MD:** Mean difference; **RCT:** Randomised controlled trial; **RR:** Risk ratio

---

**GRADE Working Group grades of evidence**

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

---

<sup>1</sup>Downgraded by one level due to imprecision.
Beta-blockers and inhibitors of the renin-angiotensin-aldosterone system for chronic heart failure with preserved ejection fraction
**BACKGROUND**

**Description of the condition**

Heart failure is a clinical syndrome characterised by breathlessness and fatigue that results when abnormalities of cardiac structure and function lead to inadequate cardiac output, elevated ventricular filling pressures, or both (Ponikowski 2016). Based on available data from the United States and Europe, the prevalence of heart failure is estimated to range from 1% to 12% of the adult population and is projected to increase with populations ageing and with improved survival from cardiovascular disease (Roger 2013). Heart failure represents a significant public health problem, accounting for 5% of emergency medical admissions to hospital in the United Kingdom (NICE 2018). It is associated with significant mortality risk, with a ten-year survival of 27%, compared with 75% in the general population, matched for age and sex (Taylor 2012). Heart failure is classified according to the left ventricular ejection fraction (LVEF) into two categories: heart failure with reduced ejection fraction (HFrEF, typically considered as LVEF less than 40%), and heart failure with preserved ejection fraction (HfPEF, typically LVEF greater than 40%). Recently, an intermediate subgroup was defined by the European Society of Cardiology as heart failure with mid-range ejection fraction (HFmrEF) defined as LVEF 40% to 49% (Ponikowski 2016). This was defined by the American College of Cardiology as borderline HfPEF, defined as LVEF 41% to 49% (Yancy 2013). In this review, we defined HfPEF as LVEF greater than 40% because completed and ongoing HfPEF trials have used a range of LVEF cut-offs, between 40% and 50%. HfPEF accounts for approximately half of all cases of HF; mortality outcomes are similar to those for HFrEF (Gerber 2015).

**Description of the intervention**

Neurohumoral inhibition with beta-blockers (BB), angiotensin converting enzyme inhibitors (ACEIs), and mineralocorticoid receptor antagonists (MRAs) leads to improved survival and a reduction in hospitalisations for heart failure in people with HFrEF (CIBIS Investigators 1999; Consensus Trial Study Group 1987; Flather 2005; Hjalmarson 2000; Kotecha 2014; MERIT-HF Study Group 1999; Packer 1999; Packer 2002; Packer 2001; Pitt 1999; Ponikowski 2016; SOLVD Investigators 1993; SOLVD Investigators 1992; Zannad 2011). Angiotensin receptor antagonists (ARBs) are recommended as an alternative to ACEIs in patients with intolerance to these agents or, in combination with ACEIs, for patients treated with BBs who are unable to tolerate MRAs (Ponikowski 2016). Angiotensin receptor neprilysin inhibitors (ARNIs) are recommended as an alternative to ACEIs, with superior efficacy in people with HFrEF who remain symptomatic despite optimal therapy (McMurray 2014). Although neurohumoral activation is observed in HfPEF (Hogg 2005), comparatively fewer clinical trials of neurohumoral inhibitor therapies have been performed in this population. The existing evidence from individual trials of BBs, MRAs, ACEIs, ARBs or MRAs in people with HfPEF does not support a reduction in mortality with these treatments (Ponikowski 2016). However, limited evidence indicates that candesartan (an ARB) (Yusuf 2003) and spironolactone (an MRA) (Pitt 2014) may be effective in reducing numbers of people hospitalised with HF.

This review sought to determine whether neurohumoral inhibition with therapies that improve mortality and morbidity in those with HFrEF (BBs, MRAs, ACEIs, ARBs, and ARNI) have similar benefit in people with HfPEF.

**How the intervention might work**

In people with HfPEF, inadequate cardiac function triggers compensatory neurohumoral responses similar to those observed in HFrEF (Hogg 2005). Activation of the renin-angiotensin aldosterone system (RAAS) and increased tone of the sympathetic nervous system may be adaptive in the short term; however, chronic activation is likely to be detrimental. Pre-clinical disease models of HfPEF suggest that RAAS activation leads to maladaptive hypertrophy and fibrosis (Sharma 2014). ACEIs, ARBs or MRAs inhibit components of the RAAS system to counter the over-activation that occurs in people with HF. ARNI combines inhibition of RAAS with an ARB (valsartan) with augmentation of the natriuretic peptide system by inhibition of neprilysin (sacubitril). Neprilysin is a neutral endopeptidase that degrades a number of endogenous vasoactive peptides serving to counteract some of the effects of RAAS activation (Mcmurray 2014). The beneficial effects of BB therapy in people with HFrEF are thought to be mediated reducing the downstream effects associated with increased tone of the sympathetic nervous system, including increased heart rate, adverse myocardial energetics, and stimulation of RAAS (Sackner-Bernstein 1995). These mechanisms may also be important in HfPEF and the effect of BBs to increase diastolic filling time may be particularly important (Sharma 2014); however, it is also possible that BB treatment may have adverse effects in this patient population. The population of people with HfPEF is heterogeneous, both with respect to disease aetiology and comorbidity. However, it is possible that neurohumoral activation represents a common pathophysiological mechanism that could be successfully targeted to improve clinical outcomes in people with heart failure across the spectrum of LVEF.

**Why it is important to do this review**

There is uncertainty as to whether BBs or RAAS inhibitors are effective at reducing mortality and heart failure hospitalisation and improving quality of life in people with HfPEF. Guidelines offer no specific treatment recommendations regarding the use of these therapies beyond the management of comorbidities, aside from a weak recommendation that ARBs and MRA might be considered to reduce hospitalisations (Yancy 2017). The European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure highlight a gap in the evidence for the effects of ARNI and BBs in the treatment of HF (Ponikowski 2016).

A recent systematic review and meta-analysis of pharmacotherapy in HfPEF included BBs and RAAS inhibitors (ACEIs, ARBs and MRAs) and suggested a reduction in cardiovascular and all-cause mortality with BB therapy (Zheng 2018). An updated review with a more comprehensive search strategy is needed to inform new guideline recommendations and to inform the conduct of further clinical trials.

**OBJECTIVES**

To assess the effects of BBs, ACEIs, ARBs, ARNI, and MRAs in people with HfPEF.
METHODS

Criteria for considering studies for this review

Types of studies
We included randomised controlled trials (RCTs) with parallel group design. We excluded cross-over trials because we considered these to be inappropriate for our review question due to the progressive nature of HF.

Studies published in full-text or as abstracts, or available only as unpublished data, were eligible for inclusion.

Types of participants
We included studies with adult participants (aged ≥ 18 years) with HFpEF defined by a LVEF greater than 40%. We recognised that there was likely to be significant heterogeneity among study populations, relating to the disease definition, and we summarise this narratively in the Discussion. In relation to ejection fraction, we contacted study authors to obtain data on the subgroup of interest for studies with mixed populations.

Types of interventions
We performed separate meta-analyses of studies that compared BBs, MRAs, ACEIs, ARBs or ARNI, in addition to standard care. For BBs, MRAs, ACEIs and ARBs, the comparator was with placebo or no-treatment control. For ARNI, we meta-analysed studies that compared sacubitril-valsartan with valsartan, an ARB.

Types of outcome measures
Reporting one of more of the listed outcomes in the trial was not an inclusion criterion for the review. We assessed outcomes at the longest reported follow-up.

Primary outcomes
1. Cardiovascular mortality.
2. Heart failure hospitalisation (number of participants with at least one hospitalisation, analysed as risk ratios (RR), and time to first event, analysed as hazard ratios (HR)).
3. Hyperkalaemia.

Secondary outcomes
1. All-cause mortality.
2. Quality of life (measured with either the 'Minnesota Living with Heart Failure Questionnaire' (MLHFAQ) or the 'Kansas City Cardiomyopathy Questionnaire' (KCCQ)).
3. Withdrawal due to adverse event (hypotension, hyperkalaemia or renal impairment).

Search methods for identification of studies

Electronic searches
We updated the systematic searches of the following bibliographic databases on 14 May 2020:
1. Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (Issue 5 of 12, 2020);
2. Epub Ahead of Print, In-Process & Other Non-Indexed Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 12 May 2020); and
3. Embase and Embase Classic (Ovid, 1947 to 13 May 2020).

The search strategies used in 2017 are included in Appendix 1 and those used in 2020 are in Appendix 2. We applied the Cochrane sensitivity-maximising RCT filter (Lefebvre 2019) to MEDLINE (Ovid). For Embase, the RCT filter with the best optimisation of sensitivity and specificity was applied, as in the previous search. (Wong 2006).

We did not impose any restriction on language of publication.

Searching other resources
We searched ClinicalTrials.gov (clinicaltrials.gov) for ongoing trials on 14 May 2020. We were unable to search the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (apps.who.int/trialsearch) as it was unavailable at the time of searching. Search terms for the trials registers are also listed in Appendix 1 (from 2017) and Appendix 2 (from 2020).

We checked all primary references of included studies and systematic reviews for additional references. For studies identified as eligible from clinical trial register records, we searched for associated publications on PubMed and in recent conference presentations.

We contacted study authors to clarify details or obtain additional information not included in the published reports.

Data collection and analysis

Selection of studies
Two review authors (KM and NM) independently screened titles and abstracts of all records identified in our search and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. In the event of disagreement, a third review author was asked to arbitrate (TL). We then retrieved the full-text study reports for records identified as eligible, potentially eligible or unclear. Two review authors (KM and NM) independently screened the full-text articles and identified studies for inclusion. We recorded reasons for exclusion of ineligible studies. We resolved any disagreement by consensus or consulted a third review author (TL). We identified and excluded duplicates and collated multiple reports of the same study so that each study rather than each report is the unit of interest in the review. We recorded the selection process and completed a PRISMA flow diagram (Figure 1) and the Characteristics of excluded studies table.
Figure 1. Study flow diagram

37 included studies (207 references) from previous review publication

1223 records identified through database searching

251 additional records identified through other sources (clinical trial register)

1130 records after duplicates removed

1130 records screened

1038 records excluded

52 studies (54 references) excluded
Wrong study design n = 7
Population does not meet protocol n = 2
Wrong comparator n = 3
Unclear eligibility/no response to query for details n = 2
Unclear eligibility/no contact details n = 2
Subgroup not of interest n = 36
3 studies (3 references) awaiting classification
11 studies (11 references)

92 full-text articles assessed for
Figure 1. (Continued)

**Data extraction and management**

We used a data collection form to record study characteristics and outcome data from included studies, which had been piloted on two studies in the review (PEP-CHF; TOPCAT). Some modifications were made after the pilot phase. Two review authors (NM and TL for Martin 2018, and NM and KM for this update) extracted study characteristics from included studies as follows:

1. **Methods**: study design, duration of follow-up, details of any ‘run in’ period, number of study centres and location, study setting, withdrawals, and start/end date of enrolment.

2. **Participants**: number randomised/withdrawn/lost to follow-up/analysed, mean age/age range, percent male, inclusion criteria, exclusion criteria, systolic blood pressure, heart rate, body mass index, serum creatinine, B-type natriuretic peptide, NT pro B-type natriuretic peptide, LVEF, New York Heart Association (NYHA) class, comorbidity (hypertension, diabetes, atrial fibrillation, hospitalisation for HF, coronary heart disease, stroke, medications at baseline).

3. **Interventions**: intervention, comparison, concomitant medications (diuretic, digoxin, BBs, ACEIs, ARBs, MRAs).

4. **Outcomes**: planned and reported.

5. **Notes**: sources of funding, and notable conflicts of interest of trial authors.

Two review authors (NM and TL for Martin 2018 and NM and KM for this update) independently extracted outcome data from included studies. Disagreements were resolved by consensus. One review author (NM) transferred data into the Review Manager 5 (RevMan 2014) file. One review author (TL) double-checked that data were entered correctly by comparing the data presented in the systematic review with the data extraction sheet.

**Assessment of risk of bias in included studies**

Two review authors (NM and TL) independently assessed risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). Disagreements were resolved by consensus. We assessed the risk of bias according to the following domains:

1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.

We judged each potential source of bias as high, low or unclear and provided quotes from study reports together with justification for our judgment in the 'Risk of bias' table. We summarised the 'Risk of bias' judgements across different studies for each of the domains listed. Where information on risk of bias related to unpublished data or correspondence with a triallist, we noted this in the 'Risk of bias' table.

When considering treatment effects in the pooled analysis, we accounted for risk of bias for the studies that contributed to each outcome tested.

**Assessment of bias in conducting the systematic review**

We conducted the review according to the published protocol and reported protocol deviations in the Differences between protocol and review section.

**Measures of treatment effect**

We analysed dichotomous data as RR with 95% confidence intervals (CIs), and continuous data as mean difference (MD) or standardized mean difference (SMD), with 95% CIs. In addition, wherever possible, we performed a pooled analysis of outcomes reported as HRs. We used SMD for one analysis when combining quality of life data reported for two different scales and followed Cohen’s effect sizes of 0.2 representing a small effect, 0.5 a moderate effect and 0.8 a large effect (Cohen 1988). We entered data presented as a scale with a consistent direction of effect.

**Unit of analysis issues**

We included one three-arm trial (Hong Kong DHF). Because two intervention arms contributed to two separate comparisons, no unit of analysis issue arose.

**Dealing with missing data**

We contacted investigators or study sponsors to verify key study characteristics and where possible, obtain missing numerical outcome data.

**Assessment of heterogeneity**

We used the I² statistic to measure heterogeneity among the trials in each analysis. We considered possible causes in cases of substantial heterogeneity (I² = 50% to 100%).

**Assessment of reporting biases**

We pooled fewer than 10 trials for each comparison. Therefore, we did not examine funnel plots to explore possible small-study biases for the primary outcomes. We plan to do so, should a sufficient number of trials become available in future updates of this review.

**Data synthesis**

We undertook meta-analyses only where this was meaningful, that is, if the treatments, participants and the underlying clinical question were similar enough for pooling to make sense. We used a fixed-effect model in the absence of substantial heterogeneity (I² < 50%) and a random-effects model when unexplained substantial heterogeneity was present (I² ≥ 50%). We applied a random-effects model for quality of life analyses for MRAs to account the high heterogeneity observed for the KCCQ (Analysis 2.7; I² = 86%) and to permit a combined analysis with outcome data from the MLHFQ (Analysis 2.6; I² = 50%).

We considered two relevant quality of life scales: the MLHFQ or KCCQ. The MLHFQ score has a range from 0 to 105, lower scores indicate better quality of life. The KCCQ score has a range from 0 to 100, higher scores indicate better quality of life. To account for the difference in the direction of the scale of the KCCQ, the mean values were multiplied by -1 (Cochrane Handbook for Systematic Reviews of Interventions, section 9.2.3.2, Deeks 2011). For the purpose of interpretation, we considered a five point difference in score as clinically significant for the MLHFQ (Rector 1995) and KCCQ (Spertus 2005).

**Subgroup analysis and investigation of heterogeneity**

We planned to carry out the following subgroup analyses.

1. Age. The potential effect of age as an effect modifier of RAAS inhibition is not well described. We planned to explore outcomes for subgroups defined by age as less than 70 years and 70 years and over. This is based on the median age of participants in two major HFpEF trials: the TOPCAT median age was 68.7 years and the PARAGON-HF mean age was 72 years.
2. Sex.
3. HFmrEF LVEF 40% to 49% and preserved LVEF equal to or greater than 50%.
4. Length of follow-up less than 12 months and equal to or greater than 12 months.

We were unable to perform subgroup analyses, due to insufficient data (Deeks 2019).

If we had been able to conduct subgroup analyses, we had planned to use the outcomes of cardiovascular mortality and hospitalisation for heart failure and the formal test for subgroup interactions in Review Manager 5 (RevMan 2014).

**Sensitivity analysis**

We performed a sensitivity analysis for risk of bias by performing a pooled analysis that included only studies with a low risk of bias (where at least four of the six domains for bias assessment were judged to be low risk, and no domain was at high risk of bias).

**Summary of findings and assessment of the certainty of the evidence**

We created ‘Summary of findings’ tables for each of our five interventions and included the following outcomes: cardiovascular mortality, heart failure hospitalisation, all-cause mortality, quality of life (when available MLHFQ, alternatively KCCQ) and hyperkalaemia. We used the five GRADE considerations (study limitations, inconsistencies, imprecision, indirectness and publication bias) to assess the certainty of the body of evidence as it related to the studies which contributed data to the meta-analyses for the prespecified outcomes. We used methods and recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011) using GRADEpro software (GRADEpro GDT). Four review authors assessed the certainty of evidence (TL, NM, KM, CD). We used footnotes to document our justification for decisions to downgrade the certainty of evidence.
RESULTS

Description of studies

Results of the search

We previously included 37 studies, reported in 207 references (Martin 2018). For this update, the database searches identified 1223 new reports, and a search of ClinicalTrials.gov retrieved 251 additional records. After de-duplication, we screened 1130 records based on the titles and abstracts. Of these, 1038 did not meet the inclusion criteria and were excluded. The remaining 92 records were assessed for eligibility in full-text and 24 references were included. We identified eight additional references for four previously included studies (CHARM-Preserved; STRUCTURE; TOPCAT; Yukek 2012). We included four new studies in this updated review (McDiarmid 2020; PARAGON-HF; PARALLAX; PARAMOUNT), reported in 17 references. PARALLAX had previously been identified as an ongoing study. We thus now include a total of 41 studies in this review.

We identified 11 new ongoing studies, bringing the total of ongoing studies to 13. Three new studies were added to the category of ‘Studies awaiting classification’ (Botoni 2010; PER-O10-15; Przewlocka-Kosmala 2017) bringing the total to nine studies in this category.

Included studies

We included 41 studies (234 reports) that involved a total of 26,059 participants.

BBs

We included 10 studies (3087 participants) that investigated BBs for HFpEF. Of these, five studies compared BBs versus placebo (ELANDD; Mittal 2017; Sahoo 2016; SENIORS; SWEDIC) and five versus usual care (Adamyan 2010; Aronow 1997; J-DHF; Shu 2005; Takeda 2004). Four studies investigated carvedilol: Adamyan 2010 (up to 50 mg daily), J-DHF (up to 10 mg twice daily), SWEDIC (up to 25 mg twice daily or 50 mg twice daily in people weighing over 85 kg), Takeda 2004 (up to 20 mg daily). Two studies used nebivolol: ELANDD (up to 10 mg daily) and SENIORS (up to 10 mg daily). One study used propranolol: Aronow 1997 (30 mg, three times daily); and two studies investigated metoprolol succinate: Mittal 2017; Sahoo 2016 (up to 100 mg daily). Shu 2005 investigated bisoprolol (up to 10 mg daily).

Numbers of participants randomised ranged from 40 (Mittal 2017; Takeda 2004) to 643 (SENIORS).

Four were multicentre studies. ELANDD was conducted across 12 centres in eight countries in Europe; J-DHF was assumed to have taken place in Japan; SENIORS took place in 11 countries (Czech Republic, France, Germany, Hungary, Italy, Netherlands, Romania, Spain, Switzerland, UK and Ukraine), and SWEDIC took place in 12 centres in Sweden. Mittal 2017 and Sahoo 2016 were each conducted in one centre in India. Adamyan 2010, Aronow 1997 and Shu 2005 did not report numbers of centres or countries, but we assumed that Adamyan 2010 likely took place in Armenia. Takeda 2004 was a single centre trial in Japan.

Three studies did not report LVEF of the included participants at baseline (Adamyan 2010; Shu 2005; SWEDIC). Six studies reported LVEF at baseline with a mean ranging from 56% to 63% (Aronow 1997; ELANDD; J-DHF; Mittal 2017; Sahoo 2016; Takeda 2004). SENIORS included participants with a "clinical history of chronic HF with at least 1 of the following features: documented hospital admission within the previous 12 months with a discharge diagnosis of congestive HF or documented LVEF ≤ 35% within the previous 6 months". The SENIORS study reported a subgroup of participants with LVEF greater than 40% and these outcome data were used in our analysis (643 participants).

Most participants were NYHA class II (51% to 78%). Shu 2005 did not report participants' NYHA class at baseline. Participants' mean age ranged from 30 years to 81 years; six studies reported mean age less than 70 years (Adamyan 2010; ELANDD; Mittal 2017; Sahoo 2016; Shu 2005; SWEDIC) and four reported mean age above 70 years (Adamyan 1997; J-DHF; SENIORS; Takeda 2004).

Three studies were funded by industry (ELANDD; SENIORS; SWEDIC); two studies were funded by not-for-profit organisations (J-DHF; Mittal 2017); and five did not report sources of funding (Adamyan 2010; Aronow 1997; Sahoo 2016; Shu 2005; Takeda 2004).

MRAs

We included 13 studies that investigated MRAs for HFpEF. Of these, eight compared MRAs versus placebo (ALDO-DHF; AREA IN-CHF; Kurrelmeyer 2014; Mottram 2004; RAAM-PEF; STRUCTURE; TOPCAT; Upadhya 2017) and five versus usual care (Karapyz 2015; Mak 2009; McDiarmid 2006; Orea-Tejeda 2007; Wang 2010). Ten studies investigated spironolactone (ALDO-DHF; Kurrelmeyer 2014 (initiated at 25 mg daily and up-titrated to a maximum of 50 mg daily); McDiarmid 2020 (25 mg daily); Mottram 2004; STRUCTURE; Upadhya 2017 (25 mg daily); Karapyz 2015; Orea-Tejeda 2007 (25 mg daily, up-titrated if tolerated to 50 mg daily); TOPCAT (15 mg daily, increased to a maximum of 45 mg daily); Wang 2010 (50 mg daily))). Two studies used eplerenone (Mak 2009; RAAM-PEF (25 mg daily to a maximum of 50 mg daily)). AREA IN-CHF investigated canrenone at a maximum dose of 50 mg daily.

Numbers of participants randomised ranged from 28 (Orea-Tejeda 2007) to 3445 (TOPCAT). Four were multicentre trials; ALDO-DHF included 10 centres in Germany and Austria; AREA IN-CHF was conducted in 46 centres in Italy; STRUCTURE had centres in Poland (the number is unclear but publication states "of each centre"); and TOPCAT was conducted across 233 sites in six countries (Argentina, Brazil, Canada, Georgia, Russia, USA). Six studies were single-centre trials; two in USA (Kurrelmeyer 2014; RAAM-PEF), one in the UK (McDiarmid 2020), one in Australia (Mottram 2004) and one in Taiwan (Wang 2010); Mak 2009 was a single-centre trial but the country was unspecified. Three trials did not report on numbers of centres or countries (Karapyz 2015; Orea-Tejeda 2007; Upadhya 2017).

Two studies (Karapyz 2015; Mottram 2004) did not report participants' LVEF at baseline. AREA IN-CHF had a mean LVEF at baseline of 39.9% (intervention) and 39.7% (control) for the overall included participants (N = 467). However, we obtained outcome data for the subgroup of participants with LVEF greater than 40% (N = 225). The LVEF in the remaining seven studies ranged from 54% to 72%.

In one study, most participants were NYHA class I (McDiarmid 2020, 61%). Most participants in five studies were NYHA class II (52% to 88%; ALDO-DHF; Mak 2009; RAAM-PEF; STRUCTURE; TOPCAT).
Most participants in two studies were NYHA class III (58% to 64%; Kurrelmeyer 2014; Upadhya 2017). Three studies did not report NYHA class for participants eligible for inclusion in our review (AREA IN-CHF; Karapysh 2015; Mottram 2004). Orea-Tejeda 2007 reported that most participants in the intervention arm were NYHA class III (57.1%) and NYHA class I (75%) in the control arm.

Participants' mean age ranged from 54.5 years to 80 years; seven studies included participants whose mean age was less than 70 years (ALDO-DHF; AREA IN-CHF; Karapysh 2015; Mottram 2004; Orea-Tejeda 2007; STRUCTURE; TOPCAT). In five studies, participants' mean age was over 70 years (Kurrelmeyer 2014; Mak 2009; McDiarmid 2020; RAAM-PEF; Upadhya 2017).

AREA IN-CHF was industry funded; seven studies were funded by not-for-profit organisations (ALDO-DHF; Kurrelmeyer 2014; McDiarmid 2020; RAAM-PEF; STRUCTURE; TOPCAT; Upadhya 2017). Five studies did not report sources of funding (Karapysh 2015; Mak 2009; Mottram 2004; Orea-Tejeda 2007; Wang 2010).

ACEIs

We included eight studies that investigated ACEIs for HFpEF. Of these, three compared ACEIs with placebo (Kitzman 2010; PEP-CHF; Zi 2003), and five versus usual care (Aronow 1993; Aronow 1998; Hong Kong DHF; SNEGOVIK; Yuksek 2012). Two studies investigated enalapril (Aronow 1993 up to 20 mg daily; Kitzman 2010 up to 10 mg daily). Aronow 1996 investigated benazepril (up to 40 mg daily). Two studies investigated perindopril (PEP-CHF up to 4 mg daily; Yuksek 2012, up to 10 mg). Hong Kong DHF investigated ramipril in one of two active arms (maximum of 10 mg daily). Two studies investigated quinapril (SNEGOVIK, dose not reported; Zi 2003, up to 40 mg daily).

Numbers of participants randomised ranged from 21 (Aronow 1993) to 850 (PEP-CHF). Two studies were reportedly multicentre trials (Hong Kong DHF; PEP-CHF). Hong Kong DHF did not report details on the number of centres. PEP-CHF was conducted at 53 centres in Bulgaria (3), Czech Republic (5), Hungary (10), Ireland (1), Poland (26), Russia (1), Slovakia (2), and the UK (5). Zi 2003 took place at one hospital in the UK and Yuksek 2012 was conducted in Turkey. The number or countries of centres were not reported in four studies (Aronow 1993; Aronow 1998; Kitzman 2010; SNEGOVIK).

The mean LVEF of the included participants at baseline was not reported by two studies (SNEGOVIK; Zi 2003). LVEF ranged from 61% to 69% in five studies (Aronow 1993; Aronow 1998; Hong Kong DHF; Kitzman 2010; PEP-CHF). Most participants were classified in NYHA class II in four studies (Hong Kong DHF; Kitzman 2010; PEP-CHF; Zi 2003) and in NYHA class III in one study (Aronow 1993). Two studies did not report participants' NYHA class at baseline (Aronow 1998; SNEGOVIK).

Participants' mean age ranged from 70 years to 82 years with all studies equal to or over a mean age of 70 years.

Four studies did not report funding sources (Aronow 1993; Aronow 1998; SNEGOVIK; Yuksek 2012). Three studies were industry-funded (Hong Kong DHF; PEP-CHF; Zi 2003) and one study was funded by a not-for-profit organisation (Kitzman 2010).

ABRs

We included eight studies that investigated ARBs for HFpEF. Of these, five compared ARBs versus placebo (CAND-HDF; CHARM-Preserved; I-PRESERVE; Kasama 2005; Parthasarathy 2009) and three compared ARBs versus usual care (CandHeart; Hong Kong DHF; SUPPORT). Four studies investigated candesartan (CAND-HDF; CandHeart; CHARM-Preserved (up to 32 mg daily), Kasama 2005 (8 mg to 12 mg daily)). Two studies investigated irbesartan (one of the two active treatment arms in Hong Kong DHF (up to 75 mg daily), I-PRESERVE (up to 300 mg)). Parthasarathy 2009 investigated valsartan (80 mg daily). SUPPORT investigated olmesartan (up to 40 mg daily).

Numbers of participants randomised ranged from 22 (CAND-HDF) to 4128 (I-PRESERVE). Seven were multicentre trials: CAND-HDF was conducted at eight centres in Germany; CandHeart at 70 centres in Italy; CHARM-Preserved was conducted at 618 centres in 26 countries; I-PRESERVE involved 293 centres in 25 countries; Parthasarathy 2009 was conducted at five centres each in Germany and the UK; and SUPPORT was conducted at 17 centres in Japan. Hong Kong DHF was reported to be a multicentre trial but no details were provided on numbers of centres or countries. Kasama 2005 was reported to be a single-centre trial in Japan.

The mean LVEF of the included participants at baseline was not reported by CAN-DHF and ranged from 49% to 72% in seven studies (CandHeart; CHARM-Preserved; Hong Kong DHF; I-PRESERVE; Kasama 2005; Parthasarathy 2009; SUPPORT). Most participants were assessed as NYHA class II at baseline in five studies (CandHeart; CHARM-Preserved; Hong Kong DHF; Kasama 2005; SUPPORT); NYHA class III in I-PRESERVE; and was not reported by two studies (CAND-HDF; Parthasarathy 2009).

Participants' mean age ranged from 61 years to 75 years. Mean age was below 70 years in six studies (CAND-HDF; CandHeart; CHARM-Preserved; Kasama 2005; Parthasarathy 2009; SUPPORT) and over 70 years in two studies (Hong Kong DHF; I-PRESERVE).

Six studies were funded by industry (CAND-HDF; CandHeart; CHARM-Preserved; Hong Kong DHF; I-PRESERVE; Parthasarathy 2009). SUPPORT was funded by a not-for-profit organisation. Kasama 2005 did not report the source of funding.

ARNIs

For this update, we elected to include three studies comparing an ARNI (sacubitril-valsartan) with an ARB (valsartan) (PARAMOUNT and PARAGON-HF), and one study comparing an ARNI (sacubitril-valsartan) with individualised medical therapy whereby the comparator was specified according to the RAAS treatment status of patients at study enrolment; patients treated with ACEI at enrolment received LCZ696 or enalapril, those treated with ARB received LCZ696 or valsartan, and those without prior treatment with RAAS inhibition received LCZ696 or matching placebo (PARALLAX).

Administration of ARBs or ACEIs in combination with sacubitril-valsartan is contraindicated due to safety concerns. Therefore, the investigators specified the active comparator of valsartan, given that many patient with HFpEF receive ARB or ACEI treatment for hypertension (Solomon 2012). Since both treatment arms received valsartan, these studies isolate the effects of neprilysin. However,
this can only be safely administered in combination with an ARB (i.e. the ARNI class of therapeutics).

Number of participants randomised ranged from 308 (PARAMOUNT) to 4822 participants (PARAGON-HF). PARAGON-HF was a multicentre trial across 848 centres in 43 countries and PARAMOUNT had 65 centres and 13 countries. The mean LVEF was 56 to 58% across the three trials. Most participants in these trials were assessed as NYHA class II at baseline. Participants’ mean age ranged from 71 to 73 years of age. Novartis funded the three studies.

PERSPECTIVE (EUCTR2016-001254-17) is an ongoing RCT to examine the effect of LCZ696 compared to valsartan on cognitive outcomes in participants with HFpEF, defined as LVEF greater than 40%.

Excluded studies

We previously excluded 303 studies (324 references) based on full-text assessment (Martin 2018). Details for the reasons for exclusion are provided in the Characteristics of excluded studies table. In this update, we have excluded 52 studies (54 references) and added these to the list for exclusions below. We referenced in the review only those that most closely missed the inclusion criteria (four references). In summary, we made exclusions based on the following considerations:

- population does not meet protocol: n = 118;
- wrong intervention: n = 8;
- wrong comparator: n = 23;
- wrong study design: n = 125;
- subgroup of interest but no response to our enquiry for data: n = 8;
- subgroup not of interest: n = 36;
- unclear eligibility and no response to our enquiry for details: n = 12;
- unclear eligibility and no current contact details: n = 15;
- completed status in trial registry record but no published results and no response to our enquiry for data: n = 1;
- missing data and response that no details can be provided: n = 6;
- retraction: n = 1; and
- did not take place as planned: n = 2.

Studies awaiting classification

We identified nine studies that are awaiting classification (Anonymous 2003d; Botoni 2010; Dielievská 2015; EUCTR2005-001306-87; EUCTR2005-002109-22 Metra 1999; PER-010-15; Przewlocka-Kosmala 2017; Ravezzi 1999. See Characteristics of studies awaiting classification. We are waiting to retrieve the full-text (n = 4), await responses from translators (n = 3) and await response from the trialists to clarify eligibility (n = 2).

Ongoing studies

From the previously identified ongoing studies, two have now been included (McDiarmid 2020; PARALLAX). We identified 11 new ongoing studies, bringing the current total to 13 ongoing studies (Characteristics of ongoing studies).

Risk of bias in included studies

The ‘Risk of bias’ assessments are detailed in the Characteristics of included studies tables. We summarised them in the text below and in Figure 2 and Figure 3.

Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all included studies.
**Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.**

<table>
<thead>
<tr>
<th>Study</th>
<th>Random sequence generation (selection bias)</th>
<th>Allocation concealment (selection bias)</th>
<th>Blinding of participants and personnel (performance bias): All outcomes</th>
<th>Blinding of outcome assessment (detection bias): All outcomes</th>
<th>Incomplete outcome data (attrition bias): All outcomes</th>
<th>Selective reporting (reporting bias)</th>
<th>Other bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adamyan 2010</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>ALDO-DHF</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>AREA IN-CHF</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>Aronow 1993</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>Aronow 1997</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>Aronow 1998</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>CandHeart</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>CAN-DHF</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>CHARM-Preserved</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>ELANDD</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>Hong Kong DHF</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>I-PRESERVE</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>J-DHF</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>Karapish 2015</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>Kasama 2005</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>Kitzman 2010</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>Kurelmeyer 2014</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>Mak 2009</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>McDiarmid 2020</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>Mittal 2017</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>Mottram 2004</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>Orea-Tejeda 2007</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
<tr>
<td>PARAGON-HF</td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
<td><img src="Assessment.png" alt="Assessment" /></td>
</tr>
</tbody>
</table>
Figure 3. (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocation</th>
<th>Blinding</th>
<th>Detection</th>
<th>Reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orea-Tejeda 2007</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>PARAGON-HF</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>PARALLAX</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>PARAMOUNT</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>Parthasarathy 2009</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>PEP-CHF</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>RAAM-PEF</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>Sahoo 2016</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>SENIORS</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>Shu 2005</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>SNEGOVIK</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>STRUCTURE</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>SUPPORT</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>SWEDIC</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>Takeda 2004</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>TOPCAT</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>Upadhya 2017</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>Wang 2010</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>Yuksek 2012</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
<tr>
<td>ZI 2003</td>
<td><img src="image" alt="Allocation" /></td>
<td><img src="image" alt="Blinding" /></td>
<td><img src="image" alt="Detection" /></td>
<td><img src="image" alt="Reporting" /></td>
</tr>
</tbody>
</table>

**Allocation**

Twelve studies reported random sequence methods and were rated as being at low risk of bias (ALDO-DHF; CandHeart; ELANDD; Hong Kong DHF; I-PRESERVE; McDiarmid 2020; PARAGON-HF; PARAMOUNT; PEP-CHF; Sahoo 2016; SENIORS; TOPCAT). We assessed 28 studies to be at unclear risk of bias for this domain because no information was provided in study reports. One study was assessed as high risk of bias in this domain as it randomised participants on the basis of admission sequence (Shu 2005).

Twelve studies used a method for allocation concealment that was judged to be at low risk of bias (ALDO-DHF; CHARMPreserved; I-PRESERVE; Kurrelmeyer 2014; McDiarmid 2020; Mittal 2017; PARAGON-HF; PARAMOUNT; PEP-CHF; SENIORS; STRUCTURE; TOPCAT). We assessed 29 studies to be at unclear risk of bias for this domain because no information was provided in study reports.

**Blinding**

We assessed 22 studies to be at low risk of bias regarding blinding of participants and personnel (ALDO-DHF; AREA IN-CHF; CAN-DHF; CHARMPreserved; ELANDD; I-PRESERVE; Kasama 2005; Kitzman 2010; Kurrelmeyer 2014; Mittal 2017; Mottram 2004; PARAGON-HF; PARAMOUNT; Parthasarathy 2009; PEP-CHF; RAAM-PEF; SENIORS; STRUCTURE; SWEDIC; TOPCAT; Upadhya 2017; ZI 2003). Six studies were open-label designs and therefore were judged to be at high risk of bias for this domain (CandHeart; Hong Kong DHF; J-DHF; Mak 2009; McDiarmid 2020; SUPPORT). The remaining 13 studies were assessed at unclear risk of bias because no information was provided.

Detection bias was judged to be at low risk in 18 studies (ALDO-DHF; CHARMPreserved; Hong Kong DHF; J-DHF; Kasama 2005; Kitzman 2010; Mak 2009; Mittal 2017; Mottram 2004; Orea-Tejeda 2007; PARAGON-HF; PARAMOUNT; PEP-CHF; RAAM-PEF; Sahoo 2016; STRUCTURE; SUPPORT; TOPCAT). One study was judged to be at high risk of detection bias as outcome assessors were not blinded (McDiarmid 2020). The remaining 22 studies did not provide information and were judged to be at unclear risk of detection bias.

**Incomplete outcome data**

Attrition bias was judged to be at low risk in 14 studies (ALDO-DHF; CHARMPreserved; ELANDD; I-PRESERVE; J-DHF; PARAGON-HF; PARAMOUNT; Parthasarathy 2009; PEP-CHF; RAAM-PEF; SENIORS; STRUCTURE; TOPCAT; ZI 2003). We judged Kasama 2005 to be at high risk of bias for this domain because the study report did not indicate if losses to follow-up or withdrawals occurred. Shu 2005 (unclear reporting of withdrawals) and McDiarmid 2020 (completed case analysis with uneven drop-out in treatment arms) were also judged to be at high risk of bias. All 24 remaining studies were assessed to be at unclear risk of bias for attrition bias as no information was reported to allow judgement.

**Selective reporting**

We assessed 12 studies to be at low risk of reporting bias (ALDO-DHF; CAN-DHF; CHARMPreserved; ELANDD; I-PRESERVE; J-DHF; PARAGON-HF; PARAMOUNT; PEP-CHF; SENIORS; SUPPORT; TOPCAT). These 12 studies reported planned outcomes in either published protocols or clinical trial registers before enrolment started. We were unable to assess reporting bias in 29 studies either because no information was available in the form of protocols or clinical trial registry entries, or they were published/entered after enrolment was completed.
Other potential sources of bias

We judged 20 studies to be at low risk of other bias (mainly based on providing details on funding and declaring any conflict of interest by the authors) (ALDO-DHF; AREA IN-CHF; CHARM-Preserved; ELANDD; J-PRESEVE; J-DHF; Kitzman 2010; Mak 2009; Mittal 2017; PARAGON-HF; PARAMOUNT; Parthasarathy 2009; PEP-CHF; RAAM-P EF; SENIORS; STRUCTURE; SUPPORT; SWEDIC; TOPCAT; Zi 2003).

We judged six studies to be at high risk of other bias. Kurrelmeyer 2014 was originally registered as an observational study and this detail was changed after completion of the trial, but before the results were published. Five studies (Adamyan 2010; CAN-DHF; Karapysh 2015; SNEGOVIC; Upadhya 2017) were published as conference abstracts only; withholding the full results from publication may present a form of bias. The remaining 15 studies were judged to be at unclear risk of bias.

Effects of interventions

See: Summary of findings 1 Beta-blockers compared to placebo or no treatment for chronic heart failure with preserved ejection fraction; Summary of findings 2 Mineralocorticoid receptor antagonists (MRAs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction; Summary of findings 3 Angiotensin-converting enzyme inhibitors (ACEIs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction; Summary of findings 4 Angiotensin receptor blockers (ARBs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction; Summary of findings 5 Angiotensin receptor nephrilysin inhibitors (ARNIs) compared to usual care for chronic heart failure with preserved ejection fraction

BBs versus placebo or no treatment

We included 10 studies involving a total of 3087 participants that assessed BBs versus placebo or no treatment. The main outcomes for this comparison are included in Summary of findings 1.

Cardiovascular mortality

Six studies reported cardiovascular mortality (Aronow 1997; ELANDD; J-DHF; SENIORS; SWEDIC; Takeda 2004). Three studies reported that no deaths occurred (ELANDD; SWEDIC; Takeda 2004). We included three studies in the meta-analysis (Aronow 1997; J-DHF; SENIORS) (15% of participants in the intervention arm versus 19% in the control arm; RR 0.78, 95% CI 0.62 to 0.99; NNTB 25; 1046 participants; I² = 0%; low-certainty evidence; Analysis 1.1).

J-DHF reported cardiovascular mortality but with different numbers for events within the same table (Table 2 in the primary reference). We contacted the study authors to seek clarification but are yet to receive a response; we used the higher numbers in the analysis.

SENIORS reported a hazard ratio (HR 0.80, 95% CI 0.49 to 1.32; 643 participants).

Heart failure hospitalisation

We included five studies that reported heart failure hospitalisation (ELANDD; J-DHF; Shu 2005; SWEDIC; Takeda 2004). ELANDD reported that no hospitalisation occurred due to HF. Data from four studies (J-DHF; Shu 2005; SWEDIC; Takeda 2004) contributed to the meta-analysis (RR 0.73, 95% CI 0.47 to 1.13; 449 participants; I² = 22%; very low-certainty evidence; Analysis 1.2).

Hyperkalaemia

J-DHF reported that one participant in the intervention group (N = 120) experienced hyperkalaemia but did not report on this outcome for the control group (very low-certainty evidence). No further data were available from any other studies.

All-cause mortality

We included seven studies that reported all-cause mortality (Adamyan 2010; Aronow 1997; ELANDD; J-DHF; SENIORS; SWEDIC; Takeda 2004). Of these, three studies reported that no deaths occurred (ELANDD; SWEDIC; Takeda 2004). We included data from four studies in the meta-analysis (Adamyan 2010; Aronow 1997; J-DHF; SENIORS) (RR 0.82, 95% CI 0.67 to 1.00; 1105 participants; I² = 0%; low-certainty evidence; Analysis 1.3).

J-DHF reported all-cause mortality but with different numbers for events within the same table (Table 2 in the primary reference). We contacted the study authors to seek clarification but are yet to receive a response. We used the higher number of deaths in the analysis.

SENIORS reported a hazard ratio (HR 0.92, 95% CI 0.61 to 1.36; 643 participants).

Quality of life

We included two studies that reported quality of life (ELANDD; Mittal 2017). Mittal 2017 reported quality of life using SF-36, which was not a scale we considered for our analysis. ELANDD reported end scores for the MLHFQ total score and showed MD -1.00 between the treatment arms, favouring the intervention (95% CI -9.05 to 7.05; 93 participants; very low-certainty evidence).

Withdrawal due to adverse event

We included five studies that reported withdrawals due to adverse events (Aronow 1997; ELANDD; J-DHF; Mittal 2017; Sahoo 2016). Mittal 2017 and Sahoo 2016 reported no withdrawals due to adverse events. Aronow 1997 reported 11 withdrawals due to "worsening CHF [chronic heart failure] in 7 patients and hypotension in 4 patients" but did not provide this information by intervention arm. Only two studies (ELANDD; J-DHF) contributed data for meta-analysis (5% of participants in the intervention arm versus 0% in the control arm, RR 18.07, 95% CI 2.45 to 133.04; 338 participants; I² = 0%; Analysis 1.5; number needed to harm (NNTH) = 11).

MRAs versus placebo or no treatment

We included 13 studies (4459 participants) that assessed MRAs versus placebo or no treatment. The main outcomes for this comparison are included in Summary of findings 2. The findings for this comparison were driven by one trial (TOPCAT). Four trials (Karapysh 2015; Mottram 2004; Orea-Tejeda 2007; Wang 2010) did not contribute any outcome data of interest for this review.

Cardiovascular mortality

We included five studies that reported cardiovascular mortality (ALDO-DHF; AREA IN-CHF; Kurrelmeyer 2014; RAAM-PEF; TOPCAT). Of these, two studies reported that no deaths occurred (Kurrelmeyer 2014; RAAM-P EF). We included data from three
studies in the meta-analysis (ALDO-DHF; AREA IN-CHF; TOPCAT) (RR 0.90, 95% CI 0.74 to 1.11; 4070 participants; I² = 0%; moderate-certainty evidence; Analysis 2.1).

TOPCAT also reported a hazard ratio (HR 0.90, 95% CI 0.73 to 1.12; 3445 participants).

Heart failure hospitalisation
We included six studies that reported heart failure hospitalisation (ALDO-DHF; AREA IN-CHF; Kurrelmeyer 2014; RAAM-PEF; TOPCAT; Upadhya 2017). Of these, three studies reported no hospitalisations due to heart failure (ALDO-DHF; Kurrelmeyer 2014; Upadhya 2017). We included data from three studies in the meta-analysis (AREA IN-CHF; RAAM-PEF; TOPCAT) (11% of participants in the intervention arm versus 14% in the control arm, RR 0.82, 95% CI 0.69 to 0.98; 3714 participants; NNTB 41; I² = 22%; moderate-certainty evidence; Analysis 2.2).

Hazard ratios for time to first heart failure hospitalisation were pooled (MD -0.78, 95% CI -28.02 to 26.46; 92 participants; I² = 98%; moderate-certainty evidence; Analysis 2.3).

Heart failure hospitalisation
We included six studies that reported heart failure hospitalisation (ALDO-DHF; AREA IN-CHF; Kurrelmeyer 2014; RAAM-PEF; STRUCTURE; TOPCAT) (16% of participants in the intervention arm versus 8% in the control arm, RR 2.11, 95% CI 1.77 to 2.51; 4291 participants; I² = 0%; high-certainty evidence; Analysis 2.4).

All-cause mortality
We included eight studies that reported all-cause mortality (ALDO-DHF; AREA IN-CHF; Kurrelmeyer 2014; Mak 2009; RAAM-PEF; STRUCTURE; TOPCAT; Upadhya 2017). Of these, three studies reported that no deaths occurred (Kurrelmeyer 2014; RAAM-PEF; STRUCTURE). The meta-analysis included data from five studies (ALDO-DHF; AREA IN-CHF; Mak 2009; TOPCAT; Upadhya 2017) (RR 0.91, 95% CI 0.78 to 1.06; 4207 participants; I² = 0%; moderate-certainty evidence; Analysis 2.5).

TOPCAT also reported a hazard ratio (HR 0.91, 95% CI 0.77 to 1.08; 3445 participants).

Quality of life
We included six studies that reported quality of life (ALDO-DHF; Kurrelmeyer 2014; Mak 2009; RAAM-PEF; TOPCAT; Upadhya 2017). TOPCAT reported quality of life in a report by Lewis 2016, but the end scores per treatment arm were not provided. We contacted the investigators and await details.

Three studies (ALDO-DHF; Mak 2009; Upadhya 2017) reported total MLHFQ scores and were pooled for analysis (MD 0.84, 95% CI -2.30 to 3.98; 511 participants; I² = 0%; low-certainty evidence; Analysis 2.6). Kurrelmeyer 2014 and RAAM-PEF reported KCCQ results and were pooled (MD -0.78, 95% CI -28.02 to 26.46; 92 participants; I² = 86%; Analysis 2.7). The substantial heterogeneity could not be explained.

All five studies that used MLHFQ and KCCQ were pooled (SMD 0.05, 95% CI -0.23 to 0.34; 603 participants; I² = 50%; Analysis 2.8). The substantial heterogeneity could not be explained.

Withdrawal due to adverse event
Five studies reported this outcome (ALDO-DHF; Kurrelmeyer 2014; McDiarmid 2020; TOPCAT; Upadhya 2017) and contributed to the meta-analysis (RR 1.10, 95% CI 1.00 to 1.21; 4037 participants; five studies; I² = 0%; Analysis 2.9).

ACEIs versus placebo or no treatment
We included eight studies involving a total of 2061 participants that assessed ACEIs versus placebo or no treatment. The main outcomes for this comparison are presented in Summary of findings 3. The findings for this comparison were driven by PEP-CHF. Two studies (Aronow 1993; Yuksek 2012) did not contribute any outcome data of interest for this review.

Cardiovascular mortality
Three studies reported cardiovascular mortality (Hong Kong DHF; Kitzman 2010; PEP-CHF). Kitzman 2010 reported that no deaths occurred. Hong Kong DHF and PEP-CHF contributed data to the meta-analysis (RR 0.93, 95% CI 0.61 to 1.42; 945 participants; I² = 0%; moderate-certainty evidence; Analysis 3.1).

PEP-CHF also reported a hazard ratio (HR 0.98, 95% CI 0.63 to 1.52; 850 participants).

Heart failure hospitalisation
Three studies (Hong Kong DHF; PEP-CHF; Zi 2003) reported heart failure hospitalisation and were pooled for analysis (RR 0.86, 95% CI 0.64 to 1.15; 1019 participants; I² = 0%; moderate-certainty evidence; Analysis 3.2).

PEP-CHF also reported a hazard ratio (HR 0.86, 95% CI 0.61 to 1.20; 850 participants).

Hyperkalaemia
Zi 2003 reported hyperkalaemia (RR 5.27, 95% CI 0.26 to 106.16; 74 participants; very low-certainty evidence; Analysis 3.3).

All-cause mortality
We included six studies that reported all-cause mortality (Aronow 1998; Hong Kong DHF; Kitzman 2010; PEP-CHF; Yuksek 2012; Zi 2003). Kitzman 2010 reported that no deaths occurred. Five studies (Aronow 1998; Hong Kong DHF; PEP-CHF; Yuksek 2012; Zi 2003) contributed to the meta-analysis (RR 1.04, 95% CI 0.75 to 1.45; 1187 participants; five studies; I² = 0%; moderate-certainty evidence; Analysis 3.4).

PEP-CHF also reported a hazard ratio (HR 1.09, 95% CI 0.75 to 1.58; 850 participants).

Quality of life
Three studies reported quality of life assessed using the MLHFQ scale (Hong Kong DHF; Kitzman 2010; SNEGOVIK). SNEGOVIK reported quality of life assessment based on the MLHFQ scale as change from baseline per treatment arm (-18.9 for intervention, -10.7 for control). We were unsuccessful in our attempts to contact study authors to obtain scores at the end of follow-up. Two studies...
(Hong Kong DHF; Kitzman 2010) contributed to the meta-analysis (MD -0.09, 95% CI -3.66 to 3.48; 154 participants; I² = 4%; low-certainty evidence; Analysis 3.5).

Zi 2003 assessed quality of life using the McMaster quality of life questionnaire and reported end scores at six months (12.9 ± 3.1 for the intervention and 13.1 ± 4.7 for the control arm).

**Withdrawal due to adverse event**

Four studies (Hong Kong DHF; PEP-CHF; Yuksek 2012; Zi 2003) reported this outcome and were pooled for analysis (RR 2.52, 95% CI 0.49 to 12.87; 1127 participants; four studies; I² = 58%; Analysis 3.6).

**ARBs versus placebo or no treatment**

We included eight studies involving a total of 8755 participants that assessed ARBs versus placebo or no treatment. The main outcomes for this comparison are included in *Summary of findings 4*. The findings for this comparison were driven by two studies (CHARM-Preserved; I-PRESERVE). Three trials (CAN-DHF; CandHeart; Kasama 2005) did not contribute any outcome data of interest for this review.

**Cardiovascular mortality**

Four studies reported this outcome (CHARM-Preserved; Hong Kong DHF; I-PRESERVE; Parthasarathy 2009). Parthasarathy 2009 reported that no deaths occurred. Three studies (CHARM-Preserved; Hong Kong DHF; I-PRESERVE) contributed to the meta-analysis (RR 1.02, 95% CI 0.90 to 1.14; 7254 participants; I² = 0%; high-certainty evidence; Analysis 4.1).

Two studies (CHARM-Preserved; I-PRESERVE) were also pooled for an analysis of hazard ratio (HR 1.00, 95% CI 0.89 to 1.13; 7148 participants; Analysis 4.2).

**Heart failure hospitalisation**

Three studies (CHARM-Preserved; Hong Kong DHF; I-PRESERVE) reported this outcome and were pooled for analysis (RR 0.92, 95% CI 0.83 to 1.02; 7254 participants; I² = 0%; high-certainty evidence; Analysis 4.3).

Two studies (CHARM-Preserved; I-PRESERVE) were also pooled for analysis of hazard ratio (HR 0.90, 95% CI 0.80 to 1.01; 7148 participants; Analysis 4.4).

**Hyperkalaemia**

Two studies reported this outcome and were pooled for analysis (CHARM-Preserved; I-PRESERVE) (0.9% of participants in the intervention group and 0.5% in the control group; RR 1.88, 95% CI 1.07 to 3.33; 7148 participants; high-certainty evidence; Analysis 4.5).

**All-cause mortality**

Five studies reported this outcome (CHARM-Preserved; Hong Kong DHF; I-PRESERVE; Parthasarathy 2009; SUPPORT). Parthasarathy 2009 reported no deaths occurred. Four studies (CHARM-Preserved; Hong Kong DHF; I-PRESERVE; SUPPORT) contributed to the meta-analysis (RR 1.01, 95% CI 0.92 to 1.11; 7964 participants; I² = 0%; high-certainty evidence; Analysis 4.6). For the SUPPORT trial, data for participants with LVEF ≥ 50% were analysed according to the definition of HFpEF used in this trial.

Two studies (I-PRESERVE; SUPPORT) were also pooled for analysis of hazard ratio (HR 0.99, 95% CI 0.88 to 1.12; 4838 participants; Analysis 4.7).

**Quality of life**

Four studies reported this outcome (CHARM-Preserved; Hong Kong DHF; I-PRESERVE; Parthasarathy 2009). CHARM-Preserved reported quality of life (MLHFQ) in a study report (Lewis 2007); however, end scores per treatment arm were not provided. Three studies (Hong Kong DHF; I-PRESERVE; Parthasarathy 2009) contributed to the meta-analysis for MLHFQ (MD 0.41, 95% CI -0.86 to 1.67; 3117 participants; I² = 19%; high-certainty evidence; Analysis 4.8).

**Withdrawal due to adverse event**

Four studies (CHARM-Preserved; Hong Kong DHF; I-PRESERVE; Parthasarathy 2009) reported this outcome and contributed to the meta-analysis (16% of participants in the intervention arm versus 13% in the control arm; RR 1.22, 95% CI 1.09 to 1.36; 7406 participants; I² = 0%; Analysis 4.9 NNTH = 33).

**ARNs versus usual care**

We included three studies that involved a total of 7702 participants. The main outcomes for this comparison are included in *Summary of findings 5*.

**Cardiovascular mortality**

One study, PARAGON-HF, reported proportional hazards and total event counts for CV mortality; a hazard ratio (HR) of 0.95 (95% CI 0.79 to 1.16) was reported and we calculated the risk ratio (RR), based on the total event counts, as 0.96 (95% CI 0.79 to 1.15; 4796 participants; moderate-certainty evidence; Analysis 5.1).

**Heart failure hospitalisation**

PARAGON-HF and PARALLAX reported data for first hospitalisation due to HF, which led to a RR of 0.89 (95% CI 0.80 to 1.00; 7362 participants; I² = 56%; moderate-certainty evidence; Analysis 5.2).

PARAGON-HF and PARALLAX also reported HRs for time to first hospitalisation due to HF, which gives a pooled effect of HR 0.87 (95% CI 0.76 to 0.99; 7362 participants; two studies; I² = 82%; Analysis 5.3).

**Hyperkalaemia**

Two studies (PARAGON-HF; PARAMOUNT) reported this outcome (RR 0.88, 95% CI 0.77 to 1.01; 5054 participants; two studies; I² = 8%; moderate-certainty evidence; Analysis 5.4).

**All-cause mortality**

The three studies reported data for all-cause mortality (RR 0.97, 95% CI 0.84 to 1.11; 7663 participants; three studies; high-certainty evidence; Analysis 5.5).

**Quality of life**

PARAMOUNT reported change from baseline for the KCCQ overall summary score for the intervention arm (n = 118) as 11.25 (2.185) and the control arm (n = 116) as 11.31 (2.183), and summarised...
the findings as “no difference in KCCQ score between treatment groups”.

PARAGON-HF reported a difference of the clinical summary score KCCQ between treatment arms as 1.0 (0.0 to 2.1).

PARALLAX reported "KCCQ improved in both treatment groups, with an early benefit of S/V that was no longer significant after 24 week".

**Withdrawal due to adverse event**

The three studies reported withdrawals due to adverse events (RR 1.02, 95% CI 0.91 to 1.14; 7663 participants; three studies; I² = 62%; Analysis 5.6).

**Subgroup analyses**

We did not have sufficient data to allow for meaningful subgroup analyses.

**Sensitivity analyses**

We conducted a sensitivity analysis by only including studies assessed at low risk of bias. Across comparisons, the estimates were not significantly changed, with the exception of BBs, where no effect on cardiovascular mortality was observed (one low risk of bias study (SENIORS): RR 0.81, 95% CI 0.50 to 1.29; versus overall analysis of three studies: RR 0.78, 95% CI 0.62 to 0.99).

**DISCUSSION**

**Summary of main results**

We examined the evidence for the effects of BBs and RAAS inhibitors for the treatment of HfPEF. We included 41 trials, reported in 234 publications that involved a total of 26,059 participants. We identified 13 ongoing trials with treatment arms that include interventions assessed in this review. A further nine studies await assessment.

We performed a pooled analysis for the outcomes of cardiovascular and all-cause mortality, heart failure hospitalisation, quality of life and hyperkalaemia. For most studies, we use the MLHQF instrument to evaluate quality of life outcomes since this was the most frequently reported measure, except for ARNI trials that used KCCQ.

Withdrawals due to adverse events were inconsistently reported; these data could not be included in 'Summary of findings' tables.

We conducted a sensitivity analysis by including only studies assessed with overall low risk of bias. The effect estimates were not significantly changed, except for BBs.

**BBs**

A total of 10 included studies (3087 participants) assessed BBs compared with placebo or no intervention. We performed meta-analyses including up to four studies and 1105 participants. The results suggested that treatment may improve cardiovascular mortality, however, the quality of evidence was low due to imprecision and risk of bias. When we performed a sensitivity analysis by including only studies with a low overall risk of bias, the effects on cardiovascular mortality did not persist. The two largest studies (J-DHF; SENIORS) reported high rates of study drug discontinuation due to intolerance rather than adverse events, which may have attenuated any true treatment effects. A recent individual participant meta-analysis found evidence that beta-blockers improve LVEF and prognosis in heart failure patients with LVEF 40 to 49%, but not in those with LVEF over 50% (Cleland 2018).

**MRAs**

A total of 13 studies (4459 participants) assessed MRA compared with placebo or no intervention. We combined evidence from up to six trials and 4291 participants in meta-analyses. We found that treatment with MRA reduces the risk of heart failure hospitalisation but found little or no effect on cardiovascular and all-cause mortality; however the certainty of evidence was moderate and uncertainty remains over these treatment effects. As expected, MRA treatment was associated with an increased risk of hyperkalaemia; potassium monitoring is therefore required in people being treated using MRA. A large, registry-randomised clinical outcomes trial of spironolactone for HFpEF is ongoing and due to complete in 2022 (NCT02901184: Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction, SPIRIT).

**ACEIs**

A total of eight included studies (2062 participants) assessed ACEIs versus placebo or no intervention. We conducted a meta-analysis of data from up to five trials and 1187 participants. We found that there was probably little or no effect on cardiovascular mortality, all-cause mortality, heart failure hospitalisation or quality of life. Data on hyperkalaemia were limited. No large clinical trials (more than 1000 participants) were available and the certainty of evidence was assessed as moderate due to imprecision. The effectiveness of ACEI therapy in the treatment of people with HFpEF remains unclear.

**ARBs**

A total of eight included studies (8755 participants) assessed ARB therapy for people with HFpEF, with the evidence certainty assessed as high. We combined evidence from up to four trials and 7964 participants for meta-analysis and found little or no overall difference on the outcomes of cardiovascular mortality, all-cause mortality, heart failure hospitalisation or quality of life. The CHARM study found a beneficial effect on HF hospitalisation based on a time-to-event analysis; the strength of this association was increased in a subsequent analysis, based on recurrent events (Rogers 2014). As expected, ARB treatment was associated with an increased risk of hyperkalaemia; potassium monitoring is therefore required.

**ARNIs**

Three studies (7696 participants) assessed ARNI therapy for people with HFpEF. Only one study (PARAGON-HF) provided usable data for cardiovascular mortality and found little or no difference between the treatment groups (moderate-certainty evidence). Meta-analysis of risk ratio for first heart failure hospitalisation from the PARAGON-HF and PARALLAX trials indicated a probable modest benefit, however there was little or no effect on cardiovascular or all-cause mortality.

A pooled analysis suggested that a slightly reduced risk of hyperkalaemia in ARNI versus standardized usual care or placebo comparison overall (moderate-certainty evidence).
Overall completeness and applicability of evidence

This review provides the most comprehensive appraisal of the evidence to date. We included 41 studies (234 reports) that involved 26,059 participants. The included trials assessed BBs (10 studies, 3087 participants), MRAs (13 studies, 4459 participants), ACEIs (eight studies, 2061 participants), ARBs (eight studies, 8755 participants) and ARNs (three studies, 7702 participants).

We searched clinical trials registries and identified 13 ongoing clinical trials, several of which have potential to influence the review findings. We also identified nine studies that were classified as Studies awaiting classification. There was insufficient information to determine whether these studies met our inclusion criteria. These studies were mostly small and it is therefore unlikely that they would influence the results of this review. In total, we identified 234 reports of 41 trials, nine studies awaiting classification, and 13 ongoing trials, compared with a total of 22 identified by Zheng 2018 for the same comparisons.

The LVEF threshold for defining the HFrEF trial populations varied among the included studies. This may contribute to indirectness, with implications for the applicability of the evidence. Nine studies included participants with an ejection fraction cut-off of 40%, 12 used 45%, 15 used 50%, and one used 55%. Adamyan 2010 included participants with preserved ejection fraction but did not specify the cut-off. SENIORS reported a subgroup of participants with LVEF greater than 40%, and for AREA IN-CHF we obtained outcomes for a subgroup with LVEF greater than 40%.

The included studies had enrolment start dates from 1997 to 2014. In more recent studies, B-type natriuretic peptides have been used as a key inclusion criterion to improve the specificity of the HFrEF population and enrich the trial populations for people at higher risk for clinical outcomes (e.g. CAN-DHF; Mak 2009; RAAM-PEF). Similarly, new measures of diastolic function have been included in more recent studies to increase the specificity (e.g. ELANDD; J-DHF; PEP-CHF). We noted considerable clinical heterogeneity among study populations with respect to comorbidities and cardiovascular therapies at baseline, which may influence the applicability of the evidence.

Quality of the evidence

We used the GRADE method to assess evidence certainty for the outcomes of cardiovascular mortality, all-cause mortality, heart failure hospitalisation, quality of life (assessed using the MLHFQ), and hyperkalaemia. For BBs, evidence certainty for clinical outcomes (cardiovascular mortality, all-cause mortality and heart failure hospitalisation) ranged from low to very low. In the combined analysis, most participants were from a subgroup of a single large trial; the other included studies were small, with high or unclear risk of bias.

For MRAs, the TOPCAT study contributed the majority of participants to the meta-analysis, for which the overall evidence certainty for clinical outcomes was assessed as moderate. We noted differences in participant populations among the included studies (TOPCAT, LVEF greater than 45%; RAAM-PEF, LVEF equal to or greater than 50%; AREA IN-CHF, LVEF 40% to 45%) and it is reported that ejection fraction is a modifier of treatment effect for MRAs (Solomon 2016). Notably, a post hoc analysis of the TOPCAT study reported important differences in the placebo event rates among participants enrolled from the Americas (Argentina, Brazil, Canada, USA) and participants enrolled from Russia and Georgia (Pfeffer 2015). Furthermore, a pharmacology substudy of participants at 12 months (206 participants from USA and Canada; 160 participants from Russia) found that drug metabolites were undetectable in a greater proportion of participants from Russia, compared with participants from the USA and Canada (30% versus 3%, P < 0.001) (de Denus 2017). A geographical subgroup analysis suggested possible clinical benefit from spironolactone in HFrEF in participants who were enrolled in the Americas (United States, Canada, Brazil, Argentina; cardiovascular mortality HR 0.74, 95% CI 0.57 to 0.97; all-cause mortality HR 0.83, 95% CI 0.68 to 1.02; heart failure hospitalisation HR 0.82, 95% CI 0.67 to 0.99). These findings will be investigated further in the ongoing SPIRIT study (NCT02901184).

For ARBs, several large trials contributed a large number of events to the meta-analysis for the clinical outcomes of mortality and heart failure hospitalisation, and the evidence certainty was high. For ACEIs, fewer trials were included in the combined analysis, event numbers were low and the evidence certainty was assessed as moderate. For BBs, the certainty of evidence was low due to small study sizes and risk of bias.

For ARNs, the evidence certainty was classified as moderate for all outcomes except for all cause mortality and quality of life which was of high certainty; the cardiovascular mortality and hyperkalaemia outcomes were downgraded due to imprecision.

Potential biases in the review process

Although we conducted a comprehensive search of major databases, it is possible we missed studies on clinical trials registers, studies that had not been reported, or both. Where information on relevant subgroups or outcomes were not reported, we attempted to contact the study authors; however, only a limited number of responses were received. Given the small number of included studies per analysis, we were unable to formally assess the presence of publication bias.

Agreements and disagreements with other studies or reviews

The results of this study were largely consistent with those from a comprehensive review of the evidence for BBs and RAAs inhibitors in people with HFrEF (Zheng 2018); however, important differences were noted. Our analysis included more studies for each comparison, but the additional studies were small and did not significantly alter the overall effect estimates. In contrast to Zheng 2018, we did not find clear evidence of an effect of BB treatment on all-cause mortality, after the exclusion of studies with an unclear or high risk of bias. Our findings were consistent with meta-analyses of ACE and ARB (Khan 2017) and MRA (Li 2018).

A recent individual-patient level analysis of RCTs of BBs in HF, across the full spectrum of LVEF, reported evidence that BBs reduced cardiovascular mortality; the benefit was observed for heart failure patients in sinus rhythm at all levels of LVEF less than 50%, including patients with LVEF 40% to 49% (Cleland 2018). Similarly, an individual patient-level pooled analysis of PARADIGM-HF and PARAGON-HF found evidence of effect modification of ARNI efficacy by LVEF, but with benefit on heart failure hospitalisation and cardiovascular mortality probably extending to patients with mid-
range LVEF (40% to 49%) (Solomon 2020). Consistent with these reports, a study-level meta-analysis of trials of RAAS interventions found beneficial effects on heart failure hospitalisation in patients with LVEF greater than 50%; however, increasing LVEF was associated with a decreasing trend for benefit (Emdin 2015). Data from the CHARMPreserved study suggests a similar benefit of ARB on heart failure hospitalisation in patients with LVEF 40% to 49%, compared to those with LVEF less than 40% (CHARM-Preserved).

Taken together, these findings suggest that the beneficial effects of BBs and RAAS inhibitors may extend beyond patients with LVEF less than 40% to include patients with LVEF 40% to 49%; however, evidence for this group of patients is currently limited.

AUTHORS' CONCLUSIONS

Implications for practice

Our findings suggest that MRA and ARNI treatments have a modest beneficial effect on the risk of heart failure hospitalisation and that BB may reduce the risk of cardiovascular mortality. We did not find evidence supporting an important beneficial effect of ARBs (high-certainty evidence), or ACEIs (moderate-certainty evidence) on mortality and hospitalisation outcomes. Although we were not able to stratify our analysis by LVEF, we note evidence from individual-participant level meta-analyses that suggest benefit from BB, MRA, and ARNI treatment in heart failure patients with LVEF 40 to 49%, in addition to those with LVEF < 40%. For all comparisons, no effect on the quality of life was observed, although the certainty of the evidence was low.

Implications for research

This review highlights persistent uncertainty concerning the effects of BBs, MRAs, ACEIs, and ARNIs in HfP EF, defined as LVEF greater than 40%. Although we were unable to explore LVEF as an effect modifier in this study-level review and meta-analysis, reports of individual participant-level pooled analyses of BBs and RAAS inhibition suggest that beneficial effects may extend beyond patients with reduced ejection fraction (LVEF less than 40%) heart failure, to include patients with heart failure with mid-range ejection fraction (LVEF 40% to 49%; HFm rEF). It is possible that heart failure patients with normal or increased LVEF have distinct aetiopathology. For example, a recent study found that one in seven patients with HFpEF had evidence of wild-type transthyretin amyloidosis (Gonzalez-Lopez 2015). The application of precision phenotyping at a population-scale may yield important information about the disease mechanisms underlying onset and progression in these patients, and provide the basis for the development of more effective therapeutic approaches.

ACKNOWLEDGEMENTS

Tom Lumbers was supported by an NIHR Clinical Lectureship and, subsequently, a UKRI Health Data Research Fellowship. We are grateful to Marta Battle Lopez, Derya Senturk, Hatoko Sasaki, Teresa Cantisani, Liliya Eugenevna Ziganshina, Hanneke Dominicus, Joanna Zajac, Anna Aryee, and Vaclav Papez for their help with the full text assessment of non-English language papers. We are also grateful to Rui Providencia and Lu Chunli for assessing and extracting data from non-English language papers, and to Juan-Pablo Casas for his guidance in designing this review. We are grateful for the contributions of James Thomas who contributed to the original version of the review.

The background and methods section of this review is based on a standard template provided by Cochrane Heart.

For the updated review we are grateful for input by peer reviewer Francisco Hidalgo, Department of Cardiology, Reina Sofia Hospital, Instituto Maimonides de Investigacion Biomedica (IMIBIC), Cordoba, Spain; and one other peer reviewer who wishes to remain anonymous.
References to studies included in this review

Adyanan 2010 (published data only)


ALDO-DHF (published data only)


AREA IN-CHF (published and unpublished data)


Aronow 1993 (published data only)
Aronow 1997 (published data only)


Aronow 1998 (published data only)


Candesartan (published data only)


CAN-DHF (published data only)


NCT00775840. Efficacy of candesartan on symptomatic heart failure in treating diabetic and hypertensive patients [Candesartan "added" therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients]. A randomized, placebo-controlled, double-blind, parallel-group and multicenter clinical phase III study investigating the effects on NT-proBNP over 6 months]. clinicaltrials.gov/ct2/show/NCT00775840 (first received 20 October 2008).

CHARM-Preserved (published data only)


Fruhwald FM, Vavrovsky AD. Resource utilization and costs for candesartan in heart failure: Assessment of reduction in
mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health 2011;14(7):A379.


Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.


**ELAN DD (published data only)**


**Hong Kong DHF (published data only)**


**I-PRESERVE (published data only)**


J-DHF (*published data only*)

Hori M. Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). *Journal of Cardiac Failure* 2005;11(7):542-7.

UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000141L (Registered 1 February 2006).


Karapyzh 2015 (*published data only*)


Kasama 2005 (*published data only*)


Kitzman 2010 (*published data only*)


Kurrelmeyer 2014 (*published and unpublished data*)


Mak 2009 \textit{(published data only)}


McDiarmid 2020 \textit{(published data only)}


Mittal 2017 \textit{(published and unpublished data)}


Mottram 2004 \textit{(published data only)}


Orea-Tejeda 2007 \textit{(published data only)}

PARAGON-HF \textit{(published data only)}


PARALLAX \textit{(published data only)}
NCT03066804. A randomized, double-blind controlled study comparing LCZ696 to medical therapy for comorbidities in HFpEF patients (PARALLAX) [A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction]. clinicaltrials.gov/show/NCT03066804 (first posted 28 February 2017).


PARAMOUNT (published data only)


NCT00887588. LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. clinicaltrials.gov/ct2/show/NCT00887588 (first posted 13 August 2015).


Parthasarathy 2009 (published and unpublished data)


PEP-CHF (published data only)


RAAM-PEF (published and unpublished data)
* Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure 2011;17(8):634-42.


Sahoo 2016 (published data only)

SENIORS (published data only)


Shu 2005 {published data only}


SENEGOVlK {published data only}


STRUCTURE {published data only}


SUPPORT {published data only}


SWEDIC {published data only}

**Takeda 2004 (published data only)**

**TOPCAT (published data only)**


NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Systolic Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004).


Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction

**Review**


**Upadhya 2017** *(published and unpublished data)*


**Wang 2010** *(published data only)*


**Yuksek 2012** *(published data only)*


**Zi 2003** *(published data only)*

References to studies excluded from this review

ACTRN12610001087044 (published data only)


Adgey 1992 (published data only)

Ammon 2001 (published data only)

Andersson 1996 (published data only)

Andersson 1999 (published data only)

Andersson 2000 (published data only)

Anonymous 1996 (published data only)

Anonymous 1999 (published data only)

Anonymous 2000 (published data only)

Anonymous 2001 (published data only)

Anonymous 2002 (published data only)

Anonymous 2003 (published data only)

Anonymous 2003a (published data only)

Anonymous 2003b (published data only)

Anonymous 2003c (published data only)

Anonymous 2005 (published data only)

Anonymous 2008 (published data only)

Anonymous 2008a (published data only)

Anonymous 2013 (published data only)

ANZ HF carvedilol (published data only)


Aoyama 2007 {published data only}


Apostolovic 2013 {published data only}


Apostolovic 2014a {published data only}


Apostolovic 2014b {published data only}


Arena 2007 {published data only}


Armstrong 1999 {published data only}


Aronow 1991 {published data only}


Aronow 2001 {published data only}


Axelsson 2015 {published data only}


Balaban 2007 {published data only}


Bao 2005 {published data only}


Barr 1995 {published data only}


Barrios 2009 {published data only}

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Barry 2003 (published data only)

Bartels 1999 (published data only)

Baruch 1999 (published data only)

Baruch 2004 (published data only)

Bauersachs 2004 (published data only)

Baumhake 2008 (published data only)

Bellenger 2004 (published data only)

Berry 2001 (published data only)

Bettencourt 1999 (published data only)

Beygui 2016 (published data only)

Blagodar 2003 (published data only)

Blomer 1990 (published data only)

Borghi 2011 (published data only)

Borgi 1990 (published data only)

Borlaug 2014 (published data only)

Bornkessel 1992 (published data only)

Bounhoure 1991 (published data only)

Braunwald 2004 (published data only)

Brilla 1989 (published data only)

Brilla 1991 (published data only)

Bristow 1994 (published data only)
**Bristow 1996** *(published data only)*


**Bussmann 1987** *(published data only)*


**Butler 2017** *(published data only)*


**Cleland 2006** *(published data only)*


**Cleland 2001** *(published data only)*


**Choi 2001** *(published data only)*


**Cicoria 2002** *(published data only)*


**Castagno 2010** *(published data only)*


**ChiCTR1800016350** *(published data only)*

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction

(Review)

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction

Comin-Colet 2002 (published data only)

CONSENSUS (published data only)


CONSENSUS II (published data only)

Conti 2005 (published data only)

Corder 1993 (published data only)

Crouse 2011 (published data only)

Dahlsrom 2007 (published data only)
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction

Davie 2001 (published data only)

DeBock 1994 (published data only)

Dekleva 2012 (published data only)

De Melo 2011 (published data only)

Demers 2001 (published data only)

Desai 2013 (published data only)

Deswal 2010 (published data only)

de Teresa 1995 (published data only)

Ding 2008 (published data only)

Ditiatkov 1999 (published data only)

Donal 2008 (published data only)

Dragana 2015 (published data only)

Edner 2013 (published data only)

Eichhorn 1994 (published data only)

Eichhorn 2003 (published data only)

Er 2005 (published data only)

Ertl 1999 (published data only)

EudraCT 2004-004169-13 (published data only)

Fauchier 2009 (published data only)

Feola 2003 (published data only)

Flammer 2013 (published data only)
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction

(Review)

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Flather 2016 (published data only)

Flesch 2006 (published data only)

Follath 1996 (published data only)

Fonarow 2004 (published data only)

Fonarow 2007 (published data only)

Fowler 1999 (published data only)

Franciosa 2002 (published data only)

Fukunami 1991 (published data only)

Galinner 2007 (published data only)

Galloo 2006 (published data only)

Gao 2010 (published data only)

Gardner 2003 (published data only)

Gardner 2004 (published data only)

Ghali 2002 (published data only)

Gheorghiade 2009 (published data only)

Good 1994 (published data only)

Goodfield 1999 (published data only)

Gottlieb 1996 (published data only)

Grajek 2008 (published data only)

Greenberg 1996 (published data only)

Gremler 2000 (published data only)
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction

(Review)

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction

Reference:

Grenning 2000 (published data only)

Grenning 2001 (published data only)

Grenning 2002 (published data only)

Gruner 2007 (published data only)

Guazzi 1998 (published data only)

Guazzi 1999 (published data only)

Gatzsche 1992 (published data only)

Hanping 1997 (published data only)

Hara 2000 (published data only)

Hauf 1993 (published data only)

Hole 2004 (published data only)

Holland 2010 (published data only)
Holland DJ, Mottram PM, Hare JL, Jenkins C, Marwick TH. Extended duration of aldosterone blockade fails to improve diastolic dysfunction over the effects of blood pressure in patients with heart failure and normal ejection fraction. *European Heart Journal* 2010;31:731-2.

Hong 2003 (published data only)

Hoppe 2007 (published data only)

Hori 2004 (published data only)

Hung 2010 (published data only)

IRIS-HF (published data only)


NCT00347087. Effect of irbesartan on insulin sensitivity in chronic heart failure [Effect of the angiotensin II receptor...

Kleber 1991a (published data only)

Kleber 1991b (published data only)

Kongstad-Rasmussen 1998 (published data only)

Krum 1996 (published data only)

Krum 2015 (published data only)

Kulbertus 2003 (published data only)

Kuznar 2003 (published data only)

Lang 1995 (published data only)

Larsen 1996 (published data only)

Lechat 1993 (published data only)


Leonetti 1999 (published data only)

Lewis 1988 (published data only)

Li 2005 (published data only)

Liebson 2004 (published data only)

Lindenfeld 2001 (published data only)

Lindsay 1999 (published data only)

Liu 2006 (published data only)

Liu 2014 (published data only)

**Logeart 2006** (published data only)

**Lopez 2000** (published data only)

**Lou 2009** (published data only)

**Luo 2007** (published data only)

**Ma 2005** (published data only)

**MacGregor 2009** (published data only)

**Mak 2008** (published data only)

**Malnick 2007** (published data only)

**Maron 2018** (published data only)


**Mazayev 1998** (published data only)

**McAnulty 2004** (published data only)

**McCullough 2012** (published data only)

**McIlwain 1997** (published data only)

**McKelvie 2012** (published data only)

**McMurray 2000** (published data only)

**McMurray 2004** (published data only)

**Melo 2011** (published data only)

**Melo 2012** (published data only)

**Messias 2016** (published data only)

**Meuleman 2007** (published data only)
Mitrovic 2005 (published data only)

Mochizuki 2004 (published data only)

Moraes 2011 (published data only)

Murdoch 2001 (published data only)

NCT00293150 (published data only)

NCT00523757 (published data only)
NCT00523757. Aldosterone blockade in heart failure (ARCTID) [Aldosterone-blockade randomized controlled trial in CHF-diastolic]. clinicaltrials.gov/show/NCT00523757 (first received 31 August 2007).

NCT01691118 (published data only)

NCT01944384 (published data only)
NCT01944384. Impacts of aldosterone blockade on myocardial remodeling in hypertensive patients with diastolic failing heart. clinicaltrials.gov/ct2/show/NCT01944384 (first posted 17 September 2013).

NCT03882710 (published data only)

Nodari 2003 (published data only)

Nunez 2016 (published data only)

O’Callaghan 1995 (published data only)

O’Keefe 2008 (published data only)

O’Keefe 2015 (published data only)

O’Meara 2012 (published data only)

Ostergren 2004 (published data only)

Palazzuoli 2005 (published data only)

Paolisso 1992 (published data only)

Paraskevaidis 2006 (published data only)

Park 2016 (published data only)
Park K, Park TH. Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial. Trials 2016;17(1):530.
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)

Cochrane Database of Systematic Reviews

Patten 1997 (published data only)

Pennell 2000 (published data only)

Pierard 2002 (published data only)

Pina 2004 (published data only)

Pitt 2005 (published data only)

Pitt 2008 (published data only)

Pitt 2011 (published data only)

Pourdjabbar 2015 (published data only)

Premkumar 2016 (published data only)

Quaife 1998 (published data only)

Ramasswamy 2003 (published data only)

Remme 2001 (published data only)

Remme 2004 (published data only)

Remme 2005 (published data only)

Rimatori 1990 (published data only)
Rimatori C, Zayat M. Captopril in the early phase of cardiac failure: effects on left ventricular diastolic function. Journal of International Medicine Supplement 1990;228(733):58.

Roongsritong 2005 (published data only)

Rosa 2011 (published data only)

Rosenkranz 2003 (published data only)

Rossignol 2011 (published data only)
Sakai 2011 (published data only)

Sanderson 1998 (published data only)

Sanghera 2011 (published data only)

Santulli 2015 (published data only)

Sardu 1991 (published data only)

Schindler 2008 (published data only)

Schwab 2009 (published data only)

Segovia 2008 (published data only)

Shimamoto 2007 (published data only)

Sidorenko 2008 (published data only)

Silva 2014 (published data only)

Smith 2012 (published data only)

Spoto 2002 (published data only)

Stecker 2005 (published data only)

Stiefelhagen 2006 (published data only)

Struthers 2004 (published data only)

Swedberg 1996 (published data only)

Swedberg 1999 (published data only)

Szajnbok 1993 (published data only)

Szymanski 2009 (published data only)

Taheri 2009 (published data only)

Takekoshi 2004 (published data only)

Tala 2011a (published data only)
Tala 2011b (published data only)

Tan 2013 (published data only)

Tatsumi 2006 (published data only)

Taylor 2003 (published data only)

Teerlink 2003 (published data only)
Teerlink JR, Massie BM. Late breaking heart failure trials from the 2003 ACC meeting: EPHESUS and COMPANION. *Journal of Cardiac Failure* 2003;9(3):158-63.

Tereshchenko 2005 (published data only)

Thornton 2004 (published data only)

Thune 2008 (published data only)

Tinoco 2004 (published data only)

Tsutamot a2000 (published data only)

Tsutamoto 2001 (published data only)

Tsutamoto 2005 (published data only)

Tumasyan 2010 (published data only)

Tumasyan 2018 (published data only)

Umemoto 2003 (published data only)

Uusimaa 2001 (published data only)

Van den Berg 1993 (published data only)

Van den Berg 1995 (published data only)

Vasiuk 2001 (published data only)

Vincent 2012 (published data only)

Vizir 2000 (published data only)
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Yamamoto 2005 *(published data only)*

Yan 2012 *(published data only)*

Yoshihiro 2011 *(published data only)*

Young 2004 *(published data only)*

Zeng 2006 *(published data only)*

Zheng 2009 *(published data only)*

References to studies awaiting assessment
Anonymous 2003d *(published data only)*

Botoni 2010 *(published data only)*

Dielievksa 2015 *(published data only)*

EUCTR2005-001306-87 *(published data only)*

EUCTR2005-002109-22 *(published data only)*

Metra 1999 *(published data only)*

PER-010-15 *(published data only)*
PER-010-15. A multicenter, randomized, double blind, parallel group, active controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA class II-IV) with preserved ejection fraction. www.ins.gob.pe/ensayosclnicos/rpec/recuperarECPNuevo.asp?ver=EN&numEc=010-15 (registration date 9 June 2015).

Przewlocka-Kosmala 2017 *(published data only)*

Rapezzi 1999 *(published data only)*

References to ongoing studies
ChiCTR-IPR-16009507 *(published data only)*

ChiCTR-TRC-09000631 *(published data only)*

CTRI/2010/091/000438 *(published data only)*
CTRI/2010/091/000438. Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction (Review)

NCT04128891 (published data only)

Zhou 2010 (published data only)

Additional references

CIBIS Investigators 1999

Cleland 2018

Cohen 1988

Consensus Trial Study Group 1987

de Denus 2017

Deeks 2011
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction

(Review)

Deeks 2019

Emedin 2015

Flather 2005

Gerber 2015

Gonzalez-Lopez 2015

GRADEpro GDT [Computer program]
McMaster University (developed by Evidence Prime) GRADEpro GDT. Version accessed prior to 12 February 2018. Hamilton, ON: McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.

Higgins 2011

Hjalmarson 2000

Hogg 2005

Khan 2017

Kotecha 2014

Lefebvre 2019

Li 2018

McMurray 2014

MERIT-HF Study Group 1999

NICE 2018

Packer 1999

Packer 2001

Packer 2002

**Pfeffer 2015**

**Pitt 1999**

**Pitt 2014**

**Ponikowski 2016**

**Rector 1995**

**RevMan 2014 [Computer program]**

**Roger 2013**

**Rogers 2014**

**Sackner-Bernstein 1995**

**Sharma 2014**

**Solomon 2012**

**Solomon 2016**

**Solomon 2020**

**SOLVD Investigators 1991**

**SOLVD Investigators 1992**

**Spertus 2005**

**Taylor 2012**

**Wong 2006**

**Yancy 2013**
Cochrane Database of Systematic Reviews


**Yancy 2017**

**Yusuf 2003**

**Zannad 2011**

**Zheng 2018**

**References to other published versions of this review**

**Lumbers 2017**

**Martin 2018**

* Indicates the major publication for the study

**CHARACTERISTICS OF STUDIES**

**Characteristics of included studies [ordered by study ID]**

**Adyan 2010**

**Study characteristics**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Study design: four arm factorial RCT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Centres: not reported, assumed one, in Armenia</td>
</tr>
<tr>
<td></td>
<td>Start of enrolment: not reported</td>
</tr>
<tr>
<td></td>
<td>End of enrolment: not reported</td>
</tr>
<tr>
<td></td>
<td>Mean follow-up: 12 months</td>
</tr>
<tr>
<td></td>
<td>Run-in period: not reported</td>
</tr>
</tbody>
</table>

| Participants     | Inclusion criteria: "III NYHA class chronic ischemic heart failure (CHF) patients (pts) with normal cholesterol who have preserved LV ejection fraction (PEF) and restrictive diastolic filling pattern" |
|------------------| Exclusion criteria: not reported |
|                  | Randomised (N): 118 in total, of interest are: carvedilol, no simvastatin (N = 31) versus no carvedilol, no simvastatin (N = 28) |
|                  | Withdrawn (N): not reported |
|                  | Lost to follow-up (N): not reported |
|                  | Analysed (N): not reported |
|                  | Age (years, mean, unspecified): 64.5, 0.3 |
|                  | Sex (% men): not reported |
Adyan 2010 (Continued)

Ethnicity (%): not reported
Systolic blood pressure: not reported
Heart rate: not reported
BMI: not reported
Serum creatinine: not reported
B-type natriuretic peptide (pg/mL): not reported
NT pro B-type natriuretic peptide (pg/mL): not reported
LVEF "preserved LV ejection fraction" but not defined
NYHA class I (%): 0
NYHA class II (%): 0
NYHA class III (%): 100
NYHA class IV (%): 0
Hypertension: not reported
Diabetes: not reported
Atrial fibrillation: not reported
Hospitalisation for heart failure: not reported
Coronary heart disease: not reported
Stroke: not reported
Diuretic: not reported
Digoxin: not reported
Beta-blockers: study drug
ACEI: not reported
ARB: not reported
MRA: not reported

Interventions

Intervention: carvedilol (up to 50 mg), simvastatin, carvedilol and simvastatin
Comparator: not receiving carvedilol or simvastatin
Concomitant medication: "in addition to ACE inhibitors, aldosterone antagonists and diuretics"

Outcomes

Planned: not reported
Reported: "prognosis, left ventricular (LV) diastolic function, plasma BNP level and inflammation status", "Assessment of relation of early (E) and late (A) diastolic filling velocities, deceleration time (DT) of E wave, levels of BNP, interleukin-6 (IL-6) and high sensitivity C-reactive protein (CRP)", mortality, hospitalisation

Notes

Two conference abstracts only.
Comparison between carvedilol and no treatment was of interest for this review.
No outcome data relevant to this review.
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;Randomly assigned&quot; but no details given</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>High risk</td>
<td>Published as conference abstracts only</td>
</tr>
</tbody>
</table>

### ALDO-DHF

#### Study characteristics

**Methods**

- **Study design**: parallel RCT
- **Centres**: 10 centres in Germany and Austria
- **Start of enrolment**: March 2007
- **End of enrolment**: April 2011
- **Mean follow-up**: 11.6 months
- **Run-in period**: not reported

**Participants**

- **Inclusion criteria**: "men and women aged 50 years or older were eligible to participate in the study if they had current heart failure symptoms consistent with New York Heart Association (NYHA) class II or III, left ventricular ejection fraction (LVEF) of 50% or greater, echocardiographic evidence of diastolic dysfunction (grade I) or atrial fibrillation at presentation, and maximum exercise capacity (peak VO2) of 25 mL/kg/min or less."
- **Exclusion criteria**: "Major exclusion criteria included prior documented reduced left ventricular ejection fraction (LVEF 40%), significant coronary artery disease (current angina pectoris or ischemia on stress tests; untreated coronary stenosis 50%), myocardial infarction or coronary artery bypass graft surgery 3 months or less prior to enrolment, clinically relevant pulmonary disease (vital capacity 80%
or forced expiratory volume in 1 second 80% of reference values on spirometry), significant laboratory abnormalities (potassium 5.1 mmol/l; hemoglobin 11 g/dl; hematocrit 33%; serum creatinine 1.8 mg/dl; or estimated glomerular filtration rate [eGFR] 30 mL/min/1.73 m², calculated using the Modification of Diet in Renal Disease formula: 186 [serum creatinine [in micromoles per liter]/ 88.4] 1.154 age [in years] 0.203 1.21 [if patient is black] 0.742 [if patient is female]), known contraindications for spironolactone or known intolerance to or therapy with a mineralocorticoid receptor antagonist within the last 3 months, concomitant therapy with a potassium-sparing diuretic (eg, triamterene, amiloride), or potassium supplementation."

**Randomised (N):** 422 (213 intervention, 209 control)

**Withdrawn (N):** for reasons other than death 16 (6 intervention, 10 control)

**Lost to follow-up (N):** 5 (2 intervention, 3 control)

**Analysed (N):** 422 (213 intervention, 209 control)

<table>
<thead>
<tr>
<th>Age (years, mean, SD)</th>
<th>intervention: 67, 8; control: 67, 8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (% men)</td>
<td>intervention: 48; control: 47</td>
</tr>
<tr>
<td>Ethnicity (%)</td>
<td>not reported</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg, mean, SD)</td>
<td>intervention: 135, 18; control: 135, 18</td>
</tr>
<tr>
<td>Heart rate (beats/min, mean, SD)</td>
<td>intervention: 66, 14; control: 64, 12</td>
</tr>
<tr>
<td>BMI (mean, SD)</td>
<td>intervention: 28.9, 3.6; control: 28.9, 3.6</td>
</tr>
<tr>
<td>Serum creatinine</td>
<td>not reported</td>
</tr>
<tr>
<td>B-type natriuretic peptide</td>
<td>not reported</td>
</tr>
<tr>
<td>NT pro B-type natriuretic peptide (pg/mL, median, IQR)</td>
<td>intervention: 179, 81 to 276; control: 148, 80-276</td>
</tr>
<tr>
<td>LVEF (%, mean, SD)</td>
<td>intervention: 67, 8; control: 68, 7</td>
</tr>
<tr>
<td>NYHA class I (%)</td>
<td>0</td>
</tr>
<tr>
<td>NYHA class II (%)</td>
<td>intervention: 85; control: 88</td>
</tr>
<tr>
<td>NYHA class III (%)</td>
<td>intervention: 15; control: 12</td>
</tr>
<tr>
<td>NYHA class IV (%)</td>
<td>0</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>intervention: 92; control: 91</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>intervention: 17; control: 16</td>
</tr>
<tr>
<td>Atrial fibrillation (%)</td>
<td>intervention: 6; control: 4</td>
</tr>
<tr>
<td>Hospitalisation for HF (%)</td>
<td>intervention: 38; control: 36</td>
</tr>
<tr>
<td>Coronary heart disease (%)</td>
<td>intervention: 43; control: 37</td>
</tr>
<tr>
<td>Stroke (%)</td>
<td>not reported</td>
</tr>
<tr>
<td>Diuretic (%)</td>
<td>intervention: 55; control: 52</td>
</tr>
<tr>
<td>Digoxin (%)</td>
<td>not reported</td>
</tr>
<tr>
<td>Beta-blocker (%)</td>
<td>intervention: 69; control: 75</td>
</tr>
<tr>
<td>ACEI (%)</td>
<td>intervention: 78; control: 76</td>
</tr>
<tr>
<td>ARB (%)</td>
<td>not reported</td>
</tr>
</tbody>
</table>
Interventions

**Intervention:** spironolactone

"The study drug could be decreased temporarily to 25 mg every other day for a potassium level greater than 5.2 mmol/L or in the presence of other reversible, non-life-threatening adverse effects. For safety reasons, study medication was stopped for relevant hyperkalaemia (serum potassium 5.5 mmol/L) and/or hyperkalaemia-associated clinical symptoms, significant renal impairment (serum creatinine 2.5 mg/dL; eGFR 20 mL/min/1.73m²), significant breast pain or gynaecomastia, or withdrawal of informed consent; rechallenge was encouraged wherever possible." "Mean daily dose of spironolactone was 21.6 mg (95% CI, 20.8-22.3 mg)"

**Comparator:** matching placebo

**Concomitant medication:** "Standard therapies for risk factor and symptom control were at the discretion of treating physicians and required to be unchanged within the 2 weeks prior to randomization." "Concomitant therapy with a potassium-sparing diuretic (eg, triamterene, amiloride), or potassium supplementation."

Outcomes

**Planned:** primary outcomes: exercise capacity, left ventricular end-diastolic pressure.

**Reported:** all-cause mortality, QoL, diastolic function, exercise capacity, "changes in echocardiographic measures of cardiac function and remodeling, measures of submaximal and maximal exercise capacity, serum biomarkers, and quality of life. Clinical tolerability was assessed as the safety end point. Morbidity and mortality (all-cause and cardiovascular-specific) were also predefined exploratory end points."

Notes

Received outcome data for CV mortality, heart failure hospitalisation and hyperkalaemia from investigators.

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>&quot;Pocock minimisation algorithm&quot;.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>&quot;The allocation sequence was implemented remotely via Internet/fax by the Coordination Center for Clinical Trials Leipzig.&quot;</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Low risk</td>
<td>&quot;Patients, the investigator team, individuals performing the assessments, and data analysts remained blinded to the identity of treatment until after database lock&quot;.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>&quot;Patients, the investigator team, individuals performing the assessments, and data analysts remained blinded to the identity of treatment until after database lock&quot;.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>ITT used, except for QoL.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>primary outcomes reported as planned, some secondary outcomes not reported as planned, e.g. all-cause mortality, cardiovascular mortality.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>&quot;Production of identical matching placebo and quality control, packaging, labelling, storage, and dispensing of both spironolactone and placebo were performed by Allphamed PHARBL.&quot;</td>
</tr>
</tbody>
</table>
ALDO-DHF (Continued)

"This work was supported by the German-Austrian Heart Failure Study Group and the German Competence Network of Heart Failure. AldoDHF was funded by the Federal Ministry of Education and Research Grant 01GI0205 (clinical trial program Aldo-DHF [FKZ 01KG0506]). The University of Goettingen was the formal sponsor."

"The sponsor and supporters of this study had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript."

---

**AREA IN-CHF**

**Study characteristics**

**Methods**

- **Study design**: RCT.
- **Centres**: 46 cardiology centres in Italy.
- **Start of enrolment**: September 2002.
- **End of enrolment**: July 2005.
- **Follow-up**: 12 months.
- **Run-in period**: not reported.

**Participants**

- **Inclusion criteria**: aged 18 to 80 years, established evidence of NYHA class II HF, stable, optimised therapy according to European Society of Cardiology criteria, and an LV ejection fraction (EF) ≤ 45%, as measured locally up to 6 months before enrolment.

- **Exclusion criteria**: creatinine 2.5 mg/dL; K 5.0 mEq/L; valvular heart disease amenable to surgical treatment; congenital heart disease; unstable angina or acute myocardial infarction or coronary revascularisation procedure within 3 months before enrolment; intravenous therapy with inotropic drugs within 3 months before enrolment; treatment with lithium salts, K+-sparking diuretics, TNF-α antagonists, or MRA during the last 3 months; history of resuscitated ventricular arrhythmias (unless this occurred within 24 h of a previous acute myocardial infarction or in subjects with an implantable cardioverter defibrillator); other clinical or general conditions contraindicating participation in a clinical trial.

- **Randomised** (N): 467 total (225 LVEF > 40%) (231 (116) intervention, 236 (109) control)
- **Withdrawn** (N): for reasons other than death 18 (14 intervention, 4 control)
- **Lost to follow-up**: not reported
- **Analysed**: not reported
- **Age** (years, mean, SD): intervention: 62.3, 9.5; control: 62.7, 9.5
- **Sex** (% men): intervention: 81.8; control: 85.2
- **Ethnicity**: not reported
- **Systolic blood pressure** (mmHg, mean, SD): intervention: 127.9, 16.2; control: 128.0, 17.2
- **Heart rate** (beats/min, mean, SD): intervention: 68.0, 11.8; control: 65.7, 10.7
- **BMI** (mean, SD): intervention: 26.7, 3.5; control: 26.9, 3.6
- **Serum creatinine** (mg/dL, mean, SD): intervention: 1.1, 0.3; control: 1.1, 0.2
- **B-type natriuretic peptide**: not reported
NT pro B-type natriuretic peptide: not reported
LVEF (% mean, SD): intervention: 39.9, 8.6; control: 39.7, 8.6
NYHA class: not reported
Hypertension (%): intervention: 48.5; control: 42.4
Diabetes (%): intervention: 20.9; control: 19.9
Chronic atrial fibrillation (%): intervention: 7.4; control: 8.5
Hospitalisation for heart failure (%): intervention: 44.6; control: 49.2
Coronary heart disease: not reported
Stroke (%): intervention: 1.7; control: 3
Diuretic (%): intervention: 67.8; control: 72
Digoxin: not reported
Beta-blocker (%): intervention: 81.3; control: 77.5
ACEI (%): intervention: 84.9; control: 74.6
ARB (%): intervention: 12.1; control: 24.2
MRA (%): study drug

Interventions

**Intervention:** canrenone. "The dose of 25 mg/o.d. of canrenone at randomization was increased to 50 mg/o.d. after the first month, if serum Kp was 5 mEq/L, and in the absence of deterioration in renal function. During follow-up, if serum Kp increased up to 5 mEq/L and/or creatinine increased up to 2.5 mg/dL, the dosage of canrenone was reduced to 25 mg/o.d. Subjects requiring down-titration of study medications were asked to return to the outpatient clinic within 2 weeks for a supplemental visit to evaluate the effectiveness of this change in therapy, if serum Kp remained 5.5 mEq/L, or if creatinine was 3 mg/dL or had increased by over 1 mg/dL, the study medication was discontinued and the patient managed with conventional treatment only."

**Comparator:** placebo

Concomitant medication: "Aspirin, diuretics, digoxin, nitrates, antiarrhythmic agents, oral anticoagulants, and any other therapy were allowed when indicated by the local investigators."

Outcomes

**Planned:** unclear

**Reported:** "The pre-specified primary endpoint was the change in echocardiographic LV end-diastolic volume (LVEDV) over 12 months, measured centrally at the Echocardiographic Reading Centre. Secondary endpoints included changes in EF, estimated diastolic filling pressure, NYHA class, BNP, cardiac mortality, hospitalization for cardiac causes, and the combination of cardiac mortality and hospitalization for cardiac causes"

Notes

Subgroup of participants of interest; response with outcome data for subgroup of participants LVEF > 40% received from trialists; baseline characteristics above are for all trial participants.

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
</tbody>
</table>
**AREA IN-CHF** (Continued)

<table>
<thead>
<tr>
<th>Feature</th>
<th>Risk of Bias</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Low risk</td>
<td>double blind, placebo-controlled</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>echocardiography data were &quot;read at the end of the study by one experienced independent observer who was blinded to all clinical data and treatment allocation&quot;</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>ITT for all outcomes</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>unable to assess as protocol and NCT record published/registered after enrolment completed</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>&quot;The ANMCO Research Center coordinated the study, managed the data, and undertook analyses, under the supervision of the steering committee, who designed the AREA IN-CHF study. The funding source (Therabel GiEnne Pharma SpA) had no role in the trial design, conduct, data collection, analyses and data interpretation.&quot;</td>
</tr>
</tbody>
</table>

**Aronow 1993**

**Study characteristics**

**Methods**
- **Study design:** parallel RCT
- **Centres:** not reported
- **Start of enrolment:** not reported
- **End of enrolment:** not reported
- **Mean follow-up:** 3 months
- **Run-in period:** 2 mornings of control period

**Participants**
- **Inclusion criteria:** "New York Heart Association functional class III CHF associated with prior myocardial infarction and normal LV ejection fraction (>50%) who were able to perform a maximal treadmill exercise test were included in the study".
- **Exclusion criteria:** "No patient had valvular heart disease, systolic blood pressure ≤100 mm Hg, lung disease, hepatic disease or renal insufficiency."
- **Randomised (N):** 21 (10 intervention, 11 control)
- **Withdrawn (N):** not reported
- **Lost to follow-up (N):** not reported
- **Analysed (N):** not reported
- **Age (years, mean, SD):** intervention: 80, 3; control: 79, 4
Sex (% men): 14.3
Ethnicity (%): not reported
Systolic blood pressure (mmHg, mean, SD): intervention: 126, 12; control: 127, 10
Heart rate (beats/min, mean, SD): intervention: 85, 6; control: 84, 3
BMI not reported
Serum creatinine not reported
B-type natriuretic peptide (pg/mL): not reported
NT pro B-type natriuretic peptide (pg/mL): not reported
LVEF (%), mean, SD): intervention: 64, 9; control: 64, 7
NYHA class I (%): 0
NYHA class II (%): 0
NYHA class III (%): 100
NYHA class IV (%): 0
Hypertension not reported
Diabetes not reported
Atrial fibrillation not reported
Hospitalisation for heart failure: not reported
Coronary heart disease not reported
Stroke not reported
Diuretic (%): 100
Digoxin (%): 0
Beta-blocker (%): 0
ACEI study drug
ARB not reported
MRA not reported

Interventions

**Intervention**: enalapril. "The initial dose of enalapril was 2.5 mg/day, which was increased to 5 mg/day during week 2, to 10 mg/day (5 mg twice daily) during week 3, to 15 mg/day (7.5 mg twice daily) during week 4 and up to a maximum of 20 mg (10 mg twice daily) during week 5, if tolerated. If the patient developed symptomatic hypotension or an increase in serum creatinine level, the dose of enalapril was reduced to the previous dose. At the time of the follow-up studies, 3 months after beginning enalapril, the dose of enalapril was 2.5 mg/day in 1 patient, 5 mg/day in 1 patient, 10 mg/day in 3 patients, 1.5 mg/day in 2 patients, and 20 mg/day in 3 patients."

**Comparator**: no treatment

Concomitant medication: "All patients received diuretic treatment with furosemide for ~2 weeks before the beginning of the study and a constant dose of furosemide during the study. Digitalis and other cardiac drugs (except enalapril) were not administered to any patient during the study."

Outcomes

**Planned**: not reported
### Aronow 1993 (Continued)

**Reported:** NYHA class, blood pressure, heart rate, cardiothoracic ratio, treadmill exercise time, LVEF, peak mitral E/A ratio, left ventricular mass

**Notes**
no outcome data relevant for this review.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>“Chest roentgenograms were interpreted by a radiologist who was unaware of the study medication. M-mode, 2-dimensional and pulsed-wave Doppler echocardiograms were interpreted by an experienced echocardiographer (IK) who was unaware of the study medication. Treadmill exercise tests were performed under the guidance of the senior author who was aware of which patients were receiving enalapril.”</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>unable to assess</td>
</tr>
</tbody>
</table>

### Aronow 1997

**Study characteristics**

**Methods**

- **Study design:** parallel RCT
- **Centres:** not reported
- **Start of enrolment:** not reported
- **End of enrolment:** not reported
- **Mean follow-up:** 32 months (intervention), 31 months (control)
- **Run-in period:** not reported

**Participants**

- **Inclusion criteria:** "≥ 62 years of age with New York Heart Association functional class II or III CHF, prior Qwave myocardial infarction, and a LV ejection fraction ≥ 40% after 2 months of treatment with diuretics and ACE inhibitors were included in the study."
Exclusion criteria: "No patient had valvular heart disease, systolic blood pressure < 100 mm Hg, lung disease with bronchospasm, hepatic disease, renal insufficiency, sinus bradycardia, greater than first-degree atrioventricular block, or severe peripheral arterial disease."

Randomised (N): 158 (79 intervention, 79 control)

Withdrawn (N): not reported

Lost to follow-up (N): not reported

Analysed (N): 158 (79 intervention, 79 control)

Age (years, mean, SD): intervention: 81, 8; control: 81, 7

Sex (% men): intervention: 29; control: 30

Ethnicity (%): not reported

Systolic blood pressure not reported

Heart rate not reported

BMI not reported

Serum creatinine not reported

B-type natriuretic peptide not reported

NT pro B-type natriuretic peptide (pg/mL):

LVEF (%, mean, SD): intervention: 56, 11; control: 57, 11

NYHA class I (%): 0

NYHA class II (%): intervention: 53; control: 51

NYHA class III (%): intervention: 47; control: 49

NYHA class IV (%): 0

Hypertension (%): intervention: 67; control: 65

Diabetes: not reported

Atrial fibrillation (%): intervention: 33; control: 34

Hospitalisation for HF: not reported

Coronary heart disease (%): 100

Stroke not reported

Diuretic (%): 100

Digoxin (%): intervention: 33; control: 34

Beta-blocker study drug

ACEI (%): 100

ARB not reported

MRA not reported

Interventions

Intervention: propranolol. "The initial dose of propranolol was 10 mg/day. This dose was increased by 10-mg increments at 10-day intervals until a dose of 30 mg 3 times daily was given. All patients treated with propranolol received a final daily dose of propranolol of 30 mg 3 times daily."
Aronow 1997 (Continued)

**Comparator**: no treatment

**Concomitant medication**: "All patients continued diuretic and ACE inhibitor therapy during the study. Digoxin was administered only if the patient had atrial fibrillation."

### Outcomes

**Planned**: no published protocol or clinical trial registry entry

**Reported**: "total mortality and total mortality plus nonfatal myocardial infarction"

### Notes

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>&quot;LV ejection fraction and LV mass were interpreted by an experienced echocardiographer (IK) who was unaware of the study medications&quot;</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>ITT analyses</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>funding not reported</td>
</tr>
</tbody>
</table>

### Aronow 1998

#### Study characteristics

**Methods**

**Study design**: RCT

**Centres**: not reported

**Start of enrolment**: not reported

**End of enrolment**: not reported

**Median follow-up**: 6 months

**Run-in period**: not reported

**Participants**

**Inclusion criteria**: "with New York Heart Association functional class II or III CHF associated with prior Q-wave myocardial infarction, a normal LV ejection fraction (50%), 7 and 30 ventricular premature complexes per hour detected by 24-hour ambulatory electrocardiograms were included in the study."
Exclusion criteria: not reported
Randomised (N): 60 (30 intervention, 30 control)
Withdrawn (N): not reported
Lost to follow-up (N): not reported
Analysed (N): 53 completed study (27 intervention, 26 control)
Age (years, mean, SD): intervention: 82, 8; control: 82, 7
Sex (% men): intervention: 27; control: 23
Ethnicity (%): not reported
Systolic blood pressure not reported
Heart rate not reported
BMI not reported
Serum creatinine not reported
B-type natriuretic peptide not reported
NT pro B-type natriuretic peptide not reported
LVEF (%; median, IQR): intervention: 61, 7; control: 62, 6
NYHA class not reported
Hypertension (%): intervention: 73; control: 70
Diabetes not reported
Atrial fibrillation not reported
Hospitalisation for HF:
Coronary heart disease (%): 100
Stroke not reported
Diuretic (%): 100
Digoxin not reported
Beta-blocker not reported
ACEI study drug
ARB not reported
MRA not reported

Interventions

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Comparator</th>
<th>Concomitant medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention: benazepril. up to 40 mg/day</td>
<td>no treatment</td>
<td>not reported</td>
</tr>
</tbody>
</table>

Outcomes

Planned: unclear

Reported: decrease in number of ventricular premature complexes/h, decrease in ventricular couplets/h, decrease in number of runs of ventricular tachycardia/24 h
### Aronow 1998 (Continued)

**Notes**

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>“The cardiologists interpreting the 24-hour ambulatory electrocardiograms were blinded to the study medications”</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>unable to assess as we are unaware of published protocol or pre-registered clinical trial registry entry</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>unable to assess</td>
</tr>
</tbody>
</table>

#### CandHeart

**Study characteristics**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Study design: parallel RCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centres:</td>
<td>70, Italy</td>
</tr>
<tr>
<td>Start of enrolment:</td>
<td>December 2005</td>
</tr>
<tr>
<td>End of enrolment:</td>
<td>May 2008</td>
</tr>
<tr>
<td>Mean follow-up:</td>
<td>48 weeks</td>
</tr>
<tr>
<td>Run-in period:</td>
<td>not reported</td>
</tr>
</tbody>
</table>

**Participants**

**Inclusion criteria:** congestive HF, “Patients aged ≥18 years, of both genders, with stable symptomatic NYHA II-IV HF and any LVEF measured at screening visit, and who provided a written informed consent were eligible. Patients with LVEF > 40% had to be hospitalized for cardiovascular events during the past 12 months before randomisation.”

**Exclusion criteria:** “Exclusion criteria were history of prior treatment with ARBs within 2 weeks from screening; severe or malignant hypertension (SBP/DBP > 180/110 mmHg); symptomatic hypotension; prior acute myocardial infarction, stroke or transient ischemic attack (TIA), percutaneous transluminal coronary angioplasty (PTCA) or coronary artery by-pass graft (CABG) within 1 month from screening; hemodynamically relevant arrhythmias or cardiac valvular defect; prior implant of pacemakers, cardiac resynchronization therapy or cardioverters within 6 months from randomisation; constrictive pericarditis or active myocarditis; likelihood of cardiac surgical intervention during the overall treatment...
period; evidence of angina pectoris in the previous month; poorly controlled diabetes mellitus (blood glucose > 140 mg/dL or HbA1c > 8%); untreated thyroid dysfunction; renal artery stenosis; angio-oedema of any etiology; significant liver (AST, ALT, total bilirubin or alkaline phosphatase > 2x the upper limit of normal range) or renal impairment (serum creatinine > 2.0 mg/dL or serum potassium > 5.0 mmol/L); anemia of any etiology (Hb <10.5 g/dL) or any other clinically relevant hematological disease; pregnant or lactating females or females at risk of pregnancy; any disease with malabsorption; presence of any non-cardiac disease that is likely to significantly shorten life expectancy; history of chronic alcohol or drug/substance abuse, or presence of other conditions potentially able to affect study subjects’ compliance; known allergy, sensitivity or intolerance to study drugs and/or study drugs’ formulation ingredients; patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study; participation in another trial in the month preceding study entry.”

Randomised (N): 128
Withdrawn (N): not reported
Lost to follow-up (N): not reported
Analysed (N): not reported
Age (years, mean, SD): 66, 12
Sex (% men): 67.2
Ethnicity (%): not reported
Systolic blood pressure (mmHg, mean, SD): 134, 19
Heart rate (beats/min, mean, SD): 67, 14
BMI (mean, SD): 28.2, 4.5
Serum creatinine (mg/dL, mean, DS): 1.0, 0.3
B-type natriuretic peptide (pg/mL): 163, 202
NT pro B-type natriuretic peptide (pg/mL): not reported
LVEF (%), mean, SD): 48.7, 8.2
NYHA class I (%): 0
NYHA class II (%): 71.9
NYHA class III (%): not reported
NYHA class IV (%): not reported
Hypertension (%): 59.8
Diabetes (%): 28.1
Atrial fibrillation (%): 21.1
Hospitalisation for HF: not reported
Coronary heart disease (%): 30.7
Stroke: not reported
Diuretic (%): 86.7
Digoxin (%): 26.6
Beta-blocker (%): 76.6
ACEI (%): 88.3
### Interventions

**Intervention:** candesartan cilexetil, "1 candesartan cilexetil was administered at an initial dose of 4 mg o.d. (one tablet) and, if tolerated, it was up titrated to 8 mg (one tablet o.d.) after 2 weeks of treatment, to 16 mg (one tablet o.d.) after 4 weeks of treatment, and to 32 mg (two tablets of 16 mg o.d.) after 6 weeks of treatment"

**Comparator:** no treatment

**Concomitant medication:** ongoing standard therapy

### Outcomes

**Planned:** both trial register entries were post-hoc, unclear what was planned

**Reported:** primary: 3-month (12-week) changes of BNP from baseline, "The secondary objectives of the study after a 48-week treatment period were to assess:1) change of BNP at 48 weeks from baseline values; 2) changes from baseline of aldosterone. Other exploratory analyses included (1) changes from baseline of LVEF, LVIDD, E wave peak velocity/A wave peak velocity (E/A), deceleration time of E wave (E-DT), atrial dimensions; (2) changes from baseline of BP and heart rate (HR); (3) persistence of active treatment and discontinuation rate; (4) quality of life by Kansas City Cardiomyopathy Questionnaire (KCCQ)."

### Notes

Only subgroup of participants with LVEF > 40% of interest to this review. The above data are for this subgroup only. No outcome data reported for this review. Emailed trialists. No response.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>&quot;centrally randomised&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>open label</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>&quot;Thirty percent of all echocardiographic exams performed during the study were randomly selected and read at the core laboratory by an experienced cardiologist unaware of study group and visit.&quot;</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>unable to assess</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>unclear as post-hoc trial registration and published protocol not identified</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>The study was funded by Takeda Italia Farmaceutici and endorsed by the Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO). &quot;The study was stopped before reaching the target number of patients since an interim analysis by the DSMB showed that an unacceptable number of patients (n=1500 per group) would have been needed to show the observed difference in 3-month change of BNP with the predefined power of 0.80, when data on 371 patients were available&quot;</td>
</tr>
</tbody>
</table>
## CAN-DHF

### Study characteristics

**Methods**

**Study design:** two-arm, individual, placebo-controlled RCT  
**Centres:** 8 sites in Germany  
**Start of enrolment:** January 2008  
**End of enrolment:** December 2008  
**Follow-up:** 24 weeks  
**Run-in period:** not reported

**Participants**

**Inclusion criteria:** “Male or female patients of at least 45 years of age suffering from a non-insulin dependent diabetes mellitus type 2 orally treated for at least 3 months and showing normotension or controlled hypertension with sitting systolic blood pressure (sSBP) < 140 mmHg and/or sitting diastolic blood pressure (sDBP) < 90 mmHg. Evidence of an abnormal left ventricular relaxation, diastolic distensibility or diastolic stiffness confirmed by echocardiography under the prerequisite of a preserved Left ventricular ejection fraction (LVEF) ≥ 45%. NT-proBNP ≥ 250 pg/ml at baseline, NYHA class II or III in stable condition since 3 months, and standard HF-therapy with an ACE-inhibitor alone or with further preparations in a constant regimen since at least 1 month (3 months in terms of β-blockers). Signed written informed consent available.”

**Exclusion criteria:** “The following criteria must not be met to enrol a single patient into the study:  

- Impaired renal function (serum creatinine > 2.2 mg/dL or > 194 μmol/l); Known bilateral renal artery stenosis (RAS) or interventional treatment for RAS in the last year; State after kidney transplantation; Serum potassium > 5.5 mmol/l or HbA1C > 9.5%; Cor pulmonale or primary pulmonary disease with dyspnea at rest; Known disposition to episodes of symptomatic hypotension or sSBP < 95 mmHg at baseline; Acute coronary syndrome or unstable angina pectoris and any coronary artery disease that was not stable during the last 3 months prior to inclusion; CABG or PTCA (incl. stent implantation) within 3 months before inclusion; Myocardial infarction or stroke within 6 months before inclusion; Patients who are dependent on a permanently paced pacemaker (i.e. a patient with a device that is not pacing during the echocardiographic examination can enter the study); Open heart surgery for other reasons than coronary revascularization; Tachycardia at rest > 100 bpm as confirmed by ECG-recordings; Known clinically relevant rhythm disorders (e.g. tachyarrhythmias, salvos of supraventricular or ventricular extrasystoles or atrial fibrillation without ventricular rate control) or symptoms suggesting a significant rhythm disorder (e.g. recurrent syncopes); Primary valvular diseases and/or restrictive or obstructive cardiomyopathy - Existing ventricular assist devices; Relevant liver diseases (cholestasis or ALAT/ASTAT > 2xULN or GT > 3xULN); History of primary hyperaldosteronism; of cancer in the last 5 years (exception: nonmetastasizing skin cancer) or of another wasting disease with life expectancy of < 2 years; Known hypersensitivity to Candesartan Cilexetil; Need for maintenance therapy with NSAIDs or Cox-2-inhibitors; Use of other ARBs throughout the entire study period; Any history of life-threatening diseases; History of drug sensitivity and/or an extensive use of alcohol; Female patients who are pregnant or breast feeding; Sexually active women of childbearing potential not consistently and correctly practicing highly effective birth control with a low failure rate (less than 1% / year) such as implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomised partner; Psychological and/or emotional problems, which render the informed consent invalid or limit the ability of the patient to comply with the study requirements; Patient is an employee or at least in dependence of the investigator and/or the sponsor or of another institution directly involved in the study or other trials under the investigator’s direction; Participation in another clinical investigation within 30 days prior to enrolment or for the course of the present study (incl. studies for compassionate use or experimental medical devices).”

**Randomised (N):** 22 (11 intervention, 11 control)  
**Withdrawn (N):** for reasons other than death 14 (intervention: 3 premature study termination, 3 adverse events, 1 randomisation / enrolment error, control: 4 premature study termination, 2 adverse events, 1 randomisation / enrolment error)
Lost to follow-up (N): 0
Analysed (N): 22 (11 intervention, 11 control)
Age (years, mean, SD): intervention: 67.0, 16.8; control: 69.0, 7.1
Sex (% men): intervention: 64; control: 55
Ethnicity (%): not reported
Systolic blood pressure: not reported
Heart rate: not reported
BMI (mean, SD): intervention: 31.4, 5.0; control: 30.0, 5.7
Serum creatinine: not reported
B-type natriuretic peptide (pg/mL): not reported
NT pro B-type natriuretic peptide (pg/mL): not reported
LVEF: not reported
NYHA class: not reported
Hypertension (%): not reported
Diabetes (%): not reported
Atrial fibrillation (%): not reported
Hospitalisation for heart failure: not reported
Myocardial infarction (%): not reported
Stroke (%): not reported
Diuretic (%): not reported
Digoxin (%): not reported
Beta-blocker (%): not reported
ACEI (%): not reported
ARB (%): study drug
MRA (%): not reported

Interventions

Intervention: candesartan. 8-32mg as tolerated. "The treatment comprised a titration period of 6 weeks and a period of constant study therapy of at least 18 weeks"
Comparator: placebo
Concomitant medication: "in an "added" regimen to a constant background-HF-therapy with at least ACE-inhibitors (or further drugs) for the treatment of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients"

Outcomes

Planned: primary: mean change from baseline for NT-proBNP, secondary: QoL, kidney function, NYHA, body weight, BP and echocardiographic measures, adverse events, rate of premature withdrawals
Reported: as planned except QoL
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Low risk</td>
<td>&quot;double-blind&quot; but no detail</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>no information</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>all outcomes reported as planned except QoL</td>
</tr>
<tr>
<td>Other bias</td>
<td>High risk</td>
<td>&quot;the study was terminated prematurely as a whole by the sponsor in December 2008 since randomization of patients was very poor until that date (low and slow recruitment (N = 42) with a high number (N = 20) of screening failures)&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Takeda funded the study.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The study results are unpublished and only available via the clinical trial registry entry.</td>
</tr>
</tbody>
</table>

### Study characteristics

**Methods**

- **Study design:** parallel RCT
- **Centres:** 618, 26 countries (Australia, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Hungary, Iceland, Italy, Luxembourg, Malaysia, Netherlands, Norway, Poland, Portugal, Russia, Singapore, South Africa, Spain, Sweden, Switzerland, UK/Ireland, USA)
- **Start of enrolment:** March 1999
- **End of enrolment:** July 2000
- **Median follow-up:** 36.6 months
- **Run-in period:** no
Inclusion criteria: "Eligible patients were aged 18 years or older, had New York Heart Association functional class II–IV of at least 4 weeks’ duration, had a history of hospital admission for a cardiac reason, and had LVEF higher than 40%.”

Exclusion criteria: Important exclusion criteria for any of the studies include current serum-creatinine > 265mmol/L (3 mg/dL); current serum-potassium > 5.5 mmol/L (5.5 mEq/L) or a history of marked ACE inhibitor-induced hyperkalemia resulting in either a serum potassium greater than or equal to 6.0 mmol/L (>6.0 mEq/L) or a life-threatening adverse event; known bilateral renal artery stenosis; current symptomatic hypotension; persistent systolic or diastolic hypertension; stroke, acute myocardial infarction, or open heart surgery within the last 4 weeks; previous heart transplant or heart transplant expected to be performed within the next 6 months; presence of any noncardiac disease (eg, cancer) that is likely to significantly shorten life expectancy to less than 2 years.

Randomised (N): 3023 (1514 intervention, 1509 control)
Withdrawn (N): for reasons other than death (270 intervention, 204 control)
Lost to follow-up (N): (2 intervention, 1 control)
Analysed (N): 3020 (1512 intervention, 1508 control)

Age (years, mean, SD): intervention: 67.2, 11.1; control: 67.1, 11.1
Sex (% men): intervention: 60.8; control: 59.0
Ethnicity (%): intervention: European 90.8, control: European 92.3
Systolic blood pressure (mmHg, mean, SD): intervention: 136.0, 18.6; control: 136.3, 18.3
Heart rate (beats/min, mean, SD): intervention: 71.2, 12.4; control: 71.4, 12.5
BMI (mean, SD): intervention: 29.3, 5.9; control: 29.0, 5.6
Serum creatinine (mg/dL): not reported
B-type natriuretic peptide (pg/mL): not reported
NT pro B-type natriuretic peptide (pg/mL): not reported
LVEF (%, mean, SD): intervention: 54.0, 9.4; control: 54.1, 9.4
NYHA class I (%): 0
NYHA class II (%): intervention: 61.5; control: 60.0
NYHA class III (%): intervention: 36.7; control: 38.7
NYHA class IV (%): intervention: 1.8; control: 1.3
Hypertension (%): intervention: 65.0; control: 63.6
Diabetes (%): intervention: 28.7; control: 28.0
Atrial fibrillation (%): intervention: 29.0; control: 29.3
Hospitalisation for heart failure (%): intervention: 69.6; control: 68.8
Coronary heart disease (%): intervention: 45.0; control: 43.7
Stroke (%): intervention: 9.2; control: 8.5
Diuretic (%): intervention: diuretic: 75.2, spironolactone 11.3; control: diuretic 74.3, spironolactone 12.0
Digoxin (%): intervention: 28.5; control: 27.2
### Interventions

#### Intervention:
Candesartan. "which could be started at 4 or 8 mg once daily, the assignment code being held by an independent centre and the data safety monitoring board. The treatment dose was doubled every 2 weeks, as tolerated, according to a forced titration protocol, with recommended monitoring of blood pressure, serum creatinine, and potassium. The target dose was 32 mg once daily from 6 weeks onwards."

#### Comparator:
"matching placebo"

#### Concomitant medication:
"Physicians were free to prescribe all treatments other than angiotensin-receptor blockers." "Initially, angiotensin converting-enzyme inhibitors were not allowed as concomitant treatment, but after publication of the Heart Outcomes Prevention Evaluation trial results, (The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53.) their use was optional in appropriate patients." "By the end of the study, 298 (20%) in the candesartan and 340 (23%) in the placebo group were receiving angiotensin-converting-enzyme inhibitors, 712 (47%) and 748 (50%) were receiving blockers, and 136 (9%) and 201 (13%) were receiving spironolactone. Non-study angiotensin-receptor blockers were used in 3% of patients in each of the two groups."

### Outcomes

#### Planned:
"The primary outcome was cardiovascular death or unplanned admission to hospital for the management of worsening CHF. Prespecified secondary outcomes were: cardiovascular death, admission to hospital for CHF, or non-fatal myocardial infarction; cardiovascular death, admission to hospital for CHF, non-fatal myocardial infarction, or non-fatal stroke; cardiovascular death, admission to hospital for CHF, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularisation; death (any cause) or admission to hospital for CHF; and development of new diabetes."

#### Reported:
as planned

### Notes

The CHARM program consisted of 3 strands, one of which was CHARM-Preserved.

Contacted investigators for end scores of MLHF QoL by treatment arms and details on subgroup data by LVEF. No response.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;We randomly assigned patient&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>&quot;the assignment code being held by an independent centre and the data safety monitoring board&quot;</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Low risk</td>
<td>&quot;We randomly assigned patients, in a double-blind way&quot;, &quot;matching placebo&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>&quot;A committee unaware of treatment assignment and which component of the CHARM programme was being undertaken adjudicated the cause of death, first myocardial infarctions, and first hospital admissions for heart failure.&quot;</td>
</tr>
</tbody>
</table>
"All final data analyses were done by the sponsor and verified independently by the statistical centre at the London school of Hygiene and Tropical Medicine, London, UK"

Incomplete outcome data (attrition bias)

| All outcomes | Low risk | “two patients who mistakenly received randomisation numbers but had no other data recorded and never received study medication”

“Two candesartan patients and one placebo patient were lost to follow-up”

207/204 withdrew due to AE

“Analysis was done by intention to treat.”

Selective reporting (reporting bias)

| Low risk | outcomes reported as planned

Other bias

| Low risk | “MA Pfeffer, K Swedberg, CB Granger, JJV McMurray, and S Yusuf have served as consultants to or received research grants from AstraZeneca and other major cardiovascular pharmaceutical companies. J Östergren has served as a consultant and received research grants from AstraZeneca. P Held, E L Michelsson, and B Olofsson are employees of AstraZeneca.”

“This study was supported by AstraZeneca R&D, Mölndal, Sweden”

ELANDD

Study characteristics

Methods

| Study design: multicenter, double-blind, placebo controlled, randomised, parallel group trial

Centres: 12 in 8 European countries

Start of enrolment: not reported

End of enrolment: not reported

Follow-up: 6 months

Run-in period: not reported

Participants

| Inclusion criteria: “To be included into the study, patients had to fulfil the following criteria: willing and able to sign the informed consent form and comply with the requirements of the study, aged ≥ 40 years, have a documented history of HF and persistent symptoms during effort [New York Heart association (NYHA) class II–III], an LVEF ≥ 45%, and LV end-diastolic internal diameter < 3.2 cm/m² or LV end-diastolic volume index < 102 mL/m² by echocardiography, radionuclide ventriculography, or nuclear magnetic imaging, or any abnormality of LV diastolic function documented by echocardiography, according to the guidelines of the European Study Group on Diastolic Heart Failure. This last inclusion criterion was revised in April 2007 following the online publication of the new consensus statement on the diagnosis of HFPEF by the European Society of Cardiology. Accordingly, an E/E ratio > 15 at tissue Doppler echocardiography was required as an inclusion criterion. Patients with an E/E' ratio between 8 and 15 could be included when additional abnormalities of diastolic function were found. These included an E/A ratio < 0.5 and/or a deceleration half-time > 280 ms in patients older than 50 years, and/or a duration of reverse pulmonary vein atrial systole flow–mitral valve atrial wave flow > 30 ms, and/or a left atrial volume index > 40 mL/m², and/or an increased LV mass index”

Exclusion criteria: “Major exclusion • Patients unable to perform 6-mi walking test • Planned invasive cardiac procedures or cardiac surgery during the time of the study • Recent (< 3 months) acute coronary syndrome or stroke • Exercise-induced myocardial ischaemia as main cause of exercise limitation as shown by symptoms (angina) or by previous exams (exercise test, stress echocardiography or my-
ocardiography) • Concomitant diseases (COPD, peripheral vasculopathy, orthopaedic disease) as main cause of exercise limitation • Major contraindications to beta-blocker therapy (sinus bradycardia, \50/min; atrio-ventricular block, bronchial asthma sensitive to beta-agonists administration) • Ongoing treatment with beta-blockers, diltiazem or verapamil • Systolic blood pressure \100 mm Hg • Pregnancy, breast feeding or childbearing potential during the study • History of alcohol or other illicit drug abuse • Expected poor compliance to drug therapy • Participation in any other clinical trial with an investigational product or scheduled to receive any such product during the study or in the 4 weeks following the study • Suffering from any other medical condition that may exclude the patient for safety reasons or interfere with the objective of the study.”

Randomised (N): 116 (57 intervention, 59 control)
Withdrawn (N): for reasons other than death 22 (14 intervention (9 lack of tolerance, 1 protocol violation, 3 consent withdrawal, 1 other), 8 control (consent withdrawal 1, protocol violation 5, 2 other))
Lost to follow-up (N): 1 (1 intervention, 0 control)
Analysed (N): 93 (42 intervention, 51 control)
Age (years, mean, SD): intervention: 66.5, 9.8; control: 65.3, 11.3
Sex (% men): intervention: 35; control: 36
Ethnicity (%): not reported
Systolic blood pressure (mmHg, mean, SD): intervention: 128, 17 (Table 3 of Conraads), 134, 21 (Table 2); control: 129, 23 (Table 3) 133, 18 (Table 2)
Heart rate (beats/min, mean, SD): intervention: 76, 15 (Table 3) 73, 14 (Table 2); control: 78, 13 (Table 3), 73, 11 (Table 2)
BMI (mean, SD): intervention: 30.3, 4.5; control: 30.2, 4.9
Serum creatinine (mg/dL, mean, SD): intervention: 88.5, 33.1; control: 85.8, 25.1
B-type natriuretic peptide (pg/mL): not reported
NT pro B-type natriuretic peptide (pg/mL, median, range): intervention: 147 (9-3577); control: 126 (15-2055)
LVEF (%), (mean, SD): intervention: 61.9, 7.8; control: 63.2, 9.2
NYHA class I (%): 0
NYHA class II (%): intervention: 77; control: 78
NYHA class III (%): intervention: 21; control: 22
NYHA class IV (%): 0
Hypertension (%): intervention: 86; control: 86.4
Diabetes (%): intervention: 21; control: 20
Atrial fibrillation (%): not reported
Hospitalisation for heart failure: not reported
Coronary heart disease (%): intervention: 17; control: 20
Stroke (%): not reported
Diuretic (%); intervention: 49; control: 54
Digoxin (%): not reported
Interventions

**Intervention**: nebivolol. "Nebivolol was started at 2.5 mg/day and gradually up-titrated to 10 mg/day over a period of 5 weeks. Down-titration to lower doses was allowed if the higher dose was not tolerated. Treatment at maintenance doses was continued for an additional 21 weeks (6 months of treatment in total)."

**Comparator**: placebo

**Concomitant medication**: "Ongoing treatment with other drugs was maintained throughout the study."

Outcomes

**Planned**: "The primary endpoint of the study is the change from baseline in the distance walked during the 6-min walking test (6MW T) after 6 months of treatment with nebivolol versus placebo. Additional secondary endpoints are the changes from baseline after 6 months, with nebivolol versus placebo, in the following measurements: • Symptoms, assessed using a five-level scale (extremely worsened, moderately worsened, unchanged, moderately improved, extremely improved); • New York Heart Association (NYHA) functional class; • Minnesota living with heart failure questionnaire [21]; • Maximal exercise duration, peak oxygen consumption, [VO2] and slope of the minute ventilation [VE] to carbon dioxide [VCO2] relation, at cardiopulmonary exercise testing. • Changes in parameters related to LV diastolic function, including peak E velocity at the Doppler recording of transmural inflow tracing, peak E0 velocity of the mitral valve annulus measured at the level of the septal and lateral wall, respectively, by tissue Doppler recording, and the E/E' ratio. Lastly, the effects of treatment on major outcomes (death, hospitalization and unexpected visit to the outpatient clinic or heart failure unit) as well as adverse events are assessed."

**Reported**: as planned

Notes

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>&quot;computer-generated 1:1 randomization&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Low risk</td>
<td>&quot;double-blinded&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>reasons provided for withdrawal</td>
</tr>
</tbody>
</table>
**ELANDD (Continued)**

<table>
<thead>
<tr>
<th>Selective reporting (reporting bias)</th>
<th>Low risk</th>
<th>reported as planned</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>The trial is funded by a grant from Menarini. &quot;We thank Joachim Klinger Director of Data Management and Statistics, Harrison Clinical Research Deutschland, and Lieven Huysse, who worked at Menarini at the time of the study, for management and statistical support.&quot;</td>
</tr>
</tbody>
</table>

**Hong Kong DHF**

**Study characteristics**

**Methods**

- **Study design:** three-arm, parallel RCT
- **Centres:** multicentre, no details
- **Start of enrolment:** not reported
- **End of enrolment:** not reported
- **Mean follow-up:** 1 year
- **Run-in period:** none

**Participants**

- **Inclusion criteria:** "The inclusion criteria were age ≥18 years, clinical history of heart failure within 2 months prior to screening including a chest x-ray demonstrating pulmonary congestion, NYHA functional class II – IV, left ventricular ejection fraction ≥45% by 2D-echocardiography or a radionuclide technique, and therapy with diuretics with stable dose.14 days prior to recruitment."

- **Exclusion criteria:** "NYHA functional class I, myocardial infarction within 3 months, unstable angina within 1 month, significant valvular heart disease, uncontrolled hypertension, serious cardiac arrhythmias, concurrent therapy with calcium channel antagonist, b-blockers (a-methyl dopa was used for treating hypertension if required), positive inotropic agents (except digoxin for control of atrial fibrillation) and other angiotensin converting enzyme inhibitors or receptor blockers."

- **Randomised (N):** 151 (intervention R: 45, intervention I: 56, control: 50)
- **Withdrawn (N):** for reasons other than death: intervention R: 6 (4 persistent irritating cough, 1 uncontrolled blood pressure, 1 refused to continue), intervention I: 1 due to onset of fast atrial fibrillation, control: 3 (1 uncontrolled high blood pressure, 1 defaulted, 1 refused to continue)
- **Lost to follow-up (N):** 0
- **Analysed (N):** 151 (intervention R: 45, intervention I: 56, control: 50)
- **Age (years, mean, SD):** intervention R: 74, 6.1; intervention I: 75, 8.5; control: 73, 8.4
- **Sex (% men):** intervention R: 40; intervention I: 34; control: 42
- **Ethnicity (%):** not reported
- **Systolic blood pressure (mmHg, mean, SD):** intervention R: 143, 22; intervention I: 145, 19; control: 145, 23
- **Heart rate (beats/min, mean, SD):** intervention R: 79, 13; intervention I: 77, 9; control: 76, 14
- **BMI (mean, SD):** intervention R: 26.8, 3.9; intervention I: 27.2, 4.1; control: 26.8, 4.2
- **Serum creatinine:** not reported
B-type natriuretic peptide (pg/mL, mean, SEM): intervention R: 488, 701; intervention I: 568, 757; control: 566, 944

NT pro B-type natriuretic peptide: not reported

LVEF (%): intervention R: 65, 1; intervention I: 66, 1; control: 69, 2

NYHA class I (%): 0

NYHA class II (%): intervention R: 66.7; intervention I: 67.9; control: 72

NYHA class III (%): intervention R: 33.3; intervention I: 30.4; control: 28

NYHA class IV (%): 0

Hypertension (%): intervention R: 73; intervention I: 71; control: 76

Diabetes (%): intervention R: 22; intervention I: 18; control: 20

Atrial fibrillation (%): intervention R: 16; intervention I: 21; control: 10

Hospitalisation for HF: 100% as it was an inclusion criteria

Coronary heart disease (%): intervention R: 18; intervention I: 11; control: 18

Stroke (%): not reported

Diuretic (%): intervention R: Hydrochlorothiazide 8.9 furosemide 80, dyazide 2.2; intervention I: Hydrochlorothiazide 10.7, furosemide 80.4, dyazide 10.7; control: Hydrochlorothiazide 6, furosemide 68, dyazide 12

Digoxin (%): not reported

Beta-blocker (%): 0

ACEI (%): study drug (R)

ARB (%): study drug (I)

MRA (%): not reported

Interventions

Intervention R: "Ramipril was started at 2.5 mg daily and similarly titrated to 10 mg daily"

Intervention I: "The initial dose of irbesartan was 18.75 mg daily which was titrated at 4 and 8 weeks to 75 mg daily."

Comparator: usual care, "continue with diuretics alone"

Concomitant medication: "Exclusion criteria were: ...concurrent therapy with calcium channel antagonist, b-blockers (a-methyl dopa was used for treating hypertension if required), positive inotropic agents (except digoxin for control of atrial fibrillation) and other angiotensin converting enzyme inhibitors or receptor blockers."

Outcomes

Planned: planned as per clinical trial registry entry; primary: 1. Number of hospital admissions for heart failure or mortality 2. Quality of life assessed by the Minnesota Quality of life Questionnaire 3. In ambulatory patients the exercise duration assessed by 6 min corridor walk test. Secondary: The incidence of side-effects, effect on levels of natriuretic peptides, effect on doppler-echocardiographic derived measurements of left ventricular diastolic function.

Reported: cardiovascular mortality, hospitalisation for heart failure, all-cause mortality, quality of life, 6MWT, blood pressure, NT-proBNP, peak early diastolic mitral annular velocities, peak systolic velocity, LV mass

Notes

retrospective clinical trial registration
**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>&quot;randomly allocated using computer-generated random numbers in blocks of 10&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>&quot;open-label&quot;</td>
</tr>
</tbody>
</table>
| Blinding of outcome assessment (detection bias) | Low risk           | "All outcomes were reviewed blind to treatment allocation."
|                                              |                    | "with blinded end point design"                             |
| Incomplete outcome data (attrition bias)   | Unclear risk       | unable to assess                                            |
| Selective reporting (reporting bias)       | Unclear risk       | retrospective clinical trial registration, no published protocol identified |
| Other bias                                 | Unclear risk       | "None of the authors received any lecture, advisory board, or consultancy fees relating to this study from the sponsors."
|                                           |                    | "This study was initially supported by a small grant from the manufacturers of irbesartan, who also donated the irbesartan medication (Sanofi-Synthelabo). Design, conduct, retention of data, analysis and writing were all entirely independent and carried out by the authors only. Data were kept at the Chinese University of Hong Kong and are available for public scrutiny." |

**I-PRESERVE**

**Study characteristics**

**Methods**

**Study design:** parallel RCT

**Centres:** 293 centres in 25 countries (Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Mexico, The Netherlands, Norway, Poland, Portugal, Russia, South Africa, Spain, Sweden, Switzerland, UK, USA)

**Start of enrolment:** June 2002

**End of enrolment:** April 2005

**Mean follow-up:** mean follow-up time was 49.5 months, and the trial included 16,798 patient-years of follow-up

**Run-in period:** "Eligible patients were treated with single-blind placebo for 1 to 2 weeks before randomization"

**Participants**

**Inclusion criteria:** "All patients were at least 60 years of age and had heart failure symptoms and a left ventricular ejection fraction of at least 45%. In addition, we required patients to have been hospital-ized for heart failure during the previous 6 months and have current New York Heart Association (NYHA)
class II, III, or IV symptoms with corroborative evidence; if they had not been hospitalized, they were re-
quired to have ongoing class III or IV symptoms with corroborative evidence. Such evidence could in-
clude findings of pulmonary congestion on radiography, left ventricular hypertrophy or left atrial en-
largement on echocardiography, or left ventricular hypertrophy or left bundle-branch block on electro-
cardiography. Treatment with an angiotensin-converting–enzyme (ACE) inhibitor was permitted only when such therapy was considered essential for an indication other than uncomplicated hyperten-
sion.”

Exclusion criteria: “Exclusion criteria included previous intolerance to an angiotensin-receptor block-
er; an alternative probable cause of the patient’s symptoms (e.g., significant pulmonary disease); any previous left ventricular ejection fraction below 40%; a history of acute coronary syndrome, coronary revascularization, or stroke within the previous 3 months; substantial valvular abnormalities; hypertro-
hpic or restrictive cardiomyopathy; pericardial disease; cor pulmonale or other cause of isolated right heart failure; a systolic blood pressure of less than 100 mm Hg or more than 160 mm Hg or a dias-
tolic blood pressure of more than 95 mm Hg despite antihypertensive therapy; other systemic disease limiting life expectancy to less than 3 years; substantial laboratory abnormalities (such as a hemoglo-in level of less than 11 g per deciliter, a creatinine level of more than 2.5 mg per deciliter [221 μmol per
liter], or liver-function abnormalities); or characteristics that might interfere with compliance with the
study protocol”

Randomised (N): 4128 (2067 intervention, 2061 control)
Withdrawn (N): for reasons other than death 1368 (702 intervention, 684 control)
Lost to follow-up (N): 73 (29 intervention, 44 control)
Analysed (N): 4128 (2067 intervention, 2061 control)
Age (years, mean, SD): intervention: 72, 7; control: 72, 7
Sex (% men): intervention: 41; control: 39
Ethnicity (%): intervention: white 94, control: white 93
Systolic blood pressure (mmHg, mean, SD): intervention: 137, 15; control: 136, 15
Heart rate (beats/min, mean, SD): intervention: 72, 11; control: 71, 10
BMI (mean, SD): intervention: 29.7, 5.2; control: 29.6, 5.3
Serum creatinine (mg/dL, mean, SD): intervention: 1.0, 0.32; control: 1.0, 0.34
B-type natriuretic peptide (pg/mL): not reported
NT pro B-type natriuretic peptide (pg/mL, median, IQR): intervention: 360, 139–987; control: 320,
131–946
LVEF (%), mean, SD): intervention: 59, 9; control: 60, 9
NYHA class I (%): 0
NYHA class II (%): intervention: 21; control: 22
NYHA class III (%): intervention: 77; control: 76
NYHA class IV (%): intervention: 3; control: 3
Hypertension (%): intervention: 89; control: 88
Diabetes (%): intervention: 28; control: 27
Atrial fibrillation (%): intervention: 29; control: 29
Hospitalisation for heart failure in the last six months (%): intervention: 44; control: 44
Myocardial infarction (%): intervention: 24; control: 23
**Interventions**

**Intervention:** irbesartan. "Patients were started on 75 mg of irbesartan or placebo once daily. The dose was doubled to 150 mg after 1 to 2 weeks and was doubled again to 300 mg after an additional 1 to 2 weeks, according to a forced-titration protocol as tolerated."

"At the end of the titration phase, 84% of the patients in the irbesartan group and 88% of those in the placebo group had reached the 300-mg dose (mean doses, 275 mg and 284 mg, respectively)."

**Comparator:** "matching placebo"

**Concomitant medication:** "During the study, the proportion of patients receiving an ACE inhibitor rose from 25% in the two groups at baseline to 39% in the irbesartan group and 40% in the placebo group, the use of spironolactone rose from 15% in the two groups at baseline to 28% in the irbesartan group and 29% in the placebo group, and the use of beta-blockers rose from 59% in the irbesartan group and 58% in the placebo group to 73% in the two groups."

**Outcomes**

**Planned:** "The primary end point is defined as time from randomization to the first occurrence of the composite outcome of death (all cause) or cardiovascular hospitalization. [...] The endpoint additionally includes myocardial infarction or stroke occurring during any hospitalization at any point during the study.

Secondary endpoints include the effect of irbesartan as compared with placebo in reducing the risk of: cardiovascular death, all-cause mortality, combined vascular endpoint: cardiovascular death, nonfatal myocardial infarction (MI) or nonfatal stroke; or combined HF endpoint: HF mortality or hospitalizations; [...] quality of life as measured by the Minnesota Living with Heart Failure questionnaire, change in New York Heart Association (NYHA) functional class, change in global assessment of symptoms, N-terminal B-type natriuretic peptide levels in blood." (Carson 2005)

**Reported:** all planned outcomes reported

**Notes**

Emailed trialists to enquire about differing data in different publications and to ask for subgroup data. No response.

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>&quot;using an automated, central randomization system&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>&quot;The randomization schedule was implemented with the use of an interactive voice-response system.&quot;</td>
</tr>
</tbody>
</table>
| Blinding of participants and personnel (performance bias) All outcomes | Low risk            | "All investigators and committee members who were involved in the conduct of the study (except for members of the data and safety monitoring board) were unaware of study-group assignments."
|                               |                    | "double-blind" (Carson 2005)                       |
### I-PRESERVE (Continued)

<table>
<thead>
<tr>
<th><strong>Blinding of outcome assessment (detection bias)</strong></th>
<th><strong>Unclear risk</strong></th>
<th>“matching placebo”</th>
</tr>
</thead>
<tbody>
<tr>
<td>All outcomes</td>
<td></td>
<td>&quot;blinded review of event rates in 2004&quot; but blinding of event adjudication not specified overall</td>
</tr>
</tbody>
</table>

| **Incomplete outcome data (attrition bias)** | **Low risk** | "At the end of the study, vital-status data were not available for 29 patients (1%) in the irbesartan group and 44 patients (2%) in the placebo group. If contact could not be made at end of study, data for these patients were censored from the analysis at the date they were last known to be alive." |
| All outcomes                                    |               | "Data from all patients who underwent randomization were analyzed according to the intention-to-treat principle." |

| **Selective reporting (reporting bias)** | **Low risk** | all planned outcomes reported (comparison between published protocol (Carson 2005) and main results paper (Massie 2008)) |

| **Other bias** | **Low risk** | "Dr. Massie reports receiving grant support from Bristol-Myers Squibb, Sanofi-Aventis, and Merck, consulting fees from Bristol-Myers Squibb, Sanofi-Aventis, Merck, Duke Clinical Research Institute, Momentum Research, Novartis, GlaxoSmithKline, Scios–Johnson & Johnson, Corthera, and Niles Therapeutics, and lecture fees from Merck; Dr. Carson, receiving consulting fees from Bristol-Myers Squibb, Sanofi-Aventis, and Merck and lecture fees from AstraZeneca and Novartis; Dr. McMurray, receiving support from Bristol-Myers Squibb (to Glasgow University) for his work on this trial; Dr. Komajda, receiving consulting fees from Bristol-Myers Squibb and Servier and lecture fees from Servier, Sanofi-Aventis, and AstraZeneca; Dr. McKelvie, receiving consulting fees from Bristol-Myers Squibb and Sanofi-Aventis and lecture fees from Bristol-Myers Squibb, Sanofi-Aventis, Pfizer, Merck, and AstraZeneca; Dr. Zile, receiving consulting fees from Bristol-Myers Squibb and Sanofi-Aventis; Ms. Anderson, being employed by the Statistical Data Analysis Center at the University of Wisconsin–Madison, which conducted statistical analysis for this trial, supported by Bristol-Myers Squibb and Sanofi-Aventis; Drs. Donovan and Ptaszynska, being employees of and having an equity interest in Bristol-Myers Squibb; and Dr. Staiger, being an employee of and having an equity interest in Sanofi-Aventis.

**study sponsors**: Bristol-Myers Squibb and Sanofi-Aventis. "The sponsors or a contract research organization collected the trial data, which were then analyzed at the Statistical Data Analysis Center at the University of Wisconsin, Madison, independently of the sponsors." |

### J-DHF

**Study characteristics**

<table>
<thead>
<tr>
<th><strong>Methods</strong></th>
<th><strong>Study design</strong>: parallel RCT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Centres</strong></td>
<td>&quot;multicenter&quot; but no further details</td>
</tr>
<tr>
<td><strong>Start of enrolment</strong></td>
<td>May 2004</td>
</tr>
<tr>
<td><strong>End of enrolment</strong></td>
<td>March 2009</td>
</tr>
<tr>
<td><strong>Mean follow-up</strong></td>
<td>3.2 years</td>
</tr>
<tr>
<td><strong>Run-in period</strong></td>
<td>no</td>
</tr>
</tbody>
</table>

| **Participants** | **Inclusion criteria**: "All patients were at least 20 years of age, and had an LVEF of > 40% when diagnosed as having heart failure. Clinical diagnosis of heart failure was based on a slight modification of..." |

---

**Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)**

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the Framingham criteria as previously described within the 12 months before study entry. There were no changes in baseline therapy and symptoms of heart failure within a month before study entry in any patients.”

**Exclusion criteria:** Current symptomatic hypotension, • Hypertension that has not been controlled to the satisfaction of the investigator by drugs other than β-blocker • Hemodynamically significant (in the investigators opinion) LV outflow tract obstruction (from either aortic stenosis or ventricular hypertrophy) or mitral valve stenosis • Important aortic or mitral regurgitation in the investigator’s opinion • Heart rate < 50 beats/min • Second- or third-degree heart block without permanent pacemaker in situ • Acute coronary syndrome • Arrhythmogenic right ventricular cardiomyopathy • Primary pulmonary hypertension or pulmonary hypertension not from LV dysfunction • Serious cerebrovascular disease • Acute myocardial infarction within the last 3 months • Patients who require intravenous inotropes • Cerebrovascular accident within the last 6 months • Percutaneous coronary intervention or open heart surgery within the last 3 months • On the waiting list for percutaneous coronary intervention or open heart surgery • Serum creatinine > 3.0 mg/dL or creatinine clearance ≤ 30 mL/min • Known bilateral renal artery stenosis • Serum potassium > 5.5 mEq/L • Serious liver disease • Prescription of β-blocker within the last month or a history of a life-threatening adverse event induced by β-blocker • Any change in cardiovascular drug therapy within a month before randomization • History of chronic obstructive pulmonary disease or restrictive lung disease • Diabetes mellitus that has not been controlled to the satisfaction of the investigator • History of any life-threatening noncardiac disease (eg, cancer) within 5 years • Other diseases likely to cause death or serious disability within 1 year • Patients unable to walk without personal aid • Arteriosclerosis obliterans with Fontaine Grade II or more. • Severe anemia (hemoglobin ≤ 6.0 g/dL) • Uncontrolled thyroid dysfunction

**Randomised (N):** 245 (120 intervention, 125 control)

**Withdrawn (N):** for reasons other than death (6 intervention, 0 control)

**Lost to follow-up (N):** (5 intervention, 3 control)

**Analysed (N):** (120 intervention, 125 control)

**Age (years, mean, SD):** intervention: 73, 10; control: 71, 11

**Sex (% men):** intervention: 57.5; control: 58.4

**Ethnicity (%):** not reported

**Systolic blood pressure (mmHg, mean, SD):** intervention: 134, 21; control: 133, 21

**Heart rate (beats/min, mean, SD):** intervention: 72, 11; control: 74, 13

**BMI (mean, SD):** intervention: 24.2, 4.4; control: 24.1, 4.1

**Serum creatinine (mg/dL, mean, SD):** intervention: 0.98, 0.37; control: 1.01, 0.45

**B-type natriuretic peptide (pg/mL, mean, SD):** intervention: 219.2, 294.9; control: 234.9, 281.6

**NT pro B-type natriuretic peptide (pg/mL):** not reported

**LVEF (%, mean, SD):** intervention: 62, 10; control: 63, 11

**NYHA class I (%):** intervention: 18.3; control: 18.4

**NYHA class II (%):** intervention: 69.2; control: 75.2

**NYHA class III (%):** intervention: 10.8; control: 4.8

**NYHA class IV (%):** intervention: 1.7; control: 1.6

**Hypertension (%):** intervention: 80.0; control: 80.8

**Diabetes (%):** intervention: 27.5; control: 33.6

**Atrial fibrillation (%):** intervention: 50.8; control: 45.6
Hospitalisation for heart failure (%): intervention: 60.0; control: 60.0
Ischaemic heart disease (%): intervention: 28.3; control: 24.0
Stroke (%): intervention: 11.7; control: 12.8
Diuretic (%): intervention: 63.3; control: 56.8
Digoxin (%): intervention: 19.2; control: 21.6
Beta-blocker (%): study drug
ACEI (%): intervention: 24.2; control: 22.4
ARB (%): intervention: 50.8; control: 56.0
MRA (%): intervention: 20.8; control: 25.6

Interventions

Intervention: carvedilol. "In the carvedilol arm, carvedilol was up-titrated from 1.25 mg twice daily to the target dose of 10 mg twice daily within 8 weeks based on tolerability. Patients were maintained at the target dose or the maximum tolerated dose for the remainder of the study."

Comparator: usual care

Concomitant medication: "In both arms, patients were treated with standard cardiovascular therapy excluding beta-blockers."

Outcomes

Planned: "The primary outcome is a composite of cardiovascular death and unplanned admission to hospital for congestive heart failure. The secondary outcomes are listed as follows: all-cause mortality; worsening of the symptoms (defined by either a decrease by 1 Mets in the SAS questionnaire score or an increase by 1 class in the New York Heart Association functional class for at least 3 months compared with the baseline); an increase in brain natriuretic peptide by 30% of the value at the randomization in patients with brain natriuretic peptide 200 pg/mL at the randomization; unplanned admission to hospital for congestive heart failure; or a need for modification of the treatment for heart failure (changes in oral medicine for at least 1 month or addition of intravenous inotropes for at least 4 hours)." (Hori 2005)

Reported: as planned

Notes

Emailed investigators on 13 November 2017 to ask about data on cardiovascular mortality and all-cause mortality as different numbers are provided in Table 2 of Yamamoto 2013 (primary reference). No response.

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;patients were randomized to the arm&quot; but no details</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>no information</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>&quot;open&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>&quot;Deaths and hospitalizations were adjudicated by a blinded independent Endpoint Committee, using prespecified criteria.&quot;</td>
</tr>
</tbody>
</table>
Incomplete outcome data (attrition bias)  
All outcomes  
Low risk  
"The primary outcome was a composite of cardiovascular death and unplanned hospitalization for heart failure using a time-to-first-event analysis and the intention-to-treat principle."

unspecified for secondary outcomes  
lost to follow-up low/similar in both groups (4.2% intervention, 2.4% control)

Selective reporting (reporting bias)  
Low risk  
outcomes reported as planned in published protocol (Hori 2005)

Other bias  
Low risk  
authors CoI: “none declared”

funding: “The Ministry of Health, Labor and Welfare, Japan; the Japan Heart Foundation.”

Karapysh 2015

Study characteristics

Methods

Study design: RCT  
Centres: not reported  
Start of enrolment: not reported  
End of enrolment: not reported  
Follow-up: 6 months  
Run-in period: not reported

Participants

Inclusion criteria: "patients with chronic heart failure (CHF) with preserved ejection fraction (EF)."  
"with stable coronary arterial disease (CAD) and mild CHF (no higher II functional class (NYHA)) with preserved systolic function of the LV (EF > 45%)"

Exclusion criteria: not reported  
Randomised (N): 79  
Withdrawn (N): not reported  
Lost to follow-up (N): not reported  
Analysed (N): not reported  
Age (years, mean, SD): 54.5, 10.5  
Sex (% men): 61  
Ethnicity (%): intervention: white, control: white  
Systolic blood pressure not reported  
Heart rate not reported  
BMI not reported  
Serum creatinine not reported
Karapypsy 2015 (Continued)

**Interventions**

**Intervention:** spironolactone. "SPRL group was treated with the standard therapy (ACE inhibitors or angiotensin receptor blockers II, beta-blockers, statins, antiplatelet agents) plus SPRL (25 mg/day, titrated to 50 mg/day if tolerated)"

**Comparator:** standard therapy

**Concomitant medication:** standard therapy (ACEI, ARB, beta-blocker, statins, antiplatelet agents)

**Outcomes**

**Planned:** unclear

**Reported:** "V posterior wall thickness (LVPWT), intraventricular septal thickness (IVST), relative wall thickness (RWT) and LV mass index (LVM)"

**Notes**

Intended to contact trialists to obtain missing details and to enquire whether outcomes of interest to this review were measured. This was not possible as we could not find contact details for trialists.

No relevant outcome data for this review.

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;were randomly divided&quot; but no further detail</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
</tbody>
</table>

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Karapysh 2015 (Continued)

Blinding of outcome assessment (detection bias)

| All outcomes | Unclear risk | not reported |

Incomplete outcome data (attrition bias)

| All outcomes | Unclear risk | could not be assessed |

Selective reporting (reporting bias)

| Unclear risk | could not be assessed |

Other bias

| High risk | reported only as conference abstract |

Kasama 2005

Study characteristics

Methods

Study design: individual, parallel RCT

Centres: 1, Japan

Start of enrolment: January 2002

End of enrolment: September 2003

Follow-up: 6 months

Run-in period: not reported

Participants

Inclusion criteria: “first episode of nonischemic heart failure and preserved LVEF. We confirmed that all patients had symptoms and signs of congestive heart failure in this study.”..."they were in New York Heart Association (NYHA) functional class II or III at the time of enrollment, and all had an LVEF > 40%. "

Exclusion criteria: “Patients were excluded if they had a history of myocardial infarction, coronary artery disease, congenital heart disease, primary hepatic failure, or active cancer.”

Randomised (N): 50 (intervention: 25, control: 25)

Withdrawn (N): not reported

Lost to follow-up (N): not reported

Analysed (N): not reported

Age (years, mean, SD): intervention: 66, 10; control: 67, 8

Sex (% men): intervention: 68; control: 64

Ethnicity (%): not reported

Systolic blood pressure (mmHg, mean, SD): intervention: 132, 18; control: 130, 20

Heart rate (beats/min, mean, SD): intervention: 72, 12; control: 74, 14

BMI not reported

Serum creatinine not reported

B-type natriuretic peptide (pg/mL): intervention: 202, 125; control: 204, 127

NT pro B-type natriuretic peptide (pg/mL): not reported
LVEF (%, mean, SD): intervention: 54, 7; control: 55, 7

NYHA class I (%): 0

NYHA class II (%): intervention: 64; control: 68

NYHA class III (%): intervention: 36; control: 32

Hypertension (%): intervention: 64; control: 60

Diabetes (%): not reported

NYHA class IV (%): 0

Hospitalisation for heart failure (%): 100

Coronary heart disease (%): intervention: 0; control: 0

Stroke (%): not reported

Diuretic (%); intervention: 92; control: 88

Digoxin (%): not reported

Beta-blocker (%): intervention: 12; control: 12

ACEI (%): intervention: 92; control: 96

ARB (%): study drug

MRA (%): intervention: 16; control: 20

Interventions

Intervention: candesartan. “the initial daily dose of candesartan was 2 to 4 mg, which was increased to a maintenance dose of 8 to 12 mg/day (mean 10.2 mg/day).”

Comparator: placebo

Concomitant medication: “in addition to baseline therapy”

Outcomes

Planned: unclear as unaware of published protocol or pre-registration with a clinical trial registry

Reported: hemodynamics, I-MIBG, echocardiographic findings, NYHA functional class, BNP

Notes

No outcomes reported for relevance to this review. Emailed trialist to ask for outcome data relevant to this review. No response.

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>“randomly classified” but no further details</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>no information</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Low risk</td>
<td>“double-blinded” but no further details</td>
</tr>
</tbody>
</table>
### Kasama 2005 (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>“assessment was performed in a blinded fashion by two independent observers with no knowledge of the clinical status or medical therapy of the patients.”</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>ITT used for all outcomes, but loss to follow-up and withdrawals not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Unable to assess as we are not aware of a published protocol or a pre-registration in a clinical trial registry</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Funding source not reported</td>
</tr>
</tbody>
</table>

### Kitzman 2010

**Study characteristics**

#### Methods
- **Study design**: individual parallel RCT
- **Centres**: not reported
- **Start of enrolment**: not reported
- **End of enrolment**: not reported
- **Follow-up**: 12 months
- **Run-in period**: not reported

#### Participants
- **Inclusion criteria**: "As previously described, isolated HFPEF was defined as history, symptoms, and signs of HF; a preserved LVEF (50%); and no evidence of significant coronary, valvular, or pulmonary disease or other medical condition that could mimic HF symptoms, such as anemia or thyroid dysfunction."
- **Exclusion criteria**: "Coronary disease was excluded by history, medical records, ECG, and rest and exercise echocardiogram. ” "Patients were excluded if they had ever been prescribed an ACEI or ARB."
- **Randomised** (N): 71 (35 intervention, 36 control)
- **Withdrawn** (N): for reasons other than death 12 (10 intervention (3 patient request, 1 pancreatitis, 1 elective rotator cuff surgery, 1 alopecia, 1 worsening cough, 1 hypotension, 1 ankle fracture, exacerbation of knee arthritis, 1 leg and hip pain and fatigue), 2 control (1 elective knee replacement surgery, no details for second participants))
- **Lost to follow-up** (N): not reported
- **Analysed** (N): 59 completed study (25 intervention, 34 control)
- **Age** (years, mean, SD): intervention: 69, 8; control: 70, 7
- **Sex** (% men): intervention: 20; control: 11
- **Ethnicity** (%): intervention: black 9, control: black 6
- **Systolic blood pressure** (mmHg, mean, SD): intervention: 143, 17; control: 144, 18
- **Heart rate** (beats/min, mean, SD): intervention: 129, 20; control: 133, 16
- **BMI** (mean, SD): intervention: 30, 5; control: 30, 5
- **Serum creatinine** (mg/dL, mean, SD): intervention: 1.1, 0.2; control: 1.1, 0.2
Kitzman 2010  (Continued)

B-type natriuretic peptide (pg/mL): not reported
NT pro B-type natriuretic peptide (pg/mL): not reported
LVEF (%; mean, SD): intervention: 65, 8; control: 65, 7
NYHA class I (%): 0
NYHA class II (%): intervention: 83; control: 75
NYHA class III (%): intervention: 17; control: 25
NYHA class IV (%): 0
Hypertension (%): intervention: 71; control: 75
Diabetes (%): intervention: 9; control: 17
Atrial fibrillation not reported
Hospitalisation for heart failure: not reported
Coronary heart disease (%): 0
Stroke not reported
Diuretic (%; intervention: 49; control: 58
Digoxin (%): 0
Beta-blocker (%): intervention: 29; control: 39
ACEI (%): study drug
ARB not reported
MRA not reported

Interventions

Intervention: enalapril. "The study drug was initiated at 2.5 mg BID and titrated up to 10 mg BID as tolerated by the patient within the first 4 weeks of the study."
Comparator: placebo
Concomitant medication: not reported

Outcomes

Planned: unclear as clinical trial registration was post hoc
Reported: exercise capacity, aortic distensibility and LV structure and function, carotid artery stiffness, LV diastolic filling, QoL

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
</tbody>
</table>
Blinding of participants and personnel (performance bias)  
All outcomes  
Low risk  
"All investigators, staff, and patients were fully blinded to treatment group assignment throughout the entire study period."

Blinding of outcome assessment (detection bias)  
All outcomes  
Low risk  
"All investigators, staff, and patients were fully blinded to treatment group assignment throughout the entire study period."

Incomplete outcome data (attrition bias)  
All outcomes  
Unclear risk  
not reported

Selective reporting (reporting bias)  
Unclear risk  
not reported

Other bias  
Low risk  
"Dr Kitzman has served as consultant for and received grant support from Synvista ($10 000), Bristol-Meyers Squibb ($10 000), Novartis ($10 000), Boston Scientific ($10 000), Relypsa ($10 000), Forest Laboratories, and Medtronic. Dr Little has served as consultant for CorAssist Cardiovascular Ltd, Celladon, Boston Scientific, Medtronic ($10 000), Bio-Control Medical, CVRx ($10 000), Amylin Pharmaceuticals, Gilead, and BristolMeyers Squibb ($10 000). Drs Hundley, Brubaker, and Morgan; Mr Moore; and Ms Steward report no conflicts."

Kurrelmeyer 2014

Study characteristics

Methods

Study design: parallel RCT
Centres: 1 hospital, Houston, Texas
Start of enrolment: 2004
End of enrolment: 2008
Follow-up: 6 months
Run-in period: "patients were treated with 25 mg open-label spironolactone for 1 week before randomization to ensure drug tolerability, defined as serum potassium < 5 mEq/L and absence of other major side effects."

Participants

Inclusion criteria: "≥ 18 years old with a previous diagnosis of HfPEF. HfPEF was defined as current New York Heart Association (NYHA) functional class II or III HF symptoms or signs, left ventricular ejection fraction (LVEF) ≥ 50% according to echocardiography, diastolic dysfunction with elevated LV filling pressure according to Dopplerechocardiograph" "the subjects had to have a blood pressure of ≤ 150/95 mm Hg for 4 weeks before enrollment and the ability to walk ≥ 50 m at the time of enrollment. Treatment with an ACEI, or ARB if ACEI intolerant, was required for ≥ 4 weeks before enrollment. "

Exclusion criteria: "Exclusion criteria included current treatment with spironolactone or epleronone, previous intolerance to spironolactone, creatinine > 2.5 mg/dL, serum potassium > 5.0mEq/L, significant valvular heart disease, pericardial disease, severe chronic lung disease with cor pulmonale, unstable angina or myocardial infarction ≤ 4 weeks before enrollment, severe peripheral vascular disease with claudication that limited walking distance, presence of other severe comorbid conditions with a life expectancy < 6 months, and pregnant or lactating women."

Randomised (N): 48 (24 intervention, 24 control)
Withdrawn (N): for reasons other than death (3 intervention (hyperkalaemia),0 control)
Lost to follow-up (N): not reported
Analysed (N): not reported
Age (years, mean, SEM): intervention: 66.3, 2.2; control: 76.4, 1.6
Sex (% men): 0
Ethnicity (%): not reported
Systolic blood pressure (mmHg, mean, SEM): intervention: 137.0, 4.1; control: 133.1, 2.8
Heart rate (beats/min, mean, SEM): intervention: 64.2, 2.3; control: 61.1, 1.2
BMI (mean, SEM): intervention: 29.4, 2.2; control: 26.3, 1.2
Serum creatinine not reported
B-type natriuretic peptide (pg/mL): not reported
NT pro B-type natriuretic peptide (pg/mL): not reported
LVEF (%, mean, SEM): intervention: 62.5, 1.2; control: 62.9, 1.2
NYHA class I (%): 0
NYHA class II (%): intervention: 33; control: 42
NYHA class III (%): intervention: 67; control: 58
NYHA class IV (%): 0
Hypertension (%): intervention: 87.5; control: 79.2
Diabetes (%): intervention: 50; control: 25
Atrial fibrillation (%): intervention: 25; control: 25
Hospitalisation for heart failure (%): intervention: 58.3; control: 54.2
Coronary heart disease (%): intervention: 37.5; control: 33.3
Stroke (%): not reported
Diuretic (%): intervention: 83.3; control: 75
Digoxin (%): intervention: 12.5; control: 8.3
Beta-blocker (%): intervention: 62.5; control: 62.5
ACEI (%): intervention: 70.8; control: 66.7
ARB (%): intervention: 29.2; control: 37.5
MRA (%): study drug

Interventions

**Intervention:** Spironolactone, 25mg once daily
**Comparator:** placebo
**Concomitant medication:** not reported

Outcomes

**Planned:** no known published protocol or pre-enrolment clinical trial registry record
**Reported:** 6 min walk distance, clinical composite score, doppler echocardiography, biomarkers, Kansas City Cardiomyopathy Questionnaire clinical summary score
**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;randomly allocated&quot;, no further details</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>&quot;subjects were randomly allocated with the use of pharmacy-controlled concealed randomization methods.&quot;, no further details</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Low risk</td>
<td>double-blind, placebo controlled, no further details</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>no able to assess due to lack of pre-registration in clinical trial registry and published protocol</td>
</tr>
<tr>
<td>Other bias</td>
<td>High risk</td>
<td>clinical trial registry entry after start of enrolment, was originally marked as an observational study (2005-2013) and changed to a randomised trial status in 2013. reported as a RCT in 2014 publication. funded by Women's Fund; Houston, Texas</td>
</tr>
</tbody>
</table>

**Study characteristics**

**Methods**

- **Study design:** RCT
- **Centres:** 1
- **Start of enrolment:** not reported
- **End of enrolment:** not reported
- **Follow-up:** 12 months
- **Run-in period:** not reported

**Participants**

- **Inclusion criteria:** heart failure with preserved systolic function, "prior New York Heart Association (NYHA) functional class IV HF admission or symptoms consistent with HF, B-type natriuretic peptide (BNP) >100 pg/ml, left ventricular ejection fraction >45%, and evidence of diastolic dysfunction on Doppler-echocardiographic study."
- **Exclusion criteria:** "Patients were excluded if they were clinically unstable as defined by any change in diuretic dose a month before enrollment or were already receiving eplerenone or spironolactone therapy. Other exclusion criteria were evidence of significant inflammatory disease, hepatic disease, or..."
metabolic bone disease that may alter parameters of collagen metabolism, serum creatinine >200 mol/l, prior documented left ventricular ejection fraction <45%, hemodynamically significant valvular disease, cor pulmonale, hypertrophic, restrictive, or constrictive cardiomyopathy, atrial fibrillation or flutter with resting ventricular rate >120 beats/min, severe anemia, clinically significant pulmonary disease as evidenced by hospitalizations, or use of oral corticosteroids for pulmonary decompensation within 12 months or patients who require home oxygen therapy.

**Randomised (N):** 44 (24 intervention, 20 control)

**Withdrawn (N):** for reasons other than death 0

**Lost to follow-up (N):** 2 (0 intervention, 2 control)

**Analysed (N):** 40 (23 intervention, 17 control)

**Age** (years, mean, SD): intervention: 80, 7.7; control: 79, 7.9

**Sex** (% men): intervention: 38; control: 55

**Ethnicity** (%): Caucasian: 100

**Systolic blood pressure** (mmHg, mean, SD): intervention: 140, 20; control: 146, 20

**Heart rate** (beats/min, mean, SD): intervention: 69, 13; control: 66, 13

**BMI** (mean, SD): intervention: 31.3, 6.9; control: 31.8, 5.7

**Serum creatinine** not reported

**B-type natriuretic peptide** (pg/mL, median, IQR): intervention: 219 (157-317); control: 192 (132-330)

**NT pro B-type natriuretic peptide**: not reported

**LVEF** (%): not reported

**NYHA class I** (%): not reported

**NYHA class II** (%): 87%

**NYHA class III** (%): not reported

**NYHA class IV** (%): not reported

**Hypertension** (%): intervention: 92; control: 90

**Diabetes** (%): intervention: 21; control: 35

**Atrial fibrillation** (%): intervention: 58; control: 60

**Hospitalisation for heart failure**: not reported

**Coronary heart disease** (%): not reported

**Stroke** (%): not reported

**Diuretic** (%): intervention: 88; control: 90

**Digoxin** (%): intervention: 38; control: 30

**Beta-blocker** (%): intervention: 62; control: 75

**ACEI** (%): intervention: 67; control: 60

**ARB** (%): intervention: 29; control: 40

**MRA** (%): study drug
### Mak 2009 (Continued)

| Interventions | **Intervention**: eplerenone. "we evaluated patients with a dose of 25 mg daily for 6 months followed by a dose increment to 50 mg until the 12-month time point"
| Comparator: usual heart failure treatment |
| Concomitant medication: not reported |

| Outcomes | Planned: unable to assess |
| Reported: serum levels of markers of collagen turnover, inflammatory markers, doppler-echocardiographic indexes, clinical and biochemical measurements, withdrawals, quality of life |

| Notes | Emailed investigators to ask whether ITT or PP analysis was used. No response. |

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;randomly allocated&quot; but no further detail</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>nor reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>&quot;open label&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>&quot;all parameters were assessed by persons blinded to treatment&quot;</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>unable to assess</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>unable to assess as unaware of published protocol or pre-trial registration</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>Dr. Mak received grant support from the Irish Heart Foundation (The Noel Hick- ey Bursary) sponsored by Pfizer. Drs. Ledwidge and McDonald have received honoraria from Pfizer.</td>
</tr>
</tbody>
</table>

### McDiarmid 2020

### Study characteristics

| Methods | Study design: RCT, open label, parallel 2-arm trial |
| Centres: 1, Leeds Teaching Hospitals NHS Trust, Leeds, UK |
| Start of enrolment: April 2014 |
| End of enrolment: June 2016 |
| Follow-up: 6 months |

---

**Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)**

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
**McDiarmid 2020 (Continued)**

**Run-in period:** no

**Participants**

**Inclusion criteria:** physical signs consistent with HF, NYHA II-IV, LV ejection fraction on clinical echocardiography of >50%, and NT-proBNP >400 pg/L at routine clinic attendance.

**Exclusion criteria:** "renal impairment with estimated glomerular filtration rate <30 mL/min per 1.73 m², serum potassium >5.0 mmol/L at enrollment, allergy to spironolactone, inability to comply with study drug monitoring, diabetes mellitus, uncontrolled hypertension (>140 mm Hg systolic blood pressure despite medical therapy), pregnancy, breastfeeding, Addison disease, and any relative or absolute contraindication to CMR. Patients with diabetes were specifically excluded as this has been shown independently to be associated with extracellular fibrosis by CMR."

**Randomised (N):** 51 (intervention: 27; control: 24)

**Withdrawn (N):** for reasons other than death: 11 (reasons given for 15, including 4 that dropped out before randomisation - deterioration in renal function (n=3), inability to tolerate CMR (n=1), protocol breach (n=3), withdrawal of consent (n=8))

**Lost to follow-up (N):** 0

**Analysed (N):** 40 (intervention: 19; control 21)

**Age (years, mean, SD):** intervention: 76.4+/-5.4; control: 74.0 +/-8.8

**Sex (% men):** intervention: 53; control: 48

**Ethnicity (%):** not reported

**Systolic blood pressure (mmHg, SD):** intervention: 130.8+/-19.1; control: 129.6+/-9.9

**Heart rate (beats/minute):** intervention: 77 +/- 10.6 (sinus), 77 +/- 19.8 (atrial fibrillation); control: 74.5+/-12.5 (sinus), 73.8+/-7.5 (atrial fibrillation)

**BMI (mean, SD):** intervention: 29.8+/-5.3; control: 29.1+/-7.1

**Serum creatinine (mg/dL, SD):** intervention: 97.4 +/- 27.2; control: 101.33 +/- 38.1

**B-type natriuretic peptide: not reported**

**NT pro B-type natriuretic peptide (pg/mL, SD):** intervention: 1667 +/- 1246; control: 1706 +/- 1588

**LVEF (% mean, SD):** intervention: 53.5+/-5.5; control: 54.8+/-5.2

**NYHA class I (%):** 0

**NYHA class II (%):** intervention: 14; control: 17

**NYHA class III (%):** intervention: 5; control: 4

**NYHA class IV (%):** 0

**Hypertension (%):** intervention: 79; control: 62

**Diabetes (%):** 0 (diabetes was excluded from study)

**Atrial fibrillation (%):** intervention: 89; control 71

**Hospitalisation for heart failure:** not reported

**Ischaemic heart disease (%):** intervention: 0; control: 5

**Stroke (%):** cerebrovascular disease - intervention: 16; control: 0

**Diuretic (%):** intervention: 63; control: 57

**Digoxin (%):** intervention: 16; control: 43
McDiarmid 2020 (Continued)

**Beta-blocker (%):** intervention: 53; control: 67

**ACEI/ARB (%):** intervention: 58; control: 57

**MRA (%):** study drug

### Interventions

**Intervention:** Spironolactone, 25 mg once daily

**Comparator:** no treatment

**Concomitant medication:** not reported

### Outcomes

**Planned:** QoL, final myocardial ECV (%), relationship between change in myocardial tissue composition and echocardiographic measures of myocardial tissue relaxation, LV geometry, blood pressure, and circulating biomarkers.

**Reported:** final myocardial ECV (%), relationship between change in myocardial tissue composition and echocardiographic measures of myocardial tissue relaxation, LV geometry, blood pressure, and circulating biomarkers.

### Notes

Contacted trialists to ask for QoL data and other outcomes of interest to our review. No response.

Funding: This study and Dr McDiarmid are funded by a British Heart Foundation (BHF) Project Grant (PG/14/10/30641). Dr Swoboda is funded by a BHF Clinical Fellowship (FS/12/88/29474).

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>1:1 randomisation without stratification, using a ranodmised permuted block strategy, with a standard block size of 20 provided by a commercial online system</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>1:1 randomisation without stratification, using a ranodmised permuted block strategy, with a standard block size of 20 provided by a commercial online system</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>unblinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>High risk</td>
<td>unblinded</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>8 participants in intervention group and 3 in control group did not complete follow-up. Analysis was conducted as a complete case analysis.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Secondary outcome: Quality of life and exercise tolerance not reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No concerns</td>
</tr>
</tbody>
</table>
### Study characteristics

#### Methods

**Study design:** RCT

**Centres:** 1, Cardiology Outpatient Department and HTN clinic of Postgraduate Institute of Medical Education and Research, India

**Start of enrolment:** 15 November 2009 (from clinical trial registry)

**End of enrolment:** not reported for pilot study, full study ongoing

**Follow-up:** 12 weeks

**Run-in period:** 2 weeks placebo run in (beta-blocker withdrawn but co-existing therapies were continued)

#### Participants

**Inclusion criteria:** "18 years and above, had New York Heart Association (NYHA) functional Class II–III of at least 4 weeks' duration, LVEF ≥ 50% in a nondilated LV (LV enddiastolic volume < 97 ml/m measured by echocardiography), echocardiographic evidence of LV diastolic dysfunction, and were willing to give written informed consent."

**Exclusion criteria:** "They were excluded if: (1) Clinically unstable as defined by any change in diuretic dose in the month before enrollment, (2) significant valvular heart disease, pericardial disease, hypertrophic or restrictive cardiomyopathy, (3) unstable angina or MI within past 4 weeks, (4) any previous LVEF below 40%, (5) any contraindication to metoprolol use, (6) patients already on beta blockers which cannot be withdrawn, (7) current participation (including prior 30 days) in any other therapeutic trial, and (8) any condition that, in the opinion of investigator, may prevent the participant from adhering to the trial protocol."

**Randomised (N):** 40 (20 intervention, 20 control)

**Withdrawn (N):** for reasons other than death 0

**Lost to follow-up (N):** 6 (3 intervention, 3 control)

**Analysed (N):** 40 (20 intervention, 20 control)

**Age (years, mean, SD):** intervention: 55.2, 7.1; control: 57.2, 9.8

**Sex (% men):** intervention: 45; control: 50

**Ethnicity (%):** not reported

**Systolic blood pressure** not reported

**Heart rate** not reported

**BMI** not reported

**Serum creatinine** not reported

**B-type natriuretic peptide** not reported

**NT pro B-type natriuretic peptide** (pg/mL, median (IQR)): intervention: 238.2 (107.7-2230.2); control: 227.6 (58.3-3645)

**LVEF (%)** (mean, SD): intervention: 62.9, 6.2; control: 62.1, 6.57

**NYHA class I (%)**: 0

**NYHA class II (%)**: intervention: 55; control: 65

**NYHA class III (%)**: intervention: 45; control: 35

**NYHA class IV (%)**: 0
Mittal 2017 (Continued)

<table>
<thead>
<tr>
<th>Hypertension (%)</th>
<th>not reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes (%)</td>
<td>not reported</td>
</tr>
<tr>
<td>Atrial fibrillation (%)</td>
<td>not reported</td>
</tr>
<tr>
<td>Hospitalisation for heart failure</td>
<td>not reported</td>
</tr>
<tr>
<td>Coronary heart disease (%)</td>
<td>not reported</td>
</tr>
<tr>
<td>Stroke (%)</td>
<td>not reported</td>
</tr>
<tr>
<td>Diuretic (%)</td>
<td>intervention: 35; control: 40</td>
</tr>
<tr>
<td>Digoxin (%)</td>
<td>not reported</td>
</tr>
<tr>
<td>Beta-blocker (%)</td>
<td>intervention: 40; control: 45</td>
</tr>
<tr>
<td>ACEI (%)</td>
<td>intervention: 15; control: 60</td>
</tr>
<tr>
<td>ARB (%)</td>
<td>intervention: 15; control: 15</td>
</tr>
<tr>
<td>MRA (%)</td>
<td>not reported</td>
</tr>
</tbody>
</table>

**Interventions**

- **Intervention**: metoprolol succinate, 25 mg. "A dose upward titration protocol with monitoring of blood pressure and heart rate (target blood pressure and heart rate as 120/80 mm Hg and 60 beats/min, respectively) was implemented for dose increments up to a maximum dose of 100 mg once daily. For patients not tolerating increased titration of drug, temporary reduction in dosage was done and decision on further escalation made on individual basis by the treating cardiologist."

- **Comparator**: placebo

**Concomitant medication**: "During the study, calcium channel blockers were added in three patients (one in placebo and two in metoprolol group) due to high blood pressure records." Coexisting therapies were continued.

**Outcomes**

- **Planned**: unable to assess

- **Reported**: Primary: NYHA class. Secondary: exercise capacity, diastolic dysfunction, change in LV wall thickness, LV mass, NT-proBNP, PICP, QoL (SF-36), adverse events, withdrawals

**Notes**

- Published results after our search date, identified via search for clinical trial registry number: CTRI/2010/091/000438 which was retrieved by search of the WHO ICTRP register

- Emailed investigators to ask when completion of full trial is anticipated. Response confirmed that full trial was not conducted.

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;block randomised&quot; but no further details</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>&quot;Randomization and allocation sequence generation were done by investigators not directly involved in the evaluation of outcomes&quot; From clinical trial registry: &quot;sequentially numbered, sealed, opaque envelopes&quot;</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Low risk</td>
<td>&quot;double-blind&quot; From clinical trial registry entry: &quot;participant and outcome assessor blinded&quot;</td>
</tr>
</tbody>
</table>
Mittal 2017 (Continued)

Blinding of outcome assessment (detection bias) All outcomes

Low risk

"To avoid interobserver variability, all the echocardiographic parameters were evaluated by a single cardiologist who was blinded to study medication and the order of assessment."

From clinical trial registry entry: "participant and outcome assessor blinded"

Incomplete outcome data (attrition bias) All outcomes

Unclear risk

pilot study - full study ongoing

same numbers lost to follow-up in both arms

ITT and per-protocol analysis used

Selective reporting (reporting bias)

Unclear risk

unable to assess due to lack of published protocol and uncertainty over trial registration date

Other bias

Low risk

"The study was supported by Postgraduate Institute of Medical Education and Research, Chandigarh, India."

"There are no conflicts of interest"

Results from pilot study only so far.

Mottram 2004

Study characteristics

Methods

Study design: individual, double-blind, placebo-controlled, RCT

Centres: 1, Australia

Start of enrolment: February 2002

End of enrolment: October 2002

Follow-up: 6 months

Run-in period: not reported

Participants

Inclusion criteria: "To be eligible, patients had to have hypertension requiring antihypertensive medication and report exertional dyspnea (New York Heart Association class II) but no history of angina or myocardial infarction."

Exclusion criteria: "Patients taking angiotensin converting enzyme inhibitors, angiotensin-receptor blockers, or spironolactone were excluded, as were patients with renal impairment (creatinine 0.20 mmol/dL) or hyperkalemia at baseline." "We excluded patients with evidence of pulmonary disease, ischemic heart disease, abnormal regional or global resting LV systolic function (ejection fraction < 50%), or significant (>mild) valvular dysfunction."

Randomised (N): 30 (not reported by treatment arm, assumed 15 in each)

Withdrawn (N): not reported

Lost to follow-up (N): 1 (intervention: 1 (migrated overseas); control: 0)

Analysed (N): not reported

Age (years, mean, SD): intervention: 61, 6; control: 62, 5

Sex (% men): intervention: 40; control: 34
Mottram 2004 (Continued)

<table>
<thead>
<tr>
<th>Ethnicity (%)</th>
<th>not reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>intervention: 199, 18; control: 198, 26</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>intervention: 139, 24; control: 153, 13</td>
</tr>
<tr>
<td>BMI</td>
<td>intervention: 29.8, 4.7; control: 31.2, 4.6</td>
</tr>
<tr>
<td>Serum creatinine (mg/dL)</td>
<td>intervention: 0.07, 0.01; control: 0.07, 0.01</td>
</tr>
<tr>
<td>B-type natriuretic peptide (pg/mL)</td>
<td>intervention: 29.3, 26.8; control: 29.7, 27.8</td>
</tr>
<tr>
<td>NT pro B-type natriuretic peptide</td>
<td>not reported</td>
</tr>
<tr>
<td>LVEF</td>
<td>intervention: 68, 5; control: 67, 4</td>
</tr>
<tr>
<td>NYHA class</td>
<td>not reported</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>not reported</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>intervention: 7; control: 0</td>
</tr>
<tr>
<td>Atrial fibrillation (%)</td>
<td>not reported</td>
</tr>
<tr>
<td>Hospitalisation for heart failure</td>
<td>not reported</td>
</tr>
<tr>
<td>Coronary heart disease (%)</td>
<td>not reported</td>
</tr>
<tr>
<td>Stroke (%)</td>
<td>not reported</td>
</tr>
<tr>
<td>Diuretic (%)</td>
<td>intervention: 40; control: 27</td>
</tr>
<tr>
<td>Digoxin (%)</td>
<td>not reported</td>
</tr>
<tr>
<td>Beta-blocker (%)</td>
<td>intervention: 40; control: 20</td>
</tr>
<tr>
<td>ACEI (%)</td>
<td>not reported</td>
</tr>
<tr>
<td>ARB (%)</td>
<td>not reported</td>
</tr>
<tr>
<td>MRA (%)</td>
<td>study drug</td>
</tr>
</tbody>
</table>

Interventions

Intervention: spironolactone, 25mg/d

Comparator: placebo

Concomitant medication: not reported

Outcomes

Planned: unable to assess as we are not aware of a published protocol or pre-registered clinical trial registry entry

Reported: mean 24hr ambulatory blood pressure, posterior wall thickness, left atrial area, SR, peak systolic strain, and CVIB

Notes

no outcome data of interest to this review

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>randomised, but no details</td>
</tr>
</tbody>
</table>

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
<table>
<thead>
<tr>
<th>Mottram 2004 (Continued)</th>
<th>Allocation concealment (selection bias)</th>
<th>Unclear risk</th>
<th>not reported</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Low risk</td>
<td>double blind, matching placebo</td>
</tr>
<tr>
<td></td>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>“Investigators remained blinded to the treatment until after analysis of results.”</td>
</tr>
<tr>
<td></td>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td></td>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>unable to assess</td>
</tr>
<tr>
<td></td>
<td>Other bias</td>
<td>Unclear risk</td>
<td>“This work was supported in part by a grant and scholarship from the National Heart Foundation of Australia, Melbourne, Australia, in association with a Centers of Clinical Research Excellence Award, National Health and Medical Research Council, Canberra, Australia. The authors are grateful to the Princess Alexandra Hospital Pharmacy for supervision of randomization and dispensing of active and placebo tablets.”</td>
</tr>
</tbody>
</table>

| Orea-Tejeda 2007 |
| Study characteristics |
| Methods |
| Study design: RCT |
| Centres: not reported |
| Start of enrolment: not reported |
| End of enrolment: not reported |
| Mean follow-up: 13.8 months |
| Run-in period: not reported |

| Participants |
| Inclusion criteria: "Patients with diastolic heart failure attending to Heart Failure Clinic were considered eligible, independently of etiology, if they had history of arterial hypertension (and/or were on antihypertensive treatment), but no history of angina, myocardial infarction or myocardial revascularization (PTCA and/or aortocoronary bypass grafting) during the 3 months previous to recruitment and they referred fatigue, dyspnea on exercise and/or orthopnea. "Diastolic dysfunction was considered when the ejection fraction was over 45%, and shortening fraction = 28%, without severe segmental dyskinesia of the left ventricle, left atrial enlargement, or increased thickness or posterior wall, interventricular septum, and left ventricular mass index.” |
| Exclusion criteria: not reported |
| Randomised (N): 28 (14 intervention, 14 control) |
| Withdrawn (N): not reported |
| Lost to follow-up (N): not reported |
**Analysed** (N): not reported

**Age** (years, mean, SD): intervention: 63.7, 21.6; control: 64.8, 11.9

**Sex** (% men): intervention: 28.6; control: 71.4

**Ethnicity** (%): not reported

**Blood pressure** (mmHg): intervention: 112, 12; control: 114, 8

**Heart rate** (beats/min): intervention: 86, 4; control: 82, 6

**BMI** (mean, SD): intervention: 27.5, 9.4; control: 26.9, 4.7

**Serum creatinine** not reported

**B-type natriuretic peptide** (pg/mL): not reported

**NT pro B-type natriuretic peptide** (pg/mL): not reported

**LVEF** (%): intervention: 48.79, 4.65; control: 51.57, 11.71

**NYHA class I** (%): intervention: 42.9; control: 75.0

**NYHA class II** (%): intervention: 0; control: 16.7

**NYHA class III** (%): intervention: 57.1; control: 8.3

**NYHA class IV** (%): 0

**Hypertension** (%): intervention: 85.7; control: 92.9

**Diabetes** (%): intervention: 28.6; control: 64.3

**Atrial fibrillation** (%): not reported

**Hospitalisation for heart failure**: not reported

**Ischaemic heart disease** (%): intervention: 42.9; control: 57.1

**Stroke** (%): not reported

**Diuretic** (%): intervention: thiazide: 76.9, loop: 5.1; control: thiazide: 62.3, loop: 13

**Digoxin** (%): not reported

**Beta-blocker** (%): intervention: 79.5; control: 79.7

**ACEi** (%): intervention: 38.5; control: 29

**ARB** (%): intervention: 69.2; control: 73.9

**MRA** (%): study drug

---

**Interventions**

**Intervention**: spironolactone, mean dose of 37.5 mg/d (25-50 mg once a day)

**Comparator**: no treatment

**Concomitant medication**: “In our study, patients with diastolic heart failure were all treated with ACE inhibitors/ARA and Beta blockers.”

---

**Outcomes**

**Planned**: We are not aware of a published protocol or pre-registered clinical trial register entry

**Reported**: echocardiographic parameters, adverse events

---

**Notes**

no outcome data of interest to this review
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>&quot;The echocardiogram was made by a Cardiologist blinded to the clinical evaluation and treatment received.&quot;</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>unable to assess</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>no funding reported</td>
</tr>
</tbody>
</table>

### PARAGON-HF

#### Study characteristics

<table>
<thead>
<tr>
<th>Methods</th>
<th>Study design: RCT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Centres: 848 centres in 43 countries</td>
</tr>
<tr>
<td></td>
<td>Start of enrolment: June 2014</td>
</tr>
<tr>
<td></td>
<td>End of enrolment: December 2016</td>
</tr>
<tr>
<td></td>
<td>Follow-up: median 35 months</td>
</tr>
<tr>
<td></td>
<td>Run-in period: &quot;Single-blind run-in period&quot;, Valsartan run in phase median 15 days (interquartile range, 12-22). Sacubitril-valsartan run in phase - 19 days (interquartile range, 15 to 23 days)</td>
</tr>
</tbody>
</table>

| Participants | Inclusion criteria: "Eligibility requirements at screening included an age of 50 years or older, signs and symptoms of heart failure, NYHA class II to IV, an ejection fraction of 45% or higher within the previous 6 months, elevated level of natriuretic peptides (with different cutoffs depending on the occurrence of recent hospitalization for heart failure and presence of atrial fibrillation or flutter), evidence of structural heart disease, and diuretic therapy." |
|--------------| Exclusion criteria: Any prior measurement of LVEF <40%, ACS, cardiac surgery, other major CV surgery within 3 months, or urgent PCI within 3 months or and elective PCI within 30 days prior to entry, Any clinical event within 6 months prior to entry that could have reduced the LVEF (MI or CABG) unless echo confirms an EF>45%, Current acute decompensated HF requiring therapy, Patients who require treatment with 2 or more of the following: an angiotensin converting enzyme inhibitor (ACEI), an angiotensin receptor blocker (ARB) or a renin inhibitor, Alternative reason for shortness of breath such as: significant pulmonary disease or severe COPD, hemoglobin (Hgb) <10 g/dl, or body mass index (BMI) >
40 kg/m², Systolic blood pressure (SBP) ≥ 180 mmHg at entry, or SBP >150 mmHg and <180 mmHg at entry unless the patient is receiving 3 or more antihypertensive drugs, or SBP < 110 mmHg at entry.

Randomised (N): 4822 (intervention: 2419; control: 2403)
Withdrawn (N): for reasons other than death: 26 (intervention: 12 patients - good clinical practice violation; control: 14 patients - due to good clinical practice violation)
Lost to follow-up (N): 2
Analysed (N): 4796 (intervention: 2407; control: 2389)

Age (years, mean, SD): intervention: 72.7, 8.3; control: 72.8, 8.5
Sex (% men): intervention: 48.4; control: 48.2
Ethnicity (%): intervention: White 81.6, Black 2.2, Asian 12.3, Other 4.0; control: White 81.4, Black 2.1, Asian 13.0, Other 3.6

Systolic blood pressure (mmHg, mean, SD): intervention: 130, 15.6; control: 130.6, 15.3
Heart rate (beats/minute, SD): intervention: 70.6, 12.3; control: 70.3, 12.2
BMI (mean, SD): intervention: 30.2, 4.9; control: 30.3, 5.1
Serum creatinine (mg/dL, SD): intervention: 1.1, 0.3; control: 1.1, 0.3

B-type natriuretic peptide not reported
NT pro B-type natriuretic peptide (pg/mL, median (IQR)): intervention: 904 (475 - 1596); control: 915 (453 - 1625)
LVEF (% mean, SD): intervention: 57.6, 7.8; control: 57.5, 8.0
NYHA class I (%): intervention: 3; control: 2
NYHA class II (%): intervention: 77.5; control: 77
NYHA class III (%): intervention: 19; control: 19.8
NYHA class IV (%): intervention: 0.3; control: 0.5
Hypertension (%): intervention: 95.7; control: 95.4
Diabetes (%): intervention: 43.5; control: 42.5
Atrial fibrillation (%): intervention: 32.2; control: 32.5
Hospitalisation for heart failure (%): intervention: 47.2; control: 49
Coronary heart disease (%): intervention: 37.4; control: 34.5
Stroke (%): intervention: 11.1; control: 10.1
Diuretic (%): intervention: 95.3; control: 95.9
Digoxin (%): not reported
Beta-blocker (%): intervention: 79.9; control: 79.5
ACEI/ARB (%): intervention: 86.2; control: 86.4
MRA (%): intervention: 24.6; control: 27.1

Interventions

Intervention: Sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily)
Comparator: valsartan (target dose, 160 mg twice daily)
Concomitant medication: From protocol: “patients will continue to take optimal background therapy to treat co-morbid conditions, as considered appropriate by the investigator and in accordance with standard therapy guidelines, with the exception of an ACEI or ARB as this will be replaced by study drug.”

Outcomes

Planned: (from protocol): Primary objective: To compare sacubitril/valsartan to valsartan in reducing the rate of the composite endpoint of cardiovascular death and total (first and recurrent) HF hospitalizations in HF patients (NYHA functional class II to IV) with preserved EF (LVEF ≥45%). Secondary objectives: changes in the clinical summary score for HF symptoms and physical limitations, as assessed by the KCCQ), improving NYHA functional classification, delaying the time to first occurrence of a composite renal endpoint, delaying the time to all-cause mortality.

Reported: "The primary outcome was a composite of total (first and recurrent) hospitalizations for heart failure and death from cardiovascular causes. Secondary outcomes were the change from baseline to 8 months in the clinical summary score on the Kansas City Cardiomyopathy Questionnaire (KCCQ)12 (scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations); the change from baseline to 8 months in NYHA class; the first occurrence of a decline in renal function (decrease in the estimated glomerular filtration rate of ≥50%, development of end-stage renal disease, or death due to renal failure) in a time-to-event analysis; and death from any cause in a time-to-first-event analysis."

Notes

Funding: Novartis "The steering committee designed and oversaw the conduct of the trial and data analysis, in collaboration with the sponsor, Novartis."

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>From protocol: &quot;all eligible patients will be randomized via Interactive Response Technology (IRT) to one of the treatment arms.&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>From protocol: &quot;A patient randomization list will be produced by the IRT provider using a validated system that automates the random assignment of patients numbers to randomization numbers. These randomization numbers are linked to the different treatment arms, which in turn are linked to medication numbers&quot;</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Low risk</td>
<td>From protocol: &quot;patients, investigator staff, persons performing the assessments, and data analysts will remain blind to the identity of the treatment from the time of randomization until database lock&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>All the outcomes except KCCQ score and NYHA class were blindly adjudicated according to pre-specified criteria.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>ITT performed on all outcomes.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Primary and secondary outcomes reported as planned.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other concerns</td>
</tr>
</tbody>
</table>
**Study characteristics**

### Methods
- **Study design:** RCT
- **Centres:** not reported
- **Start of enrolment:** 22 August 2017
- **End of enrolment:** 28 October 2019
- **Follow-up:** 24 weeks
- **Run-in period:** none

### Participants
- **Actual enrolment:** 2572

**Inclusion criteria:**
- Age ≥45 years
- Symptoms of HF (NYHA class II-IV) requiring diuretics
- LVEF > 40%
- Structural heart disease (LA E and/or LVH)
- Receiving appropriate therapy for CV comorbidities
- Patients treated with prior ACEi and ARB must have a history of hypertension
- KCCQ clinical summary score <75 at screening
- Elevated NT-proBNP at screening (>220 pg/mL if not in AF or >600 pg/mL if in AF)

**Exclusion criteria:**
- Any prior echo LVEF ≤ 40%
- Current acute decompensated HF requiring therapy
- Walk distance primarily limited by non-cardiac comorbidities at screening
- Alternative reason(s) for HF signs and symptoms (such as chronic obstructive pulmonary disorder)
- At screening SBP < 110 mmHg or ≥180 mmHg, or ≥150 to <180 mmHg unless patient is receiving three or more antihypertensive drugs

**Randomised** (N): 2572 (intervention: 1286; control: 1286)

**Withdrawn** (N): intervention: 174 (patients’ decision: 42, adverse events: 116, death: 7, others: 9); control: 149 (patients’ decision: 45, adverse events: 87, death: 9, others: 8)

**Lost to follow-up** (N): not reported

**Analysed** (N): 2566 (intervention: 1281; control: 1285)
- **Age** (years, mean, SD): intervention: 73, 8.4; control: 72, 8.6
- **Sex** (% men): intervention: 50; control: 49
- **Ethnicity** (%): intervention: White 87; control: White 87
- **Systolic blood pressure** (mmHg, mean, SD): intervention: 133, 14.0; control: 134, 14.5
- **Heart rate** (beats/minute, SD): not reported
- **BMI** (mean, SD): intervention: 31, 5.0; control: 31, 4.8
- **Serum creatinine** (mg/dL, SD): not reported
- **B-type natriuretic peptide** not reported
**NT pro B-type natriuretic peptide (pg/mL, median (IQR)):**
- Intervention: 786 (415 - 1401);
- Control: 760 (380 - 1398)

**LVEF (% , mean, SD):**
- Intervention: 57, 8.3;
- Control: 56, 8.0

**NYHA class I (%):**
- Intervention: 0.1;
- Control: 0.3

**NYHA class II (%):**
- Intervention: 67;
- Control: 68

**NYHA class III (%):**
- Intervention: 32;
- Control: 31

**NYHA class IV (%):**
- Intervention: 0.4;
- Control: 0.3

**Hypertension (%):**
- Intervention: 97;
- Control: 97

**Diabetes (%):**
- Intervention: 39;
- Control: 41

**Atrial fibrillation at any time in the past (%):**
- Intervention: 55;
- Control: 54

**Hospitalisation for heart failure (%):**
- Intervention: 35;
- Control: 36

**Coronary heart disease (%):** not reported

**Stroke (%):** not reported

**Diuretic (%):**
- Intervention: 100;
- Control: 100

**Digoxin (%):** not reported

**Beta-blocker (%):**
- Intervention: 84;
- Control: 83

**ACEI (%):**
- Intervention: 41;
- Control: 42

**ARB (%):**
- Intervention: 46;
- Control: 46

**MRA (%):**
- Intervention: 33;
- Control: 31

---

**Interventions**

Sacubitril/Valsartan up titrated to 97/103 mg bid

All patients who fulfil the inclusion/exclusion criteria were stratified before randomization based upon prior therapy for comorbidities to one of three strata: ACEi, ARB or no RASI. Patients in the ACEi strata received LCZ696 or enalapril. Patients in the ARB strata received LCZ696 or valsartan. Patients in the no RASI strata received LCZ696 or matching placebo.

---

**Outcomes**

**Primary:** Change from baseline in N-terminal pro-brain natriuretic peptide (NT-proBNP) after 12 weeks

**Secondary:**
- Mean change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) [Time Frame: baseline, week 24]
- Percentage of patients with ≥ 5-points deterioration in KCCQ CSS at Week 24 [Time Frame: baseline, week 24]
- Percentage of patients with ≥ 5-points improvement in KCCQ CSS at Week 24 [Time Frame: baseline, week 24]
- Change from baseline in the 6-minute walk test (6MW) to week 24 [Time Frame: baseline, week 24]
- Change in NYHA functional class from baseline to week 24 [Time Frame: baseline, week 24]
- Change from baseline in SF-36 physical component summary (PCS) score to week 24 [Time Frame: baseline, week 24]

**Exploratory endpoints:**
- change in eGFR
- HF hospitalisation and HF death
Notes

Comparison of interest: LCZ696 or matching placebo
Sponsor: Novartis Pharmaceuticals
Other identifiers: CLCZ696D2302, 2016-003410-28 (EudraCT Number)
Results from presentation at ESC Congress 2020 included (unpublished).

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not yet reported.</td>
<td></td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not yet reported.</td>
<td></td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>Not yet reported.</td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Not yet reported.</td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Not yet reported.</td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Not yet reported.</td>
<td></td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Unable to assess</td>
<td></td>
</tr>
</tbody>
</table>

### Paramount

#### Study characteristics

**Methods**

- **Study design:** RCT
- **Centres:** 65 centres and 13 countries
- **Start of enrolment:** 2 November 2009
- **End of enrolment:** 31 March 2011
- **Follow-up:** 36 weeks
- **Run-in period:** "2-week, single-blind, placebo run-in period" "continued background treatment" "ACE inhibitors and ARBs were required to be discontinued 24 h before randomisation"

**Participants**

- **Inclusion criteria:** "Men and women aged 40 years or older with a left ventricular ejection fraction (LVEF) of 45% or higher and a documented history of heart failure with associated signs or symptoms (dyspnoea on exertion, orthopnoea, paroxysmal dyspnoea, and peripheral oedema) were eligible. Patients were required to have NT-proBNP greater than 400 pg/mL at screening, be on diuretic therapy, and have a systolic blood pressure less than 140 mm Hg, or 160 mm Hg or less if on three or more blood
pressure drugs at randomisation, have an estimated glomerular filtration rate (eGFR) of at least 30 mL/min per 1.73 m² at screening (calculated by the Modification of Diet in Renal Disease formula), and a potassium concentration of no more than 5.2 mmol/L.

**Exclusion criteria:** "Patients were excluded if they had previous LVEF less than 45% at any time, isolated right heart failure due to pulmonary disease, dyspnoea due to non-cardiac causes such as pulmonary disease, anaemia, or severe obesity, primary valvular or myocardial diseases, or coronary artery or cerebrovascular disease needing revascularisation within 3 months of screening or likely to need revascularisation during the trial."

**Randomised (N):** 308 (intervention: 149; control: 152)

**Withdrawn (N):** for reasons other than death: 44 (intervention: 20 participants = 13 adverse events, 6 withdrawal of consent, 1 protocol violation; control: 24 participants = 16 adverse events, 8 withdrawal of consent)

**Lost to follow-up (N):** 16 (intervention: 8 participants = 1 death, 4 lost to follow up, 3 administrative reasons; control: 8 participants = 1 lost to follow up, 2 death, 5 administrative reasons)

**Analysed (N):** depending on outcome (adverse events: ITT, others PP)

**Age (years, mean, SD):** intervention: 70.9 ± 9.4; control: 71.2 ± 8.9

**Sex (% men):** intervention: 43; control: 44

**Ethnicity (%):** not reported

**Systolic blood pressure (mmHg, median, IQR):** intervention: 136 (130-145); control: 136 (126-145)

**Heart rate (beats/minutes, SD):** intervention: 69 ± 12; control: 70 ± 14

**BMI (mean, SD):** intervention: 30.1 ± 5.5; control: 29.8 ± 6.1

**Serum creatinine** not reported

**B-type natriuretic peptide** not reported

**NT pro B-type natriuretic peptide (pg/mL, median (IQR)):** intervention: 828 (460 - 1341); control: 939 (582 - 1490)

**LVEF (%, mean, SD):** intervention: 58±7.3; control: 58 ± 8.1

**NYHA class I (%):** intervention: 1; control: 1

**NYHA class II (%):** intervention: 81; control: 78

**NYHA class III (%):** intervention: 19; control: 21

**NYHA class IV (%):** 0

**Hypertension (%):** intervention: 95; control: 92

**Diabetes (%):** intervention: 41; control: 35

**Atrial fibrillation (%):** intervention: 40; control: 43

**Hospitalisation for heart failure (%):** intervention: 40; control: 45

**Coronary heart disease (myocardial infarction, %):** intervention: 21; control: 20

**Stroke (%):** not reported

**Diuretic (%):** 100

**Digoxin (%):** not reported

**Beta-blocker (%):** intervention: 79; control: 80
<table>
<thead>
<tr>
<th><strong>Interventions</strong></th>
<th><strong>Intervention:</strong> LCZ696 (Sacubitril/ Valsartan), 50 mg twice daily, titrated to final dose of 200 mg twice daily over 2 to 4 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Comparator:</strong> valsartan 40 mg twice daily, titrated to their final doses of 160 mg twice daily over 2 to 4 weeks</td>
</tr>
<tr>
<td><strong>Concomitant medication:</strong></td>
<td>&quot;at the discretion of the treating physicians&quot;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Outcomes</strong></th>
<th><strong>Planned</strong> (from first entry on clinicaltrials.gov): primary outcome measures: change in log-scale in NT-proBNP. Secondary outcome measures: change in log-scale in BNP, MR-proBNP, cGMP; change in echocardiography parameters; class indicators of signs and symptoms of heart failure at each visit; change in the overall summary score and individual domain score of the Kansas City Cardiomyopathy questionnaire; change in clinical composite score (NYHA and global patient assessment score)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Reported:</strong> &quot;The primary study endpoint was change from baseline in NT-proBNP assessed at 12 weeks. Secondary endpoints included changes in echocardiographic measures (left ventricular volumes and ejection fraction, left atrial volume, measures of diastolic function) and change in blood pressure, as well as change in New York Heart Association (NYHA) class, clinical composite assessment, and quality of life (Kansas City cardiomyopathy questionnaire; KCCQ).&quot;</td>
</tr>
</tbody>
</table>

| **Notes** | **Funding:** Novartis. "PARAMOUNT was designed jointly by the academic steering committee and the sponsor, which funded the trial. The sponsor was responsible for study management, data collection, and data analysis; all analyses were replicated by an independent statistician at the Brigham and Women’s Hospital. The report was drafted by the first author and revised by all authors who have read and agree to the report as written and the decision to submit for publication. The first author had full access to and takes full responsibility for the integrity of the data."

**Trialists’ conflict of interest:** SDS, MZ, BP, AV, AS, MP, and JJVM have received research support and have consulted for Novartis. VS, TB, JG and ML are employees of Novartis. EK-K and MT declare that they have no conflicts of interest. |

<table>
<thead>
<tr>
<th><strong>Risk of bias</strong></th>
<th><strong>Bias</strong></th>
<th><strong>Authors' judgement</strong></th>
<th><strong>Support for judgement</strong></th>
</tr>
</thead>
</table>
|                  | Random sequence generation (selection bias) | Low risk | "computer-generated random sequence with a block size of four, stratified by previous use of ACE inhibitor or ARB and region."
|                  | Allocation concealment (selection bias) | Low risk | "assignment used a central inter-active voice response system with randomisation codes generated by the sponsor. The system assigned a randomisation number to each patient, which linked the patient to a treatment group and specified a unique drug number for study drug to be dispensed. Placebo and active treatment were identical in appearance."
|                  | Blinding of participants and personnel (performance bias) All outcomes | Low risk | "study investigators and participants were masked to treatment for the duration of the trial"
|                  | Blinding of outcome assessment (detection bias) All outcomes | Low risk | Unclear - sponsor was responsible for study management, data collection, and data analysis - all analyses were replicated by an independent statistician at the Brigham and Women’s Hospital |
|                  | Incomplete outcome data (attrition bias) | Low risk | ITT used |
**PARAMOUNT (Continued)**

<table>
<thead>
<tr>
<th>All outcomes</th>
<th></th>
<th>Low risk</th>
<th>Appears all primary and secondary outcomes mentioned</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selective reporting (reporting bias)</td>
<td></td>
<td>Low risk</td>
<td></td>
</tr>
<tr>
<td>Other bias</td>
<td></td>
<td>Low risk</td>
<td>No concerns</td>
</tr>
</tbody>
</table>

**Parthasarathy 2009**

**Study characteristics**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Study design: RCT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Centres: 10 (5 in Germany, 5 in UK)</td>
</tr>
<tr>
<td></td>
<td>Start of enrolment: December 2002 (from clinical trial registry)</td>
</tr>
<tr>
<td></td>
<td>End of enrolment: March 2007 (from clinical trial registry)</td>
</tr>
<tr>
<td></td>
<td>Mean follow-up: 13.8 weeks</td>
</tr>
<tr>
<td></td>
<td>Run-in period: not reported</td>
</tr>
</tbody>
</table>

| Participants | Inclusion criteria: "Patients were ≥ 21 years of age and had the following characteristics: symptoms of breathlessness on exertion (based on patient questioning) with normal lung function at rest, an extrapolated maximum oxygen consumption (EMOC) and/or peak oxygen consumption <85% of the age-corrected normal value on cardiopulmonary exercise testing, preserved systolic function (ejection fraction ≥ 40%) with evidence of diastolic dysfunction on echocardiography (≥ 1 of the following: abnormal flow propagation velocity, prolongation of isovolumic relaxation time, E/A ratio reversal, and abnormal E deceleration time), and ability to exercise for ≥ 3 min on a treadmill." |
|              | Exclusion criteria: "Uncontrolled hypertension (sitting systolic blood pressure >160 mmHg or sitting diastolic blood pressure > 100 mmHg) Presence of clinically significant asthma or chronic obstructive pulmonary disease Abnormal lung function (forced expiratory volume in 1 s [FEV1]/forced vital capacity [FVC] ratio < 75%) Treatment with ≥ 2 bronchodilators Exercise limiting symptomatic angina Haemodynamically significant cardiac valve disease Documented evidence of systolic heart failure (ejection fraction <40%, fractional shortening <25%) Uncontrolled atrial fibrillation (> 100 b.p.m. at rest) History of myocardial infarction, percutaneous transluminal coronary angioplasty, or coronary artery bypass within the previous 3 months Use of ARBs within the previous 1 month" |
|              | Randomised (N): 152 (70 intervention, 82 control) |
|              | Withdrawn (N): for reasons other than death 5 (4 intervention (N = 2 adverse events, N = 1 protocol violation, N = 1 withdrew consent), 1 control (N = 1 protocol violation)) |
|              | Lost to follow-up (N): 0 |
|              | Analysed (N): 152 (70 intervention, 82 control), except QoL: 67 intervention, 82 placebo |
| Age (years, mean, SD): intervention: 61.0, 11.5; control: 63.1, 10.3 |
| Sex (% men): intervention: 50; control: 50 |
| Ethnicity (%): intervention: Caucasian: 95.6, Other: 4.4, control: Caucasian: 93.9, other: 6.1 |
| Systolic blood pressure not reported |
| Heart rate not reported |
| BMI (mean, SD): intervention: 31.0, 4.7; control: 29.3, 5.3 |
Serum creatinine: not reported

B-type natriuretic peptide (pg/mL): intervention: 93.2, 80.2; control: 120.3, 119.5

NT pro B-type natriuretic peptide (pg/mL): not reported

LVEF (%): intervention: 70.48, 11.43; control: 71.52, 12.08

NYHA class: not reported

Hypertension (%): intervention: 92.2; control: 89.0

Diabetes (%): intervention: 22.1; control: 14.6

Atrial fibrillation (%): intervention: 16.2; control: 9.8

Hospitalisation for heart failure: not reported

Coronary heart disease (%): not reported

Stroke (%): not reported

Diuretic (%): not reported

Digoxin (%): not reported

Beta-blocker (%): intervention: 33.8; control: 34.1

ACEI (%): intervention: 41.2; control: 37.8

ARB (%): study drug

MRA (%): not reported

Interventions

**Intervention**: valsartan. 80 mg once daily. "Study medication was force-titrated between days 5 and 14 (Visit 3) to valsartan 160 mg daily or matching placebo, and between days 10 and 28 (Visit 4) to valsartan 320 mg daily or matching placebo. Up-titration occurred provided the current dose was adequately tolerated. Down-titration occurred for any of the following: evidence of persistent symptomatic hypotension, systolic blood pressure <100 mmHg or decrease of >40 mm Hg from baseline, creatinine increase of >50% from baseline, or if the investigators judged the given dose level as potentially harmful to the patient. A safety evaluation was performed between days 15 and 42 (Visit 5). After the dose-titration period, patients received their maximum tolerated dose through to the end of the study at week 14 (+7 days) (Visit 6)."

**Comparator**: matching placebo

**Concomitant medication**: "Use of other ARBs as concomitant medication was prohibited, but other background medications (e.g. diuretics, calcium channel blockers) were allowed and continued throughout the study. Angiotensin-converting enzyme inhibitors and beta-blockers were permitted, although therapy was to be maintained at the same level throughout the study and no new treatment with one of these drugs was permitted during the trial."

Outcomes

**Planned**: unclear

**Reported**: exercise time, neurohormone levels, echocardiographic parameters, QoL, adverse events

Notes

Response to email enquiring for further details received on 2 December 2017: confirmed that no outcome data are available for heart failure hospitalisation and hyperkalaemia and provided number of centres.

Risk of bias
**Parthasarathy 2009 (Continued)**

<table>
<thead>
<tr>
<th>Study characteristic</th>
<th>Method</th>
<th>Risk of Bias</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td></td>
<td>&quot;Eligible patients were allocated to either the active treatment group or the placebo group according to a stratified randomization process in order to minimize the differences between study groups. Stratification was based on exercise test time at Visit 2 divided into sections of: 3–6 min, 6 min to 9 min, and 9 min, each stratum being randomized in blocks of 4.&quot; No details on how the random sequence was generated.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
<td></td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Low risk</td>
<td>&quot;double-blind&quot; but not specified</td>
<td>&quot;To maintain blinding, valsartan and placebo capsules were identical in appearance.&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>ITT, higher withdrawals in intervention group (5.7%) compared to control (1.2%)</td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>unable to assess, unaware of published protocol and clinical trial register entry (Sept 2005) after planned study start (Dec 2002)</td>
<td></td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>&quot;H.K.P and B.P have no conflicts of interest; C.D.A., M.W., and P.B. remain in the employ of Novartis Pharma and have no other conflicts of interest; A.D.S. received one honorarium (£1000) from Novartis for intellectual input to the rationale and the design of the study; T.M.MacD: competing interests statement Nov 2008: my department has had research grants from GSK, Aventis, Novartis, AstraZeneca, BMS, Boehringer Ingelheim, Pfizer, and Novartis, I am or have been the principal investigator on trials paid for by Pfizer and Novartis, I have been paid Consulting fees by Pfizer, Novartis, Kaiser Permanante, Take-da, Recordati, Quintiles, and Speedel.&quot; &quot;The study was funded by Novartis.&quot;</td>
<td></td>
</tr>
</tbody>
</table>

**PEP-CHF**

**Study characteristics**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Study design: RCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centres: 53 centres (Bulgaria (3), Czech Republic (5), Hungary (10), Ireland (1), Poland (26), Russia (1), Slovakia (2), and the UK (5))</td>
<td></td>
</tr>
<tr>
<td>Start of enrolment: 2000</td>
<td></td>
</tr>
<tr>
<td>End of enrolment: 2003</td>
<td></td>
</tr>
<tr>
<td>Mean follow-up: mean follow-up 26.2 months (range, excluding deaths 12.0-54.2)</td>
<td></td>
</tr>
<tr>
<td>Run-in period: &quot;A 24-h open label run in phase, during which patients will receive a single 2-mg dose of perindopril&quot;</td>
<td></td>
</tr>
</tbody>
</table>
**Inclusion criteria:** "Patients had to be aged ≥70 years and treated with diuretics for a clinical diagnosis of CHF due to LV diastolic dysfunction as defined below and to have had a cardiovascular hospitalization within the previous 6 months. Patients had to be able to walk without the aid of another person in order to exclude very frail patients who might not respond to any treatment." Patients had to be aged 70 years and treated with diuretics for a clinical diagnosis of CHF due to LV diastolic dysfunction as defined below and to have had a cardiovascular hospitalization within the previous 6 months. Patients had to be able to walk without the aid of another person in order to exclude very frail patients who might not respond to any treatment. "As there are no widely agreed criteria for the diagnosis of diastolic heart failure, at least three out of nine clinical and at least two out of four additional echocardiographic criteria were required. Clinical criteria were: exertional breathlessness; orthopnoea or paroxysmal nocturnal dyspnoea; ankle swelling; improved breathlessness with diuretic therapy; increased jugular venous pressure; prior episode of clinical pulmonary oedema; prior MI; cardiothoracic ratio > 0.55; and previous radiological pulmonary oedema. Echocardiographic criteria were: an LV wall motion index of 1.4–1.6 inclusive, roughly equivalent to an LVEF fraction between 40 and 50%, since abnormal diastolic dysfunction is often associated with some impairment of systolic function; a left atrial diameter > 25 mm/m² body surface area or > 40 mm because chronic elevation of LV filling pressure should lead to atrial dilatation; an interventricular septum or posterior LV wall ≥ 12 mm in thickness suggesting hypertrophy, a common cause of impaired diastolic function or, finally, evidence of impaired LV filling by at least one of the criteria recommended by the European Society of Cardiology Study Group on Diastolic Heart Failure. These included an E/A ratio < 0.5 or deceleration time of > 280 ms from the mitral inflow pattern or an isovolumic relaxation time of > 105 ms. These criteria effectively exclude patients with atrial fibrillation (AF) and therefore, in a protocol modification early in the course of the study, this arrhythmia was counted as equivalent to evidence of impaired LV filling by Doppler."

**Exclusion criteria:** "Patients with a wall motion index of < 1.4, roughly equivalent to an LVEF of 40%, were excluded." "Important exclusion criteria were haemodynamically significant valve disease, stroke within the previous month, sitting systolic arterial pressure < 100 mmHg, serum creatinine > 200 mmol/L or potassium > 5.4mmol/L, history of ACE-inhibitor intolerance or use of an ACE-inhibitor or angiotensin receptor blocker within the previous week, potassium-sparing diuretics (other than low-dose spironolactone), or potassium supplements."

**Randomised (N):** 850 (424 intervention, 426 control)

**Withdrawn (N):** due to serious adverse events 13 (9 intervention, 4 control)

**Lost to follow-up (N):** 4 (4 intervention, 0 control)

**Analysed (N):** 846 (420 intervention, 426 control)

**Age (years, median, IQR):** intervention: 75, 72–79; control: 75, 72-79

**Sex (% men):** intervention: 46; control: 43

**Ethnicity (%):** not reported

**Systolic blood pressure (mmHg, median, IQR):** intervention: 138, 128–150; control: 140, 129–150

**Heart rate (beats/min, median, IQR):** intervention: 74, 66 to 81; control: 73, 66 to 82

**BMI (median, IQR):** intervention: 27.5, 25.1 to 30.0; control: 27.6, 25.3 to 30.7

**Serum creatinine (mg/dL, median, IQR, converted from umol/L using http://www.endmem o.com/medical/unitconvert/Creatinine.php):** intervention: 1.07, 0.92-1.24; control: 1.10, 0.95-1.26

**B-type natriuretic peptide (pg/mL):** not reported

**NT pro B-type natriuretic peptide (pg/mL):** intervention: 335, 160–1014 (for subgroup n = 191); control: 453, 206–1045 (for subgroup n = 184)

**LVEF (% median, IQR):** intervention: 65, 56–66; control: 64, 56–66

**NYHA class I/II (%):** intervention: 77; control: 74

**NYHA class III/IV (%):** intervention: 23; control: 26
Interventions

**Intervention:** perindopril. "Patients were reviewed weekly for the first 5 weeks to ensure that treatment was tolerated and to check serum potassium and creatinine. The dose of perindopril was increased to 4 mg once daily at the second follow-up visit if no clinical contraindication, such as hypotension or worsening renal function existed. Study medication was reduced or discontinued if serum creatinine rose to > 250 mmol/L or by > 50 mmol/L from baseline or potassium rose to > 5.5 mmol/L. Patients were reviewed at 8, 12, and every 12 weeks thereafter until 1 year follow-up, then according to the investigator's judgment until the end of the study."

**Comparator:** placebo

**Concomitant medication:** not reported

Outcomes

**Planned:** "The primary end-point of this study will be the time to first occurrence of the combined end-point of total mortality and unplanned heart failure related hospitalisation."

"Secondary

1. Death all causes

2. Death or worsening symptoms and/or signs of CHF requiring hospitalisation or an increase in diuretic treatment for CHF of >40 mg/day of frusemide compared to baseline or equivalent. This will be a time to first event analysis.

3. Cardiovascular mortality.

4. Number of days alive and out of hospital.

5. Number of days alive and not in hospital for cardiovascular reasons including CHF

6. QoL questionnaire change from baseline to 1 year.

7. CHF symptom score change from baseline to 1 year.

8. NYHA heart failure score change from baseline to 1 year." (Cleland 1999)

**Reported:** primary outcome, all-cause mortality, cardiovascular mortality, HF hospitalisation, days in hospital for cardiovascular reasons, days in hospital for any reason, NYHA class, 6-min walk distance, plasma concentrations of NTproBNP, cardiovascular death or unplanned HF related hospitalisation, stroke, acute coronary syndrome, blood pressure, serum potassium and creatinine
**PEP-CHF** (Continued)

**Planned but not reported:** QoL

**Notes**
Protocol (Cleland 1999) mentions subgroup analyses by age and sex but not found in published papers. Emailed investigators. No response.

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>&quot;patients were randomly assigned from a computer-generated list in blocks of four within treatment centres&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>&quot;through a centrally administered process, concealed from the study investigators.&quot;</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Low risk</td>
<td>&quot;The study medication was provided in externally indistinguishable tablets.&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>&quot;Potential classifying events were independently classified by MT and JGFC, blind to treatment allocation.&quot;</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>4/850 lost to follow up</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Primary outcomes reported, but not all secondary outcomes reported as planned (eg QoL)</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>&quot;Servier funded the trial and provided site monitors for source data verification. The sponsor had access to the database and participated in the analysis under the supervision of an independent statistician (NF). The Steering Committee wrote the manuscript. Servier representatives commented on it prior to submission.&quot;</td>
</tr>
</tbody>
</table>

**RAAM-PEF**

**Study characteristics**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Study design: individual, placebo-controlled, double-blind RCT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Centres: 1 medical centre, USA</td>
</tr>
<tr>
<td></td>
<td>Start of study: August 2004</td>
</tr>
<tr>
<td></td>
<td>End of Study: October 2007</td>
</tr>
<tr>
<td></td>
<td>Follow-up: 24 weeks</td>
</tr>
<tr>
<td></td>
<td>Run-in period: &quot;2-week open label period of eplerenone 25 mg daily to establish tolerability&quot;</td>
</tr>
</tbody>
</table>

**Participants**

**Inclusion criteria:** "All patients were defined as having HFP EF based on the presence of all the following criteria: 1) Clinical HF for ≥ 2 months before the screening visit with New York Heart Association (NY-HA) functional Class II or III HF symptoms at enrollment; 2) left ventricular ejection fraction ≥ 50% (by echocardiography, radionuclide ventriculography, or contrast angiography) within 2 months of screening; and 3) B-type natriuretic peptide (BNP) levels ≥ 100 pg/mL within 2 months of screening. Other in-
Conclusion criteria included age ≥ 18 years, systolic blood pressure ≤ 150, and diastolic blood pressure ≤ 95 mm Hg for 4 weeks before and at enrollment, ability to walk ≥ 50 m, current use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), if tolerated, for at least 4 weeks before enrollment. Patients were expected to be euvolemic on clinical examination or all attempts were made to achieve euvolemia with change in diuretic doses prior to enrollment into the study.

Exclusion criteria: "Exclusion criteria included the need for eplerenone or spironolactone for treatment of other comorbid illnesses (e.g., ascites); hepatic impairment; serum creatinine > 2.5 mg/dL or serum potassium > 5.0 mEq/L; prior intolerance to eplerenone or spironolactone; significant valvular heart disease, pericardial disease or severe chronic lung disease; patients with technically inadequate echocardiographic windows; patients with severe mitral annular calcification; unstable angina or acute myocardial infarction within 4 weeks before enrollment; severe peripheral vascular disease with claudication or other physical conditions limiting the distance walked; pregnant or lactating females; history of active alcohol or substance abuse or history of repeated noncompliance; history of cancer within 3 years (other than resected cutaneous basal or squamous cell carcinoma); and participation in any other drug trial within 30 days before enrollment."

Randomised (N): 46 (23 intervention, 23 control)
Withdrawn (N): 0
Lost to follow-up (N): 2 (2 intervention (relocation))
Analysed (N): 44 (21 intervention, 23 control)
Age (years, mean, SD): intervention: 72.2, 9.8; control: 68.7, 9.1
Sex (% men): intervention: 95.2; control: 91.3
Ethnicity (%): not reported
Systolic blood pressure (mmHg, mean, SD): intervention: 129.7, 12.4; control: 130.6, 10.7
Heart rate (beats/min, mean, SD): intervention: 65.0, 9.3; control: 63.0, 12.1
BMI (mean, SD): intervention: 30.1, 6.1; control: 34.6, 5.8
Serum creatinine (mg/dL, mean, SD): intervention: 1.62, 0.50; control: 1.43, 0.51
B-type natriuretic peptide (pg/mL): intervention: 254.9, 163.0; control: 283.5, 211.6
NT pro B-type natriuretic peptide (pg/mL): not reported
LVEF (% median, IQR): intervention: 62.1, 5.0; control: 62.5, 7.5
NYHA class I (%): 0
NYHA class II (%): intervention: 66.7; control: 52.2
NYHA class III (%): intervention: 33.3; control: 47.8
NYHA class IV (%): 0
Hypertension (%): 100
Diabetes (%): intervention: 61.9; control: 60.9
Atrial fibrillation (%): intervention: 14.3; control: 13.0
Hospitalisation for heart failure (%): intervention: 42.8; control: 60.9
Coronary heart disease (%): intervention: 66.7; control: 47.8
Stroke (%): not reported
Diuretic (%): intervention: 95.2; control: 100
Digoxin (%): not reported
Beta-blocker (%): intervention: 76.2; control: 82.6
ACEI or ARB (%): intervention: 95.2; control: 100
MRA (%): study drug

Interventions

Intervention: eplerenone. "After randomization, patients received study drug at a dose of 25 mg daily for 2 weeks followed by 50 mg daily for 22 weeks, if tolerated" "Study drug dose was adjusted according to the following algorithm. If the serum K+ was ≥ 5.0 mEq/L but < 5.5 mEq/L, the dose of eplerenone was not increased. If the level was ≥ 5.5 but < 6.0 mEq/L, the dose of eplerenone was reduced to half. If the serum potassium was ≥ 6.0 mEq/L eplerenone was stopped, at least transiently. If an underlying condition that was correctable was identified, the medication could be restarted at the lowest dose once the serum K+ was < 5.0 mEq/L. If no correctable cause was identified for the serum potassium ≥ 6.0 mEq/L, eplerenone was discontinued permanently and serum K+ was followed with adjustments in other medications as indicated. Oral potassium supplements were allowed if the serum potassium was < 4.0 mEq/L after the study drug was started."

Comparator: matching placebo

Concomitant medication: "Potassium supplements were stopped when eplerenone was initiated."

Outcomes

Planned: in clinical trial register: all of the below, except NYHA class, hospitalisation and mortality

Reported: primary: 6MWD. Secondary: echocardiographic measures of diastolic dysfunction, biomarkers including markers of collagen turnover and B-type natriuretic peptide, HF-related quality of life measured by the Kansas City Cardiomyopathy Questionnaire, NYHA class, hospitalisation, mortality

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Low risk</td>
<td>&quot;double-blind&quot; but no details</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>&quot;all end points were evaluated blinded to treatment allocation&quot;</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>ITT not used, analysis based on participants that completed study, minimal loss to follow-up (reasons reported)</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>although there is a clinical trial registry record, it's unclear whether this was a pre- or post-registration</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>&quot;Supported by a VA Clinical Research Service grant # CLIN-010-03S (to Dr. Deswal).&quot;</td>
</tr>
</tbody>
</table>

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)  
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
RAAM-PEF (Continued)

“The study was sponsored by the Department of Veterans Affairs (VA). The study drug was provided by Pfizer Pharmaceuticals, but they did not provide any other funding for the study and did not have any role in the conduct and analysis of this study”

originally registered as assessing spironolactone, then changed to epleronone

Sahoo 2016

Study characteristics

Methods

- **Study design**: RCT
- **Centres**: 1, India
- **Start of enrolment**: not reported
- **End of enrolment**: not reported
- **Mean follow-up**: 3-6 months
- **Run-in period**: not reported

Participants

- **Inclusion criteria**: "Patients with moderate or severe MR on color flow Doppler, LVEF ≥ 55%, and LV end-systolic dimension < 40 mm were included"
- **Exclusion criteria**: "Patients with NYHA class IV symptoms, known coronary artery disease, significant other valvular disease, serum creatinine > 2.5 mg/dL, and hypertension were excluded"
- **Randomised (N)**: 100 (48 intervention, 52 control)
- **Withdrawn** not reported
- **Lost to follow-up** not reported
- **Analysed (N)**: at 3 months: 100 (48 intervention, 52 control); at 6 months: 75 (39 intervention, 36 control)
- **Age (years, mean, SD)**: intervention: 30.24, 12.76; control: 29.6, 15.58
- **Sex (% men)**: intervention: 35.6; control: 22.7
- **Ethnicity (%)**: not reported
- **Systolic blood pressure (mmHg, mean, SD)**: intervention: 125, 10.1; control: 124.4, 7.4
- **Heart rate (beats/min, mean, SD)**: intervention: 90.1, 11.78; control: 88.5, 18.12
- **BMI**: intervention: 21.04, 4.74; control: 19.04, 4.7
- **Serum creatinine** not reported
- **B-type natriuretic peptide (pg/mL)**: intervention: 194, 178.5; control: 166, 165.7
- **NT pro B-type natriuretic peptide (pg/mL)**: not reported
- **LVEF (%, mean, SD)**: intervention: 62.5, 6.5; control: 61.4, 6.9
- **NYHA class**: "most patients were in NYHA class II (77%) while 23% were in NYHA class III"
- **Hypertension (%)**: intervention: 61.1; control: 62.3
- **Diabetes (%)**: intervention: 26.9; control: 25.3
Atrial fibrillation (%): intervention: 33.8; control: 35.5

Hospitalisation for heart failure: not reported

Coronary heart disease (%): intervention: 68.9; control: 67.6

Stroke (%): intervention: 0.1; control: 0

Diuretic (%): 92

Digoxin (%): 33

Beta-blocker (%): study drug

ACEI (%): 58

ARB (%): not reported

MRA (%): not reported

Interventions

Intervention: metoprolol succinate. "initiated at 12.5–25 mg/day and titrated as tolerated at 2-week intervals to a maximum of 100 mg/day. Prior to each escalation, care was taken to ensure that resting heart rate was > 60 bpm and systolic BP > 100 mm Hg"

Comparator: placebo

Concomitant medication: "in addition to ongoing therapy"

Outcomes

Planned: unclear as we did not identify a published protocol or clinical trial registry entry

Reported: withdrawals due to adverse events, echocardiographic outcomes, blood pressure, MR grade, NYHA class

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>&quot;by a computerized random number generating protocol&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>&quot;Detailed echocardiography […] was performed by two operators who were blinded to the treatment protocol.&quot;</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>unclear loss-to-follow up of 25 participants at 6 months as no reasons given</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>unable to assess</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>&quot;The authors declare no conflict of interest&quot;</td>
</tr>
</tbody>
</table>
SENIORS

Study characteristics

Methods

Study design: RCT
Centres: multi-centre, international (Czech Republic, Hungary, Italy, Ukraine, UK, France, Germany, Romania, Spain, Switzerland, The Netherlands)
Start of enrolment: September 2000
End of enrolment: December 2002
Mean follow-up: 21 months
Run-in period: no

Participants

Inclusion criteria: "To be eligible, patients had to be age ≥ 70 years, provide written informed consent, and have a clinical history of chronic HF with at least 1 of the following features: documented hospital admission within the previous 12 months with a discharge diagnosis of congestive HF or documented LVEF ≤ 35% within the previous 6 months."

Exclusion criteria: "The main exclusion criteria were new drug therapy for heart failure in the 6 weeks prior to randomization, any change in cardiovascular drug therapy in the 2 weeks prior to randomization, heart failure due primarily to uncorrected valvular heart disease, contraindication or previous intolerance to beta-blockers (e.g. heart rate < 60 beats/min or systolic blood pressure < 90 mmHg), current use of beta-blockers, significant hepatic or renal dysfunction, cerebrovascular accidents within the previous 3 months, and being on a waiting list for percutaneous coronary intervention or cardiac surgery or other major medical conditions that may have reduced survival during the period of the study."

Randomised (N): 2128 (1067 intervention, 1061 control); subgroup of interest: 643 (nebivolol N = 320, placebo N = 323)
Withdrawn not reported
Lost to follow-up (N): 37 (16 intervention, 21 control)
Analysed (N): 2128 (1067 intervention, 1061 control)
Age (years, mean, SD): intervention: 76.1, 4.8; control: 76.1, 4.6
Sex (% men): intervention: 61.6; control: 64.7
Ethnicity (%): not reported
Systolic blood pressure (mmHg, mean, SD): intervention: 138.6, 20.1; control: 139.5, 21.1
Heart rate (beats/min, mean, SD): intervention: 79.2, 13.6; control: 78.9, 13.7
BMI: not reported
Serum creatinine (mg/dL, mean, SD)*: intervention: 1.2, 0.4; control: 1.2, 0.4
B-type natriuretic peptide (pg/mL): not reported
NT pro B-type natriuretic peptide (pg/mL): not reported
LVEF (%, mean, SD): intervention: 36, 13; control: 36, 12
<table>
<thead>
<tr>
<th>NYHA class I (%)</th>
<th>Intervention: 3.0; control: 2.7</th>
</tr>
</thead>
<tbody>
<tr>
<td>NYHA class II (%)</td>
<td>Intervention: 56.5; control: 56.3</td>
</tr>
<tr>
<td>NYHA class III (%)</td>
<td>Intervention: 38.7; control: 38.7</td>
</tr>
<tr>
<td>NYHA class IV (%)</td>
<td>Intervention: 1.8; control: 2.3</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>Intervention: 61.1; control: 62.3</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>Intervention: 26.9; control: 25.3</td>
</tr>
<tr>
<td>Atrial fibrillation (%)</td>
<td>Intervention: 33.8; control: 35.5</td>
</tr>
<tr>
<td>Hospitalisation for heart failure</td>
<td>Not reported</td>
</tr>
<tr>
<td>Coronary heart disease (%)</td>
<td>Intervention: 68.9; control: 67.6</td>
</tr>
<tr>
<td>Stroke (%)</td>
<td>Intervention: 0.1; control: 0</td>
</tr>
<tr>
<td>Diuretic (%)</td>
<td>Intervention: 85.8; control: 85.5</td>
</tr>
<tr>
<td>Digoxin (%)</td>
<td>Not reported</td>
</tr>
<tr>
<td>Beta-blocker (%)</td>
<td>Study drug</td>
</tr>
<tr>
<td>ACEI (%)</td>
<td>Intervention: 81.7; control: 82.6</td>
</tr>
<tr>
<td>ARB (%)</td>
<td>Intervention: 6.2; control: 7.1</td>
</tr>
<tr>
<td>MRA (%)</td>
<td>Intervention: 28.8; control: 26.4</td>
</tr>
</tbody>
</table>

**Interventions**

**Intervention:** nebivolol

"Nebivolol or placebo tablets were provided in identical packaging and tablet appearance. The initial dose was 1.25 mg once daily, and, if tolerated, this was increased to 2.5 and 5 mg, respectively, every 1–2 weeks, reaching a target of 10 mg once daily over a maximum of 16 weeks."

**Comparator:** placebo

**Concomitant medication:** exclusion criteria: current use of beta blockers

**Outcomes**

**Planned:** planned in protocol (Shibata 2002): primary: all cause mortality and cardiovascular hospital admissions (time to first event). Secondary: all cause mortality, composite of all cause mortality or all cause hospital admissions, cardiovascular hospital admissions, cardiovascular mortality, functional capacity by NYHA class, functional capacity by 6 min walk test

**Reported:** reported: compliance to treatment, haemodynamics, death or cardiovascular hospital admission, all cause mortality, cardiovascular hospital admissions, total mortality, cardiovascular mortality, all cause hospitalisation

**Notes**

Subgroup of interest, partial outcome data reported

Baseline data for all participants, outcome data for subgroup only (nebivolol N = 320, placebo N = 323)

Emailed trialists to ask for details on HF hospitalisation for LVEF > 40%, withdrawal due to AE, hyperkalaemia. No response.

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation</td>
<td>Low risk</td>
<td>&quot;Randomization to nebivolol or placebo on a 1:1 basis was carried out by telephone call to a central office (Clinical Data Care, Lund, Sweden).&quot;</td>
</tr>
</tbody>
</table>

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)
### SENIORS (Continued)

<table>
<thead>
<tr>
<th>Allocation concealment (selection bias)</th>
<th>Low risk</th>
<th>&quot;Patients were allocated a treatment number which corresponded to the appropriate study treatment packs.&quot;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Low risk</td>
<td>&quot;double-blind&quot;; no details</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>ITT used</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>primary outcomes reported as planned</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>&quot;Dr. van Veldhuisen has received lecture fees from Menarini and was a member of the steering committee of the SENIORS trial. Dr. Cohen-Solal has received lecture and consultancy fees from Menarini, and was a member of the steering committee for the SENIORS trial and received lecture fees. Dr. Böhm has received speaker fees from Menarini. Dr. Anker has received speaking honoraria from Menarini Ricerche SpA, Roche, Merck, and Tanabe. Dr. Babalis’s department has received a grant from Menarini. Dr. Coats has received honoraria from Menarini. Dr. Poole-Wilson has received honoraria from Menarini for speaking about the SENIORS trial. Dr. Flather has received research grant funding to his institution from Menarini and speaker fees from Menarini for lectures at scientific meetings and symposia. The original SENIORS trial was supported by Menarini Ricerche SpA, Italy. Funding for additional statistical analyses for the present study to the Clinical Trials and Evaluation Unit in London were obtained. All members of the Steering Committee of the SENIORS trial have received honoraria for speaking on aspects of heart failure and beta-blockers at meetings funded by companies in the pharmaceutical industry.&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&quot;SENIORS is sponsored by Menarini Ricerche SpA.&quot;</td>
</tr>
</tbody>
</table>

### Study characteristics

**Methods**

- **Study design:** two-arm, individual, RCT
- **Centres:** not reported
- **Start of enrolment:** August 2000
- **End of enrolment:** March 2002
- **Follow-up:** 6-12 months
- **Run-in period:** not reported

**Participants**

- **Inclusion criteria:** "Patients were included in the study if they had (1) a history of uncorrected rheumatic heart valvular disease or New York Heart Association (NYHA) functional class III or IV disease, necessitating hospitalization; (2) a cardiothoracic ratio of less than 65%; (3) AF with a resting ventricular rate of 70 beats/minute or more for at least three months, as depicted on the electrocardio-"
gram (ECG); and (4) an echocardiogram showing a significant mitral stenosis or aortic lesions and mitral valve regurgitation."

**Exclusion criteria:** "Patients were excluded from the study if they had uncorrected congenital heart disease, sustained ventricular tachycardia, severe liver and kidney dysfunction, chronic obstructive pulmonary disease, bronchial asthma, obstructive or restrictive cardiomyopathy or myocarditis, myocardial infarction, or unstable angina within the previous three months. Patients were also ineligible for enrollment if they required intensive care or concurrent intravenous therapy or if they were using calcium-channel blockers, class I or III antiarrhythmic drugs, monoamine oxidase (MAO)–inhibitors or beta2-agonists."

**Randomised (N):** 88 (not reported by treatment arm)

**Withdrawn (N):** 20 (did not complete the study) intervention: 11 (5 due to suspected adverse drug effects); control: 9

**Lost to follow-up (N):** 14 (excluded from the evaluation at follow-up - 7 had insufficient quality of echocardiography or difficulties with telephone-connection)

**Analysed (N):** 67 (intervention: 33; control: 34)

**Age (years, mean, SD):** intervention: 40.6, 6.8; control: 43.5, 7.4

**Sex (% male):** intervention: 36; control: 35

**Ethnicity** not reported

**Systolic blood pressure (mmHg, mean, SD):** intervention: 115, 12; control: 121, 14

**Heart rate** not reported

**BMI** not reported

**Serum creatinine** not reported

**B-type natriuretic peptide** not reported

**NT pro B-type natriuretic peptide** not reported

**LVEF** not reported

**NYHA class** not reported

**Hypertension** not reported

**Diabetes** not reported

**Atrial fibrillation** not reported

**Hospitalisation for heart failure:** not reported

**Coronary heart disease** not reported

**Stroke** not reported

**Diuretic** not reported

**Digoxin** not reported

**Beta-blocker** not reported

**ACEI** not reported

**ARB** not reported

**MRA** not reported
Interventions

**Intervention:** Bisoprolol, "All patients in the treatment group received bisoprolol at the initial dose of 1.25 mg/day. The recommended maximal dose was 10 mg/day. The dose schedule for titration of the selective beta1 blocker was gradually increased over three to five days, by two to three weeks, to as high as 10 mg/day, with adjustments of diuretics and ACE-inhibitors, as clinically indicated."

**Comparator:** "control" (unspecified)

**Concomitant medication:** "At the discretion of the treating physicians, all patients were given concomitant therapy consisting of one of the following:
- diuretics, as required, to control fluid retention
- digoxin, extracted from Digitalis lanata
- ACE-inhibitors (or ARBs when ACE-inhibitors were not tolerated) unless there were specific contraindications
- nitrates, depending on the presence of valvular lesions and on blood pressure readings"

Outcomes

**Planned:** we did not identify a published protocol or pre-registered clinical trial register record

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>High risk</td>
<td>&quot;On the basis of admission sequence, patients were randomly assigned to a treatment group or a control group&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>unclear reporting of withdrawals/loss-to-follow up</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>unable to assess</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>no funding source reported</td>
</tr>
</tbody>
</table>

SNEGOVIK

Study characteristics

**Methods**

**Study design:** two-arm, individual, RCT

**Centres:** not reported

**Start of enrolment:** not reported
End of enrolment: not reported
Follow-up: 3 months
Run-in period: not reported

Participants

Inclusion criteria: "in ambulatory patients (pts) with arterial hypertension and CHF and preserved systolic left ventricular (LV) function" "According including/exclusion criteria pts have had seated systolic BP(SBP) ≤ 160mmHg and diastolic BP(DBP) ≤ 95mmHg at randomization." "with stable symptomatic CHF (NYHA class II-III) as a result of arterial hypertension (AH) with preserved LV ejection fraction (EF) ≥ 50%"

Exclusion criteria: not reported
Randomised (N): 726 (416 intervention, 310 control)
Withdrawn (N): not reported
Lost to follow-up (N): not reported
Analysed (N): not reported
Age not reported
Sex not reported
Ethnicity not reported
Systolic blood pressure not reported
Heart rate not reported
BMI not reported
Serum creatinine not reported
B-type natriuretic peptide not reported
NT pro B-type natriuretic peptide not reported
LVEF not reported
NYHA class not reported
Hypertension not reported
Diabetes not reported
Atrial fibrillation not reported
Hospitalisation for heart failure: not reported
Coronary heart disease not reported
Stroke not reported
Diuretic not reported
Digoxin not reported
Beta-blocker not reported
ACEI not reported
ARB not reported
**SNEGOVIK** (Continued)

<table>
<thead>
<tr>
<th>Interventions</th>
<th>MRA not reported</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intervention:</strong></td>
<td>quinapril</td>
</tr>
<tr>
<td><strong>Comparator:</strong></td>
<td>&quot;conventional treatment, recommended for CHF [congestive heart failure] and AH [arterial hypertension] treatment&quot;</td>
</tr>
<tr>
<td><strong>Concomitant medication:</strong></td>
<td>not reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Planned: unclear</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Reported: NYHA, 6MWD, clinical status, QoL (MLHFQ), 2D echocardiography, blood pressure</td>
</tr>
</tbody>
</table>

| Notes | Unable to find contact details to ask investigators for end scores for QoL, full publication of results and mortality data. |

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;were randomly assigned&quot; but no detail</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>High risk</td>
<td>published conference abstract only</td>
</tr>
</tbody>
</table>

### STRUCTURE

**Study characteristics**

<table>
<thead>
<tr>
<th>Methods</th>
<th><strong>Study design:</strong> two-arm, individual, RCT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Centres:</strong> Poland, &quot;of each centre&quot; suggests multicentre trial, no details</td>
</tr>
<tr>
<td></td>
<td><strong>Start of enrolment:</strong> November 2011</td>
</tr>
<tr>
<td></td>
<td><strong>End of enrolment:</strong> February 2015</td>
</tr>
<tr>
<td></td>
<td><strong>Mean follow-up:</strong> 6 months</td>
</tr>
</tbody>
</table>
**Participants**

**Inclusion criteria:** "Patients who presented with signs or symptoms of HF (dyspnea, fatigue, and exercise intolerance) consistent with New York Heart Association functional class II or III, with preserved LV ejection fraction (> 50%), and with evidence of diastolic dysfunction, were considered suitable for screening."

**Exclusion criteria:** "Exclusion criteria were: Atrial fibrillation or flutter Resting heart rate > 90 beats/min Ischemic heart disease (defined by a positive coronary angiogram or inducible ischemia during exercise testing) Moderate or worse valvular heart disease Primary myocardial diseases Established or suspected pulmonary diseases (spirometry results < 80% of age- and sex-specific reference values) Hemoglobin ≤ 11 g/dl Adrenocortical, hepatic, rheumatic, neoplastic, skeletal, thyroid, and renal diseases (including renal insufficiency with serum creatinine > 1.5 mg/dl [132 mmol/l]) Hyperkalemia > 5.0 mmol/l Known intolerance or treatment with an MRA within the last 3 months Concomitant therapy with a potassium-sparing agent Current lithium use Pregnancy"

**Randomised (N):** 150 (75 intervention, 75 control)

**Withdrawn (N):** for reasons other than death 12 (7 intervention, 5 control)

**Lost to follow-up (N):** 7 (4 intervention, 3 control)

**Analysed (N):** 131 (64 intervention, 67 control)

**Age (years, mean, SD):** intervention: 66.3, 7.7; control: 67.6, 9.1

**Sex (% men):** intervention: 12; control: 19

**Ethnicity (%):** not reported

**Systolic blood pressure (mmHg, mean, SD):** intervention: 131, 15; control: 130, 18

**Heart rate (beats/min, mean, SD):** intervention: 72, 10; control: 73, 10

**BMI (mean, SD):** intervention: 30.7, 4.5; control: 29.7, 4.6

**Serum creatinine (mg/dL, mean, SD):** intervention: 0.99, 0.20; control: 1.03, 0.24

**B-type natriuretic peptide (pg/mL, median, IQR):** intervention: 40 (26-63); control: 54 (27-99)

**NT pro B-type natriuretic peptide (pg/mL):** not reported

**LVEF (% median, IQR):** intervention: 72.6 (70.4–74.8); control: 71.4 (69.2–73.5)

**NYHA class I (%):** 0

**NYHA class II (%):** intervention: 78; control: 79

**NYHA class III (%):** intervention: 22; control: 21

**NYHA class IV (%):** 0

**Hypertension (%):** intervention: 92; control: 91

**Diabetes (%):** intervention: 39; control: 40

**Atrial fibrillation (%):** not reported

**Hospitalisation for heart failure (%):** intervention: 17; control: 21

**Coronary heart disease (%):** significant CAD excluded

**Stroke (%):** not reported

**Diuretic (%):** intervention: thiazides 54, loop 13; control: thiazides 46, loop 18
**Digoxin (%)**: not reported

**Beta-blocker (%)**: intervention: 78; control: 72

**ACEI/ARB (%)**: intervention: 97; control: 95

**MRA (%)**: study drug

### Interventions

**Intervention**: spironolactone, 25mg/day

**Comparator**: matching placebo (120 mg/day of microcellulose)

**Concomitant medication**: "Enrollees continued to receive other prescribed treatments throughout the study period."

### Outcomes

**Planned**: unclear

**Reported**: "Coprimary outcomes were change at 6 months in exercise capacity (assessed by peak VO2) and exertional E/e' (reflecting LVFP). The secondary outcomes included change at follow-up in exercise blood pressure (BP) response and post-treatment global longitudinal myocardial deformation (GLS) measured by 2-dimensional strain."

### Notes

Emailed investigator to ask for additional outcome data relevant to this review. No response.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation</td>
<td>Unclear risk</td>
<td>&quot;The study coordinator, who was not involved in study procedures, was responsible for drug randomization and dispensing&quot;</td>
</tr>
<tr>
<td>Allocation concealment</td>
<td>Low risk</td>
<td>&quot;sequentially-numbered, opaque, sealed envelopes&quot;</td>
</tr>
<tr>
<td>Blinding of participants and personnel</td>
<td>Low risk</td>
<td>&quot;Patients and investigators performing the assessments and data analysis were blinded to group assignment.&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment</td>
<td>Low risk</td>
<td>&quot;core laboratory in Hobart, Australia, for independent adjudication of the primary endpoint&quot;</td>
</tr>
<tr>
<td>Incomplete outcome data</td>
<td>Low risk</td>
<td>ITT not used, withdrawals reported with reasons, lost to follow-up reported, similar numbers for treatment arms</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>unclear, clinical trial registration was post-hoc</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>&quot;The authors have reported that they have no relationships relevant to the contents of this paper to disclose&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&quot;This study was funded by grants ST-678 from Wroclaw Medical University and 13-024 from the Royal Hobart Hospital Foundation.&quot;</td>
</tr>
</tbody>
</table>
**Study characteristics**

**Methods**

- **Study design**: parallel, individual RCT
- **Centres**: 17, Japan
- **Start of enrolment**: October 2006
- **End of enrolment**: March 2010
- **Median follow-up**: 4.4 years
- **Run-in period**: not reported

**Participants**

- **Inclusion criteria**: The inclusion criteria of the present study were designed to enroll symptomatic CHF patients with hypertension aged 20 to 79 years who were treated with ACEI or beta-blocker or both. Inclusion criteria: NYHA Classes II to IV CHF, History of hypertension or treated with anti-hypertensive medications, Aged 20 or older and, 80 years at the entry, Stable with angiotensin-converting enzyme inhibitors and/or b-blockers, Not treated with angiotensin II receptor blockers

- **Exclusion criteria**: The exclusion criteria were designed to exclude patients with substantive confounding medical conditions or an inability to meaningfully participate in the SUPPORT trial. Exclusion criteria: Patients who have renal dysfunction (serum creatinine ≥3.0 mg/dL), or those who are under chronic haemodialysis, Drug hypersensitivity to olmesartan, Severe liver dysfunction, History of angioedema, History of malignant tumour or life-threatening illness of poor prognosis, Pregnant or possibly pregnant patients, Cardiovascular surgery within 6 months prior to the date of the entry, Acute myocardial infarction within 6 months prior to the date of the entry, Percutaneous coronary intervention with or without stent implantation within 6 months prior to the date of the entry.

- **Randomised (N)**: 1146 (1 patient excluded prior to this for protocol violation) (578 intervention, 568 control)
- **Withdrawn (N)**: for reasons other than death 9 (1 protocol violation, 8 no LVEF data)
- **Lost to follow-up (N)**: not reported
- **Analysed (N)**: Total 1138 (HfPEF 709, HFrEF 429) (HfPEF 363 intervention, HfPEF 346 control)
- **Age** (years, mean, SD): intervention: 66.5, 10.1; control: 65.9, 9.7
- **Sex** (% men): intervention: 70.2; control: 71.1
- **Ethnicity** (%): not reported
- **Systolic blood pressure** (mmHg, mean, SD): intervention: 131.5, 17.1; control: 130.1, 17.1
- **Heart rate** (beats/min, mean, SD): intervention: 70.6, 13.2; control: 71.4, 14.9
- **BMI** (mean, SD): intervention: 24.4, 4.2; control: 24.8, 4.2
- **Serum creatinine** (mg/dL, mean, SD): intervention: 0.9, 0.3; control: 0.9, 0.3
- **B-type natriuretic peptide** (pg/mL, median, IQR): intervention: 71.1 (30.2, 148.0); control: 58.7 (27.5, 135.0)
- **NT pro B-type natriuretic peptide** (pg/mL): not reported
- **LVEF** (%), mean, SD): intervention: 63.8, 8.8; control: 63.1, 8.6
- **NYHA class I** (%): 0
- **NYHA class II** (%): intervention: 94.2; control: 93.4
- **NYHA class III** (%): intervention: 5.5; control: 6.4
NYHA class IV (%): 0
Hypertension (%): 100
Diabetes (%): intervention: 46.6; control: 53.9
Atrial fibrillation (%): not reported
Hospitalisation for heart failure (%): intervention: 52.2; control: 44.1
Coronary heart disease (%): intervention: 48.8; control: 45.1
Stroke (%): not reported
Diuretic (%): intervention: 45.7; control: 48.0
Digoxin (%): not reported
Beta-blocker (%): intervention: 63.4; control: 65.4
ACEI (%): intervention: 79.9; control: 79.0
ARB (%): study drug
MRA (%): intervention: 18.5; control: 22.0

Interventions

Intervention: olmesartan. "Olmesartan was initiated at a dose of 5–10 mg/day, and then up titrated to 40 mg/day, if tolerable, in the olmesartan group, while no ARB use was allowed in the control group"

Comparator: no treatment

Concomitant medication: treated with ACEI and/or beta-blocker in inclusion criteria, not treated with ARB

Outcomes

Planned: Clinical trial registry entry at point of enrolment: primary outcomes all-cause death, nonfatal acute myocardial infarction, nonfatal stroke, hospital admission due to congestive heart failure

Reported:

Primary Endpoint: A composite of the following outcomes: all-cause death, non-fatal acute myocardial infarction, non-fatal stroke, hospital admission due to worsening heart failure

Secondary Endpoints: cardiovascular death, death due to heart failure, sudden death, acute myocardial infarction, stroke, hospital admission from any cardiovascular reasons, fatal arrhythmia or inappropriate ICD discharge, new-onset diabetes, development of renal dysfunction (equal to or more than twofold increase of serum creatinine level), new-onset atrial fibrillation, a need to modify treatment procedures for heart failure, a decrease in left ventricular ejection fraction (equal to or more than 20% decrease), an increase in B-type natriuretic peptide levels (> 2-fold increase if the baseline level was > 50 pg/mL and an increase of > 100 pg/mL if the baseline level was < 50 pg/mL), changes in serum markers for metabolic syndrome (high sensitive C-reactive protein, adiponectin, microRNAs)

Notes

Emailed investigators to ask for outcome data for participants with LVEF > 40%. No response.

Published (and presented above) are baseline characteristics and results for HFpEF as defined by investigators (LVEF ≥ 50%).

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
</tbody>
</table>
**SUPPORT** *(Continued)*

<table>
<thead>
<tr>
<th>Bias</th>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>open label</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>blinded endpoint study</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>withdrawals reported with reasons, not detailed by treatment arm ITT used, but after exclusion of some randomised patients</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>primary outcomes reported as planned</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>“The Department of Evidence-based Cardiovascular Medicine, Tohoku University Graduate School of Medicine, is supported in part by the unrestricted research grants from Daiichi Sankyo Co, Ltd (Tokyo, Japan), Bayer Yakuhin, Ltd (Osaka, Japan), Kyowa Hakko Kirin Co, Ltd (Tokyo, Japan), Kowa Pharmaceutical Co, Ltd (Tokyo, Japan), Novartis Pharma K.K. (Tokyo, Japan), Dainippon Sumitomo Pharma, Co, Ltd (Osaka, Japan), and Nippon Boehringer Ingelheim Co, Ltd (Tokyo, Japan). H.S. has received lecture fees from Bayer Yakuhin, Ltd (Osaka, Japan), Daiichi Sankyo Co, Ltd (Tokyo, Japan) and Novartis Pharma K.K. (Tokyo, Japan).” “This study was supported in part by the grants-in-aid from the Ministry of Health, Labour, and Welfare and those from the Ministry of Education, Culture, Sports, Science, and Technology, Japan. Funding to pay the Open Access publication charges for this article was provided by the author.”</td>
</tr>
</tbody>
</table>

**SWEDIC**

**Study characteristics**

**Methods**

- **Study design:** two-arm, individual, parallel RCT
- **Centres:** 12, Sweden
- **Start of enrolment:** not reported
- **End of enrolment:** not reported
- **Mean follow-up:** not reported
- **Run-in period:** not reported

**Participants**

- **Inclusion criteria:** “patients with symptoms and/or signs of HF, normal or almost normal systolic function and abnormal DF who did not have a contraindication to receiving therapy with a beta-adrenergic blocking agent were included into the study.” “Major inclusion criteria were a wall motion index (WMI) ≤ 1.2, i.e akinesia of one segment or less or hypokinesia of 2 segments or less, using a 16 segment model with at least 10 segments visible, corresponding to an LVEF > 45%, and evidence of abnormal DF using at least one of the following criteria to assess diastolic dysfunction”
**Exclusion criteria:** “Major exclusion criteria were restrictive or hypertrophic cardiomyopathies, significant uncorrected obstructive or regurgitant valvular diseases, unstable angina, active myocarditis, uncontrolled symptomatic ventricular arrhythmias, history of sick sinus syndrome, second or third degree AV-block, heart rate less than 60 bpm, systolic blood pressure <85 mmHg, uncontrolled hypertension, atrial fibrillation, evidence of obstructive pulmonary disease, unstable diabetes, treatment with beta-2-agonists, MAO-inhibitors, calcium channel blockers or beta-receptor blockers”

**Randomised** (N): 113

**Withdrawn** (N): for reasons other than death: “16 patients had echocardiographic data of insufficient quality and were excluded from the evaluation.”

**Lost to follow-up** (N): 2 (reasons not reported)

**Analysed** (N): 97 (47 intervention, 50 control)

**Age** (years, median, IQR): intervention: 67 (48 to 81); control: 66 (48 to 84)

**Sex** (% men): intervention: 59.6; control: 54.0

**Ethnicity** (%): not reported

**Systolic blood pressure** (mmHg, median, IQR): intervention: 155 (122 to 180); control: 150 (110 to 200)

**Heart rate** (beats/min, median, IQR): intervention: 74 (60 to 95); control: 73 (60 to 101)

**BMI** not reported

**Serum creatinine** not reported

**B-type natriuretic peptide** (pg/mL): intervention: 67.7, 76.1; control: 67.7, 67.7

**NT pro B-type natriuretic peptide** (pg/mL): not reported

**LVEF** not reported

**NYHA class I** (%): intervention: 40; control: 26

**NYHA class II** (%): intervention: 53; control: 53

**NYHA class III** (%): intervention: 7; control: 21

**NYHA class IV** (%): 0

**Hypertension** (%): intervention: 70.2; control: 62

**Diabetes** (%): intervention: 12.8; control: 16.0

**Atrial fibrillation** (%): 0

**Hospitalisation for heart failure**: not reported

**Coronary heart disease** (%): intervention: 17; control: 6

**Stroke** (%): not reported

**Diuretic** (%): not reported

**Digoxin** (%): not reported

**Beta-blocker** (%): study drug

**ACEI** (%): not reported

**ARB** (%): not reported
### SWEDIC (Continued)

**Interventions**

**Intervention:** carvedilol. "carvedilol or placebo twice daily in addition to their conventional treatment"

"All patients were up-titrated to the maximum tolerated dose or to the target dose (25 mg b.i.d., or 50 mg b.i.d. in patients weighing 85 kg) of carvedilol or matching placebo. After completion of up-titration they were to continue on double blind medication for a 6 month maintenance period. At study end patients were withdrawn from blinded study medication in a stepwise manner over a 1–3 week period. Optimal therapy for the patient’s condition was then reinstated at the investigator’s discretion" "Overall, carvedilol was well tolerated, with 81% of patients receiving the maximum dose at the end of the up-titration phase (25 mg b.i.d. or 50 mg b.i.d.) and 82% at the end of the study"

**Comparator:** placebo

**Concomitant medication:** "as an addition to conventional treatment"

### Outcomes

**Planned:** not able to assess as we are unaware of a published protocol or pre-registration in a clinical trial register

**Reported:** primary: diastolic dysfunction. Secondary: Secondary endpoints were the effects of carvedilol as compared to placebo on combined all cause mortality and cardiovascular hospitalisations, combined all-cause mortality and heart failure hospitalisation, progression of heart failure, individual cardiovascular endpoints and outcome and individual diastolic variables. Additional exploratory analyses on LV dimensions atrial size and WMI were also prespecified."

### Notes

Emailed investigators for details for RoB assessment, reasons for 2 participants not completing study, start/end of enrolment, duration of follow-up. No response.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Low risk</td>
<td>double-blind but no details, matching placebo</td>
</tr>
</tbody>
</table>
| Blinding of outcome assessment (detection bias)                     | Unclear risk       | "All assessments as to whether the LV diastolic dysfunction had improved, was unchanged, or had worsened were made by two echocardiographers from the core laboratory, who were blinded to the order of the assessment and to the study medication received by the patient."
| All outcomes                                                        |                    | only partial outcome assessment and for outcomes not relevant to this review |
| Incomplete outcome data (attrition bias)                            | Unclear risk       | unable to assess - withdrawals not reported by treatment arm |
| All outcomes                                                        |                     | ITT used               |
| Selective reporting (reporting bias)                                | Unclear risk       | unable to assess due to lack of published protocol or pre-registration in a clinical trial register |
| Other bias                                                          | Low risk           | "The study was investigator-initiated and was partly funded by F. Hoffmann-La Roche Ltd." |
Takeda 2004

Study characteristics

Methods

- **Study design**: parallel RCT
- **Centres**: 1, Japan
- **Start of enrolment**: April 2000
- **End of enrolment**: March 2001
- **Mean follow-up**: 12 months
- **Run-in period**: not reported

Participants

- **Inclusion criteria**: “All patients met Framingham criteria for diagnosis of heart failure. LVEF, as assessed by echocardiography using Simpson’s method, was ≥ 45% in each subject at the screening examination.”

- **Exclusion criteria**: “Patients with primary significant valvular disease, cor pulmonale, thyroid dysfunction, diabetes mellitus with hemoglobin A1C > 8%, alcohol abuse, other systemic diseases, obvious contraindication to carvedilol, or using angiotensin II receptor antagonists or adrenergic blockers were excluded from the initial entry.”

- **Randomised (N)**: 40 (19 intervention, 21 control)
- **Withdrawn (N)**: not reported
- **Lost to follow-up (N)**: not reported
- **Analysed (N)**: not reported
- **Age** (years, median, IQR): intervention: 69.1, 64.4–73.7; control: 73.1, 69.7–76.4
- **Sex** (% men): intervention: 68; control: 38
- **Ethnicity** (%): not reported
- **Systolic blood pressure** (mmHg, median, IQR): intervention: 129.6, 124.5–134.6; control: 138.0, 130.7–145.3
- **Heart rate** (beats/min, median, IQR): intervention: 70.6, 64.3–77.0; control: 68.9, 63.8–74.0
- **BMI** not reported
- **Serum creatinine** not reported
- **B-type natriuretic peptide** (pg/mL, median, IQR): intervention: 172, 135–209; control: 150, 114–186
- **NT pro B-type natriuretic peptide** (pg/mL): not reported
- **LVEF** (%, median, IQR): intervention: 55.8, 51.4–60.3; control: 57.5, 53.4–61.5
- **NYHA class I** (%): 0
- **NYHA class II** (%): intervention: 63.3; control: 71
- **NYHA class III** (%): intervention: 37; control: 29
- **NYHA class IV** (%): 0
- **Hypertension** not reported
- **Diabetes** not reported
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>unable to assess</td>
</tr>
</tbody>
</table>

**Interventions**

**Intervention:** carvedilol. "initial daily dosage of 1.25 mg in addition to conventional therapy, and the dose was doubled every week until reaching >= 5 mg/day. The decision to increase carvedilol to > 5 mg/day was made by the attending cardiologists on the basis of subjective symptoms, physical findings, and chest roentgenography; the cardiologists were guided to increase carvedilol to 20 mg/day if the patient tolerated it."

**Comparator:** conventional treatment

**Concomitant medication:** not reported

### Outcomes

**Planned:** we are not aware of a published protocol or a pre-registered clinical trial registry entry

**Reported:** BNP, NYHA, exercise capacity, heart failure hospitalisations, deaths

### Notes

**Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction**

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Other bias | Unclear risk | funding not reported

TOPCAT

**Study characteristics**

**Methods**
- **Study design**: parallel RCT
- **Centres**: "233 sites in 6 countries (1151 participants in the United States, 326 in Canada, 123 in Argentina, 1066 in Russia, and 612 in Georgia)"
- **Start of enrolment**: August 2006
- **End of enrolment**: January 2012
- **Mean follow-up**: 3.3 years
- **Run-in period**: no

**Participants**
- **Inclusion criteria**: "≥ 50 years old, "had at least one sign and at least one symptom of heart failure on a prespecified list of clinically defined signs and symptoms, a left ventricular ejection fraction of 45% or more as measured at the local site by means of echocardiography or radionuclide ventriculography, controlled systolic blood pressure (defined as a target systolic blood pressure of < 140 mm Hg or ≤ 160 mm Hg if the patient was taking three or more medications to control blood pressure), and a serum potassium level of less than 5.0 mmol per liter. In addition, eligible patients had a history of hospitalization within the previous 12 months, with management of heart failure a major component of the care provided (not adjudicated by the clinical-events adjudication committee), or an elevated natriuretic peptide level within 60 days before randomization (a brain natriuretic peptide [BNP] level ≥ 100 pg per milliliter or an N-terminal pro-BNP [NTproBNP] level ≥360 pg per milliliter)."
- **Exclusion criteria**: "severe systemic illness with a life expectancy of less than 3 years, severe renal dysfunction (an estimated glomerular filtration rate [GFR] of <30 ml per minute per 1.73 m² of body-surface area or a serum creatinine level that was ≥ 2.5 mg per deciliter [221 µmol per liter]), and specific coexisting conditions, medications, or acute events."
- **Randomised (N)**: 3445 (1722 intervention, 1723 control)
- **Withdrawn (N)**: 311 for reasons other than death (160 intervention, 151 control)
- **Lost to follow-up (N)**: 132 (67 intervention, 65 control)
- **Analysed (N)**: 3445 (1722 intervention, 1723 control)
- **Age (years, median, IQR)**: intervention: 68.7, 61.0 to 76.4; control: 68.7, 60.7 to 75.5
- **Sex (% men)**: intervention: 48.4; control: 48.5
- **Ethnicity (%)**: intervention: white 88.6, control: white 89.2
- **Systolic blood pressure (mmHg, median, IQR)**: intervention: 130, 120-139; control: 130, 120-140
- **Heart rate (beats/min, median, IQR)**: intervention: 68, 62-76; control: 68, 62-76
- **BMI (median, IQR)**: intervention: 31, 27-36; control: 31, 27-36
- **Serum creatinine (mg/dL, median, IQR)**: intervention: 1.0, 0.9-1.2; control: 1.1, 0.9-1.2
- **B-type natriuretic peptide (pg/mL)**: only in subgroup
- **NT pro B-type natriuretic peptide (pg/mL)**: only in subgroup
- **LVEF (%)** (median, IQR): intervention: 56, 51-61; control: 56, 51-62
NYHA class I (%): intervention: 3.3; control: 3.1
NYHA class II (%): intervention: 63.3; control: 64.1
NYHA class III (%): intervention: 33.0; control: 32.1
NYHA class IV (%): intervention: 0.4; control: 0.5
Hypertension (%): intervention: 91; control: 92
Diabetes (%): intervention: 33; control: 32
Atrial fibrillation (%): intervention: 35; control: 35
Hospitalisation for heart failure: not reported
Coronary heart disease (%): intervention: 26; control: 26
Stroke (%): intervention: 7; control: 8
Diuretic (%); intervention: 81; control: 82
Digoxin not reported
Beta-blocker (%): intervention: 78; control: 77
ACEI or ARB (%): intervention: 84; control: 84
MRA (%): 0

Interventions

**Intervention:** spironolactone

"Study drugs were initially administered at a dose of 15 mg once daily, which was increased to a maximum of 45 mg daily during the first 4 months after randomization. Subsequent dose adjustments were made as required."

**Comparator:** matching placebo

**Concomitant medication:** "Study patients continued to receive other treatments for heart failure and coexisting illnesses throughout the trial."

Outcomes

**Planned:** From NCT record 21 April 2006: primary outcomes: cardiovascular mortality, aborted cardiac arrest, composite of hospitalisation for the management of heart failure (ie hospitalisation for non-fatal myocardial infarction or non-fatal stroke). Secondary outcomes: all-cause mortality, composite of cardiovascular mortality or cardiovascular related hospitalization (i.e. hospitalization for non-fatal myocardial infarction, non-fatal stroke, or the management of heart failure), hospitalization for the management of heart failure incidence rate, sudden death or aborted cardiac arrest

**Reported:** "composite of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure; myocardial infarction; stroke; hospitalisation from any cause; hyperkalemia (potassium level, ≥ 5.5 mmol per liter); hypokalemia (potassium level, < 3.5 mmol per liter); an elevated serum creatinine level (≥ 2 times the baseline value and above the upper limit of the normal range); serum creatinine level of 3.0 mg per deciliter (265 μmol per liter) or higher; serious adverse events"

Notes

NCT record reports on QoL but no usable data. Hamo 2015 reports baseline QoL data but not by intervention arm.

**Solomon 2016** reports data for four LVEF groups for HF hospitalisation, CV death, death (table 2) - 40-49%, 50-54.99%, 55-59.99%, 60% and over.

Data for all-cause mortality, lost to follow up, hyperkalemia differ between Pitt 2014 and NCT results.
Emailed investigators to ask for end scores for QoL KCCQ, clarification on withdrawals due to adverse events and subgroup data for primary outcomes. No response.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias)   | Low risk           | "Eligible participants were randomly assigned to receive either spironolactone or placebo in a 1:1 ratio with the use of permuted blocks."
|                                                |                    | "the randomization software will return a Treatment Allocation Code correspoding to either spironolactone or placebo" |
| Allocation concealment (selection bias)       | Low risk           | "The nurse coordinator will utilize a master list of Treatment Allocation Codes to determine which labelled study drug packet to provide to the subject." |
| Blinding of participants and personnel (performance bias) All outcomes | Low risk           | "Subjects and treating physicians will be blinded to whether subjects are receiving spironolactone or placebo" |
| Blinding of outcome assessment (detection bias) All outcomes | Low risk           | "Data were collected and managed electronically by the New England Research Institutes Clinical Trial Coordinating Center, which also coordinated site monitoring and analyzed the trial results (with independent verification at Brigham and Women's Hospital)." |
| Incomplete outcome data (attrition bias) All outcomes | Low risk           | "All randomly assigned participants were included in all analyses according to the intention-to-treat principle." |
| Selective reporting (reporting bias)          | Low risk           | reported as planned                                                                   |
| Other bias                                    | Low risk           | "sponsored by National Heart, Lung and Blood Institute, National Institutes of Health"  |

### Study characteristics

**Methods**

- **Study design:** parallel, individual, RCT
- **Centres:** not reported
- **Start of enrolment:** not reported
- **End of enrolment:** not reported
- **Follow-up:** 9 months
- **Run-in period:** not reported

**Participants**

- **Inclusion criteria:** "HFpEF was defined as history, symptoms, and signs of HF, a preserved LVEF of 50% or greater and no evidence of other medical condition that could mimic HF symptoms"
- **Exclusion criteria:** "Coronary disease was excluded according to history, medical record, electrocardiogram, and rest and exercise echocardiogram" "Exclusions included aldosterone antagonist use within the previous 3 months, a known contraindication, concomitant therapy with a potassium-spar-
ing diuretic or potassium supplementation, baseline serum potassium level greater than 5.0 mEq/L, or serum creatinine level of 2.5 mg/dL or greater.”

Randomised (N): 80 (42 intervention, 38 control)
Withdrawn (N): for reasons other than death 9 (5 intervention (adverse event N = 1, patient choice N = 4), 4 control (patient choice N = 3, death N = 1))
Lost to follow-up (N): not reported
Analysed (N): 71 (37 intervention, 34 control)
Age (years, mean, SD): intervention: 70.0, 1.1; control: 72.0, 1.2
Sex (% men): intervention: 19; control: 21
Ethnicity (%): African American: intervention: 21, control: 37
Systolic blood pressure (mmHg, mean, SD): intervention: 139, 2.7; control: 143, 3.2
Heart rate not reported
BMI (mean, SD): intervention: 31.5, 0.8; control: 32.4, 1.2
Serum creatinine not reported
B-type natriuretic peptide (unit not reported): intervention: 55, 46; control: 61, 50
NT pro B-type natriuretic peptide (pg/mL): not reported
LVEF (%: mean, SD: intervention: 62.6, 1.1; control: 62.0, 1.1
NYHA class I (%): 0
NYHA class II (%): intervention: 29; control: 26
NYHA class III (%): intervention: 64; control: 63
NYHA class IV (%): 0
Hypertension (%): intervention: 83; control: 92
Diabetes (%): intervention: 17; control: 29
Atrial fibrillation (%): not reported
Hospitalisation for heart failure: not reported
Coronary heart disease (%): 0
Stroke (%): not reported
Diuretic (%): intervention: 74; control: 71
Digoxin (%): intervention: 2; control: 0
Beta-blocker (%): intervention: 31; control: 32
ACEI (%): not reported
ARB (%): not reported
MRA (%): study drug

Upadhya 2017 (Continued)

Interventions

Intervention: spironolactone. “The starting dose of spironolactone was 12.5 mg/d in individuals with baseline creatinine of 2.0 mg/dL or greater or potassium greater than 4.5 mEq/L; in all other participants, the starting dose was 25 mg/d. In participants who initiated therapy with the 12.5-mg/d dose,
the dose was increased to 25 mg/d once creatinine fell below 2.5 mg/dL and potassium fell below 5.0 mEq/L and maintained at that dosage as long as those levels were maintained. Spironolactone was discontinued if 1-week creatinine was 2.5 mg/dL or higher or potassium was 5.0 mEq/L or higher. "The mean daily dose of spironolactone was 24.3 2.9 mg/d."

**Comparator:** matching placebo

**Concomitant medication:** not reported

### Outcomes

**Planned:** July 2005, NCT record: primary outcomes: exercise intolerance, quality of life

**Reported:** exercise performance, aortic distensibility and LV structure and function, carotid artery stiffness, pulse wave velocity, LV diastolic filling, QoL

### Notes

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;randomly assigned&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Low risk</td>
<td>&quot;The research pharmacy prepared and distributed placebo and active drug using a secure methodology. All investigators, staff, and participants were fully blinded to treatment group assignment throughout the study period&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>&quot;The research pharmacy prepared and distributed placebo and active drug using a secure methodology. All investigators, staff, and participants were fully blinded to treatment group assignment throughout the study period&quot;</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>unable to assess</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>posthoc clinical trial registration</td>
</tr>
</tbody>
</table>
| Other bias                                | High risk          | "This study was funded by the National Institutes of Health (NIH; R01AG18915), the Claude D. Pepper Older Americans Independence Center, Wake Forest University (P30AG21332), the Clinical and Translational Science Institute, Wake Forest School of Medicine (NIH UL1TR001420), and the Kermit G. Phillips Chair in Cardiovascular Medicine of Wake Forest School of Medicine"

Published as conference abstract only.

---

**Wang 2010**

**Study characteristics**

**Methods**

- **Study design:** parallel, individual, RCT
- **Centres:** 1, Taiwan

---

**Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction**

(Review)

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Participants

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Data</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inclusion criteria</strong>:</td>
<td>&quot;hypertensive pts who had DHF, defined as the presence of HF signs/symptoms, diastolic dysfunction (mitral annular early diastolic velocity (E') &lt; 8 cm/s), and left ventricular (LV) ejection fraction (EF) &gt; 50%&quot;</td>
</tr>
<tr>
<td><strong>Exclusion criteria</strong>:</td>
<td>not reported</td>
</tr>
<tr>
<td><strong>Randomised</strong></td>
<td>(N): 36 (19 intervention, 17 control)</td>
</tr>
<tr>
<td><strong>Withdrawn</strong></td>
<td>(N): not reported</td>
</tr>
<tr>
<td><strong>Lost to follow-up</strong></td>
<td>(N): not reported</td>
</tr>
<tr>
<td><strong>Analysed</strong></td>
<td>(N): not reported</td>
</tr>
<tr>
<td><strong>Age</strong> (years, mean, SD)</td>
<td>not reported</td>
</tr>
<tr>
<td><strong>Sex</strong> (% men)</td>
<td>not reported</td>
</tr>
<tr>
<td><strong>Ethnicity</strong> (%):</td>
<td>not reported</td>
</tr>
<tr>
<td><strong>Systolic blood pressure</strong></td>
<td>not reported</td>
</tr>
<tr>
<td><strong>Heart rate</strong></td>
<td>not reported</td>
</tr>
<tr>
<td><strong>BMI</strong></td>
<td>not reported</td>
</tr>
<tr>
<td><strong>Serum creatinine</strong></td>
<td>not reported</td>
</tr>
<tr>
<td><strong>B-type natriuretic peptide</strong></td>
<td>not reported</td>
</tr>
<tr>
<td><strong>NT pro B-type natriuretic peptide</strong></td>
<td>not reported</td>
</tr>
<tr>
<td><strong>LVEF</strong> (% , mean, SD):</td>
<td>intervention: 67, 7; control: 66, 7</td>
</tr>
<tr>
<td><strong>NYHA class</strong></td>
<td>not reported</td>
</tr>
<tr>
<td><strong>Hypertension</strong></td>
<td>not reported</td>
</tr>
<tr>
<td><strong>Diabetes</strong></td>
<td>not reported</td>
</tr>
<tr>
<td><strong>Atrial fibrillation</strong></td>
<td>not reported</td>
</tr>
<tr>
<td><strong>Hospitalisation for heart failure</strong>:</td>
<td>not reported</td>
</tr>
<tr>
<td><strong>Coronary heart disease</strong></td>
<td>not reported</td>
</tr>
<tr>
<td><strong>Stroke</strong></td>
<td>not reported</td>
</tr>
<tr>
<td><strong>Diuretic</strong></td>
<td>not reported</td>
</tr>
<tr>
<td><strong>Digoxin</strong></td>
<td>not reported</td>
</tr>
<tr>
<td><strong>Beta-blocker</strong></td>
<td>not reported</td>
</tr>
<tr>
<td><strong>ACEI</strong></td>
<td>not reported</td>
</tr>
<tr>
<td><strong>ARB</strong></td>
<td>not reported</td>
</tr>
<tr>
<td><strong>MRA</strong> study drug</td>
<td>not reported</td>
</tr>
</tbody>
</table>
**Wang 2010 (Continued)**

**Interventions**
- **Intervention**: spironolactone. 50 mg/d
- **Comparator**: no treatment control
- **Concomitant medication**: not reported

**Outcomes**
- **Planned**: we are not aware of a published protocol or pre-registered clinical trial registry entry
- **Reported**: echo-parameters, systolic myocardial velocities

**Notes**
- does not contribute outcome data to this review

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>unable to assess</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>funding not reported</td>
</tr>
</tbody>
</table>

**Yuksek 2012**

**Study characteristics**

**Methods**
- **Study design**: parallel, individual, RCT
- **Centres**: 1, Izmir Ataturk Education and research hospital (IAERH) outpatient clinics, Turkey
- **Start of enrolment**: May 2008
- **End of enrolment**: March 2009
- **Mean follow-up**: 11 months (range: 3-16 months)
- **Run-in period**: not reported

**Participants**
- **Inclusion criteria**: "We enrolled 108 patients with DHF [diastolic heart failure], aged ≥ 50 years, who presented to Ismir Ataturk Education and Research Hospital (IAERH) cardiology out-patient clinics with
HF symptoms and were found to have an ejection fraction (EF) of ≥ 50% on transthoracic echocardiography (TTE) accompanied by an evidence of DD on TDE. The HF diagnosis was based on Framingham heart failure criteria."

**Exclusion criteria:** "Exclusion criteria included the following: EF <50%, patient age < 50 years, severe valvular disease on echocardiography, a history of acute coronary syndrome, atrial fibrillation, cardiomyopathy or pericardial disease, anaemia (serum haemoglobin levels < 10g/dl), hyperthyroidism, hypothyroidism, renal insufficiency (serum creatinine > 2 mg/dl or dialysis), serum potassium level > 5.5 mEq/l, moderate to severe pulmonary hypertension (sPAP > 50mmHg), and/or intolerance to angiotensin converting enzyme inhibitors (ACEIs) or angiotension receptor blockers (ARBs), bilateral renal artery stenosis, or any kind of malignancy. Patients with decompensated HF were also excluded."

**Randomised (N):** 108 (54 intervention, 54 control)

**Withdrawn (N):** for reasons other than death 17 (14 intervention, 3 control)

**Lost to follow-up (N):** 3 (3 intervention (death), 0 control)

**Analysed (N):** 88 (37 intervention, 51 control)

**Age (years, mean, SD):** intervention: 62, 8; control: 61,8

**Sex(%) men:** intervention: 16; control: 25

**Ethnicity** not reported

**Systolic blood pressure** (mean, mmHg, SD): intervention: 126, 16; control: 123, 19

**Heart rate** not reported

**BMI (mean, SD):** intervention: 33, 6; control: 33, 5

**Serum creatinine** (mg/dl, mean, SD): intervention: 0.29, 0.14; control: 0.98, 0.25

**B-type natriuretic peptide** not reported

**NT pro B-type natriuretic peptide** (median, pg/mL): intervention: 114; control: 128

**LVEF (%) (mean, SD):** intervention: 66, 7; control: 65, 8

**NYHA class (%):** intervention: II: 78, III: 22; control: II: 65, III: 35

**Hypertension (%):** intervention: 84; control: 80

**Diabetes (%):** intervention: 51; control: 33

**Atrial fibrillation** not reported

**Hospitalisation for heart failure** not reported

**Coronary artery disease(%)** intervention: 11; control: 22

**Stroke** not reported

**Diuretic (%)** intervention: 51; control: 59

**Digoxin** not reported

**Beta-blocker (%)** intervention: 41; control: 39

**ACEI** study drug

**ARB** not reported

**MRA** not reported
**Interventions**

**Intervention:** perindopril, "was started on oral perindopril treatment (5 mg/day)"; "perindopril dose in the study group was up-titrated to 10mg/day at the end of one month"

**Comparator:** "standard DHF treatment"

**Concomitant medication:** not reported

**Outcomes**

**Planned:** we are not aware of a published protocol or a pre-registration in a clinical trial register

**Reported:** primary endpoints: changes in $E'$, $A'$ and $S$ velocities, $E/E'$, $E/A$ and $E'/A'$ ratios, isovolumic relaxation time (9IVRT) and deceleration time (DT) at the end of the follow up period. Secondary endpoints included the changes in NT-proBNP levels and NYHA functional classes, Left Atrial Volume Index.

**Notes**

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;Patients were randomised into two groups using a basic randomisation method&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>Per-protocol analysis, 31% drop out from intervention group, 6% drop out of control group</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>unable to assess</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>funding not reported</td>
</tr>
</tbody>
</table>

**Study characteristics**

**Methods**

**Study design:** parallel, individual, RCT

**Centres:** 1, Royal Liverpool and Broadgreen University Hospitals

**Start of enrolment:** 1997

**End of enrolment:** 1999

**Follow-up:** 6 months
Run-in period: mentioned but no details

<table>
<thead>
<tr>
<th>Participants</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inclusion criteria:</strong></td>
<td>aged 65 years or older, with heart failure. They all had left ventricular ejection fraction (LVEF) on echocardiography or radionuclide ventriculography equal or greater than 40%. Where a left ventricular ejection fraction could not be measured systolic function had to be preserved or only mildly impaired by direct visualisation of the echocardiograms.</td>
</tr>
<tr>
<td><strong>Exclusion criteria:</strong></td>
<td>Patients with haemodynamically significant valvular disease, pulmonary hypertension, right ventricular systolic dysfunction, uncontrolled atrial fibrillation or flutter, unstable angina pectoris, hypotension, myocardial infarction within one month, renal failure (serum creatinine &gt;150 mmol/L), renal-artery stenosis, severe liver or pulmonary disease were excluded. Patients treated with tetracyclines, lithium, benzodiazepines, major tranquillisers, anti-depressants (with the exception of selective serotonin re-uptake inhibitors) or major psychoactive drugs were also excluded.</td>
</tr>
</tbody>
</table>

**Randomised (N):** 74 (36 intervention, 38 control)

**Withdrawn (N):** for reasons other than death 4 (0 intervention, 4 control (worsening heart failure))

**Lost to follow-up (N):** not reported

**Analysed (N):** 74 (36 intervention, 38 control)

**Age (years, mean, SD):** intervention: 77, 7; control: 78, 7

**Sex (% men):** intervention: 38.9; control: 31.6

**Ethnicity (%):** not reported

**Systolic blood pressure** not reported

**Heart rate** not reported

**BMI** not reported

**Serum creatinine** not reported

**B-type natriuretic peptide** not reported

**NT pro B-type natriuretic peptide** not reported

**LVEF** not reported

**NYHA class I (%):** intervention: 5.5; control: 0

**NYHA class II (%):** intervention: 77.8; control: 73.7

**NYHA class III (%):** intervention: 16.7; control: 26.3

**NYHA class IV (%):** 0

**Hypertension (%):** intervention: 27.8; control: 31.6

**Diabetes (%):** intervention: 11.1; control: 18.4

**Atrial fibrillation (%):** intervention: 38.9; control: 31.6

**Hospitalisation for heart failure:** not reported

**Coronary heart disease (%):** intervention: 55.6; control: 57.9

**Stroke** (%): not reported

**Diuretic** (%): intervention: 94.4; control: 97.1

**Digoxin** (%): intervention: 38.9; control: 26.3

**Beta-blocker** (%): intervention: 19.4; control: 7.9
### Interventions

**Intervention:** quinapril. "Both drugs were titrated at two-week intervals from 5 mg to 40 mg daily or equivalent within the first six weeks."

**Comparator:** placebo

**Concomitant medication:** "All patients continued concomitant treatment with diuretics, nitrates, digitalis glycosides, calcium channel blockers, and beta-blockers as appropriate without change of dose except for diuretics. Therapy with ACE inhibitors for heart failure was withdrawn at least two weeks prior to the run-in period."

### Outcomes

**Planned:** we are not aware of a published protocol or pre-registered clinical trial registry entry

**Reported:** 6-minutes walking distance, hypotension, worsening heart failure, changes of electrolytes, adverse events, quality of life, deaths, heart failure hospitalisation, hyperkalaemia

### Notes

- **Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>randomised, but no further detail</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Low risk</td>
<td>double-blind, matching placebo</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>withdrawals due to worsening heart failure reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>unable to assess</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>&quot;This study was supported by the grants from Parke Davis &amp; Co. Ltd., UK.&quot;</td>
</tr>
</tbody>
</table>

quotes are from the primary reference unless otherwise stated

* mmol/L converted to mg/dL using online converter

ACEI: angiotensin converting enzyme inhibitor

ARB: angiotensin receptor blocker

BMI: body mass index

CVD: cardiovascular disease

EF: ejection fraction

IQR: interquartile range
Characteristics of excluded studies [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTRN12610001087044</td>
<td>Trial registry entry suggested two parts of a trial of which only the second was of interest to this review. Contact with trialists confirmed that the part of interest was registered and reported on separately (ACTRN: 12614000088640, STRUCTURE study).</td>
</tr>
<tr>
<td>Adgey 1992</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Ammon 2001</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Andersson 1996</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Andersson 1999</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Andersson 2000</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Anonymous 1996</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Anonymous 1999</td>
<td>Wrong intervention</td>
</tr>
<tr>
<td>Anonymous 2000</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Anonymous 2001</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Anonymous 2002</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Anonymous 2003</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Anonymous 2003a</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Anonymous 2003b</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Anonymous 2003c</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Anonymous 2005</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Anonymous 2008</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Anonymous 2008a</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Anonymous 2013</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>ANZ HF carvedilol</td>
<td>Subgroup of participants of interest (LVEF = 40-44%). We did not receive a response from the trialists to our enquiry for details on the subgroup of interest.</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Aoyama 2007</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Apostolovic 2013</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Apostolovic 2014a</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Apostolovic 2014b</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Arena 2007</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Armstrong 1999</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Aronow 1991</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Aronow 2001</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Axelsson 2015</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Balaban 2007</td>
<td>Turkish paper. Translated methods and data extraction. Unclear if participants had heart failure. We did not receive a response from the investigator when we asked for clarification.</td>
</tr>
<tr>
<td>Bao 2005</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Barr 1995</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Barrios 2009</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Barry 2003</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Bartels 1999</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Baruch 1999</td>
<td>Ineligible participants. Emailed trialists to clarify inclusion criteria. Response received: “Our study was confined to individuals with a reduced ejection fraction and the data therefore would not be applicable to your quest.”</td>
</tr>
<tr>
<td>Baruch 2004</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Bauersachs 2004</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Baumhakel 2008</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Bellenger 2004</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Berry 2001</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Bettencourt 1999</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Beygui 2016</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Blagodar 2003</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Blomer 1990</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Borghi 2011</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>--------------------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Borgi 1990</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Borlaug 2014</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Bornkessel 1992</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Bounhoure 1991</td>
<td>EF not reported. Could not identify current contact details.</td>
</tr>
<tr>
<td>Braunwald 2004</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Brilla 1989</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Brilla 1991</td>
<td>EF unclear, unclear whether allocation was random, unable to identify current contact details.</td>
</tr>
<tr>
<td>Bristow 1994</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Bristow 1996</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Bussmann 1987</td>
<td>EF unclear. We did not receive a response to our enquiry for details.</td>
</tr>
<tr>
<td>Butler 2017</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Cafaro 2010</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Cardoso 1999</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Castagno 2010</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>ChiCTR1800016350</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Choi 2001</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Cicoira 2002</td>
<td>subgroup of participants of interest; we did not receive a response from the trialist to our enquiry for details.</td>
</tr>
<tr>
<td>Cleland 1984</td>
<td>unclear EF. contacted trialists. no response</td>
</tr>
<tr>
<td>Cleland 1999</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Cleland 2001</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Cleland 2003</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Cleland 2004</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Cleland 2006</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Cleland 2007</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Cleland 2010</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Cleland 2011</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Cleland 2013</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>Cohen-Solal 2005</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Cohn 1993</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Cohn 1996a</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Cohn 1996b</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Cohn 2007</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Coletta 2008</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Coletta 2009</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Comin-Colet 2002</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>CONSENSUS</td>
<td>EF unclear. We did not receive a response from the trialists to our enquiry for details.</td>
</tr>
<tr>
<td>CONSENSUS II</td>
<td>Mean EF suggests a subgroup of eligible participants. We did not receive a response from the trialists to our enquiry.</td>
</tr>
<tr>
<td>Conti 2005</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Corder 1993</td>
<td>EF unclear. Unable to identify current contact details.</td>
</tr>
<tr>
<td>Crouse 2011</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Dahlstrom 2007</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Davie 2001</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>DeBock 1994</td>
<td>EF unclear. Unable to find current contact details for trialists.</td>
</tr>
<tr>
<td>Dekleva 2012</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>De Melo 2011</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Demers 2001</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Desai 2013</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Deswal 2010</td>
<td>EF unclear. We did not receive a response from trialists to our query on the clarification of inclusion criteria.</td>
</tr>
<tr>
<td>de Teresa 1995</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Ding 2008</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Ditiatkov 1999</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Donal 2008</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Dragana 2015</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Edner 2013</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Eichhorn 1994</td>
<td>subgroup of participants of interest; did not receive a response from trialists to our enquiry.</td>
</tr>
<tr>
<td>Eichhorn 2003</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Er 2005</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Ertl 1999</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>EudraCT 2004-004169-13</td>
<td>Trial registry record states completed but no contact details given an no published results identifiable. Sponsor: South Manchester University Hospital NHS Trust. Emailed sponsor to ask whether results are available. Unclear whether <a href="http://www.isrctn.com/ISRCTN77645264">http://www.isrctn.com/ISRCTN77645264</a> is the same trial. Tried to contact investigator but email was undeliverable.</td>
</tr>
<tr>
<td>Fauchier 2009</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Feola 2003</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Flammer 2013</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Flather 2016</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Flesch 2006</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Follath 1996</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Fonarow 2004</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Fonarow 2007</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Fowler 1999</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Franciosa 2002</td>
<td>Wrong intervention</td>
</tr>
<tr>
<td>Fukunami 1991</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Galinier 2007</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Gallo 2006</td>
<td>Potential eligible subgroup. Did not receive a response from trialists to our enquiry for outcome data for subgroup.</td>
</tr>
<tr>
<td>Gao 2010</td>
<td>Could not obtain details on LVEF as inclusion criteria. No available subgroup data for population of interest.</td>
</tr>
<tr>
<td>Gardner 2003</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Gardner 2004</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Ghali 2002</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Gheorghiade 2009</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Good 1994</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>--------------------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Goodfield 1999</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Gottlieb 1996</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Grajek 2008</td>
<td>Review</td>
</tr>
<tr>
<td>Greenberg 1996</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Gremmel 2000</td>
<td>EF unclear. Unable to identify current contact details.</td>
</tr>
<tr>
<td>Groenning 2000</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Groenning 2001</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Groenning 2002</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Gruner 2007</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Guazzi 1998</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Guazzi 1999</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Getzsche 1992</td>
<td>subgroup with HF and LVEF &gt;40%. We did not receive a response from trialists to our enquiry.</td>
</tr>
<tr>
<td>Hanping 1997</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Hara 2000</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Hauf 1993</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Hole 2004</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Holland 2010</td>
<td>Limited information in conference abstract. Response to our enquiry for further details received: “the data you’ve requested was not collected on this group of patients beyond what has been published in that abstract”. As we could not confirm whether the participants meet our inclusion criteria, this study was excluded.</td>
</tr>
<tr>
<td>Hong 2003</td>
<td>Wrong intervention</td>
</tr>
<tr>
<td>Hoppe 2007</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Hori 2004</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Hung 2010</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>IRIS-HF</td>
<td>Response from trialists received when asked for outcome data for subgroup of interest: no data specifically for participants in subgroup of interest (LVEF 40-45%) provided. Confirmed that QoL, mortality and HF hospitalisation were not formal endpoints. Hyperkalaemia was not shown by any participants.</td>
</tr>
<tr>
<td>Ito 2012</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Jamieson 1991</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Jellis 2014</td>
<td>HF/EF unclear. No response to our enquiry for details.</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>--------------------</td>
<td>-----------------------------------------------------------</td>
</tr>
<tr>
<td>Jessup 2003</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Jong 2010</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>JPRN-jRCTs051180137</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>JPRN-UMIN000006415</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Kanoupakis 2008</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Kapel’ko 2011</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Kasama 2007</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Keren 1992</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Keren 1994</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Khalid 2013</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Khand 2015</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Kikuchi 2016</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Kimura 2011</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Kinugawa 2007</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Kjekshus 2007</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Kjøller-Hansen 1998</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Kleber 1991a</td>
<td>No participants with heart failure with preserved ejection fraction (confirmed by trialist via email on 20 November 2017).</td>
</tr>
<tr>
<td>Kleber 1991b</td>
<td>Heart failure was not an inclusion criteria (confirmed by trialist via email on 15 November 2017).</td>
</tr>
<tr>
<td>Kongstad-Rasmussen 1998</td>
<td>EF unclear (&quot;ejection fraction measurement was not part of the protocol&quot;)</td>
</tr>
<tr>
<td>Krum 1996</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Krum 2015</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Kulbertus 2003</td>
<td>wrong study design</td>
</tr>
<tr>
<td>Kuznar 2003</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Lang 1995</td>
<td>cross-over trial</td>
</tr>
<tr>
<td>Larsen 1996</td>
<td>EF unclear. Contacted trialists. Response: data are no longer available.</td>
</tr>
<tr>
<td>Lechat 1993</td>
<td>LVEF unclear, otherwise eligible. Emailed investigator but did not receive a response.</td>
</tr>
<tr>
<td>Leonetti 1999</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Lewis 1988</td>
<td>EF unclear. Unable to find current contact.</td>
</tr>
<tr>
<td>Li 2005</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Liebson 2004</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Lindenfeld 2001</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Lindsay 1999</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Liu 2014</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Logeart 2006</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Lopez 2000</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Lou 2009</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Luo 2007</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Ma 2005</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>MacGregor 2009</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Mak 2008</td>
<td>EF unclear. Unable to find current contact details for trialist.</td>
</tr>
<tr>
<td>Malnick 2007</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Maron 2018</td>
<td>Heart failure not an inclusion criteria.</td>
</tr>
<tr>
<td>Mazayev 1998</td>
<td>LVEF unclear, otherwise eligible. Unable to find current contact details for investigators.</td>
</tr>
<tr>
<td>McAnulty 2004</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>McCullough 2012</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>McIlwain 1997</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>McKelvie 2012</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>McMurray 2000</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>McMurray 2004</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Me 2011</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Me 2012</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Messias 2016</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Meuleman 2007</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Mitrovic 2005</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Mochizuki 2004</td>
<td>retraction</td>
</tr>
<tr>
<td>Morales 2011</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Murdoch 2001</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>NCT00293150</td>
<td>terminated due to lack of eligible participants</td>
</tr>
<tr>
<td>NCT00523757</td>
<td>Trial did not take place as planned (as per information from trialists: &quot;We abandoned this study as we could not adequately recruit. No results to present.&quot;)</td>
</tr>
<tr>
<td>NCT01691118</td>
<td>Completed but no publication with results identified. Emailed trialists to ask for clarification on comparator (placebo or conventional antihypertensive treatment). No response.</td>
</tr>
<tr>
<td>NCT01944384</td>
<td>Completed but no results found. No contact details for investigator provided.</td>
</tr>
<tr>
<td>NCT03882710</td>
<td>Completed but no results found. No contact details for investigator provided.</td>
</tr>
<tr>
<td>Nodari 2003</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Nunez 2016</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>O'Callaghan 1995</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>O'Keefe 2008</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>O'Keeffe 2015</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>O'Meara 2012</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Ostergren 2004</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Palazzuoli 2005</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Paolisso 1992</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Paraskevaidis 2006</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Park 2016</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Patten 1997</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Pennell 2000</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Pierard 2002</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Pina 2004</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Pitt 2005</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Pitt 2008</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Pitt 2011</td>
<td>Wrong intervention</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>-------------------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Pourdjabar 2015</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Premkumar 2016</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Quaife 1998</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Ramaswamy 2003</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Remme 2001</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Remme 2004</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Remme 2005</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Rimatori 1990</td>
<td>LVEF unclear, otherwise eligible. Unable to find current contact details for investigators.</td>
</tr>
<tr>
<td>Roongsritong 2005</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Rosa 2011</td>
<td>Wrong intervention</td>
</tr>
<tr>
<td>Rosenkranz 2003</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Rossignol 2011</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Sakai 2011</td>
<td>Wrong intervention</td>
</tr>
<tr>
<td>Sanderson 1998</td>
<td>Subgroup of interest LVEF 40-45%. Investigator responded to our enquiry for data: “the mean EF was only 26.9% and I doubt any of the patients were in the group of EF 40% to &lt;45%. [...] I do not have the original data now.”</td>
</tr>
<tr>
<td>Sanghera 2011</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Santulli 2015</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Sardu 1991</td>
<td>LVEF not specified as an inclusion criteria, mean LVEF at baseline 35.4, 4.7%. Could not find current contact details for investigator.</td>
</tr>
<tr>
<td>Schindler 2008</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Schwab 2009</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Segovia 2008</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Shimamoto 2007</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Sidorenko 2008</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Silva 2014</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Smith 2012</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Spoto 2002</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Stecker 2005</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>---------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Stiefelhagen 2006</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Struthers 2004</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Swedberg 1996</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Swedberg 1999</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Szajnbok 1993</td>
<td>Portuguese paper. Reported outcomes not of interest but subgroup of participants eligible. Emailed investigators to ask about measured outcomes for subgroup of interest. Response: data not available.</td>
</tr>
<tr>
<td>Szymanski 2009</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Taheri 2009</td>
<td>Subgroup of interest LVEF 40-45%. Contacted investigators. No response.</td>
</tr>
<tr>
<td>Takekoshi 2004</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Tala 2011a</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Tala 2011b</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Tan 2013</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Tatsumi 2006</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Taylor 2003</td>
<td>Wrong intervention</td>
</tr>
<tr>
<td>Teerlink 2003</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Tereshchenko 2005</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Thornton 2004</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Thune 2008</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Tinoco 2004</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Tsutamoto 2000</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Tsutamoto 2001</td>
<td>Subgroup of interest (LVEF 40-45%). Emailed investigators. No response.</td>
</tr>
<tr>
<td>Tsutamoto 2005</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Tumasyan 2010</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Tumasyan 2018</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Umemoto 2003</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Uusimaa 2001</td>
<td>Wrong comparator</td>
</tr>
<tr>
<td>Van den Berg 1993</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Van den Berg 1995</td>
<td>LVEF unclear; response to our enquiry for details: cannot provide data</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>--------------------</td>
<td>---------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Vasiuk 2001</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Vincent 2012</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Vizir 2000</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Vizzardi 2010</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Vizzardi 2015a</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Vizzardi 2015b</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Volpe 1992</td>
<td>Subgroup of interest LVEF 40-45%. We received a response to our enquiry for more details on the subgroup of interest confirming that the study was conducted in “patients with reduced EF”.</td>
</tr>
<tr>
<td>Volpe 2010</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Voors 2008</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Waagstein 2003</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Waldo 1995</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Waldo 1996</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Warner 1999</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Weinberg 2001</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Weintraub 2005</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Weir 2011</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Wong 2002</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Wong 2004</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Woodley 1991</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Wright 2014</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Wu 2002</td>
<td>LVEF unclear, otherwise eligible. Unable to find current contact details for investigators.</td>
</tr>
<tr>
<td>Xu 2007</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Yamamoto 2005</td>
<td>Wrong study design</td>
</tr>
<tr>
<td>Yan 2012</td>
<td>LVEF unclear, otherwise eligible. Unable to find current contact details for investigators.</td>
</tr>
<tr>
<td>Yoshihiro 2011</td>
<td>Wrong intervention</td>
</tr>
<tr>
<td>Young 2004</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>Zeng 2006</td>
<td>Population does not meet protocol</td>
</tr>
<tr>
<td>Zheng 2009</td>
<td>Was previously a study awaiting classification. Data extraction received from translator. Wrong patient population.</td>
</tr>
</tbody>
</table>

### Characteristics of studies awaiting classification [ordered by study ID]

**Anonymous 2003d**

- **Methods**: No abstract
- **Participants**: No abstract
- **Interventions**: Eplerenone
- **Outcomes**: No abstract
- **Notes**: Could not yet obtain full text

**Botoni 2010**

- **Methods**: Individual, two-arm, RCT
- **Participants**: 42
- **Interventions**: Placebo versus carvedilol
- **Outcomes**: QoL
- **Notes**: Unclear EF/HF status

**Dielievska 2015**

- **Methods**: Individual, two-arm, RCT
- **Participants**: 80 participants with EHT and COPD of II-III grade of bronchial obstruction (GOLD 2-3) with chronic heart failure of the II and III NYHA classes and evidence of diastolic dysfunction
- **Interventions**: Spironolactone versus standard therapy, 3 months
- **Outcomes**: Left ventricular diastolic function, impaired relaxation of left ventricle, adverse events
- **Notes**: Have not yet obtained full text

**EUCTR2005-001306-87**

- **Methods**: Parallel RCT, prematurely ended
Participants

1500 planned;

Inclusion criteria: Age ≥ 18 years; both sexes - Stable, symptomatic NYHA II-IV CHF with LVEF 40% had to be hospitalized for cardiovascular events during the past 12 months; - Written informed consent

Exclusion criteria: Prior treatment with Angiotensin-Receptor Blocker (ARBs) within two weeks from visit 1; - Severe or malignant hypertension (systolic blood pressure (SBP)/diastolic blood pressure (DBP)>180/110 mmHg); - Symptomatic hypotension; - Angina pectoris or acute myocardial infarction within one month from visit 1; - Stroke or transient ischemic attack (TIA) within one month from visit 1; - Percutaneous transluminal coronary angioplasty (PTCA) or coronary artery by-pass graft (CABG) within one month from visit 1; - Haemodynamically relevant arrhythmias or cardiac valvular defect; - Implant of pacemakers, cardiac resynchronization therapy (CRT) or cardioverters (ICD) within 6 months prior the randomization; - Constrictive pericarditis or active miocarditis; Likelihood of cardiac surgical intervention (of any type) during the overall treatment period; - Poorly controlled diabetes mellitus, untreated thyroid dysfunction, renal artery stenosis, angio-oedema of any aetiology, significant liver or renal impairment, anaemia of any aetiology or any other clinically relevant haematological disease; any disease with malabsorption - Pregnant or lactating females or females at risk of pregnancy - any non-cardiac (e.g. cancer) disease likely to shorten life expectancy - Chronic alcohol or drug/substance abuse - Known allergy, sensitivity or intolerance to study drugs - Patients unlikely to comply with the protocol - Participation in another trial in the month preceding study entry

Interventions

Candesartan versus control

48 weeks

Outcomes

changes of BNP; change from baseline of aldosterone, PTX3, CRP, NYHA class, LVEF, LVIDD, E wave peak velocity/A wave peak velocity (E/A) ratio, Deceleration Time of E wave (E-DT) time, atrial dimensions, BP, HR; persistence and discontinuation rate of active treatment; quality of life (KCCQ); adverse events

Notes

Need to obtain subgroup data.

**EUCTR2005-002109-22**

Methods

Parallel RCT

Participants

99 participants with symptomatic chronic heart failure proven by echocardiography or Tc-Szintigraphy (EF <45%).

Interventions

Telmisartan versus candesartan versus additional treatment

Outcomes

Insulin sensitivity; correlation between natriuretic peptides (as a surrogate for severity of heart failure) and impaired glucosemetabolism

Notes

Subgroup of interest. Trial status is completed (30 September 2008) but unable to find results. No contact details for investigator.

**Metra 1999**

Methods

No abstract

Participants

No abstract
### Metra 1999 (Continued)

<table>
<thead>
<tr>
<th>Interventions</th>
<th>No abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcomes</td>
<td>No abstract</td>
</tr>
<tr>
<td>Notes</td>
<td>Could not yet retrieve full text</td>
</tr>
</tbody>
</table>

### PER-010-15

<table>
<thead>
<tr>
<th>Methods</th>
<th>Two-arm, parallel RCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>4300 overall, 30 from Peru with symptoms of heart failure and LVEF ≥45%</td>
</tr>
<tr>
<td>Interventions</td>
<td>LCZ696 versus valsartan</td>
</tr>
<tr>
<td>Outcomes</td>
<td>CV mortality, total heart failure hospitalisations, total strokes, and total myocardial infarctions, NY-HA class</td>
</tr>
<tr>
<td>Notes</td>
<td>May be a trial record for an an included study - checking with investigator Juan Jorge Alfredo Lema Osores: <a href="mailto:juan.lema@upch.pe">juan.lema@upch.pe</a>.</td>
</tr>
</tbody>
</table>

### Przewlocka-Kosmala 2017

<table>
<thead>
<tr>
<th>Methods</th>
<th>RCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>105 HFpEF</td>
</tr>
<tr>
<td>Interventions</td>
<td>spironolactone 25mg versus placebo for 6 months</td>
</tr>
<tr>
<td>Outcomes</td>
<td>UT, E/e’</td>
</tr>
<tr>
<td>Notes</td>
<td>Contact investigators to ask for full results paper.</td>
</tr>
</tbody>
</table>

### Rapezzi 1999

<table>
<thead>
<tr>
<th>Methods</th>
<th>No abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>No abstract</td>
</tr>
<tr>
<td>Interventions</td>
<td>No abstract</td>
</tr>
<tr>
<td>Outcomes</td>
<td>No abstract</td>
</tr>
<tr>
<td>Notes</td>
<td>Could not yet retrieve full text</td>
</tr>
</tbody>
</table>

---

EF: ejection fraction  
EHT: essential hypertension  
HF: heart failure  
RCT: randomised controlled trial  
LVEF: left ventricular ejection fraction  
GRK2: G protein-coupled receptor kinase 2
**Characteristics of ongoing studies [ordered by study ID]**

<table>
<thead>
<tr>
<th>ChiCTR-IPR-16009507</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study name</strong></td>
</tr>
<tr>
<td><strong>Methods</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Participants</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
</tr>
<tr>
<td><strong>Starting date</strong></td>
</tr>
<tr>
<td><strong>Contact information</strong></td>
</tr>
<tr>
<td><strong>Notes</strong></td>
</tr>
</tbody>
</table>
Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone

**Methods**

**Study design:**

**Anticipated completion date:**

**Participants**

**Estimated enrolment:** 450

**Inclusion criteria:**

"1. Signed informed consent;
2. Age ≥18 yrs;
3. history of heart failure for 2 months prior to screening;
4. NYHA Functional Class II-IV;
5. LV EF >45% by ECHO or a radionucleotide technique;
6. Therapy with diuretics with stable dose >14 days prior to screening"

**Exclusion criteria:**

"1. NYHA class I;
2. Inability to answer the QOL questionnaire;
3. Myocardial infarction within 3 months;
4. unstable angina within 1 month;
5. Significant cardiac valvular heart disease;
6. Hypotension SBP <90 mmHg;
7. uncontrolled hypertension(DBP>105 ors SBP> 200 mmHg);
8. uncontrolled serious cardiac arrhythmias associated with a ventricular rate >100 bpm at study entry;
9. concurrent therapy with CCB, Betablocker, ACEI, All or positive inotropic agents other than digoxin for control of AF"

**Interventions**

Ramipril + Diuretics vs. Irbesartan +Diuretics vs. Diuretics alone (comparison diuretics + irbesartan versus diuretics of interest to this review)

**Outcomes**

Hospital admissions for heart failure or mortality; quality of life assessed by the Minnesota Quality of life Questionnaire; exercise duration assessed by 6 min corridor walk test; side-effects, effect on levels of natriuretic peptides, effect on doppler-echocardiographic derived measurements of left ventricular diastolic function

**Starting date**

13 July 1997

**Contact information**

Skiva Chan: skivachan@cuhk.edu.hk

**Notes**

Recruitment status: completed
**Study name**
Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial

**Methods**

**Study design:** parallel RCT

**Anticipated completion date:** November 2011

**Participants**

**Inclusion criteria:**
- Age 18 years and above of either sex
- Presence of New York Heart Association functional class II-IV of at least 4 weeks duration
- LVEF ≥ 50% in a nondilated LV (LV end-diastolic volume <97ml/m² measured by echocardiography
- Echocardiographic evidence of LV diastolic dysfunction
- Willing to give written informed consent

**Exclusion criteria:**
- Clinically unstable as defined by any change in diuretic dose in the month prior to enrolment.
- Significant valvular heart disease, pericardial disease, hypertrophic or restrictive cardiomyopathy
- Unstable angina or MI within the past 4 weeks.
- Alternative probable cause of the patient’s symptoms (e.g., significant pulmonary disease);
- Any previous left ventricular ejection fraction below 40%
- Other systemic disease limiting life expectancy to less than 3 years
- Any contraindication to metoprolol use (heart rate less than 45 beats per minute, heart block greater than first-degree i.e. PR interval ≥ 0.24 second, systolic blood pressure <100 mm Hg, asthma)
- Conditions associated with alteration in serum levels of procollagen type I e.g. alcoholic liver disease, metabolic bone disease, hyperthyroidism
- Current participation (including prior 30 days) in any other therapeutic trial
- Any condition that, in the opinion of the investigator, may prevent the participant from adhering to the trial protocol

**Interventions**

Metoprolol CR versus placebo

12 weeks

**Outcomes**

- Proportion of patients showing improvement of ≥ 1 in NYHA class
- Proportion of patients exhibiting any alteration in NYHA heart failure class from baseline
- Alteration in exercise capacity using exercise stress testing (treadmill test: Bruce protocol)
- Change in tissue doppler indices of diastolic dysfunction (ratio of mitral inflow velocity to annular relaxation velocity i.e. E/E’ ratio)
- Change in left ventricular wall thickness, left ventricular mass and left atrial volume on echocardiography
- Change in serum NT-proBNP levels from baseline
- Change in serum carboxy-terminal propeptide of procollagen type I (PICP) from baseline
- Alteration in quality of life using SF-36 questionnaire
- Incidence of adverse events

**Starting date**
15 November 2009

**Contact information**
Samir Malhotra: samirmalhotra345@yahoo.com

**Notes**
Methods

**Study design:** parallel RCT

**Anticipated completion date:** February 2020

Participants

**Estimated enrolment:** 2200

**Inclusion criteria:**

- Written informed consent must be obtained before any assessment is performed.
- LVEF ≥ 45% by echocardiography performed at site within 6 months prior to Visit 1 or during the screening epoch.
- Symptom(s) of HF requiring treatment with diuretic(s) (including loop or thiazide diuretics, or mineralocorticoid antagonist (MRAs)) for at least 30 days prior to Visit 1.
- Current symptom(s) of HF (NYHA class II-IV) at Visit 1.
- Structural heart disease demonstrated by echocardiographic evidence of left atrial enlargement (LAE) or left ventricular hypertrophy (LVH) as defined below (any local measurement made during the screening epoch or within the 6 months prior to Visit 1):
  - LAE defined by at least one of the following: LA width (diameter) ≥ 3.8 cm or LA length ≥ 5.0 cm or LA area ≥ 20 cm² or LA volume ≥ 55 mL or LA volume index ≥ 29 mL/m²
  - LVH defined by septal thickness or posterior wall thickness ≥ 1.1 cm
- Receiving evidence based therapy for comorbidities as determined by the individual clinical profile of the patient (eg age and number and type of comorbidities) with stable doses for the previous four weeks
- NT-proBNP > 220 pg/mL for patients with no atrial fibrillation/atrial flutter (AF) or > 600 pg/mL for patients with AF on the Visit 1 electrocardiogram (ECG)
- KCCQ CSS 9. Patients on angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) therapy must have a history of HTN

**Exclusion criteria:**

- Any prior echocardiographic measurement of LVEF
- Acute coronary syndrome (including myocardial infarction [MI]), cardiac surgery, other major cardiovascular (CV) surgery, or urgent percutaneous coronary intervention (PCI) within the 3 months prior to Visit 1 or an elective PCI within 30 days prior to Visit 1.
- Any clinical event within the 6 months prior to Visit 1 that could have reduced the LVEF (eg MI, coronary artery bypass graft [CABG]), unless an echo measurement was performed after the event confirming the LVEF to be ≥ 40% and LVEF ≥ 45% by the time screening.
- Current acute decompensated HF requiring augmented therapy with diuretics, vasodilators and/or inotropic drugs.
- Current use of renin inhibitor(s).
- History of hypersensitivity to LCZ696 or its components.
- Patients with a known history of angioedema Walking distance primarily limited by non-cardiac comorbid conditions.
- Probable alternative diagnoses that in the opinion of the investigator could account for the patient’s HF symptoms (ie dyspnea, fatigue) such as significant pulmonary disease (including primary pulmonary HTN), anemia or obesity. Specifically, patients with the following are excluded:
  - a. severe pulmonary disease including chronic obstructive pulmonary disease (COPD) (ie requiring home oxygen, chronic nebulizer therapy, chronic oral steroid therapy or hospitalized for pulmonary decompensation within 12 months) or
  - b. hemoglobin (Hgb) or
  - c. body mass index (BMI) > 40 kg/m²
Patients with any of the following:
* a. systolic blood pressure (SBP) \( \geq 180 \) mmHg at Visit 1, or
* b. SBP > 150 mmHg and patient is receiving 3 or more antihypertensive drugs. Antihypertensive drugs include, but are not limited to, a thiazide or other diuretic, MRA, ACEi, ARB, beta blocker and calcium channel blocker (CCB), or
* c. SBP

Patients with HbA1c > 7.5% not treated for diabetes

Patients with history of any dilated cardiomyopathy, including peripartum cardiomyopathy, chemotherapy induced cardiomyopathy, or viral myocarditis.

Evidence of right sided HF in the absence of left-sided structural heart disease

Known pericardial constriction, genetic hypertrophic cardiomyopathy, or infiltrative cardiomyopathy.

Clinically significant congenital heart disease that could be the cause of the patient’s symptoms and signs of HF.

Presence of hemodynamically significant valvular heart disease in the opinion of the investigator.

Stroke, transient ischemic attack, carotid surgery or carotid angioplasty within the 3 months prior to Visit 1.

Coronary or carotid artery disease or valvular heart disease likely to require surgical or percutaneous intervention during the trial.

Life-threatening or uncontrolled arrhythmia, including symptomatic or sustained ventricular tachycardia and atrial fibrillation or flutter with a resting ventricular rate > 110 beats per minute (bpm).

Patients with a cardiac resynchronization therapy (CRT) device.

Patients with prior major organ transplant or intent to transplant (ie on transplant list)

**Interventions**

LCZ696 versus enalapril versus valsartan (of interest to this review is comparison LCZ696 versus valsartan)

24 weeks

**Outcomes**

NT-proBNP; quality of life;

**Starting date**

15 June 2017

**Contact information**

Murugananthan K: murugananthan.k@novartis.com

**Notes**
• Chronic heart failure with current symptom(s) (NYHA class II-IV) at Screening visit.
• LVEF > 40%
  * By any method using most recent assessment within 6 months prior to screening visit OR
  * By an echocardiogram performed during the screening visit, if previous assessment is not available.
• NT-proBNP ≥ 125 pg/mL at Screening visit
• Patient with evidence of adequate functioning (e.g.: intellectual, motor, visual and auditory) to complete the study assessments and has elementary education or 6 years of sustained employment.

Exclusion criteria:
• Current acute decompensated HF requiring augmented therapy with diuretics, vasodilators and/or inotropic drugs.
• Acute coronary syndrome (including myocardial infarction (MI)), cardiac surgery, other major cardiovascular (CV) surgery, or urgent percutaneous coronary intervention (PCI), carotid surgery or carotid angioplasty, history of stroke or transient ischemic attack within the 3 months prior to Screening visit or an elective PCI within 30 days prior to Screening visit.
• Patients with history of hereditary or idiopathic angioedema or angioedema related to previous angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) therapies.
• Patients who require treatment with 2 or more of the following: an ACEi, an ARB or a renin inhibitor.
• Patients with one of the following:
  a. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 as calculated by the Modification of Diet in Renal Disease (MDRD) formula at screening visit, or
  b. eGFR <25 mL/min/1.73m2 at Visit 103 or at end of run-in / randomization visit, or
  c. eGFR reduction >35% (compared to Visit 1) at Visit 103 or Visit 199/201
• MMSE score <24 at Screening visit
• Patients with a clinical diagnosis of Alzheimer’s disease or other dementia syndromes or any indication for or current treatment with cholinesterase inhibitors and/or another prescription Alzheimer’s Disease (AD) treatment (e.g., memantine).
• Any history of medical or neurological condition likely to affect the participant’s cognition (e.g., clinically significant brain trauma with loss of consciousness > 3 minutes within 6 months prior to screening, Huntington’s disease, Parkinson’s disease, Lyme’s disease, syphilis, HIV dementia, uncontrolled seizure disorder) or clinically significant abnormalities in thyroid function tests, Vitamin B12 or folate deficiency requiring treatment at screening. (Patients who are adequately treated may be included at investigator discretion).
• Inability to perform cognitive battery or other study evaluations based on significant motor (e.g. hemiplegia, muscular-skeletal injury) or sensory (blindness, decreased or uncorrected visual or auditory acuity) skill.
• Score “yes” on item 4 or item 5 of the Suicidal Ideation section of the Columbia suicidality severity rating scale (C-SSRS), if this ideation occurred in the past 6 months, or “yes” on any item of the Suicidal Behavior section, except for the “Non-Suicidal Self-Injurious Behavior” (item also included in the Suicidal Behavior section), if this behavior occurred in the past 2 years.
• Clinically significant cerebral pathology, for example large cerebral aneurysm, space occupying lesion etc. that may impact cognition as assessed by MRI central reader.
• History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.
• History or presence of any other disease with a life expectancy of <3 years
• Women of child bearing potential defined as all women physiologically capable of becoming pregnant.

Interventions
LCZ696 versus valsartan
3 years

Outcomes
CogState Global Cognitive Composite Score (GCCS); cortical composite SUVr (standardized uptake value ratio); individual cognitive domains (memory, executive function, and attention) as assessed
EUCTR2016-001254-17 (Continued)

by the individual components of the cognitive assessment battery; summary score of the instrumental activities of daily living (IADL) as assessed with Functional Activity Questionnaire (FAQ)

Starting date: not reported

Contact information: Novartis Pharmaceuticals UK Limited: medinfo.uk@novartis.com

Notes:

EUCTR2016-003410-28

Study name: A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, exercise capacity, symptoms and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction

Methods: Study design: parallel RCT

Anticipated completion date: not reported

Participants: Estimated enrolment:

Inclusion criteria:

- Left ventricular ejection fraction (LVEF) >40% by echo within 6 months prior to study entry or during the screening epoch
- Symptom(s) of heart failure (HF) requiring treatment with diuretics (including loop, or thiazide diuretics, or mineralocorticoid antagonist [MRA]) for at least 30 days prior to study entry
- NYHA class II-IV
- Structural heart disease (left atrial enlargement or left ventricular hypertrophy) documented by echocardiogram
- NT-proBNP > 220 pg/mL for patients with no atrial fibrillation/atrial flutter (AF) or >600 pg/mL for patients with AF
- KCCQ clinical summary score < 75
- Patients on ACEi or ARB therapy must have a history of HTN
- Other protocol-defined inclusion criteria may apply

Exclusion criteria:

- Any prior measurement of LVEF ≤ 40% under stable conditions
- Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery within 3 months, or urgent percutaneous coronary intervention (PCI) within 3 months or an elective PCI within 30 days prior to study entry
- Any clinical event within the 6 months prior to Visit 1 that could have reduced the LVEF (e.g., MI, coronary artery bypass graft [CABG]), unless an echo measurement was performed after the event confirming the LVEF to be > 40%
- Current (within 30 days from visit 1) acute decompensated HF requiring therapy.
- Current (within 30 days from visit 1) use of renin inhibitor(s) dual RASblockade or LCZ696
- History of hypersensitivity to LCZ696 or its components
- Patients with a known history of angioedema
- Walk distance primarily limited by non-cardiac comorbid conditions at visit 1
- Alternative reason for shortness of breath such as: significant pulmonary disease or severe COPD, hemoglobin (Hgb) <10 g/dL males and < 9.5 g/dL females, or body mass index (BMI) > 40 kg/m².
- Systolic blood pressure (SBP) ≥ 180 mmHg at study entry, or SBP >150 mmHg and <180 mmHg at study entry unless the patient is receiving 3 or more antihypertensive drugs, or SBP < 110 mmHg at study entry.
Patients with HbA1c > 7.5% not treated for diabetes
- Patients with prior major organ transplant or intent to transplant (ie on transplant list)
- eGFR < 30 ml/min/1.73 m2 as measured by MDRD at screening
- Serum potassium > 5.2 mmol/L (or equivalent plasma potassium value) (at study entry)
- History or presence of any other disease with a life expectancy of < 3 years
- Pregnant or nursing women or women of childbearing potential unless they are using highly effective methods of contraception.
- Other protocol-defined exclusion criteria may apply.

Interventions
LCZ696 versus valsartan versus enalapril

Outcomes
NTproBNP; six-minute walk distance; quality of life; NYHA functional class;

Starting date
not reported

Contact information
Novartis Pharmaceuticals UK Limited: medinfo.uk@novartis.com

Notes

EUCTR2016-003410-28 (Continued)

Spironolactone in the treatment of heart failure: a double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid-range or preserved ejection fraction (SPIRIT-HF)

Methods
Study design: parallel RCT

Anticipated completion date: not reported

Participants
Estimated enrolment: 1300

Inclusion criteria:
1. Written informed consent
2. Male or female, age ≥ 50 years
3. Current symptoms of Heart Failure (NYHA ≥ II) on diuretic treatment (any) during VR
4. Symptom(s) of HF ≥ 30 days prior to VR
5. Left ventricular ejection fraction ≥ 40% at screening measured or MRI and evidence of structural/functional abnormalities (at least one of the following criteria):
   - LAVI > 34 ml/m2
   - E/e’ mean ≥ 13
   - Mean e’ (septal and lateral) < 9 cm/s
6. Patients with at least 1 of the following:
   - HF hospitalization (defined as HF listed as the major reason for hospitalization) within 12 months prior to Visit of Screening and NT-proBNP >200 pg/ml for patients in SR or >600 pg/ml for patients in AF on screening visit ECG (only if NT-proBNP is not available: BNP > 50/ 160 pg/ml), or
b) NT-proBNP >300 pg/ml for patients in SR or >900 pg/ml for patients in AF on the screening visit ECG (only if NT-proBNP is not available: BNP > 80/250 pg/ml); (for entering the study a historical measurement of natriuretic peptides within the last 6 months is acceptable);

7. Controlled systolic BP: defined as a target systolic BP < 140 mm Hg. Subjects with BP up to and including 160 mm Hg are eligible for enrollment if on 3 or more medications to control BP

(Patients with uncontrolled BP should be considered for Re-Screening after optimization of antihypertensive therapy has been established)

9. Serum potassium < 5.0 mmol/L prior to randomization"

Exclusion criteria:

"1. Hyperkalemia (potassium level ≥ 5.5 mmol/L) within the past two weeks before VR

2. Hyponatraemia (Na < 135 mmol/L) prior to randomization

3. Severe renal dysfunction, defined as an estimated glomerular filtration rate of less than 30 mL/min/1.73m² as calculated by the Modification in Diet in Renal Disease (MDRD) formula at VScr/VR or serum creatinine level ≥ 1,8 mg/dl (> 160 μmol/ml)

4. History of anuria or acute RF (defined by RIFLE crit. for AKI;3) within past 2 wk before VR

5. Acute CS (including MI) and elective PCI within 30 days prior to VR

6. Cardiac surgery, other maj CV surgery, or urgent percutaneous PCI within the 3 months prior to VR

7 Current acute decompens. HF requiring augmented therapy with i.v. diuretics, i.v. vasodilators and/or i.v. inotropic drugs. Patients are eligible after initial stabilization.

8. Probable alternative diagnoses that in the opinion of the investigator could account for the patient’s HF symptoms (i.e., dyspnea, fatigue) such as significant pulmonary disease (including primary pulmonary HTN), anemia or obesity. Specifically, patients with the following are not randomized:

• Severe pulmonary disease including COPD or severe asthma bronchiale as requiring continuous corticotherapy or OLD,

• Anemia (hemoglobin < 10 g/dl), or

• Body mass index (BMI) > 40 kg/m²

9. Evidence of right sided HF in the absence of left-sided structural heart disease.

10. Specific etiologies such as infiltrative, genetic hypertrophic cardiomyopathy, pericardial constriction, sarcoidosis, amyloidosis and any other storage diseases.

11. Clinically significant congenital heart disease underlying HF.

12. Life-threatening or uncontrolled dysrhythmia, including symptomatic or sustained ventricular tachycardia and uncontrolled persistent or permanent AF or flutter (with a heart rate > 100 beats per minute (bpm), RACE II) during VR. If AF with HR > 100/min, the patient may be rescreened after treatment for rate control.

13. Presence of significant (i.e., more than moderate) valvular heart disease expected to lead to surgery during the trial in the investigators opinion.

14. Stroke, transient ischemic attack, carotid surgery or carotid angioplasty within the 3 months prior to VR.

15. Coronary or carotid artery disease or valvular heart disease likely to require surgical or percutaneous intervention within the 6 months after VR in the investigators opinion.

EUCTR2017-000697-11 (Continued)
16. Patients with prior major organ transplant or intent to transplant (on transplant list) or current ventricular assist device (VAD) therapy.

17. Evidence of hepatic disease as determined by any one of the following: SGOT (AST) or SGPT (ALT) values exceeding 3x the upper limit of normal (ULN), bilirubin >1.5 mg/dl at VR.


19. Known intolerance or history of hypersensitivity to the active substance (Spironolactone) or to any of the excipients of the IMP or placebo

20. Present use of any aldosterone antagonist, potassium supplements or potassium sparing diuretics at the time of enrollment. (Consider stopping these potassium sparing drugs if clinically possible and upon discussion with the patient)

21. Required treatment with prohibited Co-medications according to the summary of product characteristics with the exception of ACE inhibitors or angiotensin receptor blockers. Concomitant use not recommended:
   • other potassium-sparing diuretics (alone or combined) (amiloride, potassium canrenoate, triamterene): risk of potentially fatal hyperkalemia, particularly in renal insufficiency (additive hyperkalemic effects).
   • potassium chloride
   • cyclosporine, tacrolimus
   • lithium: Increased plasma lithium with signs of overdose, as with a salt-free diet (decreased urinary lithium excretion). However, if the use of diuretics is necessary, careful monitoring of plasma lithium and dose adjustment are required.

22. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives before enrollment, whichever is longer.

23. Any condition that, in the opinion of the investigator, may prevent the subject from adhering to the study protocol.

24. History or presence of any other disease (i.e. including malignancies) with a life expectancy of < 1 years.

25. History of non-compliance to medical regimens and patients who are considered potentially unreliable.

26. Subjects who are legally detained in an official institution.

27. Subjects who may be dependent on the sponsor, the investigator or the trial sites, have to be excluded from the trial.

28. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.

29. WOCBP, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 7 days off study drug.”

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Spironolactone versus placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>60 months</td>
<td></td>
</tr>
</tbody>
</table>

| Outcomes | composite of death from cardiovascular cause or recurrent heart failure hospitalizations; recurrent rate of heart failure hospitalizations; rate of recurrent non-fatal hospitalizations from cardiovascular (CV) cause (i.e. hospitalization for non-fatal MI, non-fatal stroke, or the management of heart failure); recurrent rate of hospitalizations from any cause; rate of death from cardiovascular (CV) cause; rate of death from any cause; total non-fatal myocardial infarctions (MIs), and total non- |
fatal strokes; left ventricular hypertrophy (measured by local ECG); clinical summary score for HF symptoms, physical limitations and mental dimensions of quality of life (as assessed by the KCCQ, SF-36); NYHA functional classification; new onset atrial fibrillation (NOAF) in patients with no history of AF and without AF on ECG during VR; CV deaths and total worsening HF events

Starting date
not reported

Contact information
Burkert Pieske: burkert.pieske@charite.de

Notes

NCT02901184

Study name
Spirolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction, SPIRIT-HFPEF

Methods
Study design: parallel, open-label, RCT

Anticipated completion date: June 2022

Participants
Estimated enrolment: 3500

Inclusion criteria:
- Written informed consent
- Age ≥50 years
- Stable heart failure defined by symptoms and signs of heart failure as judged by local Investigator
- Left ventricular ejection fraction (LVEF) ≥40% recorded in last 12 months (stratified to max 2/3rd in either 40-49% or ≥50% group)
- NT-proBNP (the N-terminal prohormone of brain natriuretic peptide) >300 ng/L in sinus rhythm or >750 ng/L in atrial fibrillation as an outpatient or prior to hospital discharge

Exclusion criteria:
- Previously enrolled in this study
- Known Ejection Fraction < 40% ever
- Current absolute indication or contraindication for MRA (mineral receptor antagonist) in judgement of Investigator
- Any condition other than heart failure with a life expectancy < 3 years
- Known chronic liver disease
- Probable alternative explanations for symptoms: Known primary cardiomyopathy (hypertrophic, constrictive, restrictive, infiltrative, congenital)Primary hemodynamically significant valve diseaseRight-sided HF not due to left-sided HFSignificant chronic pulmonary disease defined by Investigator or by requirement for home O2 or oral steroids,Hemoglobin < 10 g/dL (100 g/L)BMI (body mass index) > 40Heart rate > 105 bpmAny other condition judged by Investigator to be responsible for symptoms and/or signs
- Heart transplant or LVAD (left ventricular assist device) recipient
- Systolic blood pressure <90 or >160
- K (potassium) >5.0 mmol/L
- eGFR (estimated glomerular filtration rate) by MDRD (Modification of Diet in Renal Disease) < 30 mL/min/1.73m2 or creatinine > 2.5 mg/dL (221 μmol/L)
- Current lithium use
- Actual or potential for pregnancy
- Participation in another clinical trial where treatment for HF is studied
- Any condition that in the opinion of the Investigator may interfere with adherence to trial protocol
Interventions  Spironolactone versus standard care

Outcomes

**Primary**: Time to death from any cause [Time Frame: Collected at data base lock, five (5) years after study start]

**Secondary**: Time to first hospitalization for heart failure [Time Frame: Collected at data base lock, five (5) years after study start]

Starting date  December 2017

Contact information  Inger Ekman (inger.ekman@ucr.uu.se)

Notes

NCT03928158

Study name  LCZ696 in advanced LV hypertrophy and HFpEF

Methods

**Study design**: parallel RCT

**Anticipated completion date**: November 2020

Participants

**Estimated enrolment**: 60

**Inclusion criteria:**

- Moderate/severe hypertensive left ventricular (LV) hypertrophy (LVMi ≥109 g/m² in women and ≥132 g/m² in men);
- New York Heart Association (NYHA) class II-III heart failure;
- Left ventricular ejection fraction > 50%;
- Increased LV filling pressures assessed at rest or at peak exercise by echocardiography
- Body mass index (BMI) > 30 kg/m²
- Signed and data informed consent

**Exclusion criteria:**

- Age ≤18 years;
- Evidence of myocardial ischemia during stress echocardiography;
- Chronic atrial flutter or atrial fibrillation;
- Alternative cause of left ventricular hypertrophy and impaired diastolic function (hypertrophic/restrictive cardiomyopathy, aortic stenosis, constrictive pericarditis and etc.);
- NYHA classification I or decompensated heart failure at screening;
- Systolic blood pressure < 110 mmHg or > 180 mmHg;
- Diastolic blood pressure < 40 mmHg or > 100 mmHg;
- Anemia (Hb < 100 g/l);
- Significant left sided structural valve disease;
- Secondary hypertension;
- Dyspnea due to non-cardiac causes such as pulmonary disease, anemia, severe obesity, primary valvular, or myocardial diseases;
- Myocardial infarction or myocardial revascularization within the last 3 months of screening;
- Stroke or TIA within the last 3 months of screening;
- Autoimmune and oncological diseases;
- Impaired renal function, defined as eGFR < 30 ml/min/1.73 m²;
- Impaired liver function;
NCT03928158 (Continued)

- Potassium concentration >5.2 mmol/L.

Interventions
LCZ696 versus valsartan
24 weeks

Outcomes
6-minute walking distance; exercise time during diastolic stress-test; left atrial volume index (LAVI); average E/e' ratio; pulmonary artery systolic pressure (PASP); left ventricular mass index (LVMI); New York Heart Association (NYHA) functional classification; Minnesota Living With Heart Failure Questionnaire (MLHFQ) score; N-terminal pro b-type natriuretic peptide (NT-proBNP); high-sensitivity C-reactive protein (hsCRP); carboxyterminal propeptide of type I collagen (PICP); carboxyterminal telopeptide of type I collagen (CITP); N-Propeptide Of Type III Procollagen (PIIIINP); Growth/differentiation factor 15 (GDF-15); sST2; Galectin-3; monocyte chemoattractant-1 (MCP-1)

Starting date
31 May 2019

Contact information
Artem Ovchinnikov: artcardio@mail.ru

Notes

NCT03948685

Study name
Carvedilol SR study for biomarkers from blood and urine and safety of in patients with heart failure with preserved ejection fraction

Methods
Study design: parallel RCT
Anticipated completion date: January 2021

Participants
Estimated enrolment: 300

Inclusion criteria:
- Provision of informed consent prior to any study specific procedure
- Male or female, aged ≥ 19 years
- Patients with chronic HF (Chronic Heart Failure) NYHA (New York Heart Association classification) class II-IV and preserved EF (Ejection Fraction)(LVEF (Left Ventricular Ejection Fraction) > 40 %) and elevated NT-proBNP (N-terminal of the prohormone brain natriuretic peptide) > 200 pg/ml for patients without AF, OR > 600 pg/ml for patients with AF, analysed at the Central laboratory at Visit 1
- Structural heart disease within 6 months prior to Visit 1 using echocardiography

Exclusion criteria:
- Myocardial infarction, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke or TIA (Transient Ischaemic Attack) in past 90 days prior to Visit 1
- Contraindication to beta blocker
- Heart transplant recipient or listed for heart transplant
- Hospitalization plan for PCI, coronary artery bypass graft surgery, other cardiac invasive interventions (e.g. catheter ablation, pacemaker, CRT, ICD implantation)
- Acute decompensated HF (Heart Failure)
- Symptomatic hypotension or systolic blood pressure < 100 mmHg
- Patients with CrCl < 30 ml/min using creatinine-based CKD-EPI equations
- Elevated liver enzymes (3 times over upper reference limit) or liver cirrhosis
- Symptomatic bradycardia or heart rate < 60/min
- Allergy, adverse drug reaction, hypersensitivity to carvedilol
NCT03948685 (Continued)

- Life expectancy < 6 months (e.g. metastatic malignancy)
- Pregnancy, or women of childbearing age

Interventions

Carvedilol SR versus placebo
24 weeks

Outcomes

NT-proBNP; changes of maximum surrogate markers values (hsTn, hsCRP, sST2, Galectine-3, IGF-BP7, Neprilysin, D-dimer, MMP-2, Cystatin C, NAG, NGAL, KIM-1, BUN, Creatinine, Chloride, Na, K, PICP and spindin-1); degree of dyspnea using VAS questionnaire; change of body weight; frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree; frequency of hypokalemia and worsening kidney function; all-cause hospitalization & mortality

Starting date

May 2019

Contact information

Seok-Min Kang: smkang@yuhs.ac

Notes

NCT03988634

Study name

Changes in NT-proBNP and outcomes, safety, and tolerability in HFrEF patients with acute decompensated heart failure (ADHF) who have been stabilized during hospitalization and initiated in-hospital or within 30 days post-discharge (PARAGLIDE-HF)

Methods

Study design: parallel RCT

Anticipated completion date: September 2021

Participants

Estimated enrolment: 800

Inclusion criteria:

1. “Signed informed consent must be obtained prior to participation in the study
2. Patients ≥40 years of age, male or female
3. Currently hospitalized for or within 30 days following discharge of an acute decompensated HFrEF admission. Patients with a diagnosis of acute heart failure had to have symptoms and signs of fluid overload (i.e. jugular venous distention, edema or rales on auscultation or pulmonary congestion on chest x-ray). Eligible patients will be randomized no earlier than 36 hours and within 30 days post-discharge after presentation with acute HFrEF decompensation and meeting the following definitions of hemodynamic stability: In-hospital randomized patients will have been hemodynamically stable defined in this study as: SBP ≥ 100 mmHg for the preceding 6 hours prior to randomization; no symptomatic hypotensionNo increase (intensification) in i.v. diuretic dose within last 6 hours prior to randomizationNo i.v. inotropic drugs for 24 hours prior to randomizationNo i.v. vasodilators including nitrates within last 6 hours prior to randomizationOut-of-hospital randomized patients will have been hemodynamically stabilized defined in this study as: SBP ≥ 100 mmHg; no symptomatic hypotensionNo increase (intensification and/or change to IV) in diuretic dose within last 24 hours prior to randomizationNo i.v. inotropic drugs for 24 hours prior to randomization
4. HFrEF with most recent LVEF >40% (within past 3 months)
5. Elevated NT-proBNP or BNP at the time of screening (and within 72 hours from inhospital screening to out-of-hospital randomization, if applicable)Patients not in AF at the time of biomarker assessment: NT-proBNP ≥ 500 pg/mL or BNP ≥ 150 pg/mL; patients in AF at the time of biomarker assessment: NT-proBNP ≥ 1000 pg/mL or BNP ≥ 300 pg/mLPatients recruited in-hospital will be randomized based on the qualifying local lab value in-hospital NT-proBNP or BNP value. In-hospital is the preferred method of enrollment. Patients enrolled out-of-hospital can be randomized based on their NT-proBNP or BNP value in the following way: if enrolling in out-of-hospital setting then
need eligible screening/local NTproBNP/BNP within 72 hours of randomization. The test value could be from recent hospitalization if within 72 hours or would require (re)drawing NT-proBNP or BNP labs in out-of-hospital setting if the lab value is not already available within the last 72 hours

6. Has not taken an ACEi for 36 hours prior to randomization

Exclusion criteria:

1. "Any clinical event within the 90 days prior to randomization that could have reduced the LVEF (i.e., MI, CABG), unless an echo measurement was performed after the event confirming the LVEF to be >40%"
2. Currently taking Entresto™ (sacubitril/valsartan) or any prior use
3. eGFR < 20 ml/min/1.73 m² as measured by the simplified Modification of Diet in Renal Disease (MDRD) formula at most recent assessment prior to randomization and within 24 hours prior to randomization
4. Serum potassium > 5.2 mEq/L at most recent assessment prior to randomization and within 24 hours prior to randomization
5. Acute coronary syndrome, stroke, transient ischemic attack; cardiac, carotid or other major CV surgery; percutaneous coronary intervention (PCI) or carotid angioplasty, within 30 days prior to randomization
6. Probable alternative diagnoses that in the opinion of the investigator could account for the patient’s HF symptoms (i.e. dyspnea, fatigue) such as significant pulmonary disease (including primary pulmonary HTN), anemia or obesity. Specifically, patients with the following are excluded: Severe pulmonary disease including chronic obstructive pulmonary disease (COPD) (i.e. requiring home oxygen, oral steroid therapy) or Hemoglobin (Hgb) < 9.5 g/dL males and < 9 g/dL females or Body mass index (BMI) > 50 kg/m² at randomization
7. Isolated right HF in the absence of left-sided structural heart disease
8. History of hypersensitivity (i.e. including angioedema), known or suspected contraindications, or intolerance to any of the study drugs including ARNs (i.e. sacubitril/valsartan), and/or ARBs
9. Patients with a known history of angioedema due to any etiology
10. Patients with a history of heart transplant or LVAD, currently on the transplant list, or with planned intent to implant LVAD or CRT device within the initial three months of enrollment during the trial
11. A cardiac or non-cardiac medical condition other than HF with an estimated life expectancy of < 12 months
12. Known pericardial constriction, genetic hypertrophic cardiomyopathy, or infiltrative cardiomyopathy including amyloid heart disease (amyloidosis)
13. Life-threatening or uncontrolled dysrhythmia, including symptomatic or sustained ventricular tachycardia and atrial fibrillation or flutter with a resting ventricular rate >110 bpm
14. Clinically significant congenital heart disease felt to be the cause of the patient’s symptoms and signs of HF
15. Coronary or carotid artery disease or valvular heart disease likely to require surgical or percutaneous intervention within the duration of the trial
16. Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study
17. Known hepatic impairment (as evidenced by total bilirubin > 3 mg/dL, or increased ammonia levels, if performed), or history of cirrhosis with evidence of portal hypertension such as varices
18. Participation in any other clinical trial involving investigational agents or devices within the past 30 days
19. Pregnant or nursing women; women of childbearing potential that are not using a highly effective method of contraception until 1 week following last dose
20. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using basic methods of contraception during dosing of study treatment”

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Sacubitril/valsartan versus valsartan</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 weeks</td>
<td></td>
</tr>
</tbody>
</table>
NCT03988634 (Continued)

Outcomes
NT-proBNP; composite hierarchical outcome consisting of: a) time to CV death, b) total HF hospitalizations, c) total urgent HF visits, and d) time-averaged proportional change in NT-proBNP; total composite events based on CV death, HF hospitalizations, and urgent HF visits; composite endpoint of worsening renal function (renal death, reaching ESRD, or decline in eGFR >/= 50%); hs-Troponin (high sensitivity)

Starting date
27 June 2019

Contact information
Novartis Pharmaceuticals: novartis.email@novartis.com

Notes

NCT04128891

Study name
Study of sacubitril/valsartan on myocardial oxygenation and fibrosis in heart failure with preserved ejection fraction (PRISTINE-HF)

Methods
Study design: parallel RCT
Anticipated completion date: 1 February 2024

Participants
Estimated enrolment: 60

Inclusion criteria:
1. "Written informed consent will be obtained before any assessment is performed
2. ≥ 40 years of age, male or female
3. LVEF ≥45% by echocardiography during the screening period
4. Symptom(s) of heart failure requiring treatment with diuretic(s) for at least 30 days prior to screening visit
5. Current symptom(s) of heart failure (NYHA functional class II to IV)
6. Structural heart disease evidenced by at least 1 of the following echocardiography findings: Left atrial (LA) enlargement defined by at least 1 of the following: LA width (diameter) ≥3.8 cm or LA length ≥5.0 cm or LA area ≥20 cm^2 or LA volume ≥55 ml or LA volume index ≥29 ml/m^2 Left ventricular hypertrophy defined by septal thickness or posterior wall thickness ≥1.2 cm
7. Elevated NT-proBNP (at least 1 of the following) NT-proBNP >300 pg/ml for patients not in atrial fibrillation or >900 pg/ml for patients in atrial fibrillation during initial screening Heart failure hospitalization (defined as heart failure listed as the major reason for hospitalization) within 9 months prior to screening visit and NT-proBNP >200 pg/ml for patients not in atrial fibrillation or >600 pg/ml for patients in atrial fibrillation during initial screening"

Exclusion criteria:
1. "Any prior echocardiographic measurement of LVEF <45%"  
2. Acute coronary syndrome (including myocardial infarction), cardiac surgery, other major cardiovascular surgery, or percutaneous coronary intervention within 3 months
3. Known unrevascularized epicardial coronary artery disease (> 50% stenosis in any major epicardial coronary artery)
4. Current acute decompensated heart failure requiring augmented therapy with intravenous diuretic agents, vasodilator agents, and/or inotropic drugs
5. Patients who require treatment with 2 or more of the following: an angiotensin converting enzyme inhibitor, an angiotensin receptor blocker, or a renin inhibitor
6. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes
7. Patients with a known history of angioedema
8. Probable alternative diagnoses that in the opinion of the investigator could account for the patient's heart failure symptoms such as significant pulmonary disease (including primary pul-

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
monary hypertension), anaemia, or obesity. Specifically, patients with the following are excluded: Severe pulmonary disease including chronic obstructive pulmonary disease (i.e., requiring home oxygen therapy, chronic oral steroid therapy or hospitalized for pulmonary decompensation within 12 months) or haemoglobin <10 g/dl, or Body mass index >40 kg/m²

9. Patients with any of the following: Systolic blood pressure (SBP) ≥180 mm Hg at entry, or SBP >150 mm Hg and <180 mm Hg at entry unless the patient is receiving 3 or more antihypertensive drugs. SBP <110 mm Hg at entry

10. Current participation in another investigational drug or device.

11. Patients with history of any dilated cardiomyopathy, including peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, or viral myocarditis

12. Evidence of right-sided heart failure in the absence of left-sided structural heart disease

13. Known pericardial constriction, genetic hypertrophic cardiomyopathy, or infiltrative cardiomyopathy

14. Clinically significant congenital heart disease that could be the cause of the patient’s symptoms and signs of heart failure

15. Presence of hemodynamically significant valvular heart disease in the opinion of the investigator

16. Stroke, transient ischemic attack, carotid surgery, or carotid angioplasty within the 3 months

17. Carotid artery disease or valvular heart disease likely to require surgical or percutaneous intervention during the trial

18. Life-threatening or uncontrolled dysrhythmia, including symptomatic or sustained ventricular tachycardia and atrial flutter or atrial flutter with a resting ventricular rate >110 beats per minute

19. Patients with a cardiac resynchronization therapy device

20. Patients with prior major organ transplant or intent to transplant (i.e., on transplant list)

21. Any surgical or medical condition that in the opinion of the investigator may place the patient at higher risk from his/her participation in the study or is likely to prevent the patient from complying with the requirements of the study or completing the study

22. Any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of study drugs, including but not limited to any of the following: any history of pancreatic injury, pancreatitis, or evidence of impaired pancreatic function/injury within the past 5 years

23. Evidence of hepatic disease as determined by any 1 of the following: SGOT (AST) or SGPT (ALT) values exceeding 3× the upper limit of normal, bilirubin >1.5 mg/dl at entry

24. Patients with severe renal impairment of the following: eGFR <30 ml/min/1.73 m² as calculated by the Modification in Diet in Renal Disease (MDRD) formula at entry

25. Presence of known functionally significant bilateral renal artery stenosis

26. Patients with serum potassium >5.2 mmol/l (mEq/l) at entry

27. History or presence of any other disease with a life expectancy of <3 years

28. History of noncompliance to medical regimens and patients who are considered potentially unreliable

29. History or evidence of drug or alcohol abuse within the past 12 months

30. Persons directly involved in the execution of this protocol

31. History of malignancy of any organ system (other than localized basal or squamous cell carcinoma of the skin or localized prostate cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases

32. Pregnant or nursing (lactating) women

33. Women of child-bearing potential

34. Contraindications to CMR (claustrophobia, implanted medical devices like pacemakers / defibrillators, cochlear implants, intracranial clips, iron fragments in eyes, inability to lie flat for the scanning period)

35. Contraindications to Gadolinium (eGFR <30 ml/min/1.73 m² as calculated by the MDRD formula at entry or previous known serious allergy)

36. Contraindications to Adenosine (second or third-degree atrioventricular block, asthma, concurrent dipyridamole use)"
### NCT04128891 (Continued)

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Sacubitril/valsartan versus valsartan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Two years</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>improvement in microvascular function and ischaemia, as assessed by OS-CMR at rest and stress; microvascular dysfunction; myocardial fibrosis; left ventricular diastolic function; NYHA class; 6-minute walk test; heart failure related hospitalisations; cardiac mortality; all-cause mortality</th>
</tr>
</thead>
</table>

| Starting date       | 1 February 2020                      |
|---------------------|                                      |

<table>
<thead>
<tr>
<th>Contact information</th>
<th>Professor Selvanayagam: <a href="mailto:joseph.selva@sa.gov.au">joseph.selva@sa.gov.au</a></th>
</tr>
</thead>
</table>

| Notes               |                                               |
|---------------------|                                               |

---

### Zhou 2010

<table>
<thead>
<tr>
<th>Study name</th>
<th>b-PRESERVE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Methods</th>
<th>Study design: &quot;multicentre, prospective, randomized, open-label, blinded endpoint trial&quot;</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Anticipated completion date:</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Participants</th>
<th>Estimated enrolment: &quot;A total of 1200 patients will be randomized to either b-blocker (metoprolol succinate) or control (n = 600 per group).&quot;</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Inclusion criteria:</th>
<th>&quot;The most essential criteria for HFNEF in this trial are: heart failure symptoms, elevated NT-proBNP 1500 pg/mL, and LVEF 50%. In addition, age.40 years and a recent hospitalization for heart failure, but not within 3 months prior to enrolment, are required.&quot;</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Exclusion criteria:</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Interventions</th>
<th>&quot;The follow-up period is a minimum of 2 years.&quot;</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>&quot;The primary endpoint is a composite of hospitalization for heart failure and cardiovascular death. The secondary endpoints include cardiovascular death, heart failure mortality or hospitalization, all-cause mortality, change in New York Heart Association class, change in left ventricular ejection fraction, increase in NT-proBNP (by 50% of the value at randomization), b-blocker tolerance, and premature termination of b-blocker therapy due to adverse events&quot;</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Starting date</th>
<th>not reported</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Contact information</th>
<th>Email: <a href="mailto:ge.junbo@zs-hospital.sh.cn">ge.junbo@zs-hospital.sh.cn</a> or <a href="mailto:jbge@zs-hospital.sh.cn">jbge@zs-hospital.sh.cn</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Notes</th>
<th>Could not find the entry in the Chinese Clinical Trial Register with ID ChiCTR-TNC-00000144. Contacted investigators to clarify status of study. No response.</th>
</tr>
</thead>
</table>

---

ACEI: angiotensin-converting-enzyme inhibitor  
ARB: angiotensin II receptor blockers  
CMR: cardiac magnetic resonance  
ECV: extra-cellular volume  
HTN: hypertension  
KCCQ: Kansas City Cardiomyopathy Questionnaire  
LVEF: left ventricular ejection fraction  
NYHA: New York Heart Association Classification of heart failure  
QoL: quality of life  
RCT: randomised controlled trial
## DATA AND ANALYSES

### Comparison 1. Beta-blockers versus placebo or no treatment

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1 Cardiovascular mortality (RR)</td>
<td>3</td>
<td>1046</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.78 [0.62, 0.99]</td>
</tr>
<tr>
<td>1.2 Heart failure hospitalisation (RR)</td>
<td>4</td>
<td>449</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.73 [0.47, 1.13]</td>
</tr>
<tr>
<td>1.3 All-cause mortality (RR)</td>
<td>4</td>
<td>1105</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.82 [0.67, 1.00]</td>
</tr>
<tr>
<td>1.4 Quality of life (Minnesota)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.5 Withdrawal due to adverse event</td>
<td>2</td>
<td>338</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>18.07 [2.45, 133.04]</td>
</tr>
</tbody>
</table>

### Analysis 1.1. Comparison 1: Beta-blockers versus placebo or no treatment, Outcome 1: Cardiovascular mortality (RR)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Beta-blocker Events</th>
<th>Beta-blocker Total</th>
<th>Placebo/no treatment Events</th>
<th>Placebo/no treatment Total</th>
<th>Weight</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aronow 1997</td>
<td>40</td>
<td>79</td>
<td>56</td>
<td>79</td>
<td>57.3%</td>
<td>0.71 [0.55, 0.93]</td>
<td></td>
</tr>
<tr>
<td>J-DHF (1)</td>
<td>8</td>
<td>120</td>
<td>7</td>
<td>125</td>
<td>7.0%</td>
<td>1.19 [0.45, 3.18]</td>
<td></td>
</tr>
<tr>
<td>SENIORS</td>
<td>28</td>
<td>320</td>
<td>35</td>
<td>323</td>
<td>35.7%</td>
<td>0.81 [0.50, 1.29]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>519</strong></td>
<td><strong>527</strong></td>
<td><strong>100.0%</strong></td>
<td></td>
<td></td>
<td><strong>0.78 [0.62, 0.99]</strong></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 1.18, df = 2 (P = 0.55); I² = 0%
Test for overall effect: Z = 2.03 (P = 0.04)
Test for subgroup differences: Not applicable

**Footnotes**
(1) different numbers for events reported in same paper, higher values used for analysis
Analysis 1.2. Comparison 1: Beta-blockers versus placebo or no treatment, Outcome 2: Heart failure hospitalisation (RR)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Beta-blocker</th>
<th>Placebo/no treatment</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>J-DHF</td>
<td>21 (120)</td>
<td>27 (125)</td>
<td>68.4% 0.81 [0.49, 1.35]</td>
<td>4.04</td>
</tr>
<tr>
<td>Shu 2005</td>
<td>3 (33)</td>
<td>10 (34)</td>
<td>25.5% 0.31 [0.09, 1.02]</td>
<td>2.09</td>
</tr>
<tr>
<td>SWEDIC</td>
<td>2 (47)</td>
<td>0 (50)</td>
<td>1.3% 5.31 [0.26, 107.85]</td>
<td>5.62</td>
</tr>
<tr>
<td>Takeda 2004</td>
<td>1 (19)</td>
<td>2 (21)</td>
<td>4.9% 0.55 [0.05, 5.62]</td>
<td>1.30</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>219</strong></td>
<td><strong>230</strong></td>
<td><strong>100.0% 0.73 [0.47, 1.13]</strong></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 27, 39
Heterogeneity: Chi² = 3.86, df = 3 (P = 0.28); I² = 22%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable

Analysis 1.3. Comparison 1: Beta-blockers versus placebo or no treatment, Outcome 3: All-cause mortality (RR)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Beta-blocker</th>
<th>Placebo/no treatment</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adamyan 2010</td>
<td>6 (31)</td>
<td>8 (28)</td>
<td>6.1% 0.68 [0.27, 1.71]</td>
<td>4.98</td>
</tr>
<tr>
<td>Aronow 1997</td>
<td>44 (79)</td>
<td>60 (79)</td>
<td>43.9% 0.73 [0.58, 0.93]</td>
<td>4.98</td>
</tr>
<tr>
<td>J-DHF (1)</td>
<td>18 (120)</td>
<td>21 (125)</td>
<td>15.0% 0.89 [0.50, 1.59]</td>
<td>4.98</td>
</tr>
<tr>
<td>SENIORS</td>
<td>44 (320)</td>
<td>48 (323)</td>
<td>34.9% 0.93 [0.63, 1.35]</td>
<td>4.98</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>550</strong></td>
<td><strong>555</strong></td>
<td><strong>100.0% 0.82 [0.67, 1.00]</strong></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 112, 137
Heterogeneity: Chi² = 1.53, df = 3 (P = 0.67); I² = 0%
Test for overall effect: Z = 1.94 (P = 0.05)
Test for subgroup differences: Not applicable

Footnotes
(1) different numbers for events reported in same paper, higher values used for analysis

Analysis 1.4. Comparison 1: Beta-blockers versus placebo or no treatment, Outcome 4: Quality of life (Minnesota)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Beta-blocker</th>
<th>Placebo/no treatment</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELANDD</td>
<td>23 (42)</td>
<td>24 (41)</td>
<td>-1.00 [-9.05, 7.05]</td>
<td>51.8</td>
</tr>
</tbody>
</table>

Mean Difference

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1: Beta-blockers versus placebo or no treatment, Outcome 5: Withdrawal due to adverse event

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Beta-blockers</th>
<th>Placebo/no treatment</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Weight</td>
<td></td>
</tr>
<tr>
<td>ELANDD</td>
<td>9</td>
<td>42</td>
<td>51</td>
<td>22.98 [1.38, 383.54]</td>
</tr>
<tr>
<td>J-DHF</td>
<td>6</td>
<td>120</td>
<td>125</td>
<td>13.54 [0.77, 237.71]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>162</td>
<td>176</td>
<td>100.0%</td>
<td>18.07 [2.45, 133.04]</td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 0.07, df = 1 (P = 0.80); I² = 0%
Test for overall effect: Z = 2.84 (P = 0.004)
Test for subgroup differences: Not applicable

Comparison 2. Mineralocorticoid receptor antagonists versus placebo or no treatment

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1 Cardiovascular mortality (RR)</td>
<td>3</td>
<td>4070</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.90 [0.74, 1.11]</td>
</tr>
<tr>
<td>2.2 Heart failure hospitalisation (RR)</td>
<td>3</td>
<td>3714</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.82 [0.69, 0.98]</td>
</tr>
<tr>
<td>2.3 Heart failure hospitalisation (HR)</td>
<td>2</td>
<td>3670</td>
<td>Hazard Ratio (IV, Fixed, 95% CI)</td>
<td>0.82 [0.69, 0.98]</td>
</tr>
<tr>
<td>2.4 Hyperkalaemia</td>
<td>6</td>
<td>4291</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>2.11 [1.77, 2.51]</td>
</tr>
<tr>
<td>2.5 All-cause mortality (RR)</td>
<td>5</td>
<td>4207</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.91 [0.78, 1.06]</td>
</tr>
<tr>
<td>2.6 Quality of life</td>
<td>5</td>
<td>603</td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>0.05 [-0.23, 0.34]</td>
</tr>
<tr>
<td>2.7 Quality of life (KCCQ)</td>
<td>2</td>
<td>92</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>-0.78 [-28.02, 26.46]</td>
</tr>
<tr>
<td>2.8 Quality of life (Minnesota)</td>
<td>3</td>
<td>511</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>0.84 [-2.30, 3.98]</td>
</tr>
<tr>
<td>2.9 Withdrawal due to adverse event</td>
<td>5</td>
<td>4037</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.10 [1.00, 1.21]</td>
</tr>
</tbody>
</table>
### Analysis 2.1. Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 1: Cardiovascular mortality (RR)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>MRA</th>
<th>Placebo/no treatment</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M-H, Fixed, 95% CI</td>
<td>M-H, Fixed, 95% CI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALDO-DHF</td>
<td>1 204 0 196 0.8% 2.88 [0.12 , 70.35]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AREA IN-CHF</td>
<td>0 116 2 109 1.4% 0.19 [0.01 , 3.87]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOPCAT</td>
<td>160 1722 176 1723 98.3% 0.91 [0.74 , 1.11]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>2042 2028 200.0% 0.90 [0.74 , 1.11]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 161

Heterogeneity: Chi² = 1.54, df = 2 (P = 0.46); I² = 0%

Test for overall effect: Z = 0.97 (P = 0.33)

Test for subgroup differences: Not applicable

### Analysis 2.2. Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 2: Heart failure hospitalisation (RR)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>MRA</th>
<th>Placebo/no treatment</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M-H, Fixed, 95% CI</td>
<td>M-H, Fixed, 95% CI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AREA IN-CHF</td>
<td>1 116 6 109 2.4% 0.16 [0.02 , 1.28]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RAAM-PEF</td>
<td>1 21 2 23 0.8% 0.55 [0.05 , 5.61]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOPCAT</td>
<td>206 1722 245 1723 96.8% 0.84 [0.71 , 1.00]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>1859 1855 100.0% 0.82 [0.69 , 0.98]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 208

Heterogeneity: Chi² = 2.58, df = 2 (P = 0.28); I² = 22%

Test for overall effect: Z = 2.24 (P = 0.03)

Test for subgroup differences: Not applicable

### Analysis 2.3. Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 3: Heart failure hospitalisation (HR)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>log[Hazard Ratio]</th>
<th>SE</th>
<th>MRA</th>
<th>Placebo/no treatment</th>
<th>Hazard Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IV, Fixed, 95% CI</td>
<td>IV, Fixed, 95% CI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AREA IN-CHF</td>
<td>-1.8971 1.0939 116 109 0.7% 0.15 [0.02 , 1.28]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOPCAT</td>
<td>-0.186 0.09 1722 1723 99.3% 0.83 [0.70 , 0.99]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>1838 1832 100.0% 0.82 [0.69 , 0.98]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 208

Heterogeneity: Chi² = 2.43, df = 1 (P = 0.12); I² = 59%

Test for overall effect: Z = 2.20 (P = 0.03)

Test for subgroup differences: Not applicable
### Analysis 2.4. Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 4: Hyperkalaemia

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>MRA Events</th>
<th>Total Placebo/no treatment Events</th>
<th>Total</th>
<th>Weight</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALDO-DHF</td>
<td>1</td>
<td>203</td>
<td>1</td>
<td>195</td>
<td>0.06</td>
<td>0.96 [0.06 , 15.25]</td>
</tr>
<tr>
<td>AREA IN-CHF</td>
<td>10</td>
<td>116</td>
<td>2</td>
<td>109</td>
<td>1.3%</td>
<td>4.70 [1.05 , 20.96]</td>
</tr>
<tr>
<td>Kurrelmeyer 2014</td>
<td>4</td>
<td>24</td>
<td>1</td>
<td>24</td>
<td>0.06</td>
<td>4.00 [0.48 , 33.22]</td>
</tr>
<tr>
<td>RAAM-PEF</td>
<td>3</td>
<td>21</td>
<td>1</td>
<td>23</td>
<td>0.06</td>
<td>3.29 [0.37 , 29.20]</td>
</tr>
<tr>
<td>STRUCTURE</td>
<td>2</td>
<td>64</td>
<td>0</td>
<td>67</td>
<td>0.3%</td>
<td>5.23 [0.26 , 106.89]</td>
</tr>
<tr>
<td>TOPCAT</td>
<td>322</td>
<td>1722</td>
<td>157</td>
<td>1723</td>
<td>96.6%</td>
<td>2.05 [1.72 , 2.45]</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>2150</strong></td>
<td><strong>2141</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>2.11 [1.77 , 2.51]</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 2.36, df = 5 (P = 0.80); I² = 0%
Test for overall effect: Z = 8.33 (P < 0.00001)
Test for subgroup differences: Not applicable

### Analysis 2.5. Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 5: All-cause mortality (RR)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>MRA Events</th>
<th>Total Placebo/no treatment Events</th>
<th>Total</th>
<th>Weight</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALDO-DHF</td>
<td>1</td>
<td>213</td>
<td>0</td>
<td>209</td>
<td>0.2%</td>
<td>2.94 [0.12 , 71.86]</td>
</tr>
<tr>
<td>AREA IN-CHF</td>
<td>0</td>
<td>116</td>
<td>3</td>
<td>109</td>
<td>1.3%</td>
<td>0.13 [0.01 , 2.57]</td>
</tr>
<tr>
<td>Mak 2009</td>
<td>1</td>
<td>24</td>
<td>1</td>
<td>20</td>
<td>0.4%</td>
<td>0.83 [0.06 , 12.49]</td>
</tr>
<tr>
<td>TOPCAT</td>
<td>252</td>
<td>1722</td>
<td>274</td>
<td>1723</td>
<td>97.6%</td>
<td>0.92 [0.79 , 1.08]</td>
</tr>
<tr>
<td>Upadhya 2017</td>
<td>0</td>
<td>37</td>
<td>1</td>
<td>34</td>
<td>0.6%</td>
<td>0.31 [0.01 , 7.29]</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>2112</strong></td>
<td><strong>2095</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>0.91 [0.78 , 1.06]</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 2.61, df = 4 (P = 0.63); I² = 0%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable

### Analysis 2.6. Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 6: Quality of life

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>MRA Mean</th>
<th>SD Total</th>
<th>Placebo/no treatment Mean</th>
<th>SD Total</th>
<th>Weight</th>
<th>Std. Mean Difference IV, Random, 95% CI</th>
<th>Std. Mean Difference IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALDO-DHF (1)</td>
<td>21</td>
<td>21.7316</td>
<td>204</td>
<td>21</td>
<td>14.1973</td>
<td>196</td>
<td>35.6%</td>
</tr>
<tr>
<td>Kurrelmeyer 2014 (2)</td>
<td>-48.5</td>
<td>26.9444</td>
<td>24</td>
<td>-61.8</td>
<td>25.4747</td>
<td>24</td>
<td>15.7%</td>
</tr>
<tr>
<td>RAAM-PEF (2)</td>
<td>-68.7</td>
<td>22.8</td>
<td>21</td>
<td>-54.2</td>
<td>22.8</td>
<td>23</td>
<td>14.7%</td>
</tr>
<tr>
<td>Upadhya 2017 (1)</td>
<td>29</td>
<td>18</td>
<td>37</td>
<td>25</td>
<td>18</td>
<td>34</td>
<td>20.0%</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>309</strong></td>
<td><strong>294</strong></td>
<td><strong>100.0%</strong></td>
<td></td>
<td><strong>85 [0.23 , 0.34]</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.05; Chi² = 7.93, df = 4 (P = 0.09); I² = 50%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable

Footnotes
(1) MLHF
(2) KCCQ
### Analysis 2.7. Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 7: Quality of life (KCCQ)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>MRA</th>
<th>Placebo/no treatment</th>
<th>Mean Difference IV, Random, 95% CI</th>
<th>Mean Difference IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>RAAM-PEF</td>
<td>-68.7</td>
<td>22.8</td>
<td>-14.50 [-27.99, -1.01]</td>
<td>-14.50 [-27.99, -1.01]</td>
</tr>
</tbody>
</table>

**Total (95% CI):** 45 100.0%

Heterogeneity: Tau² = 334.10; Chi² = 7.39, df = 1 (P = 0.007); I² = 86%

Test for overall effect: Z = 0.06 (P = 0.96)

Test for subgroup differences: Not applicable

### Analysis 2.8. Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 8: Quality of life (Minnesota)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>MRA</th>
<th>Placebo/no treatment</th>
<th>Mean Difference IV, Random, 95% CI</th>
<th>Mean Difference IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALDO-DHF</td>
<td>21</td>
<td>21.7316</td>
<td>0.00 [-3.58, 3.58]</td>
<td>0.00 [-3.58, 3.58]</td>
</tr>
<tr>
<td>Mak 2009</td>
<td>23</td>
<td>20</td>
<td>3.00 [-7.25, 13.25]</td>
<td>3.00 [-7.25, 13.25]</td>
</tr>
<tr>
<td>Upadhya 2017</td>
<td>29</td>
<td>18</td>
<td>4.00 [-4.38, 12.38]</td>
<td>4.00 [-4.38, 12.38]</td>
</tr>
</tbody>
</table>

**Total (95% CI):** 264 100.0%

Heterogeneity: Tau² = 0.00; Chi² = 0.93, df = 2 (P = 0.63); I² = 0%

Test for overall effect: Z = 0.53 (P = 0.60)

Test for subgroup differences: Not applicable

### Analysis 2.9. Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 9: Withdrawal due to adverse event

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Events</th>
<th>Total</th>
<th>M-H, Fixed, 95% CI</th>
<th>M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALDO-DHF</td>
<td>0</td>
<td>213</td>
<td>0.33 [0.01, 7.98]</td>
<td>0.33 [0.01, 7.98]</td>
</tr>
<tr>
<td>Kurrelmeyer 2014</td>
<td>3</td>
<td>24</td>
<td>7.00 [0.38, 128.61]</td>
<td>7.00 [0.38, 128.61]</td>
</tr>
<tr>
<td>Mcdarmid 2020</td>
<td>3</td>
<td>27</td>
<td>6.25 [0.34, 115.15]</td>
<td>6.25 [0.34, 115.15]</td>
</tr>
<tr>
<td>TOPCAT</td>
<td>597</td>
<td>1722</td>
<td>1.09 [0.59, 2.00]</td>
<td>1.09 [0.59, 2.00]</td>
</tr>
<tr>
<td>Upadhya 2017</td>
<td>1</td>
<td>37</td>
<td>2.76 [0.12, 65.62]</td>
<td>2.76 [0.12, 65.62]</td>
</tr>
</tbody>
</table>

**Total (95% CI):** 2023 100.0%

Test for overall effect: Z = 1.98 (P = 0.05)

Test for subgroup differences: Not applicable

### Comparison 3. Angiotensin converting enzyme inhibitors versus placebo or no treatment

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1 Cardiovascular mortality (RR)</td>
<td>2</td>
<td>945</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.93 [0.61, 1.42]</td>
</tr>
<tr>
<td>3.2 Heart failure hospitalisation (RR)</td>
<td>3</td>
<td>1019</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.86 [0.64, 1.15]</td>
</tr>
<tr>
<td>3.3 Hyperkalaemia</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>
### Analysis 3.1. Comparison 3: Angiotensin converting enzyme inhibitors versus placebo or no treatment, Outcome 1: Cardiovascular mortality (RR)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>ACEI Events</th>
<th>Placebo/No treatment Events</th>
<th>Total Events</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hong Kong DHF (1)</td>
<td>0</td>
<td>1</td>
<td>50</td>
<td>0.37 [0.02, 8.85]</td>
</tr>
<tr>
<td>PEP-CHF</td>
<td>38</td>
<td>40</td>
<td>469</td>
<td>0.93 [0.61, 1.42]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>469</td>
<td>476</td>
<td>100.0%</td>
<td>0.93 [0.61, 1.42]</td>
</tr>
</tbody>
</table>

#### Footnotes
(1) ramipril arm

### Analysis 3.2. Comparison 3: Angiotensin converting enzyme inhibitors versus placebo or no treatment, Outcome 2: Heart failure hospitalisation (RR)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>ACEI Events</th>
<th>Placebo/No treatment Events</th>
<th>Total Events</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hong Kong DHF (1)</td>
<td>5</td>
<td>6</td>
<td>50</td>
<td>0.93 [0.30, 2.83]</td>
</tr>
<tr>
<td>PEP-CHF</td>
<td>64</td>
<td>73</td>
<td>426</td>
<td>0.88 [0.65, 1.20]</td>
</tr>
<tr>
<td>Zi 2003</td>
<td>2</td>
<td>5</td>
<td>38</td>
<td>0.42 [0.09, 2.04]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>505</td>
<td>514</td>
<td>100.0%</td>
<td>0.86 [0.64, 1.15]</td>
</tr>
</tbody>
</table>

#### Footnotes
(1) ramipril arm
**Analysis 3.3. Comparison 3: Angiotensin converting enzyme inhibitors versus placebo or no treatment, Outcome 3: Hyperkalaemia**

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>ACEI Events</th>
<th>Total</th>
<th>Placebo/No treatment Events</th>
<th>Total</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zi 2003</td>
<td>2</td>
<td>36</td>
<td>0</td>
<td>38</td>
<td>5.27 [0.26, 106.16]</td>
</tr>
</tbody>
</table>

**Analysis 3.4. Comparison 3: Angiotensin converting enzyme inhibitors versus placebo or no treatment, Outcome 4: All-cause mortality (RR)**

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>ACEI Events</th>
<th>Total</th>
<th>Placebo/No treatment Events</th>
<th>Total</th>
<th>Weight</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aronow 1998</td>
<td>3</td>
<td>30</td>
<td>4</td>
<td>30</td>
<td>6.5%</td>
<td>0.75 [0.18, 3.07]</td>
</tr>
<tr>
<td>Hong Kong DHF (1)</td>
<td>0</td>
<td>45</td>
<td>3</td>
<td>50</td>
<td>5.4%</td>
<td>0.16 [0.01, 2.98]</td>
</tr>
<tr>
<td>PEP-CHF</td>
<td>56</td>
<td>424</td>
<td>53</td>
<td>426</td>
<td>85.7%</td>
<td>1.06 [0.75, 1.51]</td>
</tr>
<tr>
<td>Yolsek 2012</td>
<td>3</td>
<td>54</td>
<td>0</td>
<td>54</td>
<td>0.8%</td>
<td>7.90 [0.37, 132.35]</td>
</tr>
<tr>
<td>Zi 2003</td>
<td>1</td>
<td>36</td>
<td>1</td>
<td>38</td>
<td>1.6%</td>
<td>1.06 [0.07, 16.25]</td>
</tr>
</tbody>
</table>

Total (95% CI): 589 598 100.0% 1.04 [0.75, 1.45]

Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable

**Footnotes**
(1) ramipril arm

**Analysis 3.5. Comparison 3: Angiotensin converting enzyme inhibitors versus placebo or no treatment, Outcome 5: Quality of life (Minnesota)**

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Mean SD</th>
<th>Total</th>
<th>Mean SD</th>
<th>Total</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hong Kong DHF (1)</td>
<td>11.4 9.3915</td>
<td>45</td>
<td>10.9 9.1924</td>
<td>50</td>
<td>0.50 [-3.24, 4.24]</td>
</tr>
<tr>
<td>Kitzman 2010</td>
<td>23 25</td>
<td>25</td>
<td>29 20</td>
<td>34</td>
<td>-6.00 [-17.88, 5.88]</td>
</tr>
</tbody>
</table>

Total (95% CI): 70 84 100.0% -0.09 [-3.66, 3.48]

Heterogeneity: Chi² = 1.85, df = 1 (P = 0.21); P = 4%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable

**Footnotes**
(1) ramipril arm
Comparison 4. Angiotensin receptor blockers versus placebo or no treatment

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1 Cardiovascular mortality (RR)</td>
<td>3</td>
<td>7254</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.02 [0.90, 1.14]</td>
</tr>
<tr>
<td>4.2 Cardiovascular mortality (HR)</td>
<td>2</td>
<td>7148</td>
<td>Hazard Ratio (IV, Fixed, 95% CI)</td>
<td>1.00 [0.89, 1.13]</td>
</tr>
<tr>
<td>4.3 Heart failure hospitalisation (RR)</td>
<td>3</td>
<td>7254</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.92 [0.83, 1.02]</td>
</tr>
<tr>
<td>4.4 Heart failure hospitalisation (HR)</td>
<td>2</td>
<td>7148</td>
<td>Hazard Ratio (IV, Fixed, 95% CI)</td>
<td>0.90 [0.80, 1.01]</td>
</tr>
<tr>
<td>4.5 Hyperkalaemia</td>
<td>2</td>
<td>7148</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.88 [1.07, 3.33]</td>
</tr>
<tr>
<td>4.6 All-cause mortality (RR)</td>
<td>4</td>
<td>7964</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.01 [0.92, 1.11]</td>
</tr>
<tr>
<td>4.7 All-cause mortality (HR)</td>
<td>2</td>
<td>4838</td>
<td>Hazard Ratio (IV, Fixed, 95% CI)</td>
<td>0.99 [0.88, 1.12]</td>
</tr>
<tr>
<td>4.8 Quality of life (Minnesota)</td>
<td>3</td>
<td>3117</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.41 [-0.86, 1.67]</td>
</tr>
<tr>
<td>4.9 Withdrawal due to adverse event</td>
<td>4</td>
<td>7406</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.22 [1.09, 1.36]</td>
</tr>
</tbody>
</table>
**Analysis 4.1. Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 1: Cardiovascular mortality (RR)**

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>ARB Events</th>
<th>Total</th>
<th>placebo/no treatment Events</th>
<th>Total</th>
<th>Weight</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHARMM-Preserved</td>
<td>170</td>
<td>1512</td>
<td>170</td>
<td>1508</td>
<td>35.9%</td>
<td>1.00 [0.82, 1.22]</td>
</tr>
<tr>
<td>Hong Kong DHF (1)</td>
<td>1</td>
<td>56</td>
<td>1</td>
<td>50</td>
<td>0.2%</td>
<td>0.89 [0.06, 13.90]</td>
</tr>
<tr>
<td>I-PRESERVE</td>
<td>311</td>
<td>2067</td>
<td>302</td>
<td>2061</td>
<td>63.8%</td>
<td>1.03 [0.89, 1.19]</td>
</tr>
</tbody>
</table>

Total (95% CI) 3635 3619 100.0% 1.02 [0.90, 1.14]

Total events: 482 473

Heterogeneity: Chi² = 0.06, df = 2 (P = 0.97); I² = 0%
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable

Footnotes
(1) irbesartan arm

**Analysis 4.2. Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 2: Cardiovascular mortality (HR)**

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>log[Hazard Ratio]</th>
<th>SE</th>
<th>ARB Total</th>
<th>placebo/no treatment Total</th>
<th>Weight</th>
<th>Hazard Ratio IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHARMM-Preserved (1)</td>
<td>-0.0101</td>
<td>0.0976</td>
<td>1512</td>
<td>1508</td>
<td>41.4%</td>
<td>0.99 [0.82, 1.20]</td>
</tr>
<tr>
<td>I-PRESERVE</td>
<td>0.01</td>
<td>0.082</td>
<td>2067</td>
<td>2061</td>
<td>58.6%</td>
<td>1.01 [0.86, 1.19]</td>
</tr>
</tbody>
</table>

Total (95% CI) 3579 3569 100.0% 1.00 [0.89, 1.13]

Heterogeneity: Chi² = 0.02, df = 1 (P = 0.87); I² = 0%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable

Footnotes
(1) unadjusted HR used

**Analysis 4.3. Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 3: Heart failure hospitalisation (RR)**

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>ARB Events</th>
<th>Total</th>
<th>placebo/no treatment Events</th>
<th>Total</th>
<th>Weight</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHARMM-Preserved</td>
<td>241</td>
<td>1512</td>
<td>276</td>
<td>1508</td>
<td>44.6%</td>
<td>0.87 [0.74, 1.02]</td>
</tr>
<tr>
<td>Hong Kong DHF (1)</td>
<td>6</td>
<td>56</td>
<td>6</td>
<td>50</td>
<td>1.0%</td>
<td>0.89 [0.31, 2.59]</td>
</tr>
<tr>
<td>I-PRESERVE</td>
<td>325</td>
<td>2067</td>
<td>336</td>
<td>2061</td>
<td>54.3%</td>
<td>0.96 [0.84, 1.11]</td>
</tr>
</tbody>
</table>

Total (95% CI) 3635 3619 100.0% 0.92 [0.83, 1.02]

Total events: 572 618

Heterogeneity: Chi² = 0.91, df = 2 (P = 0.64); I² = 0%
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Not applicable

Footnotes
(1) irbesartan arm
### Analysis 4.4. Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 4: Heart failure hospitalisation (HR)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>log[Hazard Ratio]</th>
<th>SE</th>
<th>ARB placebo/no treatment Total</th>
<th>Weight</th>
<th>Hazard Ratio IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHARM-Preserved</td>
<td>-0.1625</td>
<td>0.0847</td>
<td>1512</td>
<td>1508</td>
<td>0.85 [0.72 , 1.00]</td>
</tr>
<tr>
<td>I-PRESERVE</td>
<td>-0.0513</td>
<td>0.0813</td>
<td>2067</td>
<td>2061</td>
<td>0.95 [0.81 , 1.11]</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td></td>
<td>3579</td>
<td>3569</td>
<td>0.90 [0.80 , 1.01]</td>
</tr>
</tbody>
</table>

- **Heterogeneity:** Chi² = 0.90, df = 1 (P = 0.34); I² = 0%
- **Test for overall effect:** Z = 1.78 (P = 0.07)
- **Test for subgroup differences:** Not applicable

### Analysis 4.5. Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 5: Hyperkalaemia

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>ARB Events</th>
<th>Total</th>
<th>placebo/no treatment Events</th>
<th>Total</th>
<th>Weight</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHARM-Preserved</td>
<td>22</td>
<td>1512</td>
<td>9</td>
<td>1508</td>
<td>50.0%</td>
<td>2.44 [1.13 , 5.28]</td>
</tr>
<tr>
<td>I-PRESERVE</td>
<td>12</td>
<td>2067</td>
<td>9</td>
<td>2061</td>
<td>50.0%</td>
<td>1.33 [0.56 , 3.15]</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td>3579</td>
<td>3569</td>
<td>100.0%</td>
<td>1.88 [1.07 , 3.33]</td>
<td></td>
</tr>
</tbody>
</table>

- **Total events:** 34
- **Heterogeneity:** Chi² = 1.06, df = 1 (P = 0.30); I² = 5%
- **Test for overall effect:** Z = 2.18 (P = 0.03)
- **Test for subgroup differences:** Not applicable

### Analysis 4.6. Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 6: All-cause mortality (RR)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>ARB Events</th>
<th>Total</th>
<th>placebo/no treatment Events</th>
<th>Total</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHARM-Preserved (1)</td>
<td>244</td>
<td>1512</td>
<td>237</td>
<td>1508</td>
<td>1.03 [0.87 , 1.21]</td>
</tr>
<tr>
<td>Hong Kong DHF (2)</td>
<td>1</td>
<td>56</td>
<td>3</td>
<td>50</td>
<td>0.30 [0.03 , 2.77]</td>
</tr>
<tr>
<td>I-PRESERVE</td>
<td>445</td>
<td>2067</td>
<td>436</td>
<td>2061</td>
<td>1.02 [0.91 , 1.14]</td>
</tr>
<tr>
<td>SUPPORT (3)</td>
<td>43</td>
<td>363</td>
<td>46</td>
<td>347</td>
<td>0.89 [0.61 , 1.32]</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td>3998</td>
<td>3966</td>
<td>100.0%</td>
<td>1.01 [0.92 , 1.11]</td>
</tr>
</tbody>
</table>

- **Total events:** 733
- **Heterogeneity:** Chi² = 1.59, df = 3 (P = 0.66); I² = 0%
- **Test for overall effect:** Z = 0.20 (P = 0.84)
- **Test for subgroup differences:** Not applicable

**Footnotes**

1. combined CVD and non-CVD mortality
2. irbesartan arm
3. discrepancy between number of participants in control group at baseline (n=346)
### Analysis 4.7. Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 7: All-cause mortality (HR)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>log[Hazard Ratio]</th>
<th>SE</th>
<th>ARB Total</th>
<th>placebo/no treatment Total</th>
<th>Hazard Ratio IV, Fixed, 95% CI</th>
<th>Hazard Ratio IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-PRESERVE</td>
<td>0</td>
<td>0.0652</td>
<td>2067</td>
<td>2061</td>
<td>1.00 [0.88, 1.14]</td>
<td></td>
</tr>
<tr>
<td>SUPPORT</td>
<td>-0.1054</td>
<td>0.2154</td>
<td>363</td>
<td>347</td>
<td>0.90 [0.59, 1.37]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td></td>
<td>2430</td>
<td>2408</td>
<td>1.00 [0.88, 1.12]</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 0.22, df = 1 (P = 0.64); I² = 0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable

### Analysis 4.8. Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 8: Quality of life (Minnesota)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>ARB</th>
<th>placebo/no treatment</th>
<th>Mean</th>
<th>SD</th>
<th>Mean</th>
<th>SD</th>
<th>Mean Difference</th>
<th>IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hong Kong DHF (1)</td>
<td>9.4</td>
<td>9.7283</td>
<td>56</td>
<td>10.9</td>
<td>9.1924</td>
<td>50</td>
<td>-1.50 [-5.10 , 2.10]</td>
<td></td>
</tr>
<tr>
<td>I-PRESERVE</td>
<td>32.1</td>
<td>18.10944</td>
<td>1428</td>
<td>31.6</td>
<td>18.9341</td>
<td>1434</td>
<td>4.00 [-2.02 , 10.02]</td>
<td></td>
</tr>
<tr>
<td>Parthasarathy 2009</td>
<td>23.54</td>
<td>21.36</td>
<td>67</td>
<td>19.54</td>
<td>14.71</td>
<td>82</td>
<td>0.50 [-0.89 , 1.89]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td></td>
<td>1551</td>
<td>100.0%</td>
<td>1566</td>
<td>100.0%</td>
<td>0.41 [-0.86 , 1.67]</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 2.46, df = 2 (P = 0.29); I² = 19%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable

Footnotes
(1) irbesartan arm

### Analysis 4.9. Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 9: Withdrawal due to adverse event

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>ARB Events</th>
<th>placebo/no treatment Events</th>
<th>Total</th>
<th>Mean</th>
<th>SD</th>
<th>Mean</th>
<th>SD</th>
<th>Weight</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHARM-Preserved</td>
<td>270</td>
<td>204</td>
<td>1512</td>
<td>1508</td>
<td>41.3%</td>
<td>1.32</td>
<td>[1.12 , 1.56]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hong Kong DHF (1)</td>
<td>1</td>
<td>1</td>
<td>56</td>
<td>1</td>
<td>50</td>
<td>0.2%</td>
<td>0.89</td>
<td>[0.06 , 13.90]</td>
<td></td>
</tr>
<tr>
<td>I-PRESERVE</td>
<td>331</td>
<td>288</td>
<td>2067</td>
<td>2061</td>
<td>58.4%</td>
<td>1.15</td>
<td>[0.99 , 1.33]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parthasarathy 2009</td>
<td>2</td>
<td>0</td>
<td>70</td>
<td>82</td>
<td>0.1%</td>
<td>1.01</td>
<td>[0.29 , 119.75]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>3705</td>
<td>3701</td>
<td>493</td>
<td>100.0%</td>
<td>1.22</td>
<td>[1.09 , 1.36]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 604
Heterogeneity: Chi² = 2.65, df = 3 (P = 0.45); I² = 0%
Test for overall effect: Z = 3.58 (P = 0.0003)
Test for subgroup differences: Not applicable

Footnotes
(1) irbesartan

### Comparison 5. ARNI versus usual care

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.1 Cardiovascular mortality (RR)</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>
### Outcome or subgroup title

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.2 Heart failure hospitalisation, first (RR)</td>
<td>2</td>
<td>7362</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.89 [0.80, 1.00]</td>
</tr>
<tr>
<td>5.3 Heart failure hospitalisation (HR)</td>
<td>2</td>
<td>7362</td>
<td>Hazard Ratio (IV, Fixed, 95% CI)</td>
<td>0.87 [0.76, 0.99]</td>
</tr>
<tr>
<td>5.4 Hyperkalaemia</td>
<td>2</td>
<td>5054</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.88 [0.77, 1.01]</td>
</tr>
<tr>
<td>5.5 All-cause mortality (RR)</td>
<td>3</td>
<td>7663</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.97 [0.84, 1.11]</td>
</tr>
<tr>
<td>5.6 Withdrawal due to adverse event</td>
<td>3</td>
<td>7663</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.02 [0.91, 1.14]</td>
</tr>
</tbody>
</table>

**Analysis 5.1. Comparison 5: ARNI versus usual care, Outcome 1: Cardiovascular mortality (RR)**

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>LCZ696</th>
<th></th>
<th>Valsartan</th>
<th></th>
<th>Risk Ratio</th>
<th></th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
<td>M-H, Fixed, 95% CI</td>
<td></td>
<td>M-H, Fixed, 95% CI</td>
</tr>
<tr>
<td>PARAGON-HF</td>
<td>204</td>
<td>2407</td>
<td>212</td>
<td>2389</td>
<td>0.96 [0.79, 1.15]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>3688</td>
<td>3674</td>
<td><strong>100.0%</strong></td>
<td>0.89 [0.80, 1.00]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Analysis 5.2. Comparison 5: ARNI versus usual care, Outcome 2: Heart failure hospitalisation, first (RR)**

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>ARNI</th>
<th>Usual care</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>PARAGON-HF</td>
<td>405</td>
<td>2407</td>
<td>433</td>
<td>2389</td>
</tr>
<tr>
<td>PARALLAX</td>
<td>62</td>
<td>1281</td>
<td>87</td>
<td>1285</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>467</td>
<td>3688</td>
<td>3674</td>
<td><strong>100.0%</strong></td>
</tr>
</tbody>
</table>

**Analysis 5.3. Comparison 5: ARNI versus usual care, Outcome 3: Heart failure hospitalisation (HR)**

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>log[Hazard Ratio]</th>
<th>SE</th>
<th>ARNI</th>
<th>Usual care</th>
<th>Hazard Ratio</th>
<th>Hazard Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Total</td>
<td>Total</td>
<td>IV, Fixed, 95% CI</td>
<td>IV, Fixed, 95% CI</td>
</tr>
<tr>
<td>PARAGON-HF</td>
<td>-0.1009</td>
<td>0.0688</td>
<td>2407</td>
<td>2389</td>
<td>93.0%</td>
<td>0.90 [0.79, 1.03]</td>
</tr>
<tr>
<td>PARALLAX</td>
<td>-0.7133</td>
<td>0.2503</td>
<td>1281</td>
<td>1285</td>
<td>7.0%</td>
<td>0.49 [0.30, 0.80]</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td></td>
<td>3688</td>
<td>3674</td>
<td><strong>100.0%</strong></td>
<td>0.87 [0.76, 0.99]</td>
</tr>
</tbody>
</table>

**Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)**

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Analysis 5.4. Comparison 5: ARNI versus usual care, Outcome 4: Hyperkalaemia

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>LCZ696</th>
<th>Valsartan</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>PARAGON-HF</td>
<td>316</td>
<td>2386</td>
<td>361</td>
</tr>
<tr>
<td>PARAMOUNT</td>
<td>12</td>
<td>149</td>
<td>9</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>2535</td>
<td>2519</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 1.08, df = 1 (P = 0.30); I² = 8%
Test for overall effect: Z = 1.81 (P = 0.07)
Test for subgroup differences: Not applicable

### Analysis 5.5. Comparison 5: ARNI versus usual care, Outcome 5: All-cause mortality (RR)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>LCZ696</th>
<th>Usual care</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>PARAGON-HF (1)</td>
<td>342</td>
<td>2407</td>
<td>349</td>
</tr>
<tr>
<td>PARALLAX (2)</td>
<td>7</td>
<td>1281</td>
<td>9</td>
</tr>
<tr>
<td>PARAMOUNT (1)</td>
<td>1</td>
<td>149</td>
<td>2</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>3837</td>
<td>3826</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 0.46, df = 2 (P = 0.79); I² = 0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable

Footnotes
(1) comparator: valsartan
(2) comparator: individualised medical treatment

### Analysis 5.6. Comparison 5: ARNI versus usual care, Outcome 6: Withdrawal due to adverse event

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>LCZ696</th>
<th>Usual care</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>PARAGON-HF (1)</td>
<td>370</td>
<td>2407</td>
<td>387</td>
</tr>
<tr>
<td>PARALLAX (2)</td>
<td>116</td>
<td>1281</td>
<td>87</td>
</tr>
<tr>
<td>PARAMOUNT (1)</td>
<td>15</td>
<td>149</td>
<td>17</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>3837</td>
<td>3826</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 5.25, df = 2 (P = 0.07); I² = 62%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable

Footnotes
(1) comparator: valsartan
(2) comparator: individualised medical treatment
APPENDICES

Appendix 1. Search strategies July 2017

CENTRAL

#1 MeSH descriptor: [Heart Failure] explode all trees

#2 ((heart or cardia* or myocardial) near/3 (failure or insufficienc* or decompensat*)):ab,ti,kw

#3 #1 or #2

#4 MeSH descriptor: [Ventricular Dysfunction] explode all trees

#5 MeSH descriptor: [Ventricular Function] explode all trees

#6 ((preserved or normal or greater) near/5 ("ejection fraction" or "EF" or "LVEF")):ab,ti,kw

#7 ("preserved systolic function" or "normal systolic function" or "HFpEF" or "HF-pEF" or "HFnEF" or "HF-nEF" or "DHF" or diastolic*):ab,ti,kw

#8 #4 or #5 or #6 or #7

#9 #3 and #8

#10 MeSH descriptor: [Adrenergic beta-antagonists] explode all trees

#11 (beta near/2 (antagonist* or block* or receptor*)):ab,ti,kw

#12 (acebutolol or adimolol or afurolol or alpenrolol or amosulalol or arotinolol or atenolol or befunolol or betaxolol or bevantolol or bisoprolol or bopindolol or bornaprolol or brenonalol or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or burpanolol or butofilolol or butoxamine or carazolol or carteolol or carvediol or celiprolol or cetamolol or chlortalidone or cloranolol or cyanodipindolol or cyanopindolol or deacetylmetipranolol or diacetolol or dihydroalprenolol or dilaveol or epanolol or esmolol or exaprolol or falintolol or flestolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteoolol or hydroxy benazepril or indenolol or iodocyanopindolol or ioprodolol or isoprolol or isoxaprolol or labelatol or landiolol or levobunolol or levoconpropolol or medroxolol or mepindolol or methylthiopropranolol or metipranolol or metoprolol or moprofol or nadolol or oxenrolol or penbutolol or pindolol or practolol or promidolol or prizidilol or procinolol or pronatolol or propanolol or proxodolol or ridazolol or salcardolol or soquinolol or sotalol or spirendolol or talinolol or tertiaoxolol or tilisolol or timolol or tolamolol or toliprolol or tribendiol or xibenolol or Betapace or Blocadren or Bystolic or Caltrol or Coreg or Corgard or Inderal or Kerlone or Levatol or Lopressor or Normodyne or Sectral or Tenormin or Toprol or Trandate or Visken or Zebeta):ab,ti,kw

#13 MeSH descriptor: [Angiotensin-Converting Enzyme Inhibitors] explode all trees

#14 ((angiotensin* or dipeptidyl* or 'kininase ii') near/3 (convert* or enzyme or inhibit* or recept* or block*)):ab,ti,kw

#15 (ace near/1 inhibit*):ab,ti,kw

#16 acei:ab,ti,kw

#17 (acepril or altipril or ancorenin or benazepril* or captopril or ceranapril or ceronapril or cilazapril or deacetylalacepril or delapril or derapril or enalapril* or epicappril or fasinotril* or fosinopril or foroxymithine or gemopatrilat or idrapril or ilepatril or imidapril* or indolapril or libenzapril or lisinopril or moexipril* or omapatrilat or pentopril* or perindopril* or pivopril or quinapril* or ramipril* or rentiapril or sampatrilat or saralasin* or 's n itsroscaptopril* or spirapril* or temcapril* or teprotide or trandolapril* or utipapril* or zabicapril* or zofenopril* or Acone or Accupril or Altace or Capoten or Lotensin or Movak or Monopril or Prinivil or Univas or Vasotec or Zestril):ab,ti,kw

#18 MeSH descriptor: [Angiotensin Receptor Antagonists] explode all trees

#19 (angiotensin near/3 ("receptor antagonist*" or "receptor block*")):ab,ti,kw

#20 (arb or arbs):ab,ti,kw

#21 (abitesartan or azilsartan or candesartan or elisartan or embusartan or eprosartan or fimasartan or fonsartan or forasartan or irbesartan or KT3-671* or losartan or milfiasartan or olmesartan or pomisartan or pratosartan or ripisartan or saprisartan or sparsentan or
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
17. (alacepril or altipril or ancozenin or benazepril* or captorplril or ceranapril or ceronapril or deacetylacepril or delapril or derapril or enalapril* or epicaptopril or fasidotril* or fosinopril or foroxymithine or gemopatriat or idrapril or ilepatril or imidapril* or indolapril or libenzapril or lisinopril or moexipril* or omapatriat or pentopril* or perindopril* or pivopril or quinapril* or ramipril* or rentiapril or sampilatril or saralasin or s nitrosocaptopril or spirapril* or temocapril* or teprotide or trandolapril* or utipapril* or zabicipril* or zofenopril* or Aceon or Accupril or Altace or Capoten or Lotensin or Mavik or Monopril or Prinivil or Univas or Vasotec or Zestril).mp.
18. exp Angiotensin Receptor Antagonists/
19. (angiotensin adj3 (receptor antagonist* or receptor block*)).tw.
20. (arb or arbs).tw.
21. (abitesartan or azilsartan or candesartan or elisartan or embusartan or eprosartan or fimasartan or fonsartan or forasartan or irbesartan or KT3-671 or losartan or milfasartan or olmesartan or pomisartan or pratosartan or ripisartan or saprisartan or sparsentan or tasosartan or telmisartan or valsartan or zolasartan or Edarbi or Blopress or Atacand or Amias or Ratacand or Eprozar or Aprovel or Karvea or Avapro or Cozaar or Benicar or Omlcecip or Micardis or Diovan).mp.
22. Nepriysin/ai [Antagonists & Inhibitors]
23. (nepriysin adj (inhibit* or antagonist*)).tw.
24. arni.tw.
25. (Sacubitril or "ahu 377" or ahu377 or Sacubitrilat or lbq657 or "lbq 657" or ahu377 or "ahu 377" or Entresto or lc8696 or "lc8 696").mp.
26. exp Mineralocorticoid Receptor Antagonists/
27. ((mineralocorticoid or aldosterone) adj3 (antagonist* or block* or inhibit*)).tw.
28. (canrenonic acid or canrenone or eplerenone or finerenone or oxprenoate potassium or spironolactone or Aldactone or Contaren or Inspra or Luvion or Phanuran or Spiroletan).mp.
29. or/10-28
30. 9 and 29
31. randomized controlled trial.pt.
32. controlled clinical trial.pt.
33. randomized.ab.
34. placebo.ab.
35. drug therapy.fs.
36. randomly.ab.
37. trial.ab.
38. groups.ab.
39. 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38
40. exp animals/ not humans.sh.
41. 39 not 40
42. 30 and 41

Embase
#33 #31 AND #32
#32 random*:ab,ti OR placebo* OR ((double NEXT/1 blind*):ab,ti)
#31 #10 AND #30
#30 #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28OR #29
29 'canrenonic acid' OR canrenone OR eplerenone OR finerenone OR 'exprenolate potassium' OR spironolactone OR aldactone OR contaren OR inspra OR luvin or phanurane OR sproiletan
28 ((mineralocorticoid OR aldosterone) NEAR/3 (antagonist* OR block* OR inhibit*)):ab,ti
27 'mineralocorticoid antagonist'/exp
26 sacubitril OR sacubitrilat OR 'lbq657' OR 'lbq 657' OR 'ahu377' OR 'ahu 377' OR entresto OR lcz696 OR 'lcz 696'
25 arni:ab,ti
24 (neprilysin NEAR/1 (inhibit* OR antagonist*)):ab,ti
23 'enkephaline inhibitor'/exp
22 abitesartan OR azilsartan OR candesartan OR elisartan OR embusartan OR eprosartan OR fimasartan OR fonsartan OR forasartanOR irbesartan OR 'lx3-972' OR losartan OR milfesartan OR olmesartan OR pimartan OR pratosartan OR ripasartan OR saprisartanOR spansonart OR tasosartan OR telmisartan OR valsartan OR zolasartan OR edarbi OR bloopre OR atacand OR amias OR ratacdandOR eprozor OR aprovel OR karvea OR avapre OR cozaar OR benicar OR olmecip OR micardis OR dioven
21 arb:ab,ti OR arbs:ab,ti
20 (angiotensin NEAR/3 ('receptor antagonist* OR 'receptor block*')):ab,ti
19 'angiotensin receptor antagonist'/exp
18 alacepril OR altiorpril OR anconevin OR benazepril OR captopril OR ceranapril OR ceronapril OR cilaazapril OR deacetylalacepril OR delapril OR derapril OR enalapril* OR epicaptopril OR fasidotril* OR fosinopril OR foroxymithine OR gemopatril OR idrapril OR ilepatril OR imidapril* OR indolapril OR libenzapril OR lisinopril OR moexipril* OR omapatrilat OR pentopril* OR perindopril* OR pivopril OR quinapril* OR ramipril* OR rentiapril OR sampatrilat OR sarasin OR 's nitrossocaptopril' OR spirapril* OR temocapril* OR terepoxide OR trandolapril* OR utibapril* OR zabicipril* OR zofenopril* OR aceon OR accupril OR altace OR capoten OR lotensinOR magiv OR monopril OR prinivil OR univas OR vasotec OR zestril
17 ace:ab,ti
16 (ace NEAR/1 inhibit*):ab,ti
15 ((angiotensin* OR dipetiydyl* OR 'kininase ii') NEAR/3 (convert* OR enzyme OR inhibit* OR receptor* OR block*)):ab,ti
14 'dipetidyld carboxypeptidase inhibitor'/exp
13 acebutolol OR adimolol OR afrulol OR alpenolol OR amosulol OR arotinolol OR atenolol OR befunolol OR betaxolol OR bevantololOR bisoprolol OR bopindolol OR bornapril OR brefenoal OR bucindolol OR bucumolol OR butefolol OR bufuralol OR bunitrol OR bunolol OR bupranolol OR butofiolol OR butoxamine OR carazolol OR cariolel OR carvedilol OR celiprolol OR cetamol OR chlortalidone OR cpenol OR cyanidodopindol OR cyanopindol OR deacetylmetipranol OR diactolol OR dihydralpranolO Dilevalol OR epanol OR esmolol OR exaprol OR flusalol OR fluosolol OR hydroxybenzylpindolol OR hydroxycarteolol OR hydroxymetoprolol OR indenol OR iodocyanopindol OR iopropindol OR iprocrolol OR isoxaprol OR labetalol OR landiol OR levobunolol OR levomoprolol OR medroxalol OR mepindolol OR methylthiopropanalol OR metipranololOR metoprolol OR mopenrol OR nadolol OR nebivolol OR nifenalol OR nipradilol OR oprenolol OR pafenolol OR pamenol OR penbutolol OR pindolol OR practolol OR primidol OR prizidil OR procinolol OR pronetol OR propranolol OR proxodol OR ridazolol OR salcardolol OR soquinol OR sotalol OR spirendol OR talinolol OR tertiotalol OR tienoxolol OR tilisolol OR timolol OR tolazolol OR toliprol OR trebendol OR xibenol OR betapace OR blocadren OR bystolic OR cartol OR coreg OR corgard OR inderal OR kerlone OR levatol OR lopressor OR normodyne OR sertal OR tironem OR toprol OR trandate OR visken OR zebeta
12 (beta NEAR/2 (antagonist* OR block* OR receptor*)):ab,ti
11 'beta adrenergic receptor blocking agent'/exp
10 #3 AND #9
#4 OR #5 OR #6 OR #7 OR #8
#8 'preserved systolic function':ab,ti OR 'normal systolic function':ab,ti OR hfpef:ab,ti OR 'hf-pef':ab,ti OR hfnef:ab,ti OR 'hf-nef':ab,ti OR dhf:ab,ti OR diastolic*:ab,ti
#7 ((preserved OR normal OR greater) NEAR/5 ('ejection fraction' OR ef OR lvef)):ab,ti
#6 'systolic dysfunction'/exp
#5 'diastolic dysfunction'/exp
#4 'heart ventricle function'/de
#3 #1 OR #2
#2 ('heart OR cardia* OR myocardial) NEAR/3 (failure OR insufficienc* OR decompsasat*)):ab,ti
#1 'heart failure'/exp

ClinicalTrials.gov
Advanced Search—Limited to study type: interventional studies

('heart failure' AND ('preserved ejection fraction' OR "normal ejection fraction" OR "preserved systolic function" OR "normal systolic function") OR "diastolic heart failure" OR "HFpEF" OR "HF-pEF" OR "HFNEF" OR "HF-nEF" OR "DHF"

WHO International Clinical Trials Registry Platform (ICTRP) Search Portal

Standard Search

heart failure AND preserved ejection fraction OR heart failure AND normal ejection fraction OR

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
heart failure AND preserved systolic function OR heart failure AND normal systolic function OR
diastolic heart failure OR HFpEF OR HF-pEF OR HFnEF OR HF-nEF OR DHF

Appendix 2. Search strategies May 2020

CENTRAL

#1 MeSH descriptor: [Heart Failure] explode all trees

#2 (heart or cardia* or myocardial) near/3 (failure or insufficienc* or decompensat*) : ab, ti, kw

#3 #1 or #2

#4 MeSH descriptor: [Ventricular Dysfunction] explode all trees

#5 MeSH descriptor: [Ventricular Function] explode all trees

#6 (preserved or normal or greater) near/5 ("ejection fraction" or "EF" or "LVEF") : ab, ti, kw

#7 ("preserved systolic function" or "normal systolic function" or "HFpEF" or "HF-pEF" or "HFnEF" or "HF-nEF" or "DHF" or diastolic*) : ab, ti, kw

#8 #4 or #5 or #6 or #7

#9 #3 and #8

#10 MeSH descriptor: [Adrenergic beta-Antagonists] explode all trees

#11 (beta near/2 [antagonist* or block* or receptor*]) : ab, ti, kw

#12 (acetubolol or adimolol or aforulol or alpranolol or amosulol or arotinolol or atenolol or befunolol or betaxolol or bevantolol or bisoprolol or bopindolol or bornaprolol or brefanolol or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or bupranolol or butofilolol or butoxamine or carazolol or carteolol or carvediol or celeprolol or cetamolol or chlortalidone or cloranolol or cyanoidopindolol or cyanopindolol or deacetylmetypranolol or diacetolol or dihydroaprenolol or dilevalol or epanolol or esmolol or exaprolol or falintiol or flestolol or flusoxolol or hydroxycetacarolol or hydroxybenzylpinodolol or hydroxycarteolol or hydroxy benzazepril or indenolol or iodocyanopindolol or iodopindolol or iproprocolol or isoaxaprocolol or lobetalol or landiolol or levobunolol or levomoprolol or medroxalol or mepindolol or metylethiopranolol or metipranolol or metoprolol or meprolol or nadolol or oxpenrolol or pindolol or pindolol or propranolol or pridolol or prizidiol or prucinolol or pranolol or pranolol or pranolol or propranolol or propenalor or pranolol or raloxolol or ramipril* or ramolol or renatrolol or tetalolol or timolol or tolamolol or tolinolol or tribenidol or xibenolol or Betapace or Blokaden or Bystolic or Carotil or Coreg or Cordard or Inderal or Kerlone or Levatal or Lopressor or Normodyne or Sectral or Tenormin or Toprol or Trandate or Visken or Zebeta) : ab, ti, kw

#13 MeSH descriptor: [Angiotensin-Converting Enzyme Inhibitors] explode all trees

#14 ((angiotensin* or dipeptidyl* or ’kininase ii’) near/3 (convert* or enzyme or inhibit* or recept* or block*)) : ab, ti, kw

#15 (ace near/1 inhibit*): ab, ti, kw

#16 acei: ab, ti, kw

#17 (alacepril or alipril or ancovenin or benazepril* or captopril or ceranapril or cizapril or deacetytlacepril or delapril* or derapril* or enalapril* or epicaptopril or fasilodril* or fosinopril or foroxymithine or gepronaprilat or irapril* or ilipratril or imidapril* or indolapril or libenzapril or moexipril* or omapatrilat or pentopril* or perindopril* or pivopril or quinaapril* or ramipril* or rentiapril or sampatrilat or saralasin or "s nitrosoacaptopril" or spirapril* or temocapril* or tetrodite or trandolapril* or utipapril* or zabicapril* or zofenopril* or Aceon or Accupril or Altace or Capoten or Lotensin or Mavik or Monopril or Prinivil or Univas or Vasotec or Zestril) : ab, ti, kw

#18 MeSH descriptor: [Angiotensin Receptor Antagonists] explode all trees

#19 (angiotensin near/3 (’receptor antagonist*” or “receptor block”)): ab, ti, kw

#20 (arb or arbs): ab, ti, kw

#21 (abitesartan or azilsartan or candesartan or elisartan or embusartan or eprosartan or fimasartan or fonsartan or forasartan or irbesartan or KT3-671 or losartan or milasartan or olmesartan or pimisartan or pratosartan or ripasartan or sparsentan or...
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
17. (alacepril or altiopril or ancovenin or benazepril* or captopril or ceranapril or ceronapril or cilazapril or deacetylacepril or delapril or derapril or enalapril* or epicaptopril or fasidotril* or fosinopril or foroxymthine or gemopatrilat or idrapril or ilepatri or imidapril* or indolapril or libenzapril or lisinopril or moexipril* or omapatrilat or pentopril* or perindopril* or pivopril or quinapril* or ramipril* or rentipril or sampatrilat or saralasin or s nitrosocaptopril or spirapril* or temocapril* or teprotide or trandolapril* or utibapril* or zabicipril* or zofenopril* or Aceon or Accupril or Altace or Capoten or Lotensin or Mavik or Monopril or Prinivil or Univis or Vasotec or Zestril).mp.
18. exp Angiotensin Receptor Antagonists/
19. (angiotensin adj3 (receptor antagonist* or receptor block*)).tw.
20. (arb or arbs).tw.
21. (abitesartan or azilsartan or candesartan or elisartan or embusartan or eprosartan or fimasartan or forasartan or irbesartan or KT3-671 or losartan or milfesartan or olmesartan or pomisartan or pratosartan or rapipartan or sparkling or sparsentan or tasosartan or telmisartan or valsartan or zolartan or Edarbi or Blopress or Atacand or Amias o Ratacand or Eprozar or Aprovel or Karvea or Avapro or Cozaar or Benicar or Omacor or Micardis or Diovan).mp.
22. Nepriysin/ai [Antagonists & Inhibitors]
23. (nepriysin adj (inhibit* or antagonist*)).tw.
24. arnl.tw.
25. (Sacubitril or "ahu 377" or ahu377 or Sacubitirilat or lbq657 or "lbq 657" or ahu377 or "ahu 377" or Entresto or lcz696 or "lcz 696").mp.
26. exp Mineralocorticoid Receptor Antagonists/
27. (mineralocorticoid or aldosterone) adj3 (antagonist* or block* or inhibit*).tw.
28. (canrenonic acid or canrenone or eplerenone or finerenone or spironolactone or Aldactone or Contaren or Inspra or Luvion or Phanuran or Spiroletan).mp.
29. or/10-28
30. 9 and 29
31. randomized controlled trial.pt.
32. controlled clinical trial.pt.
33. randomized.ab.
34. placebo.ab.
35. drug therapy.fs.
36. randomly.ab.
37. trial.ab.
38. groups.ab.
39. 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38
40. exp animals/ not humans.sh.
41. 39 not 40
42. 30 and 41
43. limit 42 to ed=20170725-20200514

**Embase OVID**

1 exp heart failure/
2 ((heart or cardi* or myocardial) adj3 (failure or insufficienc* or decompensat*)).ab,ti.
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction (Review)

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

3 1 or 2
4 heart ventricle function/
5 exp diastolic dysfunction/
6 exp systolic dysfunction/
7 (preserved or normal or greater) adj5 (‘ejection fraction’ or ef or lvesf).ab,ti.
8 (preserved systolic function’ or ‘normal systolic function’ or hfpef or ‘hf-pef’ or hfnef or ‘hf-nef’ or dhf or diastolic*).ab,ti.
9 4 or 5 or 6 or 7 or 8
10 3 and 9
11 exp beta adrenergic receptor blocking agent/
12 (beta adj2 (antagonist* or block* or receptor*)).ab,ti.
13 (acebutolol or adimolol or alafenol or alprenolol or amosulalol or arotinolol or atenolol or befunolol or betaxolol or bevantoLOr bisoprolol or bopindolol or bornaprolol or brefonalol or buncinolol or bufetolol or bufuralol or bunitrolol or bunolol or bupanolol or butofilolol or butoxamine or carazolol or cartecol or carvediol or cetamolol or chlortalidone or cloranolol or cyanoidopindolol or cyanopindolol or deacetylmexitranol OR diacetolol or dihydroalprenololOR dilevalol or epanolol or esmolol or exaprolol or falintol or fletolol or flusoxolol or hydroxybenzylinodolol or hydroxycarotolol or hydroxymetropolol or indenolol or iodocyanopindolol or ioprodinolol or iopropolol or iotabanolol or iotefololol or landiolol or levobunolol or levomoprolol or medroxalol or mepindolol or methylthiopropanolol or metipranololOR metropolol or moprolol or nadolol or nebivolol or nifedipanol or nipradiol or oxenolol or pafenolol or pamatolol or penbutolol or pindolol or practolol or prizidiol or pronicolin or pronetalol or propanolol or prroxodolol or radizolol or salcardolol or soquinolol or sotalol or spirendolol or talinolol or tertiadolol or tilisolol or timolol or tolamolol or toliprolol or tribendiolol or xibenolol or betapace or bocadren or bostolic or cetril or corgard or inderal or keelone or levatol or lopressor or normodyne or seclral or tenormin or toprol or trandate or viskon or zebeta).mp.
14 exp dipetidyl carboxy-peptidase inhibitor/
15 (angiotensin* or dipetidyl* or ‘kininase ii’) adj3 (convert* or enzyme or inhibit* or receptor* or block*).ab,ti.
16 (ace adj1 inhibit*).ab,ti.
17 acei.ab,ti.
18 (alacepril or altiopril or ancoevenin or benazepril* or captorpril or ceranapril or cilazapril or deacetyllacepril or delapril or derapril or enalapril* or epicaptopril or fastridol* or fosinapril or foxyomithine or gromapatrilat or idrapril or ilepatril or imidapril* or indapril or libenzapril or lisinopril or moexipril* or omapatriat or pentorpril* or perindopril* or pivopril or quinapril* or ramipril* or rentiapril or sampatrilat or saralasin or ‘s nitoscaptoopril’ or spirapril* or temocapril"OR teprotide or trandolapril* or utibapril* or zabicipril* or zofenopril* or aceon or accupril or altace or capoten or lotensinOR mavik or monopril or prinivil or univas or vasotec or Zestril).mp.
19 exp angiotensin receptor antagonist/
20 (angiotensin adj3 (‘receptor antagonist*’ or ‘receptor block*’)).ab,ti.
21 (arb or arbs).ab,ti.
22 (abitesartan or azilsartan or candesartan or elisartan or embusartan or eprosartan or fimasartan or fonsartan or forasartanOR irbesartan or ‘kt3-671’ or losartan or milasartan or olmesartan or pratosartan or ripisartan or saprisartanOR sparsentan or tasosartan or telmisartan or valsartan or zolasartan or edarbi or bloopress or atacand or amias or ratacandOR eprozor or aprovel or karvea or avapro or cozaar or benicar or olmecip or micardis or diovan).mp.
23 exp enkephalinase inhibitor/
24 (nepyrilisn adj1 (inhibit* or antagonist*)).ab,ti.
25 arni.ab,ti.
26 (sacubitril or sacubitrilat or lbq657 or 'lbq 657' or 'ahu377' or 'ahu 377' or entresto or lc2696 or 'lc 696').mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]

27 exp mineralocorticoid antagonist/

28 ((mineralocorticoid or aldosterone) adj3 (antagonist* or block* or inhibit*)).ab,ti.

29 ('canrenone acid' or canrenone or eplerenone or finerenone or 'oxprenoate potassium' or spironolactone or aldactone or contaren or inspra or livion or phanurane or spiroletan).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]

30 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29

31 10 and 30

32 random*.ab,ti. or placebo*.mp. or (double adj1 blind*).ab,ti. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]

33 31 and 32

34 limit 33 to dd=20170725-20200514

Clinicaltrials.gov

Advanced search for Study type: interventional studies

(“preserved ejection fraction” OR ”normal ejection fraction” OR ”preserved systolic function” OR ”normal systolic function”) OR ”diastolic heart failure” OR ”HFrEF” OR ”HF-pEF” OR ”HF-nEF” OR ”HF-nEF” OR ”DHF” | Interventional Studies | heart failure

WHAT'S NEW

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>17 August 2020</td>
<td>New citation required and conclusions have changed</td>
<td>Four new studies were included; three new studies contributed to the previously empty comparison of ARNs versus usual care.</td>
</tr>
<tr>
<td>17 August 2020</td>
<td>New search has been performed</td>
<td>The review was updated with searches run on 14 May 2020.</td>
</tr>
</tbody>
</table>

HISTORY

Protocol first published: Issue 7, 2017
Review first published: Issue 6, 2018

CONTRIBUTIONS OF AUTHORS

NM: selection of studies, data extraction, analysis, GRADE assessment, co-wrote the manuscript.

KM: selection of studies, GRADE assessment.

CD: contributed to review design, GRADE assessment, approved the final version.

TL: guarantor of review, designed the review, data extraction, analysis, GRADE assessment, co-wrote the manuscript.

DECLARATIONS OF INTEREST

NM: none known.

KM: none known.

CD: has received payment for lectures by AstraZeneca and support for attendance at a ESC-HF meeting by Novartis.
TL: has received research grants from UK Research and Innovation, Innovative Medicines Initiative and National Institute of Health Research via his institution.

**SOURCES OF SUPPORT**

**Internal sources**
- No sources of support provided

**External sources**
- NIHR, UK

This project was supported by the NIHR via Cochrane Infrastructure and NIHR Incentive funding to Cochrane Heart. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health and Social Care.
- R. Thomas Lumbers, UK

R. Thomas Lumbers is supported by a UK Research and Innovation Rutherford Fellowship hosted by Health Data Research UK (MR/S003754/1); the BigData@Heart Consortium funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No. 116074; and the National Institute for Health Research University College London Hospitals Biomedical Research Centre.

**DIFFERENCES BETWEEN PROTOCOL AND REVIEW**

We originally planned to include participants with LVEF ≥ 40% but changed this to LVEF > 40%, since this is a more frequently used cut-off in clinical trials.

We originally limited our population to symptomatic heart failure (NYHA class > I) at enrolment; however, this criterion was removed to include people with diagnosis of heart failure in whom symptoms had improved the functional class.

We added a clarification regarding the exclusion of cross-over trials.

We originally planned to include withdrawals due to adverse events in the 'Summary of findings' table. This was changed because this outcome was frequently reported inconsistently, which limits the applicability of a pooled analysis. Instead, we added hyperkalaemia to the 'Summary of findings' table because this adverse event outcome has relevance for clinical decision making. For the same reason, hyperkalaemia was switched from secondary to primary outcomes and withdrawals due to adverse events was switched from primary to secondary outcomes.

We did not pre specify which scale for quality of life we would focus on in the 'Summary of findings' table. To aid comparisons across the 'Summary of findings' tables we chose to include the Minnesota Living with Heart Failure Questionnaire and not the standardized mean difference across two scales which applied only to MRA versus placebo or no treatment comparison.

**INDEX TERMS**

**Medical Subject Headings (MeSH)**
- Adrenergic beta-Antagonists [*therapeutic use]; Angiotensin Receptor Antagonists [*therapeutic use]; Angiotensin-Converting Enzyme Inhibitors [*therapeutic use]; Chronic Disease; Heart Failure [*drug therapy] [mortality]; Hospitalization; Mineralocorticoid Receptor Antagonists [*therapeutic use]; Neprolysin [antagonists & inhibitors]; Quality of Life; Randomized Controlled Trials as Topic; Renin-Angiotensin System [*drug effects]; *Stroke Volume

**MeSH check words**
- Humans